Whereas O
different O
anti B
- I
CD4 I
mAb I
or O
HIV B
- I
1 I
gp120 I
could O
all O
trigger O
activation O
of O
the O
protein B
tyrosine I
kinases I
p56lck B
and O
p59fyn B
and O
phosphorylation O
of O
the O
Shc B
adaptor I
protein I
, O
which O
mediates O
signals O
to O
Ras B
, O
they O
differed O
significantly O
in O
their O
ability O
to O
activate O
NF B
- I
AT I
. O

Whereas O
different O
anti B
- I
CD4 I
mAb I
or O
HIV B
- I
1 I
gp120 I
could O
all O
trigger O
activation O
of O
the O
protein B
tyrosine I
kinases I
p56lck B
and O
p59fyn B
and O
phosphorylation O
of O
the O
Shc B
adaptor I
protein I
, O
which O
mediates O
signals O
to O
Ras B
, O
they O
differed O
significantly O
in O
their O
ability O
to O
activate O
NF B
- I
AT I
. O

Whereas O
different O
anti B
- I
CD4 I
mAb I
or O
HIV B
- I
1 I
gp120 I
could O
all O
trigger O
activation O
of O
the O
protein B
tyrosine I
kinases I
p56lck B
and O
p59fyn B
and O
phosphorylation O
of O
the O
Shc B
adaptor I
protein I
, O
which O
mediates O
signals O
to O
Ras B
, O
they O
differed O
significantly O
in O
their O
ability O
to O
activate O
NF B
- I
AT I
. O

ER B
- O
mediated O
repression O
of O
GATA B
- I
1 I
activity O
occurs O
on O
an O
artificial B
promoter I
containing O
a O
single O
GATA B
- I
binding I
site I
, O
as O
well O
as O
in O
the O
context O
of O
an O
intact B
promoter I
which O
is O
normally O
regulated O
by O
GATA B
- I
1 I
. O

In O
coimmunoprecipitatio O
experiments O
using O
transfected O
COS O
cells O
, O
GATA B
- I
1 I
and O
ER B
associate O
in O
a O
ligand O
- O
dependent O
manner O
. O

The O
appearance O
of O
the O
BamHI B
ZLF I
- I
1 I
gene I
product I
, O
ZEBRA B
, O
by O
RT O
- O
PCR O
, O
was O
observed O
within O
8 O
hr O
of O
infection O
. O

Overexpression O
of O
UDG B
in O
Saos O
2 O
cells O
was O
observed O
to O
delay O
growth O
late O
in O
G1 O
phase O
and O
transiently O
arrest O
these O
cells O
from O
progressing O
into O
the O
S O
phase O
. O

In O
addition O
, O
IL B
- I
2 I
but O
not O
IL B
- I
12 I
induced O
nuclear B
factors I
NF B
- I
kappa I
B I
and O
AP1 B
, O
and O
regulation O
of O
the O
nuclear O
levels O
of O
these O
two O
DNA B
binding I
protein I
complexes I
is O
correlated O
with O
IFN O
- O
gamma O
and O
GM O
- O
CSF O
gene O
expression O
. O

One O
substrate O
is O
p95vav B
, O
which O
is O
expressed O
exclusively O
in O
hematopoietic O
and O
trophoblast O
cells O
. O

Furthermore O
, O
p95vav B
synergizes O
with O
TCR B
stimulation O
in O
inducing O
NFAT O
- O
and O
interleukin O
- O
2 O
- O
dependent O
transcription O
. O

Furthermore O
, O
p95vav B
synergizes O
with O
TCR B
stimulation O
in O
inducing O
NFAT O
- O
and O
interleukin O
- O
2 O
- O
dependent O
transcription O
. O

Furthermore O
, O
the O
activating O
function O
of O
p95vav B
is O
blocked O
by O
FK506 O
, O
suggesting O
that O
its O
activity O
also O
depends O
on O
calcineurin B
. O

Furthermore O
, O
the O
activating O
function O
of O
p95vav B
is O
blocked O
by O
FK506 O
, O
suggesting O
that O
its O
activity O
also O
depends O
on O
calcineurin B
. O

Although O
further O
studies O
are O
required O
to O
determine O
the O
precise O
role O
of O
PEBP2 B
in O
the O
GM B
- I
CSF I
promoter O
activity O
, O
the O
present O
findings O
suggested O
the O
importance O
of O
the O
relative O
ratio O
of O
different O
PEBP2 B
isoforms I
in O
regulating O
the O
levels O
of O
the O
promoter O
activity O
. O

IFN B
- I
gamma I
priming O
of O
monocytes O
enhances O
LPS O
- O
induced O
TNF B
production O
by O
augmenting O
both O
transcription O
and O
MRNA O
stability O
. O

The O
induction O
of O
cytokine B
expression O
in O
monocytes O
/ O
macrophages O
by O
bacterial B
endotoxin I
or O
lipopolysaccharide O
is O
a O
critical O
, O
highly O
regulated O
host O
defence O
response O
. O

Consistent O
with O
the O
increased O
mRNA B
stability O
, O
the O
duration O
of O
mRNA B
accumulation O
was O
longer O
following O
LPS O
stimulation O
in O
primed O
monocytes O
, O
in O
addition O
to O
being O
of O
greater O
magnitude O
. O

Consistent O
with O
the O
increased O
mRNA B
stability O
, O
the O
duration O
of O
mRNA B
accumulation O
was O
longer O
following O
LPS O
stimulation O
in O
primed O
monocytes O
, O
in O
addition O
to O
being O
of O
greater O
magnitude O
. O

Since O
the O
terminal O
events O
of O
erythropoiesis O
are O
controlled O
by O
the O
glycoprotein B
hormone I
erythropoietin I
( O
Epo B
) O
, O
we O
investigated O
whether O
the O
expression O
or O
activity O
of O
the O
TAL1 B
gene I
and O
its O
protein B
products I
were O
affected O
by O
Epo B
in O
splenic O
erythroblasts O
from O
mice O
infected O
with O
an O
anemia O
- O
inducing O
strain O
of O
Friend O
virus O
( O
FVA O
cells O
) O
. O

Since O
the O
terminal O
events O
of O
erythropoiesis O
are O
controlled O
by O
the O
glycoprotein B
hormone I
erythropoietin I
( O
Epo B
) O
, O
we O
investigated O
whether O
the O
expression O
or O
activity O
of O
the O
TAL1 B
gene I
and O
its O
protein B
products I
were O
affected O
by O
Epo B
in O
splenic O
erythroblasts O
from O
mice O
infected O
with O
an O
anemia O
- O
inducing O
strain O
of O
Friend O
virus O
( O
FVA O
cells O
) O
. O

The O
role O
of O
shared B
receptor I
motifs I
and O
common B
Stat I
proteins I
in O
the O
generation O
of O
cytokine B
pleiotropy O
and O
redundancy O
by O
IL B
- I
2 I
, O
IL B
- I
4 I
, O
IL B
- I
7 I
, O
IL B
- I
13 I
, O
and O
IL B
- I
15 I
. O

IL B
- I
13 I
Induced O
the O
same O
complexes O
as O
IL B
- I
4 I
, O
a O
finding O
explained O
by O
our O
studies O
implicating O
IL B
- I
4R I
as O
a O
shared O
component O
of O
the O
receptors B
. O

Erythropoietin B
( O
Epo B
) O
, O
the O
primary O
regulator O
of O
the O
production O
of O
erythroid O
cells O
, O
acts O
by O
binding O
to O
a O
cell B
surface I
receptor I
( O
EpoR B
) O
on O
erythroid O
progenitors O
. O

Erythropoietin B
( O
Epo B
) O
, O
the O
primary O
regulator O
of O
the O
production O
of O
erythroid O
cells O
, O
acts O
by O
binding O
to O
a O
cell B
surface I
receptor I
( O
EpoR B
) O
on O
erythroid O
progenitors O
. O

Erythropoietin B
( O
Epo B
) O
, O
the O
primary O
regulator O
of O
the O
production O
of O
erythroid O
cells O
, O
acts O
by O
binding O
to O
a O
cell B
surface I
receptor I
( O
EpoR B
) O
on O
erythroid O
progenitors O
. O

The O
deduced O
amino O
acid O
sequence O
similarity O
to O
the O
proteins O
encoded O
by O
these O
two O
latter O
genes O
is O
approximately O
65 O
% O
and O
includes O
domains O
and O
amino O
acid O
residues O
( O
the O
leucine B
zipper I
- I
like I
and O
the O
RGD B
domain I
, O
a O
serine O
and O
a O
histidine O
residue O
in O
the O
NH2 B
- I
and O
in O
the O
COOH B
- I
terminal I
portion I
of O
the O
protein O
, O
respectively O
) O
postulated O
to O
be O
important O
for O
nm23 B
function O
. O

The O
Fc B
gamma I
RIC I
GIRE I
is O
homologous O
to O
the O
IFN B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
of O
the O
guanylate B
binding I
protein I
and O
to O
X B
box I
elements I
of O
class B
II I
MHC I
genes I
. O

In O
HTLV O
- O
I O
- O
infected O
cord O
blood O
lymphocytes O
, O
the O
transition O
from O
IL B
- I
2 I
- O
dependent O
to O
IL B
- I
2 I
- O
independent O
growth O
correlated O
with O
the O
acquisition O
of O
a O
constitutively O
activated O
Jak B
- B
STAT I
pathway O
, O
which O
suggests O
that O
this O
pathway O
participates O
in O
HTLV O
- O
I O
- O
mediated O
T O
cell O
transformation O
. O

Murine B
macrophage I
inflammatory I
protein I
1 I
alpha I
( O
MIP B
- I
1 I
alpha I
) O
and O
its O
human B
equivalent I
( O
GOS19 B
, O
LD78 B
, O
or O
AT464 B
) O
are O
members O
of O
the O
- B
C I
- I
C I
family I
of O
low B
- I
molecular I
- I
weight I
chemokines I
. O

Murine B
macrophage I
inflammatory I
protein I
1 I
alpha I
( O
MIP B
- I
1 I
alpha I
) O
and O
its O
human B
equivalent I
( O
GOS19 B
, O
LD78 B
, O
or O
AT464 B
) O
are O
members O
of O
the O
- B
C I
- I
C I
family I
of O
low B
- I
molecular I
- I
weight I
chemokines I
. O

Murine B
macrophage I
inflammatory I
protein I
1 I
alpha I
( O
MIP B
- I
1 I
alpha I
) O
and O
its O
human B
equivalent I
( O
GOS19 B
, O
LD78 B
, O
or O
AT464 B
) O
are O
members O
of O
the O
- B
C I
- I
C I
family I
of O
low B
- I
molecular I
- I
weight I
chemokines I
. O

The O
signal O
is O
subsequently O
propagated O
through O
the O
activation O
of O
Raf B
- I
1 I
, O
MEK B
, O
and O
MAP B
kinases I
as O
shown O
by O
their O
increased O
autophosphorylation O
in O
vitro O
and O
phosphorylation O
in O
situ O
. O

We O
conclude O
that O
IL B
- I
5 I
induced O
signals O
are O
propagated O
through O
two O
distinct O
pathways O
: O
( O
1 O
) O
Lyn B
- O
- O
> O
Ras B
- O
- O
> O
Raf B
- I
1 I
- O
- O
> O
MEK B
- O
- O
> O
MAP B
kinase I
and O
( O
2 O
) O
Jak2 B
- O
- O
> O
STAT1 B
. O

We O
conclude O
that O
IL B
- I
5 I
induced O
signals O
are O
propagated O
through O
two O
distinct O
pathways O
: O
( O
1 O
) O
Lyn B
- O
- O
> O
Ras B
- O
- O
> O
Raf B
- I
1 I
- O
- O
> O
MEK B
- O
- O
> O
MAP B
kinase I
and O
( O
2 O
) O
Jak2 B
- O
- O
> O
STAT1 B
. O

We O
conclude O
that O
IL B
- I
5 I
induced O
signals O
are O
propagated O
through O
two O
distinct O
pathways O
: O
( O
1 O
) O
Lyn B
- O
- O
> O
Ras B
- O
- O
> O
Raf B
- I
1 I
- O
- O
> O
MEK B
- O
- O
> O
MAP B
kinase I
and O
( O
2 O
) O
Jak2 B
- O
- O
> O
STAT1 B
. O

We O
conclude O
that O
IL B
- I
5 I
induced O
signals O
are O
propagated O
through O
two O
distinct O
pathways O
: O
( O
1 O
) O
Lyn B
- O
- O
> O
Ras B
- O
- O
> O
Raf B
- I
1 I
- O
- O
> O
MEK B
- O
- O
> O
MAP B
kinase I
and O
( O
2 O
) O
Jak2 B
- O
- O
> O
STAT1 B
. O

We O
conclude O
that O
IL B
- I
5 I
induced O
signals O
are O
propagated O
through O
two O
distinct O
pathways O
: O
( O
1 O
) O
Lyn B
- O
- O
> O
Ras B
- O
- O
> O
Raf B
- I
1 I
- O
- O
> O
MEK B
- O
- O
> O
MAP B
kinase I
and O
( O
2 O
) O
Jak2 B
- O
- O
> O
STAT1 B
. O

We O
found O
that O
the O
retinoblastoma B
susceptibility I
gene I
product I
( O
Rb B
) O
dramatically O
suppressed O
this O
IE2 B
transactivation O
of O
various B
promoters I
. O

We O
found O
that O
the O
retinoblastoma B
susceptibility I
gene I
product I
( O
Rb B
) O
dramatically O
suppressed O
this O
IE2 B
transactivation O
of O
various B
promoters I
. O

Retinoblastoma B
protein I
( O
RB B
) O
is O
a O
tumor O
suppressor O
and O
functions O
as O
a O
transcriptional B
repressor I
by O
binding O
and O
inactivating O
the O
transactivator B
E2F I
- I
I I
. O

We O
also O
examined O
the O
IFN B
- I
gamma I
induction O
of O
CIITA B
in O
RB B
- O
defective O
lines O
. O

We O
also O
examined O
the O
IFN B
- I
gamma I
induction O
of O
CIITA B
in O
RB B
- O
defective O
lines O
. O

We O
have O
recently O
demonstrated O
that O
stimulation O
of O
human O
T O
and O
natural O
killer O
cells O
with O
IL B
- I
12 I
induces O
tyrosine O
phosphorylation O
of O
the O
Janus B
family I
tyrosine I
kinase I
JAK2 B
and O
Tyk2 B
, O
implicating O
these O
kinases B
in O
the O
immediate O
biochemical O
response O
to O
IL B
- I
12 I
. O

We O
have O
recently O
demonstrated O
that O
stimulation O
of O
human O
T O
and O
natural O
killer O
cells O
with O
IL B
- I
12 I
induces O
tyrosine O
phosphorylation O
of O
the O
Janus B
family I
tyrosine I
kinase I
JAK2 B
and O
Tyk2 B
, O
implicating O
these O
kinases B
in O
the O
immediate O
biochemical O
response O
to O
IL B
- I
12 I
. O

We O
have O
recently O
demonstrated O
that O
stimulation O
of O
human O
T O
and O
natural O
killer O
cells O
with O
IL B
- I
12 I
induces O
tyrosine O
phosphorylation O
of O
the O
Janus B
family I
tyrosine I
kinase I
JAK2 B
and O
Tyk2 B
, O
implicating O
these O
kinases B
in O
the O
immediate O
biochemical O
response O
to O
IL B
- I
12 I
. O

Furthermore O
, O
we O
show O
that O
IL B
- I
12 I
stimulates O
formation O
of O
a O
DNA B
- I
binding I
complex I
that O
recognizes O
a O
DNA O
sequence O
previously O
shown O
to O
bind O
STAT B
proteins I
and O
that O
this O
complex O
contains O
STAT4 B
. O

Integrin O
- O
mediated O
tyrosine O
phosphorylation O
and O
cytokine B
message O
induction O
in O
monocytic O
cells O
. O

The O
tyrosine O
kinase O
inhibitors O
genistein O
and O
herbimycin O
A O
block O
both O
integrin B
- O
mediated O
tyrosine O
phosphorylation O
and O
increases O
in O
IL B
- I
1 I
beta I
message O
levels O
, O
indicating O
a O
causal O
relationship O
between O
the O
two O
events O
. O

These O
observations O
indicate O
that O
the O
Syk B
tyrosine O
kinase O
may O
be O
an O
important O
component O
of O
an O
integrin B
signaling O
pathway O
in O
monocytic O
cells O
, O
leading O
to O
activation O
of O
NF B
- I
kappa I
B I
and O
to O
increased O
levels O
of O
cytokine B
messages O
. O

These O
observations O
indicate O
that O
the O
Syk B
tyrosine O
kinase O
may O
be O
an O
important O
component O
of O
an O
integrin B
signaling O
pathway O
in O
monocytic O
cells O
, O
leading O
to O
activation O
of O
NF B
- I
kappa I
B I
and O
to O
increased O
levels O
of O
cytokine B
messages O
. O

These O
observations O
indicate O
that O
the O
Syk B
tyrosine O
kinase O
may O
be O
an O
important O
component O
of O
an O
integrin B
signaling O
pathway O
in O
monocytic O
cells O
, O
leading O
to O
activation O
of O
NF B
- I
kappa I
B I
and O
to O
increased O
levels O
of O
cytokine B
messages O
. O

To O
determine O
if O
New O
World O
primates O
express O
an O
inhibitor O
that O
influences O
glucocorticoid B
receptor I
( O
GR B
) O
binding O
characteristics O
, O
we O
examined O
[ O
3H O
] O
dexamethasone O
binding O
in O
cytosol O
prepared O
from O
B95 O
- O
8 O
lymphoid O
cells O
, O
derived O
from O
the O
cotton O
top O
tamarin O
( O
Saguinus O
oedipus O
) O
, O
in O
combination O
with O
cytosol O
prepared O
from O
human O
or O
rat O
tissues O
. O

The O
results O
further O
demonstrated O
the O
activation O
of O
S6 B
kinase I
( O
pp90rsk B
) O
, O
evidenced O
by O
phosphorylation O
of O
S6 B
and O
serum O
response O
factor O
( O
SRF O
) O
peptides O
, O
in O
PWM O
treated O
B O
cells O
. O

The O
results O
further O
demonstrated O
the O
activation O
of O
S6 B
kinase I
( O
pp90rsk B
) O
, O
evidenced O
by O
phosphorylation O
of O
S6 B
and O
serum O
response O
factor O
( O
SRF O
) O
peptides O
, O
in O
PWM O
treated O
B O
cells O
. O

We O
have O
recently O
found O
a O
novel O
conserved B
motif I
in O
the O
promoters B
of O
several O
T B
- I
cell I
- I
expressed I
cytokines I
[ O
human B
interleukin I
- I
2 I
, I
- I
4 I
, I
- I
5 I
and I
- I
13 I
and O
human B
and I
mouse I
granulocyte I
/ I
macrophage I
- I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
] O
. O

In O
different O
genes B
, O
the O
core B
sequences I
are O
separated O
by O
integer O
numbers O
of O
helical O
turns O
. O

These O
effects O
of O
aspirin O
were O
not O
related O
to O
the O
inhibition O
of O
cyclooxygenase B
activity O
, O
since O
indomethacin O
was O
ineffective O
. O

Together O
, O
these O
results O
suggest O
that O
phosphorylation O
of O
I B
kappa I
B I
alpha I
, O
mediated O
through O
both O
the O
TNF B
- I
alpha I
- O
inducible O
and O
the O
PP B
- I
2A I
- I
opposing I
kinases I
, O
may O
serve O
to O
target O
I B
kappa I
B I
alpha I
for O
proteasome B
- O
mediated O
degradation O
. O

Finally O
, O
we O
show O
by O
both O
footprint O
analysis O
and O
functional O
assays O
that O
the O
ability O
of O
the O
G B
+ I
C I
- I
rich I
region I
to O
increase O
alpha B
- I
globin I
promoter I
activity O
from O
a O
stably O
integrated O
alpha B
- I
globin I
gene I
is O
mediated O
by O
its O
multiple B
binding I
sites I
for O
the O
transcription B
factor I
Sp1 B
. O

LFA B
- I
3 I
induced O
moderate O
levels O
of O
AP B
- I
1 I
, O
but O
did O
not O
influence O
the O
levels O
of O
NF B
- I
kappa I
B I
, O
while O
B7 B
costimulation O
strongly O
induced O
both O
AP B
- I
1 I
and O
substantially O
enhanced O
NF B
- I
kappa I
B I
binding I
proteins I
. O

The O
Ah B
receptor I
recognizes O
DNA B
binding I
sites I
for O
the O
B B
cell I
transcription I
factor I
, O
BSAP B
: O
a O
possible O
mechanism O
for O
dioxin O
- O
mediated O
alteration O
of O
CD19 B
gene I
expression O
in O
human O
B O
lymphocytes O
. O

In O
addition O
, O
the O
Ah B
receptor I
complex I
recognized O
a O
DNA B
binding I
site I
for O
B B
cell I
lineage I
- I
specific I
activator I
protein I
( O
BSAP B
) O
in O
the O
promoter B
region I
of O
the O
human O
CD19 B
gene I
which O
is O
similar O
to O
the O
consensus B
Ah I
receptor I
DNA I
binding I
site I
. O

Delayed O
administration O
of O
rBPI21 B
also O
affected O
LPS O
- O
mediated O
activation O
of O
the O
nuclear B
factor I
, O
NF B
- I
kappa I
B I
. O

Two O
to O
4 O
h O
following O
LPS O
addition O
to O
endothelial O
cells O
, O
when O
NF B
- I
kappa I
B I
was O
already O
activated O
, O
addition O
of O
rBPI21 B
resulted O
in O
marked O
reduction O
of O
NF B
- I
kappa I
B I
detectable O
at O
4 O
or O
6 O
h O
. O

Antigen O
complexed O
with O
major B
histocompatibility I
complex I
class I
I I
or I
II I
molecules I
on O
the O
surface O
of O
antigen O
presenting O
cells O
interacts O
with O
the O
T B
cell I
receptor I
( O
TCR B
) O
on O
the O
surface O
of O
T O
cells O
and O
initiates O
an O
activation O
cascade O
. O

This O
observation O
, O
together O
with O
the O
fact O
that O
both O
GM B
- I
CSF I
and O
IL B
- I
2 I
respond O
to O
TCR B
signals O
via O
NFAT B
, O
implies O
a O
high O
degree O
of O
conservation O
in O
the O
regulation O
of O
cytokine B
gene O
expression O
in O
T O
cells O
. O

This O
observation O
, O
together O
with O
the O
fact O
that O
both O
GM B
- I
CSF I
and O
IL B
- I
2 I
respond O
to O
TCR B
signals O
via O
NFAT B
, O
implies O
a O
high O
degree O
of O
conservation O
in O
the O
regulation O
of O
cytokine B
gene O
expression O
in O
T O
cells O
. O

This O
observation O
, O
together O
with O
the O
fact O
that O
both O
GM B
- I
CSF I
and O
IL B
- I
2 I
respond O
to O
TCR B
signals O
via O
NFAT B
, O
implies O
a O
high O
degree O
of O
conservation O
in O
the O
regulation O
of O
cytokine B
gene O
expression O
in O
T O
cells O
. O

We O
examined O
mRNA B
levels O
of O
various O
V B
- I
ATPase I
subunits O
during O
differentiation O
of O
both O
native O
monocytes O
and O
the O
cell O
line O
THP O
- O
1 O
, O
and O
found O
that O
transcriptional O
and O
post O
- O
transcriptional O
mechanisms O
could O
account O
for O
increases O
in O
cell O
V B
- I
ATPase I
content O
. O

Primer O
extension O
and O
ribonuclease B
protection O
analyses O
indicate O
a O
single O
major B
transcriptional I
start I
site I
. O

These O
results O
imply O
that O
at O
least O
three O
signals O
are O
required O
to O
activate O
the O
GM B
- I
CSF I
proximal I
promoter I
, O
and O
that O
the O
signals O
impinge O
on O
distinct O
transcription B
factors I
that O
bind O
to O
the O
hCLEO B
and I
NF I
- I
kappa I
B I
regions I
of O
the O
promoter B
. O

In O
this O
report O
, O
we O
show O
that O
in O
monocytes O
and O
T O
cells O
IL B
- I
10 I
stimulates O
tyrosine O
phosphorylation O
of O
the O
signal B
transducers I
and O
activators B
of I
transcription I
, O
STAT1 B
alpha I
and O
STAT3 B
, O
in O
a O
differential O
manner O
such O
that O
the O
relative O
formation O
of O
homo B
- I
and I
heterodimers I
varies O
between O
the O
two O
cell O
types O
. O

IL B
- I
10 I
treatment O
of O
both O
T O
cells O
and O
monocytes O
results O
in O
the O
ligand O
- O
induced O
tyrosine O
phosphorylation O
of O
tyk2 B
and O
Jak1 B
, O
but O
not O
Jak2 B
or O
Jak3 B
. O

IL B
- I
10 I
treatment O
of O
both O
T O
cells O
and O
monocytes O
results O
in O
the O
ligand O
- O
induced O
tyrosine O
phosphorylation O
of O
tyk2 B
and O
Jak1 B
, O
but O
not O
Jak2 B
or O
Jak3 B
. O

IL B
- I
10 I
treatment O
of O
both O
T O
cells O
and O
monocytes O
results O
in O
the O
ligand O
- O
induced O
tyrosine O
phosphorylation O
of O
tyk2 B
and O
Jak1 B
, O
but O
not O
Jak2 B
or O
Jak3 B
. O

IL B
- I
10 I
treatment O
of O
both O
T O
cells O
and O
monocytes O
results O
in O
the O
ligand O
- O
induced O
tyrosine O
phosphorylation O
of O
tyk2 B
and O
Jak1 B
, O
but O
not O
Jak2 B
or O
Jak3 B
. O

They O
also O
display O
constitutively O
high O
levels O
of O
p59fyn B
and O
CD3 B
zeta I
tyrosine O
phosphorylation O
. O

We O
demonstrate O
that O
cross O
- O
linking O
CD30 B
with O
an O
anti O
- O
CD30 B
- O
specific O
monoclonal O
antibody O
, O
which O
mimics O
the O
described O
biological O
activities O
of O
the O
CD30 B
ligand I
( O
CD30L B
) O
, O
results O
in O
HIV O
expression O
. O

We O
demonstrate O
that O
cross O
- O
linking O
CD30 B
with O
an O
anti O
- O
CD30 B
- O
specific O
monoclonal O
antibody O
, O
which O
mimics O
the O
described O
biological O
activities O
of O
the O
CD30 B
ligand I
( O
CD30L B
) O
, O
results O
in O
HIV O
expression O
. O

We O
demonstrate O
that O
cross O
- O
linking O
CD30 B
with O
an O
anti O
- O
CD30 B
- O
specific O
monoclonal O
antibody O
, O
which O
mimics O
the O
described O
biological O
activities O
of O
the O
CD30 B
ligand I
( O
CD30L B
) O
, O
results O
in O
HIV O
expression O
. O

Type B
II I
major I
histocompatibility I
complex I
combined O
immune O
deficiency O
( O
type O
II O
MHC B
CID O
or O
bare O
lymphocyte O
syndrome O
) O
is O
a O
congenital O
immunodeficiency O
disease O
characterized O
by O
absent O
MHC B
class I
II I
expression O
. O

Here O
, O
we O
demonstrate O
that O
CIITA B
is O
an O
MHC B
class I
II I
gene I
- I
specific I
transcription I
activator I
. O

These O
results O
demonstrate O
that O
P B
- I
selectin I
, O
through O
its O
ligands O
on O
monocytes O
, O
may O
locally O
regulate O
cytokine B
secretion O
in O
inflamed O
tissues O
. O

Here O
, O
we O
report O
that O
nitric O
oxide O
( O
NO O
) O
activates O
p21ras B
in O
human O
T O
cells O
as O
evidenced O
by O
an O
increase O
in O
GTP B
- I
bound I
p21ras I
. O

Circular O
dichroism O
analysis O
reveals O
that O
NO O
induces O
a O
profound O
conformational O
change O
in O
p21ras B
in O
association O
with O
GDP O
/ O
GTP O
exchange O
. O

Furthermore O
, O
we O
demonstrate O
that O
p21ras B
is O
essential O
for O
NO O
- O
induced O
downstream O
signaling O
, O
such O
as O
NF B
- I
kappa I
B I
activation O
, O
and O
that O
endogenous O
NO O
can O
activate O
p21ras B
in O
the O
same O
cell O
. O

Furthermore O
, O
we O
demonstrate O
that O
p21ras B
is O
essential O
for O
NO O
- O
induced O
downstream O
signaling O
, O
such O
as O
NF B
- I
kappa I
B I
activation O
, O
and O
that O
endogenous O
NO O
can O
activate O
p21ras B
in O
the O
same O
cell O
. O

These O
studies O
identify O
p21ras B
as O
a O
target O
of O
the O
same O
cell O
. O

These O
studies O
identify O
p21ras B
as O
a O
target O
of O
NO O
in O
T O
cells O
and O
suggest O
that O
NO O
activates O
p21ras B
by O
an O
action O
which O
mimics O
that O
of O
guanine B
nucleotide I
exchange I
factors I
. O

These O
studies O
identify O
p21ras B
as O
a O
target O
of O
NO O
in O
T O
cells O
and O
suggest O
that O
NO O
activates O
p21ras B
by O
an O
action O
which O
mimics O
that O
of O
guanine B
nucleotide I
exchange I
factors I
. O

Transient O
transfections O
using O
reporter B
constructs I
with O
multiples O
of O
transcription B
factor I
binding I
sites I
from O
the O
IL B
- I
2 I
promoter I
[ O
distal B
nuclear I
factor I
( I
NF I
) I
- I
AT I
, O
proximal B
NF I
- I
AT I
, O
AP B
- I
1 I
/ I
Octamer I
( O
UPS B
) O
or O
NF B
- I
chi I
B I
( O
TCEd B
) O
sites O
] O
were O
performed O
. O

Transient O
transfections O
using O
reporter B
constructs I
with O
multiples O
of O
transcription B
factor I
binding I
sites I
from O
the O
IL B
- I
2 I
promoter I
[ O
distal B
nuclear I
factor I
( I
NF I
) I
- I
AT I
, O
proximal B
NF I
- I
AT I
, O
AP B
- I
1 I
/ I
Octamer I
( O
UPS B
) O
or O
NF B
- I
chi I
B I
( O
TCEd B
) O
sites O
] O
were O
performed O
. O

Latent B
membrane I
protein I
- I
1 I
induces O
cyclin B
D2 I
expression O
, O
pRb B
hyperphosphorylation O
, O
and O
loss O
of O
TGF B
- I
beta I
1 I
- O
mediated O
growth O
inhibition O
in O
EBV O
- O
positive O
B O
cells O
. O

A O
further O
decrease O
in O
the O
T O
cell O
reactivity O
to O
TSHR B
peptides O
was O
observed O
3 O
- O
6 O
months O
after O
surgery O
. O

Alanine O
substitutions O
introduced O
at O
two O
serine O
residues O
positioned O
within O
this O
N B
- I
terminal I
regulatory I
region I
of O
I B
kappa I
B I
alpha I
also O
yielded O
constitutive O
repressors O
that O
escaped O
from O
Tax B
- O
induced O
turnover O
and O
that O
potently O
inhibited O
immune O
activation O
pathways O
for O
NF B
- I
kappa I
B I
induction O
, O
including O
those O
initiated O
from O
antigen B
and I
cytokine I
receptors I
. O

These O
included O
vimentin B
, O
correlating O
to O
cell O
shape O
changes O
, O
cytokeratins B
8 I
and I
18 I
, O
associated O
with O
differentiated O
cell O
types O
of O
prostate O
epithelia O
, O
and O
neuron B
- I
specific I
enolase I
and O
serotonin O
, O
associated O
with O
neuroendocrine O
cells O
. O

Human O
peripheral O
blood O
monocytes O
responded O
to O
stimulation O
of O
platelet B
- I
activating I
factor I
( O
PAF B
) O
with O
up O
- O
regulation O
of O
the O
transcript O
for O
heparin B
- I
binding I
epidermal I
growth I
factor I
- I
like I
growth I
factor I
( O
HB B
- I
EGF I
) O
, O
a O
potent B
mitogen I
for O
vascular O
smooth O
muscle O
cells O
. O

This O
function O
of O
PAF B
was O
observed O
at O
nanomolar O
concentrations O
of O
the O
ligand O
, O
starting O
at O
30 O
min O
after O
stimulation O
. O

These O
functions O
of O
PAF B
appeared O
to O
be O
mediated O
through O
the O
cell B
surface I
PAF I
receptors I
, O
as O
two O
PAF B
receptor O
antagonists O
, O
WEB O
2086 O
and O
L O
- O
659 O
, O
989 O
, O
blocked O
both O
the O
up O
- O
regulation O
of O
HB B
- I
EGF I
mRNA I
and O
kappa O
B O
binding O
activity O
induced O
by O
PAF B
. O

These O
functions O
of O
PAF B
appeared O
to O
be O
mediated O
through O
the O
cell B
surface I
PAF I
receptors I
, O
as O
two O
PAF B
receptor O
antagonists O
, O
WEB O
2086 O
and O
L O
- O
659 O
, O
989 O
, O
blocked O
both O
the O
up O
- O
regulation O
of O
HB B
- I
EGF I
mRNA I
and O
kappa O
B O
binding O
activity O
induced O
by O
PAF B
. O

These O
functions O
of O
PAF B
appeared O
to O
be O
mediated O
through O
the O
cell B
surface I
PAF I
receptors I
, O
as O
two O
PAF B
receptor O
antagonists O
, O
WEB O
2086 O
and O
L O
- O
659 O
, O
989 O
, O
blocked O
both O
the O
up O
- O
regulation O
of O
HB B
- I
EGF I
mRNA I
and O
kappa O
B O
binding O
activity O
induced O
by O
PAF B
. O

ZEBRA B
is O
a O
bZIP B
transcriptional I
activator I
which O
binds O
as O
a O
dimer O
to O
7 B
- I
bp I
response I
elements I
within O
EBV B
promoters I
and O
is O
directly O
involved O
in O
the O
stimulation O
of O
virus O
replication O
at O
the O
EBV B
lytic I
origin I
. O

Both O
chimeras O
were O
found O
to O
transactivate O
model O
and O
native O
promoters O
at O
equivalent O
or O
better O
levels O
than O
ZEBRA B
itself O
. O

These O
activation O
domains O
restored O
ZEBRA B
' O
s O
ability O
to O
induce O
early B
antigen I
and O
to O
stimulate O
origin O
replication O
to O
levels O
that O
were O
equal O
to O
or O
greater O
than O
those O
of O
wild O
type O
. O

Because O
these O
are O
the O
characteristics O
of O
a O
signal B
transducer I
and I
activator I
of I
transcription I
( I
Stat I
) I
protein I
, O
we O
determined O
whether O
antibodies B
to I
Stat I
proteins I
will O
interfere O
with O
gel O
mobility O
shift O
and O
found O
that O
antibodies B
to I
IL I
- I
4 I
Stat I
, O
also O
known O
as O
Stat6 B
, O
but O
not O
antibodies B
to O
other O
Stat B
proteins I
, O
interfere O
with O
the O
formation O
of O
the O
IL B
- I
4 I
NAF I
complex I
. O

Because O
these O
are O
the O
characteristics O
of O
a O
signal B
transducer I
and I
activator I
of I
transcription I
( I
Stat I
) I
protein I
, O
we O
determined O
whether O
antibodies B
to I
Stat I
proteins I
will O
interfere O
with O
gel O
mobility O
shift O
and O
found O
that O
antibodies B
to I
IL I
- I
4 I
Stat I
, O
also O
known O
as O
Stat6 B
, O
but O
not O
antibodies B
to O
other O
Stat B
proteins I
, O
interfere O
with O
the O
formation O
of O
the O
IL B
- I
4 I
NAF I
complex I
. O

Monoallelic O
expression O
of O
TAL1 B
was O
observed O
in O
the O
leukemic O
cells O
of O
all O
patients O
( O
8 O
of O
8 O
) O
bearing O
a O
TAL1 B
gene I
rearrangement O
. O

In O
the O
leukemic O
cells O
of O
patients O
without O
detectable O
TAL1 B
rearrangements O
, O
TAL1 B
transcription O
occurred O
in O
either O
a O
monoallelic O
( O
3 O
of O
7 O
patients O
) O
or O
a O
biallelic O
( O
4 O
of O
7 O
patients O
) O
fashion O
. O

In O
the O
leukemic O
cells O
of O
patients O
without O
detectable O
TAL1 B
rearrangements O
, O
TAL1 B
transcription O
occurred O
in O
either O
a O
monoallelic O
( O
3 O
of O
7 O
patients O
) O
or O
a O
biallelic O
( O
4 O
of O
7 O
patients O
) O
fashion O
. O

In O
vitro O
translated O
Spi B
- I
B I
protein I
can O
bind O
to O
PU B
. I
1 I
binding I
sites I
in O
myeloid B
promoters I
and O
transactivate O
these O
promoters B
in O
nonmyeloid O
cells O
. O

The O
promoters B
were O
used O
without O
enhancers B
, O
or O
with O
enhancers B
derived O
from O
the O
beta B
- I
globin I
locus I
control I
region I
and O
the O
alpha B
- I
globin I
HS I
- I
40 I
enhancer I
. O

The O
promoters B
were O
used O
without O
enhancers B
, O
or O
with O
enhancers B
derived O
from O
the O
beta B
- I
globin I
locus I
control I
region I
and O
the O
alpha B
- I
globin I
HS I
- I
40 I
enhancer I
. O

The O
promoters B
were O
used O
without O
enhancers B
, O
or O
with O
enhancers B
derived O
from O
the O
beta B
- I
globin I
locus I
control I
region I
and O
the O
alpha B
- I
globin I
HS I
- I
40 I
enhancer I
. O

When O
transfected O
into O
K562 O
cells O
, O
which O
express O
zeta B
- I
globin I
, O
comparable O
amounts O
of O
activity O
were O
obtained O
from O
the O
- B
557 I
and I
- I
417 I
zeta I
- I
luciferase I
constructs I
and O
the O
alpha B
- I
luciferase I
constructs I
when O
no O
enhancers B
or O
the O
alpha B
- I
globin I
locus I
enhancers I
were O
used O
. O

Accordingly O
, O
the O
effects O
of O
the O
constitutively B
active I
PKCs I
were O
compared O
to O
the O
effects O
of O
mutationally O
activated O
p21ras B
. O

Moreover O
, O
the O
data O
comparing O
the O
effects O
of O
activated B
Ras I
and O
PKC B
mutants I
suggest O
that O
PKC B
- I
alpha I
, O
p21ras B
, O
and O
PKC B
- I
epsilon I
are O
not O
positioned O
linearly O
on O
a O
single O
signal O
transduction O
pathway O
. O

We O
examined O
the O
ability O
of O
nuclear O
translocated O
glucocorticoid B
receptors I
to O
bind O
to O
their O
DNA B
binding I
sites I
( O
GRE B
) O
using O
electrophoretic O
mobility O
shift O
assays O
in O
PBMC O
from O
patients O
with O
steroid O
- O
sensitive O
and O
steroid O
- O
resistant O
asthma O
. O

Scatchard O
analysis O
of O
glucocorticoid B
receptor I
- O
GRE B
binding O
showed O
no O
change O
in O
binding O
affinity O
but O
did O
show O
a O
reduced O
number O
of O
receptors B
available O
for O
DNA O
binding O
in O
the O
steroid O
- O
resistant O
patients O
. O

Scatchard O
analysis O
of O
glucocorticoid B
receptor I
- O
GRE B
binding O
showed O
no O
change O
in O
binding O
affinity O
but O
did O
show O
a O
reduced O
number O
of O
receptors B
available O
for O
DNA O
binding O
in O
the O
steroid O
- O
resistant O
patients O
. O

Signaling O
by O
a O
wide O
variety O
of O
cytokines B
, O
including O
interferons B
, O
interleukins B
, O
and O
growth B
factors I
, O
involves O
activation O
of O
JAK B
kinases I
and O
Stat B
( I
Signal I
transducers I
and I
activators I
of I
transcription I
) I
proteins I
. O

Signaling O
by O
a O
wide O
variety O
of O
cytokines B
, O
including O
interferons B
, O
interleukins B
, O
and O
growth B
factors I
, O
involves O
activation O
of O
JAK B
kinases I
and O
Stat B
( I
Signal I
transducers I
and I
activators I
of I
transcription I
) I
proteins I
. O

Signaling O
by O
a O
wide O
variety O
of O
cytokines B
, O
including O
interferons B
, O
interleukins B
, O
and O
growth B
factors I
, O
involves O
activation O
of O
JAK B
kinases I
and O
Stat B
( I
Signal I
transducers I
and I
activators I
of I
transcription I
) I
proteins I
. O

Here O
we O
show O
that O
the O
lymphoid B
- I
specific I
transcription I
factor I
Oct I
- I
2A I
plays O
a O
critical O
role O
in O
HLA B
- I
DRA I
gene I
expression O
in O
class O
II O
- O
positive O
B O
cell O
lines O
, O
and O
that O
the O
high B
mobility I
group I
protein I
( O
HMG B
) O
I B
/ I
Y I
binds O
to O
multiple O
sites O
within O
the O
DRA B
promoter I
, O
including O
the O
Oct B
- I
2A I
binding I
site I
. O

In O
lymphoblastoid O
cell O
lines O
, O
six O
EBV B
- I
encoded I
nuclear I
antigens I
( O
EBNA1 B
, I
2 I
, I
3A I
, I
3B I
, I
3C I
, I
- I
LP I
) O
, O
three O
latent B
membrane I
proteins I
( O
LMP1 B
, O
2A B
, O
2B B
) O
, O
and O
two O
nuclear B
RNAs I
( O
EBERs B
) O
are O
expressed O
. O

In O
lymphoblastoid O
cell O
lines O
, O
six O
EBV B
- I
encoded I
nuclear I
antigens I
( O
EBNA1 B
, I
2 I
, I
3A I
, I
3B I
, I
3C I
, I
- I
LP I
) O
, O
three O
latent B
membrane I
proteins I
( O
LMP1 B
, O
2A B
, O
2B B
) O
, O
and O
two O
nuclear B
RNAs I
( O
EBERs B
) O
are O
expressed O
. O

In O
lymphoblastoid O
cell O
lines O
, O
six O
EBV B
- I
encoded I
nuclear I
antigens I
( O
EBNA1 B
, I
2 I
, I
3A I
, I
3B I
, I
3C I
, I
- I
LP I
) O
, O
three O
latent B
membrane I
proteins I
( O
LMP1 B
, O
2A B
, O
2B B
) O
, O
and O
two O
nuclear B
RNAs I
( O
EBERs B
) O
are O
expressed O
. O

In O
lymphoblastoid O
cell O
lines O
, O
six O
EBV B
- I
encoded I
nuclear I
antigens I
( O
EBNA1 B
, I
2 I
, I
3A I
, I
3B I
, I
3C I
, I
- I
LP I
) O
, O
three O
latent B
membrane I
proteins I
( O
LMP1 B
, O
2A B
, O
2B B
) O
, O
and O
two O
nuclear B
RNAs I
( O
EBERs B
) O
are O
expressed O
. O

In O
EBV O
- O
positive O
cases O
of O
Hodgkin O
' O
s O
disease O
, O
the O
EBERs B
, O
EBNA1 B
, O
and O
the O
LMPs B
are O
expressed O
( O
latency O
II O
) O
, O
whereas O
in O
Burkitt O
' O
s O
lymphoma O
( O
BL O
) O
only O
the O
EBERs B
and O
EBNA1 B
have O
been O
detected O
( O
latency O
I O
) O
. O

In O
EBV O
- O
positive O
cases O
of O
Hodgkin O
' O
s O
disease O
, O
the O
EBERs B
, O
EBNA1 B
, O
and O
the O
LMPs B
are O
expressed O
( O
latency O
II O
) O
, O
whereas O
in O
Burkitt O
' O
s O
lymphoma O
( O
BL O
) O
only O
the O
EBERs B
and O
EBNA1 B
have O
been O
detected O
( O
latency O
I O
) O
. O

In O
EBV O
- O
positive O
cases O
of O
Hodgkin O
' O
s O
disease O
, O
the O
EBERs B
, O
EBNA1 B
, O
and O
the O
LMPs B
are O
expressed O
( O
latency O
II O
) O
, O
whereas O
in O
Burkitt O
' O
s O
lymphoma O
( O
BL O
) O
only O
the O
EBERs B
and O
EBNA1 B
have O
been O
detected O
( O
latency O
I O
) O
. O

In O
EBV O
- O
positive O
cases O
of O
Hodgkin O
' O
s O
disease O
, O
the O
EBERs B
, O
EBNA1 B
, O
and O
the O
LMPs B
are O
expressed O
( O
latency O
II O
) O
, O
whereas O
in O
Burkitt O
' O
s O
lymphoma O
( O
BL O
) O
only O
the O
EBERs B
and O
EBNA1 B
have O
been O
detected O
( O
latency O
I O
) O
. O

In O
EBV O
- O
positive O
cases O
of O
Hodgkin O
' O
s O
disease O
, O
the O
EBERs B
, O
EBNA1 B
, O
and O
the O
LMPs B
are O
expressed O
( O
latency O
II O
) O
, O
whereas O
in O
Burkitt O
' O
s O
lymphoma O
( O
BL O
) O
only O
the O
EBERs B
and O
EBNA1 B
have O
been O
detected O
( O
latency O
I O
) O
. O

Expression O
of O
LMP1 B
was O
seen O
in O
variable O
proportions O
of O
tumor O
cells O
in O
two O
cases O
and O
EBNA2 B
was O
detected O
in O
some O
tumor O
cells O
in O
three O
other O
cases O
. O

Expression O
of O
LMP1 B
was O
seen O
in O
variable O
proportions O
of O
tumor O
cells O
in O
two O
cases O
and O
EBNA2 B
was O
detected O
in O
some O
tumor O
cells O
in O
three O
other O
cases O
. O

Whereas O
PHA B
- O
induced O
proliferation O
of O
PBMCs O
derived O
from O
patients O
with O
breast O
cancer O
preoperatively O
was O
significantly O
decreased O
when O
compared O
with O
data O
obtained O
in O
healthy O
control O
individuals O
( O
P O
< O
0 O
. O
001 O
) O
, O
the O
degree O
of O
the O
defect O
in O
PHA B
- O
induced O
proliferation O
of O
PBMCs O
depended O
upon O
the O
tumour O
burden O
as O
manifested O
by O
tumour O
size O
and O
axillary O
lymph O
node O
involvement O
( O
P O
< O
0 O
. O
003 O
in O
each O
case O
) O
. O

Whereas O
PHA B
- O
induced O
proliferation O
of O
PBMCs O
derived O
from O
patients O
with O
breast O
cancer O
preoperatively O
was O
significantly O
decreased O
when O
compared O
with O
data O
obtained O
in O
healthy O
control O
individuals O
( O
P O
< O
0 O
. O
001 O
) O
, O
the O
degree O
of O
the O
defect O
in O
PHA B
- O
induced O
proliferation O
of O
PBMCs O
depended O
upon O
the O
tumour O
burden O
as O
manifested O
by O
tumour O
size O
and O
axillary O
lymph O
node O
involvement O
( O
P O
< O
0 O
. O
003 O
in O
each O
case O
) O
. O

PHA B
- O
induced O
proliferation O
of O
PBMCs O
dropped O
significantly O
in O
patients O
who O
received O
adjuvant O
chemotherapy O
consisting O
of O
cyclophosphamide O
, O
methotrexate O
and O
fluorouracil O
( O
CMF O
) O
after O
an O
observation O
period O
of O
6 O
months O
( O
P O
< O
0 O
. O
01 O
) O
, O
but O
not O
in O
patients O
under O
adjuvant O
treatment O
with O
tamoxifen O
only O
. O

We O
thus O
conclude O
that O
PHA B
- O
induced O
proliferation O
of O
PBMCs O
derived O
from O
patients O
with O
breast O
cancer O
depends O
upon O
the O
tumour O
load O
and O
is O
a O
good O
clinical O
predictor O
for O
the O
further O
course O
of O
the O
disease O
. O

A O
previously O
unrecognized O
element O
, O
located O
downstream O
of O
the O
start B
site I
of I
transcription I
in O
the O
first O
exon B
of O
the O
DR B
alpha I
gene I
, O
has O
been O
defined O
that O
enhances O
promoter O
activity O
up O
to O
eightfold O
in O
a O
position O
- O
dependent O
manner O
. O

One O
of O
the O
genes O
that O
encodes O
a O
CBF B
alpha I
subunit I
is O
AML1 B
, O
also O
called O
Cbf B
alpha I
2 I
. O

These O
results O
indicated O
that O
at O
least O
in O
certain O
cell O
types O
, O
the O
maximum O
activity O
of O
CBF B
required O
both O
subunits O
. O

We O
also O
examined O
whether O
CBF B
could O
distinguish O
a O
1 O
- O
bp O
difference O
between O
the O
enhancer O
core O
of O
SL3 O
and O
the O
core O
of O
the O
nonleukemogenic O
virus O
, O
Akv O
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Both O
cases O
tested O
also O
showed O
MYH11 B
genomic O
rearrangement O
. O

HIV B
- I
1 I
Tat I
potentiates O
TNF B
- O
induced O
NF B
- I
kappa I
B I
activation O
and O
cytotoxicity O
by O
altering O
the O
cellular O
redox O
state O
. O

In O
HeLa O
cells O
stably O
transfected O
with O
the O
HIV B
- I
1 I
tat I
gene I
( O
HeLa O
- O
tat O
cells O
) O
, O
expression O
of O
the O
Tat B
protein I
enhanced O
both O
TNF B
- O
induced O
activation O
of O
NF B
- I
kappa I
B I
and O
TNF B
- O
mediated O
cytotoxicity O
. O

In O
HeLa O
cells O
stably O
transfected O
with O
the O
HIV B
- I
1 I
tat I
gene I
( O
HeLa O
- O
tat O
cells O
) O
, O
expression O
of O
the O
Tat B
protein I
enhanced O
both O
TNF B
- O
induced O
activation O
of O
NF B
- I
kappa I
B I
and O
TNF B
- O
mediated O
cytotoxicity O
. O

Thus O
, O
Mn B
- I
SOD I
RNA O
protein O
levels O
and O
activity O
were O
markedly O
reduced O
in O
the O
presence O
of O
Tat B
. O

EBNA B
- I
2 I
is O
known O
to O
interact O
with O
the O
cellular B
DNA I
- I
binding I
protein I
J B
kappa I
and O
is O
recruited O
to O
promoters B
containing O
the O
GTGGGAA O
J B
kappa I
recognition I
sequence I
. O

To O
identify O
other O
factors O
which O
interact O
with O
the O
LMP B
- I
1 I
EBNA I
- I
2 I
response I
element I
( O
E2RE B
) O
, O
a O
- B
236 I
/ I
- I
145 I
minimal I
E2RE I
was O
used O
as O
a O
probe O
in O
an O
electrophoretic O
mobility O
shift O
assay O
. O

LBF4 B
is O
B O
- O
and O
T O
- O
cell O
specific O
and O
recognizes O
the O
PU B
. I
1 I
GGAA I
core I
sequence I
as O
shown O
by O
methylation O
interference O
. O

Abnormal O
fast O
feedback O
and O
negative O
feedback O
of O
the O
hypothalamic O
- O
pituitary O
- O
adrenal O
axis O
implicates O
a O
dampened O
limbic B
- I
hippocampal I
glucocorticoid I
type I
II I
receptor I
( O
GCII B
) O
. O

The O
role O
of O
NFATp B
in O
cyclosporin B
A I
- I
sensitive I
tumor I
necrosis I
factor I
- I
alpha I
gene I
transcription O
. O

Thus O
, O
although O
the O
kappa B
3 I
element I
has O
little O
sequence O
similarity O
to O
other O
NFATp B
- I
binding I
sites I
, O
it O
appears O
to O
function O
as O
a O
cyclosporin B
- I
sensitive I
promoter I
element I
in O
T O
cells O
by O
virtue O
of O
its O
ability O
to O
bind O
NFATp B
. O

By O
contrast O
, O
three O
lymphoblastoid O
cell O
lines O
( O
immortalized O
in O
vitro O
with O
Epstein O
- O
Barr O
virus O
) O
were O
weakly O
positive O
and O
MNDA B
was O
up O
- O
regulated O
by O
interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
treatment O
. O

Changes O
in O
MNDA B
expression O
occurred O
slowly O
( O
hours O
to O
days O
) O
, O
suggesting O
that O
MNDA B
could O
mediate O
changes O
realized O
over O
a O
long O
period O
. O

Changes O
in O
MNDA B
expression O
occurred O
slowly O
( O
hours O
to O
days O
) O
, O
suggesting O
that O
MNDA B
could O
mediate O
changes O
realized O
over O
a O
long O
period O
. O

Enhanced O
Ig B
synthesis O
is O
a O
result O
of O
coordinated O
transcriptional O
activation O
of O
Ig B
genes I
without O
promoter O
or O
isotype O
specificity O
, O
and O
differential O
accumulation O
of O
the O
mRNA B
encoding O
the O
secreted O
form O
of O
Ig B
heavy I
chain I
. O

Enhanced O
Ig B
synthesis O
is O
a O
result O
of O
coordinated O
transcriptional O
activation O
of O
Ig B
genes I
without O
promoter O
or O
isotype O
specificity O
, O
and O
differential O
accumulation O
of O
the O
mRNA B
encoding O
the O
secreted O
form O
of O
Ig B
heavy I
chain I
. O

We O
have O
previously O
shown O
that O
treatment O
of O
Jurkat O
T O
cells O
with O
phytohemaglutinin B
( O
PHA B
) O
and O
the O
phorbol O
ester O
, O
PMA O
, O
activated O
transcription O
initiation O
from O
the O
IL B
- I
3 I
gene I
. O

We O
have O
previously O
shown O
that O
treatment O
of O
Jurkat O
T O
cells O
with O
phytohemaglutinin B
( O
PHA B
) O
and O
the O
phorbol O
ester O
, O
PMA O
, O
activated O
transcription O
initiation O
from O
the O
IL B
- I
3 I
gene I
. O

TNF O
- O
alpha O
, O
IL O
- O
1 O
beta O
and O
phorbol O
myristate O
acetate O
( O
PMA O
) O
treatment O
increased O
AP B
- I
1 I
and O
NF O
kappa O
B O
DNA O
binding O
by O
up O
to O
200 O
% O
but O
decreased O
CREB B
binding O
( O
38 O
% O
) O
over O
a O
60 O
- O
min O
time O
course O
. O

In O
contrast O
, O
the O
addition O
of O
GM B
- I
CSF I
to O
the O
M O
- O
TAT O
/ O
EPO O
cell O
culture O
decreased O
the O
amount O
of O
hemoglobin O
, O
even O
in O
the O
presence O
of O
EPO B
, O
indicating O
that O
the O
EPO B
signal O
for O
erythroid O
differentiation O
is O
suppressed O
by O
GM B
- I
CSF I
. O

In O
contrast O
, O
the O
addition O
of O
GM B
- I
CSF I
to O
the O
M O
- O
TAT O
/ O
EPO O
cell O
culture O
decreased O
the O
amount O
of O
hemoglobin O
, O
even O
in O
the O
presence O
of O
EPO B
, O
indicating O
that O
the O
EPO B
signal O
for O
erythroid O
differentiation O
is O
suppressed O
by O
GM B
- I
CSF I
. O

Transcriptional O
activity O
of O
p105 B
is O
also O
increased O
in O
infected O
cells O
and O
is O
also O
mediated O
by O
NF B
- I
kappa I
B I
through O
a O
specific O
kappa B
B I
motif I
. O

HIV O
type O
1 O
protease B
activation O
of O
NF B
- I
kappa I
B I
within O
T O
lymphoid O
cells O
. O

Insertion O
of O
this O
chimeric B
promoter I
( O
ISG15 B
LTR I
) O
upstream O
of O
the O
human B
IFNA2 I
gene I
directed O
high O
levels O
of O
IFN B
synthesis O
in O
Tat O
- O
expressing O
cells O
, O
while O
this O
promoter O
was O
not O
responsive O
to O
tumor B
necrosis I
factor I
alpha I
- O
mediated O
activation O
. O

Selected O
transfected O
clones O
produced O
low O
levels O
of O
IFN B
A I
( O
IFNA B
) O
constitutively O
, O
and O
their O
abilities O
to O
express O
interleukin B
- I
2 I
and O
interleukin B
- I
2 I
receptor I
upon O
stimulation O
with O
phytohemagglutinin B
and O
phorbol O
myristate O
acetate O
were O
retained O
. O

Selected O
transfected O
clones O
produced O
low O
levels O
of O
IFN B
A I
( O
IFNA B
) O
constitutively O
, O
and O
their O
abilities O
to O
express O
interleukin B
- I
2 I
and O
interleukin B
- I
2 I
receptor I
upon O
stimulation O
with O
phytohemagglutinin B
and O
phorbol O
myristate O
acetate O
were O
retained O
. O

Flow O
cytometric O
analysis O
also O
showed O
that O
at O
72 O
h O
of O
virus O
exposure O
fewer O
T O
cells O
from O
the O
elderly O
produced O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
, O
suggesting O
a O
link O
between O
the O
magnitude O
of O
the O
Fos B
and O
Jun B
and O
IFN B
- I
gamma I
responses O
. O

Flow O
cytometric O
analysis O
also O
showed O
that O
at O
72 O
h O
of O
virus O
exposure O
fewer O
T O
cells O
from O
the O
elderly O
produced O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
, O
suggesting O
a O
link O
between O
the O
magnitude O
of O
the O
Fos B
and O
Jun B
and O
IFN B
- I
gamma I
responses O
. O

The O
second O
abnormality O
in O
kappa O
B O
- O
binding O
activity O
in O
T O
cells O
from O
these O
patients O
is O
that O
RelA B
, O
a O
member O
of O
the O
Rel B
homology I
family I
which O
is O
part O
of O
the O
normal O
NF B
- I
kappa I
B I
complex I
, O
was O
not O
induced O
in O
the O
nucleus O
following O
activation O
. O

In O
extracts O
from O
nonstimulated O
cells O
the O
receptor O
is O
recovered O
in O
an O
inducible O
cytoplasmic O
form O
associated O
with O
the O
90 B
- I
kDa I
heat I
shock I
protein I
( O
hsp90 B
) O
, O
a O
molecular B
chaperone I
. O

In O
line O
with O
these O
observations O
, O
reticulocyte O
lysate O
but O
not O
wheat O
germ O
lysate O
promoted O
the O
association O
of O
de O
novo O
synthesized O
dioxin B
receptor I
with O
hsp90 B
. O

Protein B
kinase I
C I
is O
not O
a O
downstream O
effector O
of O
p21ras B
in O
activated O
T O
cells O
. O

Data O
is O
presented O
, O
using O
the O
potent O
and O
selective O
PKC B
inhibitor O
Ro O
31 O
- O
8425 O
and O
transient O
expression O
of O
a O
constitutively O
active O
ras O
mutant O
, O
which O
clearly O
shows O
that O
PKC B
is O
not O
downstream O
of O
p21ras B
in O
the O
induction O
of O
NF B
- I
AT I
and O
AP B
- I
1 I
transcriptional O
activity O
and O
in O
the O
expression O
of O
IL B
- I
2 I
in O
human O
Jurkat O
T O
cells O
. O

Data O
is O
presented O
, O
using O
the O
potent O
and O
selective O
PKC B
inhibitor O
Ro O
31 O
- O
8425 O
and O
transient O
expression O
of O
a O
constitutively O
active O
ras O
mutant O
, O
which O
clearly O
shows O
that O
PKC B
is O
not O
downstream O
of O
p21ras B
in O
the O
induction O
of O
NF B
- I
AT I
and O
AP B
- I
1 I
transcriptional O
activity O
and O
in O
the O
expression O
of O
IL B
- I
2 I
in O
human O
Jurkat O
T O
cells O
. O

Data O
is O
presented O
, O
using O
the O
potent O
and O
selective O
PKC B
inhibitor O
Ro O
31 O
- O
8425 O
and O
transient O
expression O
of O
a O
constitutively O
active O
ras O
mutant O
, O
which O
clearly O
shows O
that O
PKC B
is O
not O
downstream O
of O
p21ras B
in O
the O
induction O
of O
NF B
- I
AT I
and O
AP B
- I
1 I
transcriptional O
activity O
and O
in O
the O
expression O
of O
IL B
- I
2 I
in O
human O
Jurkat O
T O
cells O
. O

The O
signaling O
pathways O
involving O
PKC B
activation O
, O
calcium O
mobilization O
and O
ras B
activation O
combine O
to O
provide O
the O
necessary O
components O
for O
production O
of O
IL B
- I
2 I
during O
T O
cell O
activation O
. O

The O
signaling O
pathways O
involving O
PKC B
activation O
, O
calcium O
mobilization O
and O
ras B
activation O
combine O
to O
provide O
the O
necessary O
components O
for O
production O
of O
IL B
- I
2 I
during O
T O
cell O
activation O
. O

Here O
, O
we O
report O
that O
stimulation O
through O
the O
IL B
- I
2R I
induced O
tyrosine O
phosphorylation O
and O
subsequent O
nuclear O
translocation O
of O
stat3 B
, O
a O
newly O
identified O
member O
of O
the O
signal B
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
family I
of O
proteins O
. O

Apart O
from O
stat3 B
, O
another O
cytoplasmic B
protein I
was O
tyrosine O
phosphorylated O
and O
subsequently O
translocated O
to O
the O
nucleus O
in O
response O
to O
IL B
- I
2 I
. O

This O
protein O
had O
an O
apparent O
molecular O
mass O
of O
84 O
kDa O
and O
was O
not O
recognized O
by O
stat3 B
or O
stat1 B
mAb I
or O
antisera O
. O

Taken O
together O
, O
we O
report O
that O
IL B
- I
2 I
induces O
tyrosine O
phosphorylation O
and O
subsequent O
nuclear O
translocation O
of O
stat3 B
and O
an O
as O
yet O
undefined O
84 B
- I
kDa I
protein I
in O
antigen O
- O
specific O
human O
T O
cell O
lines O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
Tax B
activation O
of O
NF B
- I
kappa I
B I
/ I
Rel I
involves O
phosphorylation O
and O
degradation O
of O
I B
kappa I
B I
alpha I
and O
RelA B
( O
p65 B
) O
- O
mediated O
induction O
of O
the O
c B
- I
rel I
gene I
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
Tax B
activation O
of O
NF B
- I
kappa I
B I
/ I
Rel I
involves O
phosphorylation O
and O
degradation O
of O
I B
kappa I
B I
alpha I
and O
RelA B
( O
p65 B
) O
- O
mediated O
induction O
of O
the O
c B
- I
rel I
gene I
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
Tax B
activation O
of O
NF B
- I
kappa I
B I
/ I
Rel I
involves O
phosphorylation O
and O
degradation O
of O
I B
kappa I
B I
alpha I
and O
RelA B
( O
p65 B
) O
- O
mediated O
induction O
of O
the O
c B
- I
rel I
gene I
. O

Isolation O
of O
differentially O
expressed O
sequence O
tags O
from O
steroid O
- O
responsive O
cells O
using O
mRNA B
differential O
display O
. O

In O
this O
paper O
we O
describe O
results O
using O
mRNA B
differential O
display O
reverse B
transcriptase I
PCR O
( O
DDPCR O
) O
to O
identify O
and O
isolate O
short O
cDNA O
sequence O
tags O
from O
thymocyte O
and O
prostate O
cells O
under O
various O
hormone O
conditions O
. O

GIG10 B
is O
a O
novel O
sequence O
and O
GIG18 B
is O
the O
mouse O
homologue O
of O
a O
human B
expressed I
sequence I
tag I
isolated O
from O
activated O
B O
lymphocytes O
. O

GIG10 B
is O
a O
novel O
sequence O
and O
GIG18 B
is O
the O
mouse O
homologue O
of O
a O
human B
expressed I
sequence I
tag I
isolated O
from O
activated O
B O
lymphocytes O
. O

We O
have O
shown O
that O
, O
within O
the O
thymus O
, O
a O
population O
of O
large O
, O
immature O
cells O
expresses O
CD21 B
. O

This O
function O
was O
a O
result O
of O
the O
interaction O
of O
EBV O
with O
its O
receptor O
, O
CD21 B
, O
but O
was O
caused O
by O
infection O
rather O
than O
surface O
signaling O
, O
because O
neither O
specific B
mAb I
nor O
the O
P3HR O
- O
1 O
strain O
of O
virus O
mimicked O
the O
effect O
of O
B95 O
- O
8 O
. O

A O
second O
transcript O
was O
identified O
as O
encoding O
the O
recently O
characterized O
RAZ B
, O
which O
also O
is O
associated O
with O
replicative O
infection O
. O

A O
factor O
that O
regulates O
the O
class B
II I
major I
histocompatibility I
complex I
gene I
DPA B
is O
a O
member O
of O
a O
subfamily O
of O
zinc B
finger I
proteins I
that O
includes O
a O
Drosophila B
developmental I
control I
protein I
. O

One O
of O
the O
Drosophila B
sequences I
, O
ttk B
, O
is O
a O
developmental B
control I
gene I
, O
while O
a O
second O
does O
not O
contain O
a O
zinc B
finger I
region I
but O
encodes O
a O
structure O
important O
in O
oocyte O
development O
. O

We O
also O
show O
that O
both O
Fos B
and O
Jun B
components O
of O
the O
AP B
- I
1 I
factors O
participate O
in O
the O
OAP40 B
complex I
. O

We O
also O
show O
that O
both O
Fos B
and O
Jun B
components O
of O
the O
AP B
- I
1 I
factors O
participate O
in O
the O
OAP40 B
complex I
. O

OAP B
confers O
to O
Oct B
- I
2 I
responsivity O
to O
both O
TPA O
/ O
Ca2 O
+ O
and O
RA O
, O
since O
specific O
mutations O
of O
the O
AP B
- I
1 I
/ I
OAP I
- I
binding I
site I
significantly O
reduce O
the O
transactivation O
by O
Oct B
- I
2 I
in O
response O
to O
TPA O
and O
Ca2 O
+ O
and O
abolish O
the O
inhibition O
by O
RA O
. O

Therefore O
, O
we O
propose O
that O
the O
TPA O
/ O
calcium O
- O
activated O
AP B
- I
1 I
/ B
OAP I
element O
is O
the O
main O
target O
of O
positive O
or O
negative O
regulatory O
signals O
influencing O
the O
IL B
- I
2 I
octamer I
motif I
, O
through O
synergism O
with O
Oct B
- I
2 I
and O
antagonism O
by O
RAR B
. O

PMA B
- I
but I
not I
TG I
- I
induced I
IL I
- I
2R I
alpha I
is O
inhibited O
by O
the O
PKC B
inhibitor O
H7 O
, O
whereas O
TG B
- I
but I
not I
PMA I
- I
induced I
IL I
- I
2R I
alpha I
was O
inhibited O
by O
cholera O
toxin O
, O
forskolin O
and O
1 O
, O
9 O
- O
dideoxy O
forskolin O
. O

However O
, O
PDTC O
failed O
to O
inhibit O
the O
endonuclease B
activity O
contained O
in O
the O
whole O
cell O
lysates O
. O

It O
is O
surprising O
that O
the O
faster B
- I
migrating I
complex I
was O
composed O
also O
of O
p50 B
and O
p65 B
. O

It O
is O
surprising O
that O
the O
faster B
- I
migrating I
complex I
was O
composed O
also O
of O
p50 B
and O
p65 B
. O

Erythropoietin B
( O
Epo B
) O
, O
granulocyte B
/ I
macrophage I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
interleukin B
3 I
( O
IL B
- I
3 I
) O
promoted O
the O
growth O
of O
NS O
- O
Meg O
cells O
. O

Erythropoietin B
( O
Epo B
) O
, O
granulocyte B
/ I
macrophage I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
interleukin B
3 I
( O
IL B
- I
3 I
) O
promoted O
the O
growth O
of O
NS O
- O
Meg O
cells O
. O

Ten O
- O
day O
exposure O
to O
Epo B
induced O
mature O
erythroblasts O
and O
red O
cells O
. O

These O
benzidine O
- O
positive O
cells O
were O
positive O
for O
hemoglobin B
F O
staining O
. O

The O
T B
cell I
surface I
molecule I
CD28 B
binds O
to O
ligands O
on O
accessory O
cells O
and O
APCs O
, O
playing O
an O
important O
costimulatory O
role O
in O
the O
response O
of O
T O
cells O
to O
Ags B
. O

The O
T B
cell I
surface I
molecule I
CD28 B
binds O
to O
ligands O
on O
accessory O
cells O
and O
APCs O
, O
playing O
an O
important O
costimulatory O
role O
in O
the O
response O
of O
T O
cells O
to O
Ags B
. O

In O
a O
wide O
range O
of O
cell O
types O
, O
the O
basal O
transcriptional O
activity O
of O
the O
LTR B
from O
SIVsmmPBj14 O
was O
found O
to O
be O
2 O
- O
to O
4 O
. O
5 O
- O
fold O
higher O
than O
that O
of O
an O
LTR B
from O
a O
non O
- O
acutely O
pathogenic O
strain O
. O

In O
a O
wide O
range O
of O
cell O
types O
, O
the O
basal O
transcriptional O
activity O
of O
the O
LTR B
from O
SIVsmmPBj14 O
was O
found O
to O
be O
2 O
- O
to O
4 O
. O
5 O
- O
fold O
higher O
than O
that O
of O
an O
LTR B
from O
a O
non O
- O
acutely O
pathogenic O
strain O
. O

Activated O
macrophages O
contribute O
to O
chronic O
inflammation O
by O
the O
secretion O
of O
cytokines B
and O
proteinases B
. O

Activated O
macrophages O
contribute O
to O
chronic O
inflammation O
by O
the O
secretion O
of O
cytokines B
and O
proteinases B
. O

We O
have O
used O
mutants O
of O
these O
kinases B
and O
phosphatases B
( O
gamma B
B I
* I
CaM I
- I
K I
and O
delta B
CaM I
- I
AI I
, O
respectively O
) O
to O
explore O
their O
relative O
role O
in O
cytokine B
gene I
transcription O
and O
their O
interactions O
with O
PKC B
- O
dependent O
signaling O
systems O
. O

We O
have O
used O
mutants O
of O
these O
kinases B
and O
phosphatases B
( O
gamma B
B I
* I
CaM I
- I
K I
and O
delta B
CaM I
- I
AI I
, O
respectively O
) O
to O
explore O
their O
relative O
role O
in O
cytokine B
gene I
transcription O
and O
their O
interactions O
with O
PKC B
- O
dependent O
signaling O
systems O
. O

We O
have O
used O
mutants O
of O
these O
kinases B
and O
phosphatases B
( O
gamma B
B I
* I
CaM I
- I
K I
and O
delta B
CaM I
- I
AI I
, O
respectively O
) O
to O
explore O
their O
relative O
role O
in O
cytokine B
gene I
transcription O
and O
their O
interactions O
with O
PKC B
- O
dependent O
signaling O
systems O
. O

Induction O
of O
TaxI B
in O
a O
human O
T O
- O
cell O
line O
Jurkat O
carrying O
the O
TaxI B
gene I
under O
the O
metallothionein B
promoter I
led O
to O
increases O
in O
mRNA B
and O
surface O
expression O
of O
ICAM B
- I
I I
. O

Induction O
of O
TaxI B
in O
a O
human O
T O
- O
cell O
line O
Jurkat O
carrying O
the O
TaxI B
gene I
under O
the O
metallothionein B
promoter I
led O
to O
increases O
in O
mRNA B
and O
surface O
expression O
of O
ICAM B
- I
I I
. O

Three O
other O
ATL O
cell O
lines O
( O
TL O
- O
OmI O
, O
H582 O
, O
HuT102 O
) O
were O
found O
to O
have O
little O
mRNA B
for O
the O
LFA B
- I
I I
beta I
chain I
( O
CD18 B
) O
. O

Three O
other O
ATL O
cell O
lines O
( O
TL O
- O
OmI O
, O
H582 O
, O
HuT102 O
) O
were O
found O
to O
have O
little O
mRNA B
for O
the O
LFA B
- I
I I
beta I
chain I
( O
CD18 B
) O
. O

T O
. O
annulata O
- O
infected O
leucocytes O
produce O
a O
number O
of O
novel O
metalloproteinase B
activities O
. O

One O
of O
these O
, O
previously O
called O
B1 B
, O
is O
a O
97 B
- I
kDa I
protein I
which O
is O
secreted O
in O
large O
amounts O
and O
has O
been O
purified O
from O
protein O
- O
free O
, O
conditioned O
medium O
. O

In O
addition O
we O
assayed O
the O
level O
of O
mRNA B
encoding O
c B
- I
Fos I
, O
a O
common O
component O
of O
AP B
- I
1 I
and O
observed O
that O
it O
was O
indeed O
up O
- O
regulated O
in O
infected O
cells O
. O

We O
generated O
conditional O
EBV O
mutants O
by O
expressing O
EBNA2 B
as O
chimeric B
fusion I
protein I
with O
the O
hormone O
binding O
domain O
of O
the O
estrogen B
receptor I
on O
the O
genetic O
background O
of O
the O
virus O
. O

Computer O
analysis O
of O
the O
SM B
protein I
sequence O
showed O
a O
C B
terminal I
section I
of O
SM B
to O
be O
related O
to O
genome B
positional I
homologues I
of O
four O
other O
herpesviruses O
and O
revealed O
consensus B
CKII I
sites I
near O
the O
N B
termini I
of O
the O
EBV B
SM I
protein I
, O
the O
herpes B
simplex I
virus I
( I
HSV I
) I
ICP27 I
protein I
and O
the O
herpesvirus B
saimiri I
( I
HVS I
) I
open I
reading I
frame I
57 I
protein I
. O

Mutagenesis O
of O
the O
CKII B
site O
in O
SM B
made O
no O
difference O
to O
the O
transactivation O
in O
this O
transient O
transfection O
assay O
. O

Mutagenesis O
of O
the O
CKII B
site O
in O
SM B
made O
no O
difference O
to O
the O
transactivation O
in O
this O
transient O
transfection O
assay O
. O

The O
serum B
response I
element I
( O
SRE B
) O
in O
the O
c B
- I
fos I
regulatory I
region I
participates O
in O
induction O
of O
transcription O
by O
various O
growth B
factors I
and O
by O
phorbol O
esters O
and O
subsequent O
squelching O
of O
transcription O
. O

Elf B
- I
1 I
physically O
associated O
with O
HMG B
- I
I I
and O
with O
NF B
- I
kappa I
B I
p50 B
and O
c B
- I
Rel I
in O
vitro O
, O
suggesting O
that O
protein O
- O
protein O
interactions O
might O
functionally O
coordinate O
the O
actions O
of O
the O
upstream B
and I
downstream I
positive I
regulatory I
elements I
. O

ALDs O
induced O
QR B
activity O
in O
the O
M4 O
cells O
in O
the O
same O
range O
of O
concentrations O
that O
protected O
the O
cells O
against O
BQ O
toxicity O
. O

These O
findings O
suggest O
a O
molecular O
mechanism O
of O
positive O
regulation O
of O
PAFR B
gene O
expression O
by O
PAF B
through O
NF B
- I
kappa I
B I
, O
possibly O
by O
a O
phosphorylation O
reaction O
involving O
protein B
kinase I
C I
by O
PAF B
. O

These O
findings O
suggest O
a O
molecular O
mechanism O
of O
positive O
regulation O
of O
PAFR B
gene O
expression O
by O
PAF B
through O
NF B
- I
kappa I
B I
, O
possibly O
by O
a O
phosphorylation O
reaction O
involving O
protein B
kinase I
C I
by O
PAF B
. O

These O
findings O
suggest O
a O
molecular O
mechanism O
of O
positive O
regulation O
of O
PAFR B
gene O
expression O
by O
PAF B
through O
NF B
- I
kappa I
B I
, O
possibly O
by O
a O
phosphorylation O
reaction O
involving O
protein B
kinase I
C I
by O
PAF B
. O

One O
gene O
, O
two O
transcripts B
: O
isolation O
of O
an O
alternative O
transcript O
encoding O
for O
the O
autoantigen B
La I
/ I
SS I
- I
B I
from O
a O
cDNA B
library I
of O
a O
patient O
with O
primary O
Sjogrens O
' O
syndrome O
. O

As O
XIST B
transcription O
is O
well O
correlated O
with O
inactivation O
of O
the O
X B
chromosome I
in O
female O
somatic O
cells O
and O
spermatogonia O
, O
nonexpression O
of O
the O
locus O
even O
when O
it O
is O
present O
suggests O
that O
these O
chromosomes B
are O
transcriptionally O
active O
. O

As O
XIST B
transcription O
is O
well O
correlated O
with O
inactivation O
of O
the O
X B
chromosome I
in O
female O
somatic O
cells O
and O
spermatogonia O
, O
nonexpression O
of O
the O
locus O
even O
when O
it O
is O
present O
suggests O
that O
these O
chromosomes B
are O
transcriptionally O
active O
. O

We O
examined O
the O
transcriptional O
activity O
of O
ring O
X B
chromosomes I
lacking O
XIST B
expression O
( O
XISTE O
- O
) O
, O
from O
three O
females O
with O
severe O
phenotypes O
. O

The O
increase O
in O
IL B
- I
2 I
gene O
expression O
triggered O
by O
CD28 B
involves O
a O
kappa B
B I
- I
like I
sequence I
in O
the O
5 B
' I
- I
regulatory I
region I
of O
the O
IL B
- I
2 I
promoter I
, O
called O
CD28 B
- I
responsive I
element I
. O

Here O
we O
report O
that O
CD28 B
engagement O
, O
however O
, O
exerts O
opposite O
effects O
on O
the O
transcription B
factor I
AP I
- I
1 I
. O

Antiandrogens O
result O
in O
protection O
of O
both O
the O
hinge B
region I
and O
C B
- I
terminus I
of O
the O
androgen B
receptor I
agonist O
proteolytic O
attack O
, O
whereas O
other O
studies O
showed O
that O
antiestrogens O
and O
antiprogestagens O
expose O
the O
C B
- I
terminal I
end I
of O
the O
ligand B
binding I
domain I
of O
their O
respective O
receptors O
to O
protease B
. O

However O
, O
reagents O
such O
as O
nerve B
growth I
factor I
( O
NGF B
) O
and O
the O
phorbol O
ester O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
, O
which O
induce O
phenotypical O
differentiation O
of O
the O
SH O
- O
SY5Y O
neuroblastoma O
cell O
line O
, O
activated O
NF B
- I
kappa I
B I
, O
but O
only O
in O
that O
particular O
cell O
line O
. O

To O
identify O
ets B
- I
related I
transcriptional I
regulators I
expressed O
in O
pre O
- O
B O
lymphocytes O
that O
may O
interact O
with O
either O
the O
pi B
or O
the O
microB B
site I
, O
we O
have O
used O
a O
PCR O
approach O
with O
degenerate O
oligonucleotides O
encoding O
conserved O
sequences O
in O
all O
members O
of O
the O
ets B
family I
. O

We O
have O
cloned O
the O
gene O
for O
a O
new O
ets B
- I
related I
transcription I
factor I
, O
ERP B
( O
ets B
- I
related I
protein I
) O
, O
from O
the O
murine O
pre O
- O
B O
cell O
line O
BASC O
6C2 O
and O
from O
mouse O
lung O
tissue O
. O

Full O
- O
length O
ERP B
expresses O
only O
negligible O
DNA O
- O
binding O
activity O
by O
itself O
. O

Two O
cis B
- I
acting I
elements I
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
and O
CLE0 B
, O
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
gene I
are O
required O
for O
maximal O
induction O
in O
Jurkat O
T O
cells O
by O
costimulation O
with O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
Ca2 O
+ O
ionophore O
( O
A23187 O
) O
. O

Our O
experiments O
also O
show O
that O
activated O
PR B
does O
not O
confer O
direct O
transcriptional O
control O
on O
the O
dPRL B
promoter I
. O

One O
of O
the O
nuclear B
factors I
( O
NFs B
) O
that O
regulates O
the O
response O
of O
the O
IL B
- I
5 I
promoter I
to O
cAMP O
and O
PMA O
has O
properties O
similar O
to O
NF B
for O
activated O
t O
cell O
. O

One O
of O
the O
nuclear B
factors I
( O
NFs B
) O
that O
regulates O
the O
response O
of O
the O
IL B
- I
5 I
promoter I
to O
cAMP O
and O
PMA O
has O
properties O
similar O
to O
NF B
for O
activated O
t O
cell O
. O

JNK B
is O
involved O
in O
signal O
integration O
during O
costimulation O
of O
T O
lymphocytes O
. O

T O
lymphocyte O
activation O
and O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
production O
require O
at O
least O
two O
signals O
, O
generated O
by O
phorbol O
ester O
( O
TPA O
) O
and O
Ca2 O
+ O
ionophore O
or O
costimulation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
and O
the O
CD28 B
auxiliary I
receptor I
. O

Full O
activation O
of O
the O
MAP B
kinases I
that O
phosphorylate O
the O
Jun B
activation I
domain I
, O
JNK1 B
and O
JNK2 B
, O
required O
costimulation O
of O
T O
cells O
with O
either O
TPA O
and O
Ca2 O
+ O
ionophore O
or O
antibodies O
to O
TCR B
and O
CD28 B
. O

Full O
activation O
of O
the O
MAP B
kinases I
that O
phosphorylate O
the O
Jun B
activation I
domain I
, O
JNK1 B
and O
JNK2 B
, O
required O
costimulation O
of O
T O
cells O
with O
either O
TPA O
and O
Ca2 O
+ O
ionophore O
or O
antibodies O
to O
TCR B
and O
CD28 B
. O

Full O
activation O
of O
the O
MAP B
kinases I
that O
phosphorylate O
the O
Jun B
activation I
domain I
, O
JNK1 B
and O
JNK2 B
, O
required O
costimulation O
of O
T O
cells O
with O
either O
TPA O
and O
Ca2 O
+ O
ionophore O
or O
antibodies O
to O
TCR B
and O
CD28 B
. O

Full O
activation O
of O
the O
MAP B
kinases I
that O
phosphorylate O
the O
Jun B
activation I
domain I
, O
JNK1 B
and O
JNK2 B
, O
required O
costimulation O
of O
T O
cells O
with O
either O
TPA O
and O
Ca2 O
+ O
ionophore O
or O
antibodies O
to O
TCR B
and O
CD28 B
. O

Again O
, O
in O
vitro O
supershift O
studies O
indicate O
that O
the O
presence O
of O
p50 B
, O
p52 B
, O
p65 B
, O
and O
cRel B
correlates O
with O
positive O
function O
whereas O
the O
presence O
of O
only O
p50 B
and O
p52 B
correlates O
with O
negative O
function O
. O

Again O
, O
in O
vitro O
supershift O
studies O
indicate O
that O
the O
presence O
of O
p50 B
, O
p52 B
, O
p65 B
, O
and O
cRel B
correlates O
with O
positive O
function O
whereas O
the O
presence O
of O
only O
p50 B
and O
p52 B
correlates O
with O
negative O
function O
. O

Again O
, O
in O
vitro O
supershift O
studies O
indicate O
that O
the O
presence O
of O
p50 B
, O
p52 B
, O
p65 B
, O
and O
cRel B
correlates O
with O
positive O
function O
whereas O
the O
presence O
of O
only O
p50 B
and O
p52 B
correlates O
with O
negative O
function O
. O

Again O
, O
in O
vitro O
supershift O
studies O
indicate O
that O
the O
presence O
of O
p50 B
, O
p52 B
, O
p65 B
, O
and O
cRel B
correlates O
with O
positive O
function O
whereas O
the O
presence O
of O
only O
p50 B
and O
p52 B
correlates O
with O
negative O
function O
. O

Again O
, O
in O
vitro O
supershift O
studies O
indicate O
that O
the O
presence O
of O
p50 B
, O
p52 B
, O
p65 B
, O
and O
cRel B
correlates O
with O
positive O
function O
whereas O
the O
presence O
of O
only O
p50 B
and O
p52 B
correlates O
with O
negative O
function O
. O

Again O
, O
in O
vitro O
supershift O
studies O
indicate O
that O
the O
presence O
of O
p50 B
, O
p52 B
, O
p65 B
, O
and O
cRel B
correlates O
with O
positive O
function O
whereas O
the O
presence O
of O
only O
p50 B
and O
p52 B
correlates O
with O
negative O
function O
. O

OBJECTIVE O
: O
To O
determine O
whether O
activation O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
replication O
in O
tumour O
cells O
of O
AIDS O
- O
related O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
ARNHL O
) O
is O
correlated O
with O
CD4 B
+ I
cell O
counts O
and O
influences O
antibody O
response O
to O
EBV O
[ O
anti B
- I
Z I
Epstein I
- I
Barr I
replicative I
activator I
( O
ZEBRA B
) O
, O
anti B
- I
early I
antigen I
( O
EA B
) O
, O
anti B
- I
viral I
capsid I
antigen I
( O
VCA B
) O
] O
. O

OBJECTIVE O
: O
To O
determine O
whether O
activation O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
replication O
in O
tumour O
cells O
of O
AIDS O
- O
related O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
ARNHL O
) O
is O
correlated O
with O
CD4 B
+ I
cell O
counts O
and O
influences O
antibody O
response O
to O
EBV O
[ O
anti B
- I
Z I
Epstein I
- I
Barr I
replicative I
activator I
( O
ZEBRA B
) O
, O
anti B
- I
early I
antigen I
( O
EA B
) O
, O
anti B
- I
viral I
capsid I
antigen I
( O
VCA B
) O
] O
. O

OBJECTIVE O
: O
To O
determine O
whether O
activation O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
replication O
in O
tumour O
cells O
of O
AIDS O
- O
related O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
ARNHL O
) O
is O
correlated O
with O
CD4 B
+ I
cell O
counts O
and O
influences O
antibody O
response O
to O
EBV O
[ O
anti B
- I
Z I
Epstein I
- I
Barr I
replicative I
activator I
( O
ZEBRA B
) O
, O
anti B
- I
early I
antigen I
( O
EA B
) O
, O
anti B
- I
viral I
capsid I
antigen I
( O
VCA B
) O
] O
. O

DESIGN O
: O
Retrospective O
study O
based O
on O
immunohistochemistry O
and O
in O
situ O
hybridization O
to O
detect O
EBV O
replicative O
gene O
products O
in O
tissue O
samples O
from O
patients O
affected O
by O
ARNHL O
and O
correlation O
with O
CD4 B
+ I
cell O
counts O
and O
results O
of O
EBV O
serology O
( O
including O
anti O
- O
ZEBRA B
activity O
) O
in O
sera O
from O
the O
same O
patients O
. O

In O
cells O
stimulated O
with O
anti B
- I
CD3 I
mAb I
, O
PGE2 B
inhibited O
cell O
proliferation O
and O
the O
production O
of O
all O
the O
cytokines B
examined O
. O

In O
cells O
stimulated O
with O
anti B
- I
CD3 I
mAb I
, O
PGE2 B
inhibited O
cell O
proliferation O
and O
the O
production O
of O
all O
the O
cytokines B
examined O
. O

Addition O
of O
rIL B
- I
2 I
fully O
restored O
the O
proliferative O
response O
and O
partially O
restored O
the O
production O
of O
IL B
- I
4 I
and O
IL B
- I
5 I
, O
but O
not O
that O
of O
other O
cytokines B
. O

It O
seems O
therefore O
that O
PGE2 B
, O
by O
elevating O
cAMP O
levels O
, O
interferes O
with O
the O
activation O
pathway O
for O
NF B
- I
kappa I
B I
but O
not O
for O
NF B
- I
AT I
, O
AP B
- I
1 I
or O
CLE0 B
binding I
protein I
. O

Moreover O
, O
rapamycin O
, O
an O
inhibitor O
of O
pp70S6K B
activation O
, O
had O
no O
effect O
on O
induction O
of O
EGR B
- I
1 I
expression O
. O

In O
contrast O
, O
analysis O
of O
pp90rsk B
activity O
by O
phosphorylation O
of O
a O
peptide O
derived O
from O
S6 B
protein I
demonstrated O
stimulation O
of O
this O
kinase B
in O
TPA O
- O
treated O
U O
- O
937 O
, O
and O
not O
TUR O
, O
cells O
. O

In O
contrast O
, O
analysis O
of O
pp90rsk B
activity O
by O
phosphorylation O
of O
a O
peptide O
derived O
from O
S6 B
protein I
demonstrated O
stimulation O
of O
this O
kinase B
in O
TPA O
- O
treated O
U O
- O
937 O
, O
and O
not O
TUR O
, O
cells O
. O

We O
have O
identified O
a O
` B
` I
two I
- I
handed I
' I
' I
zinc I
finger I
protein I
, O
denoted O
ZEB B
, O
the O
DNA O
- O
binding O
specificity O
of O
which O
mimics O
that O
of O
the O
cellular B
repressor I
. O

By O
employing O
a O
derivative O
E B
box I
that O
binds O
ZEB B
but O
not O
E2A B
, O
we O
have O
shown O
that O
the O
repressor B
is O
active O
in O
B O
cells O
and O
the O
IgH B
enhancer I
is O
silenced O
in O
the O
absence O
of O
binding O
competition O
by O
bHLH B
proteins I
. O

By O
employing O
a O
derivative O
E B
box I
that O
binds O
ZEB B
but O
not O
E2A B
, O
we O
have O
shown O
that O
the O
repressor B
is O
active O
in O
B O
cells O
and O
the O
IgH B
enhancer I
is O
silenced O
in O
the O
absence O
of O
binding O
competition O
by O
bHLH B
proteins I
. O

By O
employing O
a O
derivative O
E B
box I
that O
binds O
ZEB B
but O
not O
E2A B
, O
we O
have O
shown O
that O
the O
repressor B
is O
active O
in O
B O
cells O
and O
the O
IgH B
enhancer I
is O
silenced O
in O
the O
absence O
of O
binding O
competition O
by O
bHLH B
proteins I
. O

In O
order O
to O
elucidate O
the O
role O
of O
c B
- I
myb I
gene I
in O
erythroid O
differentiation O
of O
K562 O
cell O
induced O
by O
hemin B
( O
Hm B
) O
and O
erythropoietin B
( O
Epo B
) O
, O
we O
constructed O
recombinant B
plasmid I
that O
could O
produce O
antisense B
myb I
RNA I
after O
induction O
with O
dexamethasone O
. O

In O
order O
to O
elucidate O
the O
role O
of O
c B
- I
myb I
gene I
in O
erythroid O
differentiation O
of O
K562 O
cell O
induced O
by O
hemin B
( O
Hm B
) O
and O
erythropoietin B
( O
Epo B
) O
, O
we O
constructed O
recombinant B
plasmid I
that O
could O
produce O
antisense B
myb I
RNA I
after O
induction O
with O
dexamethasone O
. O

In O
order O
to O
elucidate O
the O
role O
of O
c B
- I
myb I
gene I
in O
erythroid O
differentiation O
of O
K562 O
cell O
induced O
by O
hemin B
( O
Hm B
) O
and O
erythropoietin B
( O
Epo B
) O
, O
we O
constructed O
recombinant B
plasmid I
that O
could O
produce O
antisense B
myb I
RNA I
after O
induction O
with O
dexamethasone O
. O

In O
order O
to O
elucidate O
the O
role O
of O
c B
- I
myb I
gene I
in O
erythroid O
differentiation O
of O
K562 O
cell O
induced O
by O
hemin B
( O
Hm B
) O
and O
erythropoietin B
( O
Epo B
) O
, O
we O
constructed O
recombinant B
plasmid I
that O
could O
produce O
antisense B
myb I
RNA I
after O
induction O
with O
dexamethasone O
. O

During O
treatment O
with O
Hm B
, O
K562 O
cells O
constitutively O
expressed O
c B
- I
myb I
mRNA I
, O
and O
50 O
% O
of O
them O
began O
to O
synthesize O
hemoglobin B
( O
Hb B
) O
. O

During O
treatment O
with O
Hm B
, O
K562 O
cells O
constitutively O
expressed O
c B
- I
myb I
mRNA I
, O
and O
50 O
% O
of O
them O
began O
to O
synthesize O
hemoglobin B
( O
Hb B
) O
. O

During O
treatment O
with O
Hm B
, O
K562 O
cells O
constitutively O
expressed O
c B
- I
myb I
mRNA I
, O
and O
50 O
% O
of O
them O
began O
to O
synthesize O
hemoglobin B
( O
Hb B
) O
. O

Both O
groups O
showed O
substantial O
decreases O
in O
mineralocorticoid O
( O
MR O
) O
and O
glucocorticoid O
receptor O
( O
GR O
) O
levels O
in O
the O
hippocampus O
, O
a O
limbic O
brain O
structure O
critical O
for O
HPA O
axis O
regulation O
, O
whereas O
GR B
concentrations O
in O
the O
hypothalamus O
were O
unchanged O
and O
in O
anterior O
pituitary O
were O
slightly O
increased O
. O

NM23 B
was O
identified O
in O
a O
system O
of O
murine O
melanoma O
cell O
lines O
, O
in O
which O
an O
inverse O
relationship O
was O
found O
between O
NM23 B
expression O
and O
metastatic O
ability O
. O

NM23 B
was O
identified O
in O
a O
system O
of O
murine O
melanoma O
cell O
lines O
, O
in O
which O
an O
inverse O
relationship O
was O
found O
between O
NM23 B
expression O
and O
metastatic O
ability O
. O

Human O
T O
- O
cell O
clones O
reactive O
with O
gC B
and O
VP16 B
are O
reported O
here O
for O
the O
first O
time O
. O

Human O
T O
- O
cell O
clones O
reactive O
with O
gC B
and O
VP16 B
are O
reported O
here O
for O
the O
first O
time O
. O

In O
this O
regard O
, O
the O
cytokine B
interleukin B
6 I
( O
IL B
- I
6 I
) O
may O
play O
a O
role O
in O
the O
clinical O
manifestations O
and O
pathological O
events O
of O
tuberculosis O
infection O
. O

LAM B
and O
LPS O
were O
potent O
inducers O
of O
IL B
- I
6 I
gene I
expression O
in O
peripheral O
blood O
monocytes O
. O

We O
conclude O
that O
the O
NF B
- I
IL6 I
and I
NF I
- I
kappa I
B I
sites I
mediate O
IL B
- I
6 I
induction O
in O
response O
to O
both O
LPS O
and O
LAM B
, O
acting O
as O
bacterial B
or I
mycobacterial I
response I
elements I
. O

Using O
FACS O
, O
Northern O
blotting O
, O
and O
nuclear O
run O
- O
on O
analyses O
, O
we O
demonstrate O
that O
the O
up O
- O
regulation O
of O
CD14 B
expression O
during O
monocytic O
cell O
maturation O
is O
regulated O
mainly O
at O
the O
level O
of O
gene O
transcription O
, O
and O
that O
new O
protein O
synthesis O
is O
required O
for O
CD14 B
induction O
. O

Using O
FACS O
, O
Northern O
blotting O
, O
and O
nuclear O
run O
- O
on O
analyses O
, O
we O
demonstrate O
that O
the O
up O
- O
regulation O
of O
CD14 B
expression O
during O
monocytic O
cell O
maturation O
is O
regulated O
mainly O
at O
the O
level O
of O
gene O
transcription O
, O
and O
that O
new O
protein O
synthesis O
is O
required O
for O
CD14 B
induction O
. O

To O
define O
the O
mechanism O
of O
action O
of O
the O
Nef B
protein O
, O
the O
signal O
transduction O
pathways O
which O
may O
be O
affected O
in O
T O
cells O
by O
constitutive O
expression O
of O
the O
nef O
gene O
were O
examined O
. O

This O
resulted O
in O
only O
a O
partial O
inhibition O
of O
TNF B
- O
or O
PMA O
- O
induced O
HIV O
replication O
in O
U1 O
cells O
, O
and O
no O
detectable O
effect O
on O
HIV O
replication O
in O
chronically O
infected O
U937 O
cells O
. O

Furthermore O
, O
we O
found O
that O
20 O
% O
to O
25 O
% O
of O
both O
the O
adhesion B
protein I
Mac I
- I
1 I
and O
the O
NADPH B
- I
oxidase I
component I
cytochrome I
b558 B
is O
localized O
in O
gelatinase B
granules O
. O

Furthermore O
, O
we O
found O
that O
20 O
% O
to O
25 O
% O
of O
both O
the O
adhesion B
protein I
Mac I
- I
1 I
and O
the O
NADPH B
- I
oxidase I
component I
cytochrome I
b558 B
is O
localized O
in O
gelatinase B
granules O
. O

This O
shows O
that O
gelatinase B
granules O
are O
functionally O
important O
relative O
to O
specific O
granules O
in O
mediating O
early O
inflammatory O
responses O
. O

Rather O
, O
the O
data O
indicate O
that O
mitogen O
increases O
the O
levels O
of O
a O
nuclear O
factor O
( O
s O
) O
that O
dimerizes O
with O
CREB B
. O

Central O
nervous O
system O
- O
derived O
cells O
express O
a O
kappa O
B O
- O
binding O
activity O
that O
enhances O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
in O
vitro O
and O
facilitates O
TAR B
- O
independent O
transactivation O
by O
Tat B
. O

Central O
nervous O
system O
- O
derived O
cells O
express O
a O
kappa O
B O
- O
binding O
activity O
that O
enhances O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
in O
vitro O
and O
facilitates O
TAR B
- O
independent O
transactivation O
by O
Tat B
. O

Tat B
transactivation O
mediated O
by O
the O
kappa B
B I
domain I
is O
sufficient O
to O
allow O
replication O
of O
TAR B
- O
deleted O
mutant O
HIV O
- O
1 O
in O
astrocytes O
. O

Tat B
transactivation O
mediated O
by O
the O
kappa B
B I
domain I
is O
sufficient O
to O
allow O
replication O
of O
TAR B
- O
deleted O
mutant O
HIV O
- O
1 O
in O
astrocytes O
. O

For O
one O
of O
these O
proteins O
, O
p57 B
, O
binding O
to O
the O
IRES B
correlates O
with O
translation O
. O

For O
one O
of O
these O
proteins O
, O
p57 B
, O
binding O
to O
the O
IRES B
correlates O
with O
translation O
. O

Retinoid B
- I
like I
receptors I
play O
a O
central O
role O
in O
hormonal O
responses O
by O
forming O
heterodimers B
with O
other O
nuclear B
hormone I
receptors I
. O

Hence O
, O
PPAR B
can O
positively O
or O
negatively O
influence O
TH O
action O
depending O
on O
TRE B
structure O
and O
THR B
isotype I
. O

Hence O
, O
PPAR B
can O
positively O
or O
negatively O
influence O
TH O
action O
depending O
on O
TRE B
structure O
and O
THR B
isotype I
. O

Lymphoid O
cells O
transformed O
by O
Abelson O
murine O
leukemia O
virus O
have O
provided O
one O
of O
the O
classic O
models O
for O
study O
of O
early O
B O
- O
cell O
development O
and O
immunoglobulin B
rearrangement O
. O

The O
expression O
of O
the O
M B
- I
CSF I
gene I
, O
that O
has O
been O
recently O
reassigned O
to O
the O
short B
arm I
of I
chromosome I
1 I
( O
lp B
) O
, O
was O
also O
investigated O
. O

Similar O
analysis O
of O
poly B
( I
A I
) I
RNA I
from O
a O
variety O
of O
adult O
tissues O
demonstrated O
HB9 B
transcripts O
in O
pancreas O
, O
small O
intestine O
, O
and O
colon O
. O

The O
two O
human B
GATA3 I
zinc I
fingers I
are O
encoded O
by O
two O
separate O
exons B
highly O
conserved O
with O
those O
of O
GATA1 B
, O
but O
no O
other O
structural O
homologies O
between O
these O
two O
genes O
can O
be O
found O
. O

The O
two O
human B
GATA3 I
zinc I
fingers I
are O
encoded O
by O
two O
separate O
exons B
highly O
conserved O
with O
those O
of O
GATA1 B
, O
but O
no O
other O
structural O
homologies O
between O
these O
two O
genes O
can O
be O
found O
. O

CD38 B
is O
a O
leukocyte B
differentiation I
antigen I
that O
has O
been O
thought O
to O
be O
a O
phenotypic O
marker O
of O
different O
subpopulations O
of O
T O
- O
and O
B O
- O
lymphocytes O
. O

In O
myeloid O
cells O
, O
CD38 B
is O
expressed O
during O
early O
stages O
of O
differentiation O
. O

Inhibition O
of O
cytokine B
production O
was O
gene O
selective O
and O
not O
due O
to O
general O
effects O
on O
protein O
synthesis O
. O

Much O
higher O
concentrations O
of O
other O
antioxidants O
- O
- O
including O
ascorbic O
acid O
, O
trolox O
, O
alpha O
- O
tocopherol O
, O
butylated O
hydroxytoluene O
, O
and O
the O
5 O
- O
lipoxygenase O
inhibitor O
zileuton O
- O
- O
did O
not O
affect O
the O
production O
of O
these O
cytokines B
. O

Thus O
antioxidants O
vary O
widely O
in O
potency O
as O
inhibitors O
of O
the O
activation O
of O
transcription B
factors I
and O
of O
the O
transcription O
of O
genes B
for O
pro B
- I
inflammatory I
cytokines I
. O

The O
magnitude O
and O
time O
kinetics O
of O
the O
LIF B
effects O
were O
similar O
to O
interleukin B
1 I
( O
IL B
- I
1 I
) O
, O
IL B
- I
6 I
, O
and O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
other O
cytokines O
known O
to O
induce O
HIV O
replication O
in O
this O
cell O
line O
. O

The O
magnitude O
and O
time O
kinetics O
of O
the O
LIF B
effects O
were O
similar O
to O
interleukin B
1 I
( O
IL B
- I
1 I
) O
, O
IL B
- I
6 I
, O
and O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
other O
cytokines O
known O
to O
induce O
HIV O
replication O
in O
this O
cell O
line O
. O

To O
characterize O
mechanisms O
responsible O
for O
these O
LIF B
effects O
, O
levels O
of O
HIV B
mRNA I
, O
activation O
of O
the O
DNA B
binding I
protein I
nuclear I
factor I
( B
NF I
) I
- I
kB I
, O
signal O
transduction O
pathways O
, O
and O
potential O
interactions O
with O
other O
cytokines B
were O
analyzed O
. O

To O
characterize O
mechanisms O
responsible O
for O
these O
LIF B
effects O
, O
levels O
of O
HIV B
mRNA I
, O
activation O
of O
the O
DNA B
binding I
protein I
nuclear I
factor I
( B
NF I
) I
- I
kB I
, O
signal O
transduction O
pathways O
, O
and O
potential O
interactions O
with O
other O
cytokines B
were O
analyzed O
. O

In O
both O
cell O
lines O
LIF B
increased O
NF B
- I
kB I
activity O
. O

Induction O
of O
NF B
- I
kB I
and O
HIV O
replication O
by O
cytokines B
are O
at O
least O
in O
part O
dependent O
on O
reactive O
oxygen O
intermediates O
. O

The O
mechanisms O
involved O
in O
the O
inhibition O
of O
growth O
of O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
by O
anti B
- I
MHC I
class I
II I
antibodies I
( O
Ab B
) O
were O
compared O
with O
those O
in O
anti B
- I
IgM I
Ab I
- O
induced O
B104 O
growth O
inhibition O
. O

The O
Sp1 B
transcription B
factor I
bound O
to O
three O
different O
regions O
in O
the O
CD14 B
promoter I
. O

Stimulation O
of O
the O
CD28 B
cell I
surface I
molecule I
delivers O
costimulatory O
signals O
essential O
for O
lymphokine B
production O
in O
activated O
T O
cells O
via O
a O
conserved B
sequence I
element I
found O
in O
the O
promoter B
of O
several O
lymphokine B
genes I
. O

Stimulation O
of O
the O
CD28 B
cell I
surface I
molecule I
delivers O
costimulatory O
signals O
essential O
for O
lymphokine B
production O
in O
activated O
T O
cells O
via O
a O
conserved B
sequence I
element I
found O
in O
the O
promoter B
of O
several O
lymphokine B
genes I
. O

That O
RA O
promotes O
both O
neutrophil O
and O
monocyte O
differentiation O
has O
implications O
for O
the O
use O
of O
RA O
and O
D3 O
in O
treatment O
of O
leukemias O
and O
provides O
insight O
into O
mechanisms O
whereby O
RAR O
, O
VDR B
and O
RXR B
facilitate O
monocyte O
differentiation O
. O

That O
RA O
promotes O
both O
neutrophil O
and O
monocyte O
differentiation O
has O
implications O
for O
the O
use O
of O
RA O
and O
D3 O
in O
treatment O
of O
leukemias O
and O
provides O
insight O
into O
mechanisms O
whereby O
RAR O
, O
VDR B
and O
RXR B
facilitate O
monocyte O
differentiation O
. O

Thrombin B
and O
thrombin B
receptor I
agonist O
peptide O
induce O
early O
events O
of O
T O
cell O
activation O
and O
synergize O
with O
TCR B
cross O
- O
linking O
for O
CD69 B
expression O
and O
interleukin O
2 O
production O
. O

Thrombin B
and O
thrombin B
receptor I
agonist O
peptide O
induce O
early O
events O
of O
T O
cell O
activation O
and O
synergize O
with O
TCR B
cross O
- O
linking O
for O
CD69 B
expression O
and O
interleukin O
2 O
production O
. O

Thrombin B
and O
thrombin B
receptor I
agonist O
peptide O
induce O
early O
events O
of O
T O
cell O
activation O
and O
synergize O
with O
TCR B
cross O
- O
linking O
for O
CD69 B
expression O
and O
interleukin O
2 O
production O
. O

There O
was O
a O
good O
correlation O
between O
thrombin B
- O
induced O
tyrosine O
phosphorylation O
of O
the O
latter O
three O
proteins O
and O
Ca2 O
+ O
mobilization O
. O

Stress O
response O
of O
senescent O
T O
lymphocytes O
: O
reduced O
hsp70 B
is O
independent O
of O
the O
proliferative O
block O
. O

Wortmannin O
, O
an O
inhibitor O
of O
receptor O
- O
coupled O
PLD B
activation O
, O
blocked O
the O
anti B
- I
CD3 I
- O
induced O
increases O
in O
both O
PLD B
activity O
and O
AP B
- I
1 I
enhancer I
activity O
. O

Wortmannin O
, O
an O
inhibitor O
of O
receptor O
- O
coupled O
PLD B
activation O
, O
blocked O
the O
anti B
- I
CD3 I
- O
induced O
increases O
in O
both O
PLD B
activity O
and O
AP B
- I
1 I
enhancer I
activity O
. O

We O
found O
a O
good O
correlation O
in O
the O
transfected O
cells O
between O
PLD B
activation O
and O
induction O
of O
AP B
- I
1 I
enhancer I
activity O
under O
different O
experimental O
conditions O
. O

We O
therefore O
reexamined O
this O
issue O
by O
using O
two O
different O
experimental O
approaches O
that O
allowed O
LMP1 B
- O
induced O
effects O
to O
be O
monitored O
immediately O
following O
expression O
of O
the O
viral O
protein O
and O
in O
the O
absence O
of O
selective O
pressures O
; O
activation O
of O
the O
NF B
- I
kappa I
B I
transcription B
factor I
and O
upregulation O
of O
the O
cell B
adhesion I
molecule I
ICAM B
- I
1 I
were O
used O
as O
early O
indices O
of O
LMP1 B
function O
. O

We O
therefore O
reexamined O
this O
issue O
by O
using O
two O
different O
experimental O
approaches O
that O
allowed O
LMP1 B
- O
induced O
effects O
to O
be O
monitored O
immediately O
following O
expression O
of O
the O
viral O
protein O
and O
in O
the O
absence O
of O
selective O
pressures O
; O
activation O
of O
the O
NF B
- I
kappa I
B I
transcription B
factor I
and O
upregulation O
of O
the O
cell B
adhesion I
molecule I
ICAM B
- I
1 I
were O
used O
as O
early O
indices O
of O
LMP1 B
function O
. O

In O
the O
second O
approach O
, O
we O
tested O
the O
generality O
of O
this O
phenomenon O
by O
transiently O
expressing O
LMP1 B
from O
a O
strong O
constitutively O
active O
promoter O
in O
a O
range O
of O
different O
cell O
types O
. O

We O
found O
that O
tyrosine B
kinase I
activity O
was O
similar O
for O
both O
mAbs B
over O
a O
period O
of O
hours O
. O

However O
, O
the O
inositol O
phosphate O
response O
was O
stronger O
for O
64 B
. I
1 I
than O
for O
OKT3 B
. O

Both O
stimuli O
induced O
the O
appearance O
of O
the O
NF B
- I
kappa I
B I
components I
( O
c B
- I
Rel I
, O
p65 B
( O
RelA B
) O
, O
and O
p50 B
( O
NF B
- I
kappa I
B1 I
) O
) O
and O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
in O
the O
nucleus O
. O

Both O
stimuli O
induced O
the O
appearance O
of O
the O
NF B
- I
kappa I
B I
components I
( O
c B
- I
Rel I
, O
p65 B
( O
RelA B
) O
, O
and O
p50 B
( O
NF B
- I
kappa I
B1 I
) O
) O
and O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
in O
the O
nucleus O
. O

Both O
stimuli O
induced O
the O
appearance O
of O
the O
NF B
- I
kappa I
B I
components I
( O
c B
- I
Rel I
, O
p65 B
( O
RelA B
) O
, O
and O
p50 B
( O
NF B
- I
kappa I
B1 I
) O
) O
and O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
in O
the O
nucleus O
. O

From O
a O
consecutive O
series O
of O
350 O
cases O
of O
adult O
de O
novo O
acute O
myeloid O
leukemia O
( O
AML O
) O
, O
we O
identified O
20 O
cases O
( O
6 O
% O
) O
with O
a O
unique O
immunophenotype O
: O
CD33 O
+ O
, O
CD56 O
+ O
, O
CD11a O
+ O
, O
CD13lo O
, O
CD15lo O
, O
CD34 O
+ O
/ O
- O
, O
HLA B
- I
DR I
- O
, O
CD16 B
- O
. O

Although O
these O
data O
suggest O
AP B
- I
1 I
regulated O
cytokine B
mRNA O
expression O
, O
results O
from O
PBMo O
are O
not O
in O
accordance O
with O
this O
notion O
. O

Sequence O
analyses O
of O
pCD41 B
indicate O
that O
there O
are O
two O
potential O
open B
reading I
frames I
( O
ORFs B
) O
, O
A B
and O
B B
, O
which O
are O
homologous O
to O
the O
ORFs B
found O
in O
the O
genomic O
clone O
pGD41 B
. O

Sequence O
analyses O
of O
pCD41 B
indicate O
that O
there O
are O
two O
potential O
open B
reading I
frames I
( O
ORFs B
) O
, O
A B
and O
B B
, O
which O
are O
homologous O
to O
the O
ORFs B
found O
in O
the O
genomic O
clone O
pGD41 B
. O

Sequence O
analyses O
of O
pCD41 B
indicate O
that O
there O
are O
two O
potential O
open B
reading I
frames I
( O
ORFs B
) O
, O
A B
and O
B B
, O
which O
are O
homologous O
to O
the O
ORFs B
found O
in O
the O
genomic O
clone O
pGD41 B
. O

Sequence O
analyses O
of O
pCD41 B
indicate O
that O
there O
are O
two O
potential O
open B
reading I
frames I
( O
ORFs B
) O
, O
A B
and O
B B
, O
which O
are O
homologous O
to O
the O
ORFs B
found O
in O
the O
genomic O
clone O
pGD41 B
. O

Sequence O
analyses O
of O
pCD41 B
indicate O
that O
there O
are O
two O
potential O
open B
reading I
frames I
( O
ORFs B
) O
, O
A B
and O
B B
, O
which O
are O
homologous O
to O
the O
ORFs B
found O
in O
the O
genomic O
clone O
pGD41 B
. O

Sequence O
analyses O
of O
pCD41 B
indicate O
that O
there O
are O
two O
potential O
open B
reading I
frames I
( O
ORFs B
) O
, O
A B
and O
B B
, O
which O
are O
homologous O
to O
the O
ORFs B
found O
in O
the O
genomic O
clone O
pGD41 B
. O

CD14 B
- O
mediated O
translocation O
of O
nuclear B
factor I
- I
kappa I
B I
induced O
by O
lipopolysaccharide O
does O
not O
require O
tyrosine B
kinase I
activity O
. O

The O
stimulatory O
effects O
of O
gp160 O
are O
mediated O
through O
the O
CD4 B
molecule I
, O
since O
pretreatment O
with O
soluble O
CD4 B
abrogates O
its O
activity O
. O

The O
CD14 B
LPS O
receptor O
is O
, O
however O
, O
up O
- O
regulated O
( O
not O
down O
- O
regulated O
) O
in O
tolerant O
cells O
, O
and O
LPS O
can O
, O
in O
fact O
, O
still O
lead O
to O
activation O
of O
tolerant O
cells O
as O
evidenced O
by O
mobilization O
of O
the O
transcription B
factor I
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
. O

This O
increase O
in O
p50 B
homodimers I
coincides O
with O
an O
increase O
in O
p105 B
mRNA I
, O
suggestive O
of O
a O
transcriptional O
up O
- O
regulation O
of O
p50 B
. O

A O
new O
exon B
containing O
a O
highly O
basic O
region O
( O
4c O
) O
was O
characterized O
, O
between B
exons I
4 I
and I
5 I
. O

In O
addition O
, O
a O
new O
combination O
isoform O
containing O
Oct2a B
' I
s I
amino I
terminal I
insert I
( O
exon B
7a I
) O
and O
Oct2b B
' I
s I
carboxy I
terminal I
insert I
( O
exon B
13 I
) O
was O
found O
that O
created O
a O
novel O
large O
isoform O
, O
Oct2ab B
. O

Furthermore O
, O
the O
NFKB2 B
precursor O
is O
physically O
associated O
with O
c B
- I
Rel I
and O
with O
Tax B
in O
HTLV O
- O
I O
infected O
cells O
. O

Furthermore O
, O
the O
NFKB2 B
precursor O
is O
physically O
associated O
with O
c B
- I
Rel I
and O
with O
Tax B
in O
HTLV O
- O
I O
infected O
cells O
. O

This O
phenomenon O
is O
correlated O
with O
inhibition O
of O
GATA1 B
induction O
in O
the O
early O
stages O
of O
erythropoietic O
differentiation O
. O

We O
have O
previously O
shown O
that O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
expressed O
surface B
IgM I
( O
sIgM B
) O
and O
surface B
IgD I
( O
sIgD B
) O
, O
and O
that O
crosslinking O
of O
sIgM B
and O
sIgD B
by O
anti B
- I
IgM I
antibody I
( I
Ab I
) I
and O
anti B
- I
IgD I
Ab I
, O
respectively O
, O
induced O
Ca2 O
+ O
influx O
to O
almost O
the O
same O
degree O
, O
whereas O
only O
sIgM B
- O
crosslinking O
caused O
B104 O
cell O
death O
. O

We O
have O
previously O
shown O
that O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
expressed O
surface B
IgM I
( O
sIgM B
) O
and O
surface B
IgD I
( O
sIgD B
) O
, O
and O
that O
crosslinking O
of O
sIgM B
and O
sIgD B
by O
anti B
- I
IgM I
antibody I
( I
Ab I
) I
and O
anti B
- I
IgD I
Ab I
, O
respectively O
, O
induced O
Ca2 O
+ O
influx O
to O
almost O
the O
same O
degree O
, O
whereas O
only O
sIgM B
- O
crosslinking O
caused O
B104 O
cell O
death O
. O

We O
have O
previously O
shown O
that O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
expressed O
surface B
IgM I
( O
sIgM B
) O
and O
surface B
IgD I
( O
sIgD B
) O
, O
and O
that O
crosslinking O
of O
sIgM B
and O
sIgD B
by O
anti B
- I
IgM I
antibody I
( I
Ab I
) I
and O
anti B
- I
IgD I
Ab I
, O
respectively O
, O
induced O
Ca2 O
+ O
influx O
to O
almost O
the O
same O
degree O
, O
whereas O
only O
sIgM B
- O
crosslinking O
caused O
B104 O
cell O
death O
. O

We O
have O
previously O
shown O
that O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
expressed O
surface B
IgM I
( O
sIgM B
) O
and O
surface B
IgD I
( O
sIgD B
) O
, O
and O
that O
crosslinking O
of O
sIgM B
and O
sIgD B
by O
anti B
- I
IgM I
antibody I
( I
Ab I
) I
and O
anti B
- I
IgD I
Ab I
, O
respectively O
, O
induced O
Ca2 O
+ O
influx O
to O
almost O
the O
same O
degree O
, O
whereas O
only O
sIgM B
- O
crosslinking O
caused O
B104 O
cell O
death O
. O

We O
have O
previously O
shown O
that O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
expressed O
surface B
IgM I
( O
sIgM B
) O
and O
surface B
IgD I
( O
sIgD B
) O
, O
and O
that O
crosslinking O
of O
sIgM B
and O
sIgD B
by O
anti B
- I
IgM I
antibody I
( I
Ab I
) I
and O
anti B
- I
IgD I
Ab I
, O
respectively O
, O
induced O
Ca2 O
+ O
influx O
to O
almost O
the O
same O
degree O
, O
whereas O
only O
sIgM B
- O
crosslinking O
caused O
B104 O
cell O
death O
. O

Irrespective O
of O
the O
human O
cell O
partner O
used O
for O
fusion O
, O
a O
certain O
number O
of O
hybrids O
lost O
CD5 B
surface O
expression O
over O
a O
period O
of O
time O
in O
culture O
. O

Acetylsalicylic O
acid O
and O
sodium O
salicylate O
inhibit O
LPS O
- O
induced O
NF B
- I
kappa I
B I
/ I
c I
- I
Rel I
nuclear O
translocation O
, O
and O
synthesis O
of O
tissue B
factor I
( O
TF B
) O
and O
tumor B
necrosis I
factor I
alfa I
( O
TNF B
- I
alpha I
) O
in O
human O
monocytes O
. O

Interferon O
augments O
PML B
and O
PML B
/ I
RAR I
alpha I
expression O
in O
normal O
myeloid O
and O
acute O
promyelocytic O
cells O
and O
cooperates O
with O
all O
- O
trans O
retinoic O
acid O
to O
induce O
maturation O
of O
a O
retinoid O
- O
resistant O
promyelocytic O
cell O
line O
. O

PML B
is O
expressed O
in O
diverse O
tissues O
and O
cell O
lines O
and O
localized O
in O
the O
nucleus O
with O
a O
typical O
speckled O
pattern O
. O

Neutral B
sphingomyelinase I
( O
SMase B
) O
can O
be O
activated O
by O
extracellular O
signals O
to O
produce O
ceramide O
, O
which O
may O
affect O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
activities O
. O

Neutral B
sphingomyelinase I
( O
SMase B
) O
can O
be O
activated O
by O
extracellular O
signals O
to O
produce O
ceramide O
, O
which O
may O
affect O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
activities O
. O

Ara O
- O
C O
activated O
JNKs B
only O
after O
prolonged O
incubation O
( O
90 O
- O
120 O
minutes O
) O
. O

We O
have O
observed O
that O
the O
R24 B
mAb I
stimulates O
GD3 O
+ O
T O
cell O
proliferation O
, O
cytotoxicity O
, O
and O
surface O
marker O
expression O
of O
IL B
- I
2R I
alpha I
- I
chain I
, O
IL B
- I
2R I
beta I
- I
chain I
, O
HLA B
- I
DR I
, O
CD11a B
, O
and O
CD11c B
. O

We O
have O
observed O
that O
the O
R24 B
mAb I
stimulates O
GD3 O
+ O
T O
cell O
proliferation O
, O
cytotoxicity O
, O
and O
surface O
marker O
expression O
of O
IL B
- I
2R I
alpha I
- I
chain I
, O
IL B
- I
2R I
beta I
- I
chain I
, O
HLA B
- I
DR I
, O
CD11a B
, O
and O
CD11c B
. O

R24 B
- O
stimulated O
increases O
in O
proliferation O
, O
cytotoxicity O
, O
and O
cell O
surface O
protein O
expression O
could O
be O
blocked O
by O
cyclosporin O
and O
staurosporin O
, O
indicating O
that O
cyclophilin B
/ I
calcineurin I
and O
protein B
kinase I
C I
may O
be O
involved O
in O
the O
R24 B
signaling O
pathway O
. O

R24 B
- O
stimulated O
increases O
in O
proliferation O
, O
cytotoxicity O
, O
and O
cell O
surface O
protein O
expression O
could O
be O
blocked O
by O
cyclosporin O
and O
staurosporin O
, O
indicating O
that O
cyclophilin B
/ I
calcineurin I
and O
protein B
kinase I
C I
may O
be O
involved O
in O
the O
R24 B
signaling O
pathway O
. O

Additionally O
, O
herbimycin O
A O
, O
a O
tyrosine B
kinase I
inhibitor O
, O
blocked O
the O
R24 B
- O
stimulated O
increase O
in O
proliferation O
but O
not O
cytotoxicity O
at O
concentrations O
consistent O
with O
specificity O
for O
tyrosine B
kinases I
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB B
, O
TFIIE B
alpha I
, O
TFIIE B
beta I
, O
RAP30 B
, O
RAP74 B
and O
the O
62 B
kDa I
subunit I
, O
of O
TFIIH B
are O
located O
at O
the O
human B
chromosomal I
bands I
6q26 I
- I
27 I
, I
1p21 I
- I
22 I
, I
3q21 I
- I
24 I
, I
8p12 I
, I
13q14 I
, I
19p13 I
. I
3 I
and I
11p14 I
- I
15 I
. I
1 I
, O
respectively O
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB B
, O
TFIIE B
alpha I
, O
TFIIE B
beta I
, O
RAP30 B
, O
RAP74 B
and O
the O
62 B
kDa I
subunit I
, O
of O
TFIIH B
are O
located O
at O
the O
human B
chromosomal I
bands I
6q26 I
- I
27 I
, I
1p21 I
- I
22 I
, I
3q21 I
- I
24 I
, I
8p12 I
, I
13q14 I
, I
19p13 I
. I
3 I
and I
11p14 I
- I
15 I
. I
1 I
, O
respectively O
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB B
, O
TFIIE B
alpha I
, O
TFIIE B
beta I
, O
RAP30 B
, O
RAP74 B
and O
the O
62 B
kDa I
subunit I
, O
of O
TFIIH B
are O
located O
at O
the O
human B
chromosomal I
bands I
6q26 I
- I
27 I
, I
1p21 I
- I
22 I
, I
3q21 I
- I
24 I
, I
8p12 I
, I
13q14 I
, I
19p13 I
. I
3 I
and I
11p14 I
- I
15 I
. I
1 I
, O
respectively O
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB B
, O
TFIIE B
alpha I
, O
TFIIE B
beta I
, O
RAP30 B
, O
RAP74 B
and O
the O
62 B
kDa I
subunit I
, O
of O
TFIIH B
are O
located O
at O
the O
human B
chromosomal I
bands I
6q26 I
- I
27 I
, I
1p21 I
- I
22 I
, I
3q21 I
- I
24 I
, I
8p12 I
, I
13q14 I
, I
19p13 I
. I
3 I
and I
11p14 I
- I
15 I
. I
1 I
, O
respectively O
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB B
, O
TFIIE B
alpha I
, O
TFIIE B
beta I
, O
RAP30 B
, O
RAP74 B
and O
the O
62 B
kDa I
subunit I
, O
of O
TFIIH B
are O
located O
at O
the O
human B
chromosomal I
bands I
6q26 I
- I
27 I
, I
1p21 I
- I
22 I
, I
3q21 I
- I
24 I
, I
8p12 I
, I
13q14 I
, I
19p13 I
. I
3 I
and I
11p14 I
- I
15 I
. I
1 I
, O
respectively O
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB B
, O
TFIIE B
alpha I
, O
TFIIE B
beta I
, O
RAP30 B
, O
RAP74 B
and O
the O
62 B
kDa I
subunit I
, O
of O
TFIIH B
are O
located O
at O
the O
human B
chromosomal I
bands I
6q26 I
- I
27 I
, I
1p21 I
- I
22 I
, I
3q21 I
- I
24 I
, I
8p12 I
, I
13q14 I
, I
19p13 I
. I
3 I
and I
11p14 I
- I
15 I
. I
1 I
, O
respectively O
. O

To O
further O
elucidate O
the O
role O
of O
this O
variant O
octamer B
motif I
in O
the O
regulation O
of O
germline B
transcription O
from O
the O
unrearranged O
kappa B
locus I
, O
we O
have O
quantitated O
the O
relative O
binding O
affinity O
of O
Oct B
- I
1 I
and O
Oct B
- I
2 I
for O
the O
variant O
octamer B
motif I
and O
determined O
the O
functional O
role O
of O
this O
octamer B
motif I
in O
transcriptional O
activation O
. O

Flow O
cytometry O
analyses O
on O
cultured O
cells O
that O
were O
treated O
with O
tepoxalin O
or O
antisense O
oligonucleotides O
to O
the O
P65 B
/ I
p50 I
subunit I
of O
NF B
- I
kappa I
B I
, O
and O
then O
stimulated O
with O
PMA O
, O
revealed O
a O
reduced O
expression O
of O
CD11b B
/ I
CD18 I
on O
monocytic O
HL60 O
cells O
, O
and O
endothelial B
adhesion I
molecule I
- I
1 I
( O
CD62E B
) O
and O
vascular B
adhesion I
molecule I
- I
1 I
( O
CD106 B
) O
on O
human O
umbilical O
vein O
endothelial O
cells O
. O

Flow O
cytometry O
analyses O
on O
cultured O
cells O
that O
were O
treated O
with O
tepoxalin O
or O
antisense O
oligonucleotides O
to O
the O
P65 B
/ I
p50 I
subunit I
of O
NF B
- I
kappa I
B I
, O
and O
then O
stimulated O
with O
PMA O
, O
revealed O
a O
reduced O
expression O
of O
CD11b B
/ I
CD18 I
on O
monocytic O
HL60 O
cells O
, O
and O
endothelial B
adhesion I
molecule I
- I
1 I
( O
CD62E B
) O
and O
vascular B
adhesion I
molecule I
- I
1 I
( O
CD106 B
) O
on O
human O
umbilical O
vein O
endothelial O
cells O
. O

The O
monoclonal B
antibody I
( O
mAb B
) O
J393 B
induces O
apoptosis O
in O
Jurkat O
T O
- O
cells O
. O

The O
monoclonal B
antibody I
( O
mAb B
) O
J393 B
induces O
apoptosis O
in O
Jurkat O
T O
- O
cells O
. O

NH2 B
- O
terminal O
amino O
acid O
sequence O
analysis O
identified O
the O
140 B
- I
kDa I
surface I
antigen I
for O
mAb B
J393 I
as O
CD43 B
/ I
leukosialin I
, O
the O
major O
sialoglycoprotein B
of O
leukocytes O
. O

NH2 B
- O
terminal O
amino O
acid O
sequence O
analysis O
identified O
the O
140 B
- I
kDa I
surface I
antigen I
for O
mAb B
J393 I
as O
CD43 B
/ I
leukosialin I
, O
the O
major O
sialoglycoprotein B
of O
leukocytes O
. O

While O
Jurkat O
cells O
co O
- O
expressed O
two O
discrete O
cell B
- I
surface I
isoforms I
of O
CD43 B
, O
recognized O
by O
mAb B
J393 I
and O
mAb B
G10 I
- I
2 I
, O
respectively O
, O
only O
J393 B
/ I
CD43 I
signaled O
apoptosis O
. O

To O
understand O
the O
mechanism O
by O
which O
PRL B
regulates O
the O
biphasic O
expression O
of O
IRF B
- I
1 I
, O
we O
cloned O
the O
rat B
IRF I
- I
1 I
gene I
and O
functionally O
characterized O
the O
IRF B
- I
1 I
promoter I
. O

Hence O
, O
the O
PRL B
- O
induced O
biphasic O
expression O
of O
the O
IRF B
- I
1 I
gene I
appears O
to O
be O
controlled O
by O
separate O
PRL B
- I
responsive I
elements I
: O
elements O
in O
the O
first O
0 O
. O
2 O
kb O
of O
the O
IRF B
- I
1 I
promoter I
region I
act O
during O
early O
activation O
, O
and O
elements O
between O
0 O
. O
2 O
and O
1 O
. O
7 O
kb O
act O
in O
concert O
with O
the O
proximal O
0 O
. O
2 O
- O
kb O
region O
during O
S O
phase O
progression O
. O

Signals O
transduced O
via O
the O
TCR B
activate O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
which O
, O
in O
turn O
, O
is O
critical O
to O
the O
transcriptional O
induction O
of O
many O
genes O
important O
for O
the O
proliferation O
and O
expression O
of O
a O
differentiated O
phenotype O
. O

Here O
we O
identify O
intracellular O
signaling O
components O
involved O
in O
activation O
of O
NF B
- I
kappaB I
following O
TCR B
stimulation O
. O

We O
have O
shown O
elsewhere O
that O
both O
the O
major B
immediate I
- I
early I
gene I
( O
MIE B
) O
and O
lytic O
cycle O
infectious O
progeny O
virus O
expression O
can O
be O
induced O
in O
otherwise O
nonpermissive O
monocyte O
- O
like O
U O
- O
937 O
cell O
cultures O
infected O
with O
either O
human O
CMV O
( O
HCMV O
) O
or O
simian O
CMV O
( O
SCMV O
) O
by O
treatment O
with O
the O
phorbol O
ester O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
. O

Therefore O
, O
to O
evaluate O
the O
mechanism O
of O
TPA O
responsiveness O
of O
the O
SNE B
motifs I
and O
of O
a O
related O
16 O
- O
bp O
SEE B
( O
SRF B
/ I
ETS I
element I
) O
motif O
found O
in O
the O
HCMV B
and I
chimpanzee I
CMV I
MIE I
enhancers I
, O
we O
have O
examined O
the O
functional O
responses O
and O
protein O
binding O
properties O
of O
multimerized B
wild I
- I
type I
and I
mutant I
elements I
added O
upstream O
to O
the O
SCMV B
MIE I
or O
simian B
virus I
40 I
minimal I
promoter I
regions I
in O
the O
U O
- O
937 O
, O
K O
- O
562 O
, O
HL O
- O
60 O
, O
THP O
- O
1 O
, O
and O
Jurkat O
cell O
lines O
. O

TSC2 B
is O
a O
gene O
on O
chromosome B
16p13 I
. I
3 I
associated O
with O
the O
autosomal O
dominant O
neurocutaneous O
disorder O
, O
tuberous O
sclerosis O
complex O
( O
TSC O
) O
. O

Fas B
- O
mediated O
apoptosis O
plays O
an O
important O
role O
in O
regulating O
the O
immune O
response O
in O
peripheral O
T O
cells O
. O

In O
contrast O
, O
interleukin O
- O
1beta O
- O
converting O
enzyme O
family O
protease O
inhibitors O
Ac O
- O
DEVD O
- O
CHO O
and O
CrmA O
blocked O
Fas B
- O
mediated O
apoptosis O
. O

Furthermore O
, O
the O
physical O
interaction O
of O
Tax B
with O
p100 B
leads O
to O
the O
inhibition O
of O
Tax B
- O
induced O
activation O
of O
the O
HTLV O
- O
I O
and O
human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeats I
, O
reflecting O
p100 B
- O
mediated O
cytoplasmic O
sequestration O
of O
the O
normally O
nuclearly O
expressed O
Tax B
protein I
. O

Furthermore O
, O
the O
physical O
interaction O
of O
Tax B
with O
p100 B
leads O
to O
the O
inhibition O
of O
Tax B
- O
induced O
activation O
of O
the O
HTLV O
- O
I O
and O
human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeats I
, O
reflecting O
p100 B
- O
mediated O
cytoplasmic O
sequestration O
of O
the O
normally O
nuclearly O
expressed O
Tax B
protein I
. O

Furthermore O
, O
the O
physical O
interaction O
of O
Tax B
with O
p100 B
leads O
to O
the O
inhibition O
of O
Tax B
- O
induced O
activation O
of O
the O
HTLV O
- O
I O
and O
human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeats I
, O
reflecting O
p100 B
- O
mediated O
cytoplasmic O
sequestration O
of O
the O
normally O
nuclearly O
expressed O
Tax B
protein I
. O

Furthermore O
, O
the O
physical O
interaction O
of O
Tax B
with O
p100 B
leads O
to O
the O
inhibition O
of O
Tax B
- O
induced O
activation O
of O
the O
HTLV O
- O
I O
and O
human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeats I
, O
reflecting O
p100 B
- O
mediated O
cytoplasmic O
sequestration O
of O
the O
normally O
nuclearly O
expressed O
Tax B
protein I
. O

S107 O
plasmacytoma O
cells O
, O
which O
express O
CD40 B
but O
are O
defective O
for O
the O
nuclear O
appearance O
of O
p50 B
/ I
p65 I
- I
NF I
- I
kappaB I
, O
do O
not O
express O
RelB B
after O
CD40 B
stimulation O
. O

S107 O
plasmacytoma O
cells O
, O
which O
express O
CD40 B
but O
are O
defective O
for O
the O
nuclear O
appearance O
of O
p50 B
/ I
p65 I
- I
NF I
- I
kappaB I
, O
do O
not O
express O
RelB B
after O
CD40 B
stimulation O
. O

S107 O
plasmacytoma O
cells O
, O
which O
express O
CD40 B
but O
are O
defective O
for O
the O
nuclear O
appearance O
of O
p50 B
/ I
p65 I
- I
NF I
- I
kappaB I
, O
do O
not O
express O
RelB B
after O
CD40 B
stimulation O
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
amino B
- I
terminal I
portion I
of O
Sp140 B
was O
similar O
to O
Sp100 B
, O
a O
previously O
identified O
NB B
protein I
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
amino B
- I
terminal I
portion I
of O
Sp140 B
was O
similar O
to O
Sp100 B
, O
a O
previously O
identified O
NB B
protein I
. O

B O
lymphocyte O
stimulation O
via O
both O
CD40 B
and O
surface B
Ig I
( I
sIg I
) I
receptors I
substantially O
induced O
fra B
- I
1 I
expression O
, O
and O
for O
both O
receptors O
, O
induction O
was O
protein B
kinase I
C I
( O
PKC B
) O
dependent O
. O

B O
lymphocyte O
stimulation O
via O
both O
CD40 B
and O
surface B
Ig I
( I
sIg I
) I
receptors I
substantially O
induced O
fra B
- I
1 I
expression O
, O
and O
for O
both O
receptors O
, O
induction O
was O
protein B
kinase I
C I
( O
PKC B
) O
dependent O
. O

Induction O
of O
fra B
- I
1 I
following O
engagement O
of O
CD40 B
did O
not O
require O
protein O
synthesis O
, O
suggesting O
that O
the O
PKC B
- O
dependent O
linkage O
between O
CD40 B
and O
fra B
- I
1 I
is O
direct O
. O

Induction O
of O
fra B
- I
1 I
following O
engagement O
of O
CD40 B
did O
not O
require O
protein O
synthesis O
, O
suggesting O
that O
the O
PKC B
- O
dependent O
linkage O
between O
CD40 B
and O
fra B
- I
1 I
is O
direct O
. O

Induction O
of O
fra B
- I
1 I
following O
engagement O
of O
CD40 B
did O
not O
require O
protein O
synthesis O
, O
suggesting O
that O
the O
PKC B
- O
dependent O
linkage O
between O
CD40 B
and O
fra B
- I
1 I
is O
direct O
. O

The O
other O
two O
SR O
patients O
had O
an O
abnormally O
low O
GR B
number O
with O
normal O
binding O
affinity O
that O
was O
not O
limited O
to O
T O
cells O
. O

This O
may O
be O
due O
to O
the O
low O
prevalence O
of O
overexpressed O
ER B
and O
the O
small O
number O
of O
controls O
. O

Inhibition O
of O
RANTES B
expression O
did O
not O
appear O
to O
be O
secondary O
to O
IL B
- I
2 I
inhibition O
and O
required O
binding O
to O
the O
intracellular O
glucocorticoid B
receptor I
. O

Association O
of O
TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
with O
an O
Epstein B
- I
Barr I
virus I
LMP1 I
domain I
important O
for O
B O
- O
lymphocyte O
transformation O
: O
role O
in O
NF B
- I
kappaB I
activation O
. O

Association O
of O
TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
with O
an O
Epstein B
- I
Barr I
virus I
LMP1 I
domain I
important O
for O
B O
- O
lymphocyte O
transformation O
: O
role O
in O
NF B
- I
kappaB I
activation O
. O

Association O
of O
TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
with O
an O
Epstein B
- I
Barr I
virus I
LMP1 I
domain I
important O
for O
B O
- O
lymphocyte O
transformation O
: O
role O
in O
NF B
- I
kappaB I
activation O
. O

The O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
transforming I
protein I
LMP1 I
appears O
to O
be O
a O
constitutively B
activated I
tumor I
necrosis I
factor I
receptor I
( O
TNFR B
) O
on O
the O
basis O
of O
an O
intrinsic O
ability O
to O
aggregate O
in O
the O
plasma O
membrane O
and O
an O
association O
of O
its O
cytoplasmic B
carboxyl I
terminus I
( O
CT B
) O
with O
TNFR B
- I
associated I
factors I
( O
TRAFs B
) O
. O

The O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
transforming I
protein I
LMP1 I
appears O
to O
be O
a O
constitutively B
activated I
tumor I
necrosis I
factor I
receptor I
( O
TNFR B
) O
on O
the O
basis O
of O
an O
intrinsic O
ability O
to O
aggregate O
in O
the O
plasma O
membrane O
and O
an O
association O
of O
its O
cytoplasmic B
carboxyl I
terminus I
( O
CT B
) O
with O
TNFR B
- I
associated I
factors I
( O
TRAFs B
) O
. O

The O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
transforming I
protein I
LMP1 I
appears O
to O
be O
a O
constitutively B
activated I
tumor I
necrosis I
factor I
receptor I
( O
TNFR B
) O
on O
the O
basis O
of O
an O
intrinsic O
ability O
to O
aggregate O
in O
the O
plasma O
membrane O
and O
an O
association O
of O
its O
cytoplasmic B
carboxyl I
terminus I
( O
CT B
) O
with O
TNFR B
- I
associated I
factors I
( O
TRAFs B
) O
. O

TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
bind O
to O
a O
single O
site O
in O
the O
LMP1 B
CT I
corresponding O
to O
amino O
acids O
( O
aa O
) O
199 O
to O
214 O
, O
within O
a O
domain O
which O
is O
important O
for O
B O
- O
lymphocyte O
growth O
transformation O
( O
aa O
187 O
to O
231 O
) O
. O

TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
bind O
to O
a O
single O
site O
in O
the O
LMP1 B
CT I
corresponding O
to O
amino O
acids O
( O
aa O
) O
199 O
to O
214 O
, O
within O
a O
domain O
which O
is O
important O
for O
B O
- O
lymphocyte O
growth O
transformation O
( O
aa O
187 O
to O
231 O
) O
. O

TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
bind O
to O
a O
single O
site O
in O
the O
LMP1 B
CT I
corresponding O
to O
amino O
acids O
( O
aa O
) O
199 O
to O
214 O
, O
within O
a O
domain O
which O
is O
important O
for O
B O
- O
lymphocyte O
growth O
transformation O
( O
aa O
187 O
to O
231 O
) O
. O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

Two O
pp56 B
( I
lck I
) I
mutants I
lacking O
either O
the O
entire O
catalytic B
domain I
or O
the O
entire O
NH2 B
regulatory B
domain I
were O
generated O
, O
and O
their O
abilities O
to O
trigger O
transactivation O
of O
the O
TCR B
- I
regulated I
nuclear I
factor I
of I
activated I
T I
cells I
( I
NF I
- I
AT I
) I
region I
of O
the O
IL B
- I
2 I
promoter I
were O
compared O
. O

The O
results O
showed O
that O
the O
average O
number O
of O
GCR B
in O
asthmatics O
was O
significantly O
lower O
than O
that O
in O
healthy O
subjects O
( O
P O
< O
0 O
. O
01 O
) O
, O
and O
there O
was O
a O
linear O
correlation O
between O
the O
number O
of O
GCR B
and O
the O
course O
of O
asthma O
. O

The O
results O
showed O
that O
the O
average O
number O
of O
GCR B
in O
asthmatics O
was O
significantly O
lower O
than O
that O
in O
healthy O
subjects O
( O
P O
< O
0 O
. O
01 O
) O
, O
and O
there O
was O
a O
linear O
correlation O
between O
the O
number O
of O
GCR B
and O
the O
course O
of O
asthma O
. O

These O
findings O
suggest O
that O
there O
is O
no O
primary O
and O
general O
impairment O
of O
glucocorticoid O
metabolism O
in O
the O
asthmatics O
, O
but O
the O
number O
of O
GCR B
in O
the O
asthmatics O
is O
lower O
than O
that O
in O
healthy O
controls O
. O

The O
macrophage B
colony I
- I
stimulating I
factor I
( I
M I
- I
CSF I
) I
receptor I
is O
expressed O
in O
a O
tissue O
- O
specific O
fashion O
from O
two O
distinct O
promoters B
in O
monocytes O
/ O
macrophages O
and O
the O
placenta O
. O

The O
number O
of O
GCR B
may O
be O
improved O
by O
inhalation O
of O
oxygen O
. O

Signaling O
via O
IL B
- I
2 I
and O
IL B
- I
4 I
in O
JAK3 O
- O
deficient O
severe O
combined O
immunodeficiency O
lymphocytes O
: O
JAK3 B
- O
dependent O
and O
independent O
pathways O
. O

However O
, O
IL B
- I
4 I
- O
induced O
effects O
were O
clearly O
improved O
following O
JAK3 B
expression O
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

Differential O
nuclear O
localization O
of O
p50 B
, O
p52 B
, O
and O
RelB B
proteins O
in O
human O
accessory O
cells O
of O
the O
immune O
response O
in O
situ O
. O

Differential O
nuclear O
localization O
of O
p50 B
, O
p52 B
, O
and O
RelB B
proteins O
in O
human O
accessory O
cells O
of O
the O
immune O
response O
in O
situ O
. O

Differential O
nuclear O
localization O
of O
p50 B
, O
p52 B
, O
and O
RelB B
proteins O
in O
human O
accessory O
cells O
of O
the O
immune O
response O
in O
situ O
. O

The O
different O
patterns O
of O
p50 B
, O
p52 B
and O
RelB B
protein O
nuclear O
localization O
may O
provide O
insight O
into O
their O
different O
roles O
during O
the O
immune O
response O
in O
vivo O
. O

The O
different O
patterns O
of O
p50 B
, O
p52 B
and O
RelB B
protein O
nuclear O
localization O
may O
provide O
insight O
into O
their O
different O
roles O
during O
the O
immune O
response O
in O
vivo O
. O

The O
different O
patterns O
of O
p50 B
, O
p52 B
and O
RelB B
protein O
nuclear O
localization O
may O
provide O
insight O
into O
their O
different O
roles O
during O
the O
immune O
response O
in O
vivo O
. O

When O
the O
promoter B
region I
was O
linked O
with O
a O
heterologous B
reporter I
gene I
, O
we O
found O
that O
the O
promoter B
region I
is O
inducible O
by O
both O
interferons B
( O
interferon B
- I
alpha I
and I
- I
gamma I
) O
and O
interferon B
regulatory I
factor I
1 I
. O

This O
reduced O
level O
of O
mRNA B
could O
then O
be O
elevated O
with O
subsequent O
interferon B
alpha I
treatment O
. O

These O
results O
describe O
for O
the O
first O
time O
the O
rapid O
modulation O
of O
the O
NT3R B
in O
response O
to O
the O
combined O
influence O
of O
cold O
exposure O
and O
reduced O
circulating O
T4 O
and O
TSH O
. O

In O
preincubated O
cells O
, O
the O
cycloheximide O
response O
is O
decreased O
, O
especially O
in O
the O
case O
of O
FOSB B
. O

Cell O
specific O
expression O
of O
human B
Bruton I
' I
s I
agammaglobulinemia I
tyrosine I
kinase I
gene I
( O
Btk B
) O
is O
regulated O
by O
Sp1 B
- I
and O
Spi B
- I
1 I
/ I
PU I
. I
1 I
- I
family I
members I
. O

In O
vitro O
footprinting O
analysis O
within O
this O
part O
of O
the O
promoter B
revealed O
two O
Sp1 B
binding I
sites I
as O
well O
as O
a O
PU B
- I
box I
. O

In O
addition O
Spi B
- I
B I
as O
well O
as O
PU B
. I
1 I
were O
able O
to O
transactivate O
Btk B
expression O
. O

CD14 B
- O
mediated O
signal O
pathway O
of O
Porphyromonas O
gingivalis O
lipopolysaccharide O
in O
human O
gingival O
fibroblasts O
. O

In O
this O
study O
, O
we O
observed O
unexpectedly O
by O
immunohistochemical O
, O
Western O
blotting O
( O
immunoblotting O
) O
, O
and O
Northern O
( O
RNA O
) O
blotting O
assays O
that O
CD14 B
is O
expressed O
at O
high O
density O
in O
human O
gingival O
fibroblasts O
. O

As O
showed O
on O
tissue O
sections O
, O
we O
detected O
the O
p50 B
in O
both O
cytoplasm O
and O
nucleus O
of O
FDC O
. O

Moreover O
, O
ZK161422 O
, O
but O
not O
ZK157202 O
, O
showed O
preference O
for O
gene O
activation O
from O
a O
promoter B
carrying O
a O
VD B
response I
element I
with O
a O
palindromic O
arrangement O
of O
two O
hexameric B
receptor I
binding I
sites I
spaced O
by O
9 O
nucleotides O
( O
IP9 O
) O
rather O
than O
for O
activation O
from O
a O
response B
element I
formed O
by O
a O
direct O
repeat O
spaced O
by O
3 O
nucleotides O
( O
DR3 O
) O
. O

The O
process O
of O
activation O
involves O
calcium O
mobilization O
, O
activation O
of O
protein B
kinase I
C I
( O
PKC B
) O
, O
and O
phosphorylation O
of O
tyrosine B
kinases I
. O

Calcineurin B
acts O
in O
synergy O
with O
PMA O
to O
inactivate O
I B
kappa I
B I
/ I
MAD3 I
, O
an O
inhibitor O
of O
NF B
- I
kappa I
B I
. O

Calcineurin B
stimulates O
the O
NF B
- I
kappa I
B I
element I
by O
enhancing O
inactivation O
of O
I B
kappa I
B I
/ I
MAD3 I
, O
an O
inhibitor O
of O
NF B
- I
kappa I
B I
, O
thereby O
increasing O
the O
amount O
of O
nuclear O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
. O

The O
protein B
- I
tyrosine I
kinase I
ZAP B
- I
70 I
is O
implicated O
, O
together O
with O
the O
Src B
kinase I
p56 B
( I
lck I
) I
, O
in O
controlling O
the O
early O
steps O
of O
the O
T O
- O
cell O
antigen O
receptor O
( O
TCR B
) O
signaling O
cascade O
. O

Peripheral O
blood O
mononuclear O
cell O
GCR B
binding O
affinities O
for O
dexamethasone O
and O
budesonide O
were O
also O
determined O
for O
both O
patient O
groups O
by O
using O
a O
radioligand O
binding O
assay O
and O
Scatchard O
analysis O
. O

The O
GCR B
binding O
affinity O
for O
budesonide O
was O
significantly O
higher O
in O
both O
groups O
( O
i O
. O
e O
. O
, O
lower O
dissociation O
constant O
) O
than O
that O
obtained O
for O
dexamethasone O
. O

Characterization O
of O
the O
murine B
cyclin I
- I
dependent I
kinase I
inhibitor I
gene I
p27Kip1 B
. O

TCDD O
mediates O
atrophy O
induction O
through O
its O
specific O
receptor O
( O
the O
AhR B
) O
and O
not O
through O
effects O
on O
the O
estrogen O
receptor O
. O

It O
predicts O
for O
two O
open B
reading I
frames I
( O
ORFs B
) O
. O

ORF1 B
consists O
of O
240 O
bp O
that O
would O
encode O
80 O
amino O
acids O
, O
while O
the O
major B
ORF2 I
consists O
of O
648 O
bp O
capable O
of O
coding O
for O
216 O
amino O
acids O
. O

In O
all O
cells O
tested O
, O
IL B
- I
10 I
activated O
Stat1 B
and O
Stat3 B
and O
induced O
the O
formation O
of O
three O
distinct O
DNA B
binding I
complexes I
that O
contained O
different O
combinations O
of O
these O
two O
transcription B
factors I
. O

In O
all O
cells O
tested O
, O
IL B
- I
10 I
activated O
Stat1 B
and O
Stat3 B
and O
induced O
the O
formation O
of O
three O
distinct O
DNA B
binding I
complexes I
that O
contained O
different O
combinations O
of O
these O
two O
transcription B
factors I
. O

Using O
a O
structure O
- O
function O
mutagenesis O
approach O
, O
two O
tyrosine O
residues O
( O
Tyr427 O
and O
Tyr477 O
) O
in O
the O
intracellular B
domain I
of O
the O
murine O
IL B
- I
10 I
receptor O
were O
found O
to O
be O
redundantly O
required O
for O
receptor O
function O
and O
for O
activation O
of O
Stat3 B
but O
not O
for O
Stat1 B
or O
Stat5 B
. O

Using O
a O
structure O
- O
function O
mutagenesis O
approach O
, O
two O
tyrosine O
residues O
( O
Tyr427 O
and O
Tyr477 O
) O
in O
the O
intracellular B
domain I
of O
the O
murine O
IL B
- I
10 I
receptor O
were O
found O
to O
be O
redundantly O
required O
for O
receptor O
function O
and O
for O
activation O
of O
Stat3 B
but O
not O
for O
Stat1 B
or O
Stat5 B
. O

Using O
a O
structure O
- O
function O
mutagenesis O
approach O
, O
two O
tyrosine O
residues O
( O
Tyr427 O
and O
Tyr477 O
) O
in O
the O
intracellular B
domain I
of O
the O
murine O
IL B
- I
10 I
receptor O
were O
found O
to O
be O
redundantly O
required O
for O
receptor O
function O
and O
for O
activation O
of O
Stat3 B
but O
not O
for O
Stat1 B
or O
Stat5 B
. O

Silencing O
of O
human O
fetal O
globin B
expression O
is O
impaired O
in O
the O
absence O
of O
the O
adult B
beta I
- I
globin I
gene I
activator I
protein I
EKLF B
. O

Silencing O
of O
human O
fetal O
globin B
expression O
is O
impaired O
in O
the O
absence O
of O
the O
adult B
beta I
- I
globin I
gene I
activator I
protein I
EKLF B
. O

E3 B
, O
a O
hematopoietic B
- I
specific I
transcript I
directly O
regulated O
by O
the O
retinoic B
acid I
receptor I
alpha I
. O

E3 B
, O
one O
of O
nine O
sequences O
identified O
, O
was O
upregulated O
in O
an O
immediate O
- O
early O
manner O
, O
with O
transcript O
levels O
peaking O
after O
60 O
minutes O
exposure O
to O
RA O
. O

These O
results O
indicate O
that O
E3 B
is O
a O
hematopoietic B
- I
specific I
gene I
that O
is O
an O
immediate O
target O
for O
the O
activated O
RAR B
alpha I
during O
myelopoiesis O
. O

To O
examine O
whether O
an O
active O
negative O
regulatory O
process O
occurs O
, O
we O
created O
a O
reporter B
construct I
containing O
as O
an O
enhancer B
four O
copies O
of O
the O
NF B
- I
AT I
site I
and O
one O
copy O
of O
the O
octamer B
site I
( O
4X B
NF I
- I
AT I
- I
Oct I
) O
. O

In O
contrast O
, O
expression O
of O
the O
activation B
- I
dependent I
cell I
surface I
markers I
CD25 B
and O
CD69 B
was O
within O
normal O
limits O
. O

In O
contrast O
, O
expression O
of O
the O
activation B
- I
dependent I
cell I
surface I
markers I
CD25 B
and O
CD69 B
was O
within O
normal O
limits O
. O

Whereas O
AP B
- I
1 I
, O
NF O
- O
kappa O
B O
, O
Oct B
, O
CREB B
and O
SP1 B
displayed O
normal O
binding O
activities O
in O
nuclear O
extracts O
, O
the O
binding O
of O
NF B
- I
AT I
to O
its O
IL B
- I
2 I
promoter O
response O
element O
was O
barely O
detectable O
both O
before O
and O
after O
T O
cell O
stimulation O
. O

Whereas O
AP B
- I
1 I
, O
NF O
- O
kappa O
B O
, O
Oct B
, O
CREB B
and O
SP1 B
displayed O
normal O
binding O
activities O
in O
nuclear O
extracts O
, O
the O
binding O
of O
NF B
- I
AT I
to O
its O
IL B
- I
2 I
promoter O
response O
element O
was O
barely O
detectable O
both O
before O
and O
after O
T O
cell O
stimulation O
. O

Whereas O
AP B
- I
1 I
, O
NF O
- O
kappa O
B O
, O
Oct B
, O
CREB B
and O
SP1 B
displayed O
normal O
binding O
activities O
in O
nuclear O
extracts O
, O
the O
binding O
of O
NF B
- I
AT I
to O
its O
IL B
- I
2 I
promoter O
response O
element O
was O
barely O
detectable O
both O
before O
and O
after O
T O
cell O
stimulation O
. O

Our O
results O
strongly O
suggest O
that O
this O
NF B
- I
AT I
/ O
DNA O
binding O
defect O
is O
responsible O
for O
the O
multiple O
cytokine B
deficiency O
and O
the O
SCID O
phenotype O
observed O
in O
the O
two O
infant O
brothers O
. O

During O
Epstein O
- O
Barr O
virus O
latent O
infection O
of O
B O
lymphocytes O
in O
vitro O
, O
six O
viral B
nuclear I
antigens I
( O
EBNAs B
) O
are O
expressed O
from O
one O
of O
two O
promoters B
, O
Cp B
or O
Wp B
, O
whose O
activities O
are O
mutually O
exclusive O
. O

During O
Epstein O
- O
Barr O
virus O
latent O
infection O
of O
B O
lymphocytes O
in O
vitro O
, O
six O
viral B
nuclear I
antigens I
( O
EBNAs B
) O
are O
expressed O
from O
one O
of O
two O
promoters B
, O
Cp B
or O
Wp B
, O
whose O
activities O
are O
mutually O
exclusive O
. O

During O
Epstein O
- O
Barr O
virus O
latent O
infection O
of O
B O
lymphocytes O
in O
vitro O
, O
six O
viral B
nuclear I
antigens I
( O
EBNAs B
) O
are O
expressed O
from O
one O
of O
two O
promoters B
, O
Cp B
or O
Wp B
, O
whose O
activities O
are O
mutually O
exclusive O
. O

During O
Epstein O
- O
Barr O
virus O
latent O
infection O
of O
B O
lymphocytes O
in O
vitro O
, O
six O
viral B
nuclear I
antigens I
( O
EBNAs B
) O
are O
expressed O
from O
one O
of O
two O
promoters B
, O
Cp B
or O
Wp B
, O
whose O
activities O
are O
mutually O
exclusive O
. O

Deletion O
of O
the O
EBNA2 B
- I
dependent I
enhancer I
located O
upstream O
of O
Cp B
resulted O
in O
a O
ca O
. O
two O
- O
to O
fivefold O
reduction O
in O
Cp B
activity O
in O
the O
LCLs O
assayed O
. O

Deletion O
of O
the O
EBNA2 B
- I
dependent I
enhancer I
located O
upstream O
of O
Cp B
resulted O
in O
a O
ca O
. O
two O
- O
to O
fivefold O
reduction O
in O
Cp B
activity O
in O
the O
LCLs O
assayed O
. O

Deletion O
of O
the O
glucocorticoid O
response O
elements O
located O
at O
ca B
. I
bp I
- I
850 I
upstream O
of O
Cp B
did O
not O
result O
in O
a O
significant O
loss O
in O
activity O
. O

The O
identification O
of O
oriP B
and O
the O
EBNA2 B
- I
dependent I
enhancer I
as O
the O
major O
positive O
cis B
elements I
involved O
in O
regulating O
Cp B
activity O
in O
LCL O
suggests O
that O
EBNA B
gene I
transcription O
is O
largely O
autoregulated O
by O
EBNA B
1 I
and O
EBNA B
2 I
. O

The O
identification O
of O
oriP B
and O
the O
EBNA2 B
- I
dependent I
enhancer I
as O
the O
major O
positive O
cis B
elements I
involved O
in O
regulating O
Cp B
activity O
in O
LCL O
suggests O
that O
EBNA B
gene I
transcription O
is O
largely O
autoregulated O
by O
EBNA B
1 I
and O
EBNA B
2 I
. O

Expression O
of O
interleukin B
1beta I
and O
other O
cytokines B
, O
such O
as O
interleukin B
6 I
and O
tumor B
necrosis I
factor I
alpha I
, O
has O
been O
shown O
to O
be O
dependent O
on O
the O
activation O
of O
the O
transcription B
factor I
, O
NFkappaB B
. O

Expression O
of O
interleukin B
1beta I
and O
other O
cytokines B
, O
such O
as O
interleukin B
6 I
and O
tumor B
necrosis I
factor I
alpha I
, O
has O
been O
shown O
to O
be O
dependent O
on O
the O
activation O
of O
the O
transcription B
factor I
, O
NFkappaB B
. O

HIV O
- O
1 O
infection O
resulted O
in O
constitutive O
, O
low O
- O
level O
expression O
of O
type B
1 I
interferon I
( O
IFN B
) O
at O
the O
mRNA O
level O
. O

We O
suggest O
that O
HIV O
- O
1 O
infection O
of O
myeloid O
cells O
induces O
IFN B
production O
and O
PKR B
activity O
, O
which O
in O
turn O
contribute O
to O
enhanced O
IkappaBalpha B
phosphorylation O
and O
subsequent O
degradation O
. O

We O
suggest O
that O
HIV O
- O
1 O
infection O
of O
myeloid O
cells O
induces O
IFN B
production O
and O
PKR B
activity O
, O
which O
in O
turn O
contribute O
to O
enhanced O
IkappaBalpha B
phosphorylation O
and O
subsequent O
degradation O
. O

We O
suggest O
that O
HIV O
- O
1 O
infection O
of O
myeloid O
cells O
induces O
IFN B
production O
and O
PKR B
activity O
, O
which O
in O
turn O
contribute O
to O
enhanced O
IkappaBalpha B
phosphorylation O
and O
subsequent O
degradation O
. O

Here O
, O
we O
report O
that O
differentiated O
B O
cells O
contain O
a O
novel O
substoichiometric O
TAF B
of O
105 O
kDa O
not O
found O
associated O
with O
TFIID B
isolated O
from O
other O
cell O
types O
. O

Here O
, O
we O
report O
that O
differentiated O
B O
cells O
contain O
a O
novel O
substoichiometric O
TAF B
of O
105 O
kDa O
not O
found O
associated O
with O
TFIID B
isolated O
from O
other O
cell O
types O
. O

All O
cells O
tested O
express O
TAFII105 B
mRNA I
, O
but O
only O
B O
cells O
contain O
significant O
levels O
of O
protein O
associated O
with O
TFIID B
. O

Although O
CD40 B
ligand I
( O
CD40L B
) O
triggers O
a O
shift O
from O
dephosphorylated O
to O
phosphorylated O
pRB B
and O
proliferation O
of O
B O
cells O
, O
the O
addition O
of O
exogenous O
IL B
- I
6 I
to O
CD40L B
- O
treated O
B O
cells O
does O
not O
alter O
either O
pRB B
or O
proliferation O
, O
as O
observed O
in O
MM O
cells O
. O

Although O
CD40 B
ligand I
( O
CD40L B
) O
triggers O
a O
shift O
from O
dephosphorylated O
to O
phosphorylated O
pRB B
and O
proliferation O
of O
B O
cells O
, O
the O
addition O
of O
exogenous O
IL B
- I
6 I
to O
CD40L B
- O
treated O
B O
cells O
does O
not O
alter O
either O
pRB B
or O
proliferation O
, O
as O
observed O
in O
MM O
cells O
. O

Although O
CD40 B
ligand I
( O
CD40L B
) O
triggers O
a O
shift O
from O
dephosphorylated O
to O
phosphorylated O
pRB B
and O
proliferation O
of O
B O
cells O
, O
the O
addition O
of O
exogenous O
IL B
- I
6 I
to O
CD40L B
- O
treated O
B O
cells O
does O
not O
alter O
either O
pRB B
or O
proliferation O
, O
as O
observed O
in O
MM O
cells O
. O

Although O
CD40 B
ligand I
( O
CD40L B
) O
triggers O
a O
shift O
from O
dephosphorylated O
to O
phosphorylated O
pRB B
and O
proliferation O
of O
B O
cells O
, O
the O
addition O
of O
exogenous O
IL B
- I
6 I
to O
CD40L B
- O
treated O
B O
cells O
does O
not O
alter O
either O
pRB B
or O
proliferation O
, O
as O
observed O
in O
MM O
cells O
. O

In O
lymphoid O
cell O
lines O
only O
, O
the O
E B
( I
gre I
) I
- I
binding I
protein I
complexes I
included O
ALF1 B
or O
HEB B
and O
E2A B
basic I
helix I
- I
loop I
- I
helix I
proteins I
. O

In O
lymphoid O
cell O
lines O
only O
, O
the O
E B
( I
gre I
) I
- I
binding I
protein I
complexes I
included O
ALF1 B
or O
HEB B
and O
E2A B
basic I
helix I
- I
loop I
- I
helix I
proteins I
. O

ALF1 B
transactivated O
transcription O
of O
Akv O
MLV O
through O
the O
two O
E B
( I
gre I
) I
motifs I
equally O
, O
whereas O
E2A B
protein I
required O
the O
promoter O
- O
proximal O
E B
( I
gre I
) I
motif O
. O

We O
cloned O
human O
nur77 B
beta I
cDNA I
, O
called O
TINUR B
. O

By O
contrast O
, O
glucocorticoids O
failed O
to O
inhibit O
IFNalpha B
production O
from O
AIDS O
- O
GR O
monocytes O
( O
approximately O
20 O
% O
inhibition O
) O
. O

This O
activation O
differed O
substantially O
from O
that O
mediated O
by O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
and O
Ca2 O
+ O
ionophore O
or O
produced O
by O
costimulation O
with O
antibodies B
against O
the O
T B
cell I
receptor I
- I
CD3 I
complex I
and O
to O
CD28 B
. O

This O
activation O
differed O
substantially O
from O
that O
mediated O
by O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
and O
Ca2 O
+ O
ionophore O
or O
produced O
by O
costimulation O
with O
antibodies B
against O
the O
T B
cell I
receptor I
- I
CD3 I
complex I
and O
to O
CD28 B
. O

These O
stimuli O
result O
in O
phosphorylation O
of O
CREB B
at O
serine O
133 O
. O

MNDA B
( O
myeloid B
cell I
nuclear I
differentiation I
antigen I
) O
is O
an O
interferon B
alpha I
regulated I
nuclear I
protein I
expressed O
only O
in O
cells O
of O
the O
human O
myelomonocytic O
lineage O
. O

In O
addition O
, O
DNA O
methylation O
was O
revealed O
as O
one O
of O
the O
possible O
factors O
in O
establishing O
MNDA B
expression O
. O

Characterization O
of O
a O
new O
isoform O
of O
the O
NFAT B
( O
nuclear B
factor I
of I
activated I
T I
cells I
) O
gene O
family O
member O
NFATc B
[ O
published O
erratum O
appears O
in O
J O
Biol O
Chem O
1996 O
Dec O
27 O
; O
271 O
( O
52 O
) O
: O
33705 O
] O

Characterization O
of O
a O
new O
isoform O
of O
the O
NFAT B
( O
nuclear B
factor I
of I
activated I
T I
cells I
) O
gene O
family O
member O
NFATc B
[ O
published O
erratum O
appears O
in O
J O
Biol O
Chem O
1996 O
Dec O
27 O
; O
271 O
( O
52 O
) O
: O
33705 O
] O

The O
amino B
acid I
sequence I
of O
NFATc B
. I
beta I
differs O
from O
that O
of O
NFATc B
. O

The O
proximal B
sequence I
element I
( I
PSE I
) I
- I
binding I
transcription I
factor I
( O
PTF B
) O
, O
which O
binds O
the O
PSE B
of O
both O
RNA B
polymerase I
II I
- I
and I
RNA I
polymerase I
III I
- I
transcribed I
mammalian I
small I
nuclear I
RNA I
( I
snRNA I
) I
genes I
, O
is O
essential O
for O
their O
transcription O
. O

The O
proximal B
sequence I
element I
( I
PSE I
) I
- I
binding I
transcription I
factor I
( O
PTF B
) O
, O
which O
binds O
the O
PSE B
of O
both O
RNA B
polymerase I
II I
- I
and I
RNA I
polymerase I
III I
- I
transcribed I
mammalian I
small I
nuclear I
RNA I
( I
snRNA I
) I
genes I
, O
is O
essential O
for O
their O
transcription O
. O

Here O
we O
describe O
the O
isolation O
and O
expression O
of O
a O
cDNA B
encoding O
PTF B
beta I
, O
as O
well O
as O
functional O
studies O
using O
anti B
- I
PTF I
beta I
antibodies I
. O

Tyloxapol O
inhibits O
NF B
- I
kappa I
B I
and O
cytokine B
release O
, O
scavenges O
HOCI B
, O
and O
reduces O
viscosity O
of O
cystic O
fibrosis O
sputum O
. O

Tyloxapol O
inhibits O
NF B
- I
kappa I
B I
and O
cytokine B
release O
, O
scavenges O
HOCI B
, O
and O
reduces O
viscosity O
of O
cystic O
fibrosis O
sputum O
. O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

In O
this O
study O
, O
we O
examined O
the O
molecular O
mechanism O
by O
which O
agents O
that O
elevate O
intracellular O
cAMP O
inhibit O
the O
expression O
of O
the O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
) O
, O
tissue B
factor I
, O
endothelial B
leukocyte I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
genes I
. O

The O
primary O
and O
recurrent O
tumors O
in O
Group O
A O
did O
not O
show O
structural O
alterations O
in O
the O
p16 B
, I
p15 I
or I
CDK4 I
genes I
, O
whereas O
homozygous O
codeletion O
of O
p16 B
and O
p15 B
was O
observed O
in O
both O
primary O
and O
recurrent O
tumors O
in O
Group O
B O
. O

The O
primary O
and O
recurrent O
tumors O
in O
Group O
A O
did O
not O
show O
structural O
alterations O
in O
the O
p16 B
, I
p15 I
or I
CDK4 I
genes I
, O
whereas O
homozygous O
codeletion O
of O
p16 B
and O
p15 B
was O
observed O
in O
both O
primary O
and O
recurrent O
tumors O
in O
Group O
B O
. O

The O
primary O
tumors O
in O
Group O
C O
had O
a O
normal O
profile O
of O
p16 B
, O
p15 B
and O
CDK4 B
at O
presentation O
. O

The O
primary O
tumors O
in O
Group O
C O
had O
a O
normal O
profile O
of O
p16 B
, O
p15 B
and O
CDK4 B
at O
presentation O
. O

The O
primary O
tumors O
in O
Group O
C O
had O
a O
normal O
profile O
of O
p16 B
, O
p15 B
and O
CDK4 B
at O
presentation O
. O

In O
transient O
transfectin O
experiments O
, O
BCL6 B
can O
repress O
transcription O
from O
promoters B
linked O
to O
its O
DNA B
target I
sequence I
and O
this O
activity O
is O
dependent O
upon O
specific O
DNA O
- O
binding O
and O
the O
presence O
of O
an O
intact O
N B
- I
terminal I
half I
of O
the O
protein O
. O

In O
transient O
transfectin O
experiments O
, O
BCL6 B
can O
repress O
transcription O
from O
promoters B
linked O
to O
its O
DNA B
target I
sequence I
and O
this O
activity O
is O
dependent O
upon O
specific O
DNA O
- O
binding O
and O
the O
presence O
of O
an O
intact O
N B
- I
terminal I
half I
of O
the O
protein O
. O

As O
the O
NF B
- I
kappa I
B I
transcription I
factor I
has O
a O
central O
role O
in O
the O
control O
of O
transcription O
of O
several O
genes B
involved O
in O
immune O
and O
inflammatory O
responses O
, O
the O
authors O
have O
analysed O
the O
activation O
of O
NF B
- I
kappa I
B I
in O
human O
umbilical O
cord O
T O
lymphocytes O
. O

The O
key O
role O
of O
erythropoietin B
( O
Epo B
) O
for O
colony O
formation O
by O
early O
erythroid O
progenitors O
( O
burst O
- O
forming O
units O
- O
erythroid O
[ O
BFU O
- O
E O
] O
) O
has O
been O
confirmed O
. O

The O
key O
role O
of O
erythropoietin B
( O
Epo B
) O
for O
colony O
formation O
by O
early O
erythroid O
progenitors O
( O
burst O
- O
forming O
units O
- O
erythroid O
[ O
BFU O
- O
E O
] O
) O
has O
been O
confirmed O
. O

Three O
subtypes O
of O
retinoic B
acid I
receptors I
( O
RAR B
) O
, O
termed O
RAR B
alpha I
, O
RAR B
beta I
, O
and O
RAR B
gamma I
, O
have O
been O
described O
. O

RARs B
specifically O
bind O
all O
- O
trans O
- O
retinoic O
acid O
( O
RA O
) O
, O
9 O
- O
cis O
- O
RA O
, O
and O
retinoid O
analogs O
. O

In O
spite O
of O
this O
similar O
downstream O
signalling O
, O
IL4 B
and O
IL13 B
used O
a O
different O
set O
of O
Janus B
kinases I
: O
IL13 B
is O
unable O
to O
activate O
JAK1 B
and O
JAK3 B
. O

In O
spite O
of O
this O
similar O
downstream O
signalling O
, O
IL4 B
and O
IL13 B
used O
a O
different O
set O
of O
Janus B
kinases I
: O
IL13 B
is O
unable O
to O
activate O
JAK1 B
and O
JAK3 B
. O

In O
spite O
of O
this O
similar O
downstream O
signalling O
, O
IL4 B
and O
IL13 B
used O
a O
different O
set O
of O
Janus B
kinases I
: O
IL13 B
is O
unable O
to O
activate O
JAK1 B
and O
JAK3 B
. O

In O
spite O
of O
this O
similar O
downstream O
signalling O
, O
IL4 B
and O
IL13 B
used O
a O
different O
set O
of O
Janus B
kinases I
: O
IL13 B
is O
unable O
to O
activate O
JAK1 B
and O
JAK3 B
. O

In O
spite O
of O
this O
similar O
downstream O
signalling O
, O
IL4 B
and O
IL13 B
used O
a O
different O
set O
of O
Janus B
kinases I
: O
IL13 B
is O
unable O
to O
activate O
JAK1 B
and O
JAK3 B
. O

Our O
findings O
support O
the O
recently O
determined O
calcineurin B
X O
- O
ray O
crystal O
structure O
, O
provide O
evidence O
that O
calcineurin B
is O
the O
only O
CsA B
- I
sensitive I
component I
limiting O
signaling O
from O
the O
T B
cell I
receptor I
to O
the O
nucleus O
, O
and O
suggest O
a O
means O
to O
render O
cells O
and O
tissues O
resistant O
to O
the O
toxic O
side O
effects O
of O
CsA O
and O
FK506 O
. O

Our O
findings O
support O
the O
recently O
determined O
calcineurin B
X O
- O
ray O
crystal O
structure O
, O
provide O
evidence O
that O
calcineurin B
is O
the O
only O
CsA B
- I
sensitive I
component I
limiting O
signaling O
from O
the O
T B
cell I
receptor I
to O
the O
nucleus O
, O
and O
suggest O
a O
means O
to O
render O
cells O
and O
tissues O
resistant O
to O
the O
toxic O
side O
effects O
of O
CsA O
and O
FK506 O
. O

A O
3 O
' O
- O
- O
> O
5 O
' O
XPB B
helicase I
defect O
in O
repair B
/ I
transcription I
factor I
TFIIH B
of O
xeroderma O
pigmentosum O
group O
B O
affects O
both O
DNA O
repair O
and O
transcription O
. O

Although O
identical O
in O
composition O
and O
stoichiometry O
to O
TFIIHwt B
, O
TFIIHmut B
shows O
a O
reduced O
3 O
' O
- O
- O
> O
5 O
' O
XPB B
helicase O
activity O
. O

Although O
identical O
in O
composition O
and O
stoichiometry O
to O
TFIIHwt B
, O
TFIIHmut B
shows O
a O
reduced O
3 O
' O
- O
- O
> O
5 O
' O
XPB B
helicase O
activity O
. O

Although O
identical O
in O
composition O
and O
stoichiometry O
to O
TFIIHwt B
, O
TFIIHmut B
shows O
a O
reduced O
3 O
' O
- O
- O
> O
5 O
' O
XPB B
helicase O
activity O
. O

The O
XPB B
mutation O
causes O
a O
severe O
NER O
defect O
. O

DNase B
I I
hypersensitive I
site I
( O
DHS B
) O
mapping O
revealed O
that O
the O
perforin B
locus I
contained O
six O
DHS B
within O
7 O
. O
0 O
kb O
of O
the O
5 B
' I
upstream I
sequence I
( O
- O
7 O
. O
0 O
kb O
) O
and O
two O
DHS B
in O
intron B
2 I
. O

DNase B
I I
hypersensitive I
site I
( O
DHS B
) O
mapping O
revealed O
that O
the O
perforin B
locus I
contained O
six O
DHS B
within O
7 O
. O
0 O
kb O
of O
the O
5 B
' I
upstream I
sequence I
( O
- O
7 O
. O
0 O
kb O
) O
and O
two O
DHS B
in O
intron B
2 I
. O

DNase B
I I
hypersensitive I
site I
( O
DHS B
) O
mapping O
revealed O
that O
the O
perforin B
locus I
contained O
six O
DHS B
within O
7 O
. O
0 O
kb O
of O
the O
5 B
' I
upstream I
sequence I
( O
- O
7 O
. O
0 O
kb O
) O
and O
two O
DHS B
in O
intron B
2 I
. O

Chloramphenicol B
acetyltransferase I
( O
CAT B
) O
activities O
directed O
by O
5 B
' I
upstream I
promoter I
were O
detected O
preferentially O
in O
perforin O
- O
expressing O
cell O
lines O
. O

When O
single O
- O
point O
mutation O
was O
introduced O
to O
each O
GC B
box I
, O
EBS B
, O
and O
GT B
box I
in O
PFP9a20 B
, O
at O
least O
3 O
- O
fold O
less O
CAT B
activity O
was O
observed O
in O
CTLL O
- O
R8 O
cells O
. O

When O
single O
- O
point O
mutation O
was O
introduced O
to O
each O
GC B
box I
, O
EBS B
, O
and O
GT B
box I
in O
PFP9a20 B
, O
at O
least O
3 O
- O
fold O
less O
CAT B
activity O
was O
observed O
in O
CTLL O
- O
R8 O
cells O
. O

When O
single O
- O
point O
mutation O
was O
introduced O
to O
each O
GC B
box I
, O
EBS B
, O
and O
GT B
box I
in O
PFP9a20 B
, O
at O
least O
3 O
- O
fold O
less O
CAT B
activity O
was O
observed O
in O
CTLL O
- O
R8 O
cells O
. O

The O
results O
suggest O
that O
a O
combination O
of O
the O
three O
proximal O
cis B
- I
acting I
elements I
may O
constitute O
a O
minimal O
region O
responsible O
for O
CTL O
- O
specific O
expression O
of O
perforin B
. O

Instead O
, O
ATF B
- I
2 I
and O
Jun B
proteins I
bind O
to O
the O
composite B
kappa I
3 I
/ I
CRE I
site I
and O
NFATp B
binds O
to O
a O
newly O
identified O
second O
NFAT B
site I
centered O
at O
- B
76 I
nucleotides I
relative O
to O
the O
TNF B
- I
alpha I
transcription I
start I
site I
. O

Consistent O
with O
these O
results O
, O
quantitative O
DNase B
footprinting O
of O
the O
TNF B
- I
alpha I
promoter I
using O
increasing O
amounts O
of O
recombinant O
NFATp B
demonstrated O
that O
the O
- B
76 I
site I
binds O
to O
NFATp B
with O
a O
higher O
affinity O
than O
the O
kappa B
3 I
site I
. O

Consistent O
with O
these O
results O
, O
quantitative O
DNase B
footprinting O
of O
the O
TNF B
- I
alpha I
promoter I
using O
increasing O
amounts O
of O
recombinant O
NFATp B
demonstrated O
that O
the O
- B
76 I
site I
binds O
to O
NFATp B
with O
a O
higher O
affinity O
than O
the O
kappa B
3 I
site I
. O

Consistent O
with O
these O
results O
, O
quantitative O
DNase B
footprinting O
of O
the O
TNF B
- I
alpha I
promoter I
using O
increasing O
amounts O
of O
recombinant O
NFATp B
demonstrated O
that O
the O
- B
76 I
site I
binds O
to O
NFATp B
with O
a O
higher O
affinity O
than O
the O
kappa B
3 I
site I
. O

Nuclear B
factor I
of I
activated I
T I
cells I
- I
family I
proteins I
( O
NFAT1 B
/ I
NFATp I
, O
NFATc B
, O
NFAT3 B
, O
and O
NFAT4 B
/ I
NFATx I
/ I
NFATc3 I
) O
play O
a O
key O
role O
in O
the O
transcription O
of O
cytokine B
genes I
and O
other O
genes O
during O
the O
immune O
response O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
- I
family I
proteins I
( O
NFAT1 B
/ I
NFATp I
, O
NFATc B
, O
NFAT3 B
, O
and O
NFAT4 B
/ I
NFATx I
/ I
NFATc3 I
) O
play O
a O
key O
role O
in O
the O
transcription O
of O
cytokine B
genes I
and O
other O
genes O
during O
the O
immune O
response O
. O

A O
major O
obstacle O
in O
understanding O
the O
signaling O
events O
that O
follow O
CD28 B
receptor O
ligation O
arises O
from O
the O
fact O
that O
CD28 B
acts O
as O
a O
costimulus O
to O
TCR B
engagement O
, O
making O
it O
difficult O
to O
assess O
the O
relative O
contribution O
of O
CD28 B
signals O
as O
distinct O
from O
those O
of O
the O
TCR B
. O

A O
major O
obstacle O
in O
understanding O
the O
signaling O
events O
that O
follow O
CD28 B
receptor O
ligation O
arises O
from O
the O
fact O
that O
CD28 B
acts O
as O
a O
costimulus O
to O
TCR B
engagement O
, O
making O
it O
difficult O
to O
assess O
the O
relative O
contribution O
of O
CD28 B
signals O
as O
distinct O
from O
those O
of O
the O
TCR B
. O

A O
major O
obstacle O
in O
understanding O
the O
signaling O
events O
that O
follow O
CD28 B
receptor O
ligation O
arises O
from O
the O
fact O
that O
CD28 B
acts O
as O
a O
costimulus O
to O
TCR B
engagement O
, O
making O
it O
difficult O
to O
assess O
the O
relative O
contribution O
of O
CD28 B
signals O
as O
distinct O
from O
those O
of O
the O
TCR B
. O

A O
major O
obstacle O
in O
understanding O
the O
signaling O
events O
that O
follow O
CD28 B
receptor O
ligation O
arises O
from O
the O
fact O
that O
CD28 B
acts O
as O
a O
costimulus O
to O
TCR B
engagement O
, O
making O
it O
difficult O
to O
assess O
the O
relative O
contribution O
of O
CD28 B
signals O
as O
distinct O
from O
those O
of O
the O
TCR B
. O

A O
major O
obstacle O
in O
understanding O
the O
signaling O
events O
that O
follow O
CD28 B
receptor O
ligation O
arises O
from O
the O
fact O
that O
CD28 B
acts O
as O
a O
costimulus O
to O
TCR B
engagement O
, O
making O
it O
difficult O
to O
assess O
the O
relative O
contribution O
of O
CD28 B
signals O
as O
distinct O
from O
those O
of O
the O
TCR B
. O

To O
investigate O
the O
presence O
of O
various O
isoforms O
of O
the O
estrogen B
receptor I
( O
ER B
) O
in O
SLE O
we O
isolated O
RNA O
from O
mononuclear O
cells O
of O
lupus O
patients O
and O
normal O
controls O
. O

Sialoadhesin B
expression O
was O
functional O
as O
shown O
by O
cell O
adhesion O
assays O
with O
human O
RBCs O
. O

In O
contrast O
to O
freshly O
isolated O
T O
cells O
, O
in O
vitro O
- O
cultured O
T O
cells O
did O
not O
require O
costimulation O
for O
cytokine B
secretion O
in O
response O
to O
anti B
- I
CD3 I
alone O
. O

The O
induction O
of O
T O
cell O
proliferation O
requires O
signals O
from O
the O
TCR B
and O
a O
co B
- I
receptor I
molecule I
, O
such O
as O
CD28 B
, O
that O
activate O
parallel O
and O
partially O
cross O
- O
reactive O
signaling O
pathways O
. O

The O
induction O
of O
T O
cell O
proliferation O
requires O
signals O
from O
the O
TCR B
and O
a O
co B
- I
receptor I
molecule I
, O
such O
as O
CD28 B
, O
that O
activate O
parallel O
and O
partially O
cross O
- O
reactive O
signaling O
pathways O
. O

Our O
results O
suggest O
that O
PKA B
inhibits O
T O
cell O
activation O
by O
interfering O
with O
multiple O
events O
along O
the O
two O
signaling O
pathways O
operating O
downstream O
of O
the O
TCR B
and O
the O
CD28 B
co I
- I
receptor I
molecules I
. O

Our O
results O
suggest O
that O
PKA B
inhibits O
T O
cell O
activation O
by O
interfering O
with O
multiple O
events O
along O
the O
two O
signaling O
pathways O
operating O
downstream O
of O
the O
TCR B
and O
the O
CD28 B
co I
- I
receptor I
molecules I
. O

This O
pattern O
of O
STAT B
activation O
was O
seen O
in O
all O
BCP O
- O
ALL O
cases O
that O
respond O
to O
IL B
- I
7 I
in O
proliferation O
assays O
. O

The O
percentage O
of O
cells O
expressing O
CD40 B
in O
T O
and O
B O
cell O
co O
- O
cultures O
increased O
from O
4 O
. O
2 O
% O
to O
13 O
. O
8 O
% O
after O
oligo O
stimulation O
in O
patients O
, O
while O
it O
increased O
form O
4 O
. O
7 O
% O
to O
48 O
. O
6 O
% O
in O
healthy O
controls O
. O

We O
demonstrate O
that O
CaMKIV B
/ I
Gr I
reconstitutes O
the O
capacity O
of O
the O
cytosolic O
component O
of O
NFAT B
to O
direct O
transcription O
from O
NFAT B
sites I
in O
non O
- O
T O
cells O
. O

This O
was O
identified O
as O
the O
mRNA B
encoding O
the O
transcription B
factor I
egr B
- I
1 I
, O
which O
is O
expressed O
with O
fast O
kinetics O
in O
T O
and O
NK O
cells O
upon O
IL B
- I
2 I
, O
but O
not O
IL B
- I
12 I
, O
stimulation O
. O

However O
, O
the O
transcription O
and O
synthesis O
of O
interleukin B
2 I
and O
other O
delayed O
early O
cytokines B
were O
markedly O
attenuated O
by O
BCL B
- I
2 I
. O

On O
the O
basis O
of O
several O
independent O
assays O
, O
we O
now O
report O
a O
physical O
and O
functional O
interaction O
between O
Tax B
and O
the O
transcription B
factor I
, O
TFIIA B
. O

On O
the O
basis O
of O
several O
independent O
assays O
, O
we O
now O
report O
a O
physical O
and O
functional O
interaction O
between O
Tax B
and O
the O
transcription B
factor I
, O
TFIIA B
. O

Finally O
, O
TFIIA B
facilitates O
Tax B
transactivation O
in O
vitro O
and O
in O
vivo O
. O

Finally O
, O
TFIIA B
facilitates O
Tax B
transactivation O
in O
vitro O
and O
in O
vivo O
. O

Inhibition O
of O
transcription B
factor I
Stat1 B
activity O
in O
mononuclear O
cell O
cultures O
and O
T O
cells O
by O
the O
cyclic O
AMP O
signaling O
pathway O
. O

GM B
- I
CSF I
gene I
activation O
in O
T O
cells O
is O
known O
to O
involve O
the O
transcription B
factors I
nuclear B
factor I
- I
kappa I
B I
, O
AP B
- I
1 I
, O
NFAT B
, O
and O
Sp1 O
. O

A O
2 B
- I
bp I
mutation I
within O
the O
CBF B
site O
resulted O
in O
a O
2 O
- O
3 O
- O
fold O
decrease O
in O
the O
activities O
of O
both O
a O
69 B
- I
bp I
proximal I
promoter I
fragment I
and O
a O
627 B
- I
bp I
full I
- I
length I
promoter I
fragment I
. O

The O
AML1 B
and I
CBF I
beta I
genes I
that O
encode O
CBF B
each O
have O
the O
ability O
to O
influence O
cell O
growth O
and O
differentiation O
and O
have O
been O
implicated O
as O
proto B
- I
oncogenes I
in O
acute O
myeloid O
leukemia O
. O

The O
GM B
- I
CSF I
locus I
may O
represent O
one O
of O
several O
target O
genes B
that O
are O
dysregulated O
in O
acute O
myeloid O
leukemia O
. O

In O
vitro O
, O
human O
B O
lymphocytes O
undergo O
long O
- O
term O
proliferation O
when O
activated O
through O
CD40 B
, O
a O
protein O
expressed O
on O
their O
cell O
surface O
. O

Rather O
, O
tyrosine O
phosphorylation O
was O
shown O
to O
be O
directly O
involved O
in O
mediating O
CD40 B
- O
dependent O
signals O
. O

To O
examine O
the O
potential O
effects O
of O
stress O
on O
TH1 O
/ O
TH2 O
balance O
, O
we O
studied O
the O
ability O
of O
three O
prototype O
stress O
hormones O
- O
dexamethasone O
( O
a O
synthetic O
glucocorticoid O
) O
and O
the O
catecholamines O
norepinephrine O
and O
epinephrine O
- O
to O
alter O
the O
production O
of O
IL B
- I
12 I
( O
p70 B
) O
and O
IL B
- I
10 I
induced O
by O
bacterial O
lipopolysaccharide O
( O
LPS O
) O
in O
human O
whole O
blood O
. O

There O
is O
increasing O
evidence O
that O
lipoproteins B
of O
Treponema O
pallidum O
and O
Borrelia O
burgdorferi O
are O
key O
inflammatory O
mediators O
during O
syphilis O
and O
Lyme O
disease O
. O

Acylation O
of O
OspA B
and O
the O
synthetic O
peptides O
was O
requisite O
for O
cell O
activation O
. O

Finally O
, O
the O
biological O
relevance O
of O
the O
observation O
that O
T B
. I
pallidum I
lipoproteins I
- O
lipopeptides O
induce O
both O
NF B
- I
kappa I
B I
and O
cytokine B
production O
in O
monocytes O
was O
supported O
by O
the O
ability O
of O
the O
synthetic O
analogs O
to O
promote O
human O
immunodeficiency O
virus O
replication O
in O
chronically O
infected O
U1 O
monocytoid O
cells O
; O
these O
observations O
also O
suggest O
a O
potential O
mechanism O
whereby O
a O
syphilitic O
chancre O
can O
serve O
as O
a O
cofactor O
for O
human O
immunodeficiency O
virus O
transmission O
. O

The O
present O
study O
describes O
the O
cloning O
of O
a O
lymphoid B
- I
restricted I
gene I
, O
LYSP100 B
, O
that O
is O
homologous O
to O
another O
protein O
that O
localizes O
to O
PML O
NBs O
, O
SP100 B
. O

The O
present O
study O
describes O
the O
cloning O
of O
a O
lymphoid B
- I
restricted I
gene I
, O
LYSP100 B
, O
that O
is O
homologous O
to O
another O
protein O
that O
localizes O
to O
PML O
NBs O
, O
SP100 B
. O

We O
term O
the O
LYSP100 B
structures O
` O
` O
LANDs O
, O
' O
' O
for O
LYSP100 B
- O
associated O
nuclear O
domains O
. O

We O
term O
the O
LYSP100 B
structures O
` O
` O
LANDs O
, O
' O
' O
for O
LYSP100 B
- O
associated O
nuclear O
domains O
. O

To O
better O
understand O
the O
contribution O
of O
the O
GR B
N I
- I
terminal I
transactivation I
domain I
in O
mediating O
murine O
thymocyte O
apoptosis O
, O
we O
stably O
transfected O
GR B
, O
GR B
variants I
, O
and O
the O
androgen B
receptor I
( O
AR B
) O
into O
receptor O
- O
negative O
S49 O
murine O
thymoma O
cells O
. O

To O
better O
understand O
the O
contribution O
of O
the O
GR B
N I
- I
terminal I
transactivation I
domain I
in O
mediating O
murine O
thymocyte O
apoptosis O
, O
we O
stably O
transfected O
GR B
, O
GR B
variants I
, O
and O
the O
androgen B
receptor I
( O
AR B
) O
into O
receptor O
- O
negative O
S49 O
murine O
thymoma O
cells O
. O

One O
p21ras B
effector O
pathway O
involves O
the O
MAP B
kinase I
ERK B
- I
2 I
, O
and O
we O
have O
examined O
its O
role O
in O
NFAT B
regulation O
. O

One O
p21ras B
effector O
pathway O
involves O
the O
MAP B
kinase I
ERK B
- I
2 I
, O
and O
we O
have O
examined O
its O
role O
in O
NFAT B
regulation O
. O

Gel O
mobility O
shift O
and O
immunoprecipitation O
analyses O
revealed O
that O
in O
addition O
to O
activating O
STAT3 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
) O
and O
STAT5 B
, O
IL B
- I
2 I
induced O
tyrosine O
and O
serine O
phosphorylation O
of O
STAT1 B
alpha I
, O
which O
formed O
IFN B
- I
gamma I
- I
activated I
sequence I
- I
binding I
complexes I
by O
itself O
and O
with O
STAT3 B
. O

Gel O
mobility O
shift O
and O
immunoprecipitation O
analyses O
revealed O
that O
in O
addition O
to O
activating O
STAT3 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
) O
and O
STAT5 B
, O
IL B
- I
2 I
induced O
tyrosine O
and O
serine O
phosphorylation O
of O
STAT1 B
alpha I
, O
which O
formed O
IFN B
- I
gamma I
- I
activated I
sequence I
- I
binding I
complexes I
by O
itself O
and O
with O
STAT3 B
. O

Gel O
mobility O
shift O
and O
immunoprecipitation O
analyses O
revealed O
that O
in O
addition O
to O
activating O
STAT3 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
) O
and O
STAT5 B
, O
IL B
- I
2 I
induced O
tyrosine O
and O
serine O
phosphorylation O
of O
STAT1 B
alpha I
, O
which O
formed O
IFN B
- I
gamma I
- I
activated I
sequence I
- I
binding I
complexes I
by O
itself O
and O
with O
STAT3 B
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

In O
addition O
, O
NAC O
blocks O
the O
suppression O
of O
T O
cell O
mitogenesis O
and O
cytokine B
production O
by O
protease O
inhibitors O
such O
as O
N O
- O
tosylphenylalanine O
chloromethyl O
ketone O
( O
TPCK O
) O
. O

Recently O
it O
has O
become O
clear O
that O
these O
cytokines B
activate O
a O
number O
of O
important O
intracellular B
signaling I
molecules I
, O
including O
the O
Janus B
kinases I
JAK1 B
and O
JAK3 B
and O
members O
of O
the O
transcription B
factor I
family I
of O
signal B
transducers I
and O
activators B
of I
transcription I
( O
STATs B
) O
. O

Recently O
it O
has O
become O
clear O
that O
these O
cytokines B
activate O
a O
number O
of O
important O
intracellular B
signaling I
molecules I
, O
including O
the O
Janus B
kinases I
JAK1 B
and O
JAK3 B
and O
members O
of O
the O
transcription B
factor I
family I
of O
signal B
transducers I
and O
activators B
of I
transcription I
( O
STATs B
) O
. O

Recently O
it O
has O
become O
clear O
that O
these O
cytokines B
activate O
a O
number O
of O
important O
intracellular B
signaling I
molecules I
, O
including O
the O
Janus B
kinases I
JAK1 B
and O
JAK3 B
and O
members O
of O
the O
transcription B
factor I
family I
of O
signal B
transducers I
and O
activators B
of I
transcription I
( O
STATs B
) O
. O

Recently O
it O
has O
become O
clear O
that O
these O
cytokines B
activate O
a O
number O
of O
important O
intracellular B
signaling I
molecules I
, O
including O
the O
Janus B
kinases I
JAK1 B
and O
JAK3 B
and O
members O
of O
the O
transcription B
factor I
family I
of O
signal B
transducers I
and O
activators B
of I
transcription I
( O
STATs B
) O
. O

Therefore O
, O
we O
analyzed O
the O
expression O
, O
DNA O
binding O
, O
and O
transcriptional O
activity O
of O
the O
endogenous B
RA I
and I
VitD3 I
receptors I
[ O
retinoic B
acid I
receptors I
( O
RARs B
) O
, O
retinoid B
X I
receptors I
( O
RXRs B
) O
, O
and O
VitD3 B
receptor I
( O
VDR B
) O
] O
in O
the O
U O
- O
937 O
cell O
line O
, O
in O
which O
RA O
and O
VitD3 O
induce O
distinct O
monocytic O
differentiation O
pathways O
. O

Therefore O
, O
we O
analyzed O
the O
expression O
, O
DNA O
binding O
, O
and O
transcriptional O
activity O
of O
the O
endogenous B
RA I
and I
VitD3 I
receptors I
[ O
retinoic B
acid I
receptors I
( O
RARs B
) O
, O
retinoid B
X I
receptors I
( O
RXRs B
) O
, O
and O
VitD3 B
receptor I
( O
VDR B
) O
] O
in O
the O
U O
- O
937 O
cell O
line O
, O
in O
which O
RA O
and O
VitD3 O
induce O
distinct O
monocytic O
differentiation O
pathways O
. O

Therefore O
, O
we O
analyzed O
the O
expression O
, O
DNA O
binding O
, O
and O
transcriptional O
activity O
of O
the O
endogenous B
RA I
and I
VitD3 I
receptors I
[ O
retinoic B
acid I
receptors I
( O
RARs B
) O
, O
retinoid B
X I
receptors I
( O
RXRs B
) O
, O
and O
VitD3 B
receptor I
( O
VDR B
) O
] O
in O
the O
U O
- O
937 O
cell O
line O
, O
in O
which O
RA O
and O
VitD3 O
induce O
distinct O
monocytic O
differentiation O
pathways O
. O

Also O
, O
VitD3 O
inhibited O
the O
expression O
of O
CD23 B
and O
CD49f B
, O
characteristic O
markers O
of O
retinoid O
- O
induced O
U O
- O
937 O
cell O
differentiation O
. O

Also O
, O
VitD3 O
inhibited O
the O
expression O
of O
CD23 B
and O
CD49f B
, O
characteristic O
markers O
of O
retinoid O
- O
induced O
U O
- O
937 O
cell O
differentiation O
. O

Freshly O
isolated O
monocytes O
expressed O
94 B
- I
kD I
STAT5A I
, O
92 O
- O
kD O
STAT5B B
, O
and O
an O
80 B
- I
kD I
STAT5A I
molecule I
. O

Translocation B
( I
3 I
; I
14 I
) I
( I
q27 I
; I
q11 I
) I
: O
a O
new O
variant O
translocation O
in O
a O
patient O
with O
non O
- O
Hodgkin O
' O
s O
lymphoma O
of O
B O
- O
cell O
type O
with O
BCL6 B
rearrangement O
. O

Southern O
blot O
analysis O
showed O
rearrangement O
of O
BCL6 B
, O
JH B
, O
and O
TCR B
beta I
but O
not O
of O
TCR B
delta I
. O

Southern O
blot O
analysis O
showed O
rearrangement O
of O
BCL6 B
, O
JH B
, O
and O
TCR B
beta I
but O
not O
of O
TCR B
delta I
. O

B O
- O
cell O
immortalization O
by O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
is O
dependent O
on O
permanent O
control O
of O
the O
cellular O
processes O
which O
normally O
regulate O
cell O
division O
and O
apoptosis O
, O
functions O
possessed O
by O
p53 B
in O
a O
number O
of O
normal O
cell O
types O
. O

Latent B
membrane I
protein I
1 I
and O
, O
to O
a O
lesser O
extent O
, O
EBV B
nuclear I
antigen I
2 I
mediated O
the O
increase O
in O
p53 B
levels O
via O
activation O
of O
the O
NF B
- I
kappaB I
transcription B
factor I
. O

In O
the O
current O
studies O
, O
IL B
- I
2 I
production O
by O
T O
cells O
from O
elderly O
( O
mean O
78 O
years O
) O
and O
young O
( O
mean O
37 O
years O
) O
humans O
was O
measured O
in O
cultures O
stimulated O
with O
PHA B
, O
PHA B
plus O
PMA O
, O
crosslinked O
anti O
- O
CD3 O
mAB O
OKT3 O
plus O
PMA O
, O
or O
PMA O
plus O
ionomycin O
. O

In O
the O
current O
studies O
, O
IL B
- I
2 I
production O
by O
T O
cells O
from O
elderly O
( O
mean O
78 O
years O
) O
and O
young O
( O
mean O
37 O
years O
) O
humans O
was O
measured O
in O
cultures O
stimulated O
with O
PHA B
, O
PHA B
plus O
PMA O
, O
crosslinked O
anti O
- O
CD3 O
mAB O
OKT3 O
plus O
PMA O
, O
or O
PMA O
plus O
ionomycin O
. O

IL B
- I
13 I
caused O
rapid O
phosphorylation O
of O
the O
three O
out O
of O
four O
members O
of O
the O
known O
Janus B
family I
of I
kinases I
( O
JAKs B
) O
. O

IL B
- I
4 I
also O
stimulated O
all O
three O
kinases B
and O
substrates O
, O
but O
unlike O
in O
immune O
cells O
, O
IL B
- I
4 I
did O
not O
involve O
JAK3 B
activation O
for O
its O
signaling O
in O
colon O
cancer O
cell O
lines O
. O

IL B
- I
4 I
also O
stimulated O
all O
three O
kinases B
and O
substrates O
, O
but O
unlike O
in O
immune O
cells O
, O
IL B
- I
4 I
did O
not O
involve O
JAK3 B
activation O
for O
its O
signaling O
in O
colon O
cancer O
cell O
lines O
. O

Furthermore O
, O
JAK2 B
associated O
with O
the O
IL B
- I
4R I
p140 I
before O
and O
after O
stimulation O
with O
IL B
- I
13 I
. O

Electrophoretic O
mobility O
shift O
assay O
showed O
the O
induction O
of O
a O
CsA B
- I
resistant I
NFAT I
complex I
in O
the O
nuclear O
extracts O
of O
peripheral O
blood O
T O
cells O
stimulated O
with O
PMA O
plus O
alphaCD28 B
. O

In O
this O
study O
we O
have O
analysed O
the O
structural O
requirements O
for O
transcriptional O
activation O
by O
BSAP B
. O

We O
have O
demonstrated O
that O
the O
level O
of O
CRE B
binding I
protein I
( O
CREB B
) O
was O
the O
same O
in O
all O
cell O
lines O
and O
that O
the O
putative O
AR B
- I
CRE I
forms O
specific O
and O
compatible O
protein O
interactions O
with O
CREB B
. O

We O
have O
demonstrated O
that O
the O
level O
of O
CRE B
binding I
protein I
( O
CREB B
) O
was O
the O
same O
in O
all O
cell O
lines O
and O
that O
the O
putative O
AR B
- I
CRE I
forms O
specific O
and O
compatible O
protein O
interactions O
with O
CREB B
. O

In O
these O
cells O
, O
CD36 B
is O
involved O
in O
phagocytosis O
of O
apoptotic O
cells O
, O
and O
foam O
cell O
formation O
by O
uptake O
of O
oxidized B
low I
density I
lipoprotein I
. O

Appearance O
of O
the O
STAT1 B
factor O
is O
significantly O
reduced O
in O
the O
presence O
of O
cyclosporin O
A O
, O
and O
blocked O
by O
cycloheximide O
, O
indicating O
that O
its O
activation O
is O
dependent O
upon O
a O
protein O
( O
s O
) O
synthesized O
in O
response O
to O
initial O
signaling O
events O
. O

Neutralizing O
antiserum O
against O
IFN B
- I
gamma I
, O
but O
not O
other O
cytokines B
tested O
, O
blocked O
activation O
of O
the O
factor O
almost O
completely O
, O
and O
IFN B
- I
gamma I
was O
found O
in O
the O
culture O
supernatants O
of O
stimulated O
cells O
at O
levels O
at O
which O
recombinant O
IFN B
- I
gamma I
could O
activate O
the O
factor O
in O
naive O
cells O
. O

Therefore O
, O
a O
STAT1 B
transcription B
factor I
is O
activated O
by O
IFN B
- I
gamma I
synthesized O
and O
released O
upon O
stimulation O
of O
T O
lymphocyte O
populations O
. O

While O
Jurkat O
cells O
both O
secrete O
and O
respond O
to O
IFN B
- I
gamma I
in O
an O
autocrine O
loop O
, O
it O
seems O
likely O
that O
the O
responding O
cells O
may O
differ O
from O
those O
synthesizing O
this O
cytokine B
in O
the O
mononuclear O
cell O
cultures O
in O
the O
light O
of O
the O
recent O
report O
that O
Th1 O
cells O
lack O
the O
IFN B
- I
gamma I
receptor O
chain O
necessary O
for O
activation O
of O
STAT1 B
( O
Pernis O
, O
A O
. O
, O
Gupta O
, O
S O
. O
, O
Gollob O
, O
K O
. O
J O
. O
, O
Garfein O
, O
E O
. O
, O
Coffman O
, O
R O
. O
L O
. O
, O
Schindler O
, O
C O
. O
, O
and O
Rothman O

While O
Jurkat O
cells O
both O
secrete O
and O
respond O
to O
IFN B
- I
gamma I
in O
an O
autocrine O
loop O
, O
it O
seems O
likely O
that O
the O
responding O
cells O
may O
differ O
from O
those O
synthesizing O
this O
cytokine B
in O
the O
mononuclear O
cell O
cultures O
in O
the O
light O
of O
the O
recent O
report O
that O
Th1 O
cells O
lack O
the O
IFN B
- I
gamma I
receptor O
chain O
necessary O
for O
activation O
of O
STAT1 B
( O
Pernis O
, O
A O
. O
, O
Gupta O
, O
S O
. O
, O
Gollob O
, O
K O
. O
J O
. O
, O
Garfein O
, O
E O
. O
, O
Coffman O
, O
R O
. O
L O
. O
, O
Schindler O
, O
C O
. O
, O
and O
Rothman O

Based O
on O
the O
presence O
of O
T B
cell I
receptor I
- I
beta I
( I
TcR I
- I
beta I
) I
gene I
rearrangements I
in O
L428 O
and O
HDLM O
- O
1 O
cells O
, O
the O
expression O
of O
CD2 B
in O
HDLM O
- O
1 O
cells O
, O
and O
the O
presence O
of O
immunoglobulin B
heavy I
- I
chain I
( I
IgH I
) I
gene I
rearrangement I
in O
KM O
- O
H2 O
cells O
, O
some O
researchers O
have O
concluded O
that O
these O
long O
- O
term O
cell O
lines O
derived O
from O
patients O
with O
Hodgkin O
' O
s O
disease O
are O
lymphoid O
in O
nature O
. O

Expression O
of O
the O
MAP B
kinase I
- I
specific I
phosphatase I
, O
MKP B
- I
1 I
, O
which O
blocks O
ERK B
activation O
, O
inhibited O
IL B
- I
2 I
promoter I
and O
NF B
- I
AT I
- O
driven O
transcription O
stimulated O
by O
a O
calcium O
ionophore O
and O
PMA O
, O
and O
in O
addition O
, O
MKP B
- I
1 I
neutralized O
the O
transcriptional O
enhancement O
caused O
by O
active O
Raf O
- O
1 O
and O
MEK1 O
expression O
. O

Using O
these O
T O
cells O
as O
a O
model O
of O
IL B
- I
12 I
signal O
transduction O
, O
we O
confirmed O
that O
these O
events O
involve O
members O
of O
the O
Janus B
kinase I
family I
of O
nonreceptor B
tyrosine I
kinases I
JAK2 B
, O
TYK2 B
, O
and O
signal B
transducer I
and I
activator I
of I
transcription I
4 I
. O

Using O
these O
T O
cells O
as O
a O
model O
of O
IL B
- I
12 I
signal O
transduction O
, O
we O
confirmed O
that O
these O
events O
involve O
members O
of O
the O
Janus B
kinase I
family I
of O
nonreceptor B
tyrosine I
kinases I
JAK2 B
, O
TYK2 B
, O
and O
signal B
transducer I
and I
activator I
of I
transcription I
4 I
. O

Following O
PHA B
stimulation O
of O
PBL O
, O
the O
increase O
in O
AP B
- I
1 I
activity O
was O
delayed O
with O
respect O
to O
the O
augmentation O
of O
p39c B
- I
jun I
expression O
. O

However O
, O
no O
cytoplasmic B
p62c I
- I
fos I
was O
detected O
in O
unstimulated O
PBL O
, O
although O
in O
some O
cases O
cytoplasmic B
p39c I
- I
jun I
was O
detected O
, O
suggesting O
that O
subcellular O
compartmentalization O
of O
these O
proteins B
may O
occur O
under O
certain O
circumstances O
. O

However O
, O
the O
inducible O
degradation O
of O
p105 B
is O
not O
coupled O
with O
the O
generation O
of O
p50 B
. O

However O
, O
the O
inducible O
degradation O
of O
p105 B
is O
not O
coupled O
with O
the O
generation O
of O
p50 B
. O

Together O
, O
these O
studies O
demonstrate O
that O
the O
processing O
and O
inducible O
degradation O
of O
p105 B
are O
differentially O
regulated O
. O

However O
, O
synthesis O
of O
the O
26 B
- I
kDa I
membrane I
form I
of O
TNF B
was O
effectively O
blocked O
by O
CNI O
- O
1493 O
. O

r B
- I
hTBP I
- I
1 I
and O
rhu B
TNFR I
: I
Fc I
also O
decreased O
p24 B
antigen I
synthesized O
by O
U1 O
cells O
in O
response O
to O
other O
stimuli O
, O
including O
phytohemagglutinin B
( I
PHA I
) I
- I
induced I
supernatant I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
interleukin B
- I
6 I
, O
and O
TNF B
. O

Efficient O
gene O
activation O
requires O
the O
heterodimerization O
of O
VDR B
with O
Retinoid B
X I
Receptors I
( O
RXR B
) O
. O

Efficient O
gene O
activation O
requires O
the O
heterodimerization O
of O
VDR B
with O
Retinoid B
X I
Receptors I
( O
RXR B
) O
. O

We O
have O
generated O
rabbit O
antisera O
against O
this O
putative O
p13MTCP1 B
protein I
and O
screened O
for O
expression O
of O
p13MTCP1 B
normal O
lymphoid O
tissues O
and O
33 O
cases O
of O
immature O
and O
mature O
lymphoid O
T O
- O
cell O
proliferations O
using O
a O
sensitive O
Western O
blot O
assay O
. O

A O
variety O
of O
cytokines B
and O
growth B
factors I
act O
through O
an O
induction O
of O
gene O
expression O
mediated O
by O
a O
family O
of O
latent B
transcription I
factors I
called O
STAT B
( I
signal I
transducers I
and I
activators I
of I
transcription I
) I
proteins I
. O

Electrophoretic O
mobility O
shift O
assays O
( O
EMSAs O
) O
demonstrated O
that O
unstimulated O
monocytes O
predominantly O
expressed O
p50 B
NF B
- I
kappa I
B I
. O

However O
, O
the O
combined O
stimulation O
did O
not O
result O
in O
enhanced O
p50 B
and O
p65 B
protein I
expression O
. O

We O
conclude O
that O
the O
effects O
of O
IFN B
- I
gamma I
on O
the O
expression O
of O
the O
transcription B
factors I
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
may O
be O
important O
for O
the O
modulatory O
effects O
of O
IFN B
- I
gamma I
on O
the O
cytokine B
expression O
in O
activated O
human O
monocytes O
. O

The O
direct O
coupling O
between O
cytokine B
receptor I
and O
transcription B
factor I
helps O
to O
explain O
how O
different O
cytokines B
elicit O
distinct O
patterns O
of O
gene O
expression O
. O

Here O
we O
identify O
the O
gene O
encoding O
the O
lymphocyte B
homing I
and I
migration I
protein I
CD44 B
as O
a O
target O
of O
EGR1 B
regulation O
in O
B O
cells O
. O

Here O
we O
identify O
the O
gene O
encoding O
the O
lymphocyte B
homing I
and I
migration I
protein I
CD44 B
as O
a O
target O
of O
EGR1 B
regulation O
in O
B O
cells O
. O

The O
EGR1 B
binding I
motif I
was O
shown O
to O
be O
necessary O
for O
stimulus O
- O
induced O
expression O
of O
a O
CD44 B
promoter B
- I
chloramphenicol I
acetyltransferase I
reporter I
construct I
in O
nontransformed O
B O
lymphocytes O
and O
was O
required O
for O
transactivation O
by O
an O
EGR1 B
expression I
vector I
in O
a O
B O
- O
cell O
line O
. O

These O
studies O
identify O
EGR1 B
as O
an O
intermediary O
linking O
BCR B
- O
derived O
signals O
to O
the O
induction O
of O
CD44 B
. O

These O
studies O
identify O
EGR1 B
as O
an O
intermediary O
linking O
BCR B
- O
derived O
signals O
to O
the O
induction O
of O
CD44 B
. O

These O
studies O
identify O
EGR1 B
as O
an O
intermediary O
linking O
BCR B
- O
derived O
signals O
to O
the O
induction O
of O
CD44 B
. O

Electrophoretic O
mobility O
shift O
analyses O
demonstrated O
that O
the O
151 B
- I
bp I
region I
contains O
nuclear B
protein I
binding I
sites I
for O
Sp1 B
, O
PU B
. I
1 I
, O
and O
/ O
or O
Elf B
- I
1 I
, O
and O
a O
novel B
factor I
. O

IL B
- I
10 I
markedly O
reduces O
nuclear O
factor O
( B
NF I
) I
- I
kappa I
B I
/ I
Rel I
nuclear O
activity O
induced O
in O
PBMC O
by O
stimulation O
with O
the O
anti B
- I
CD3 I
mAb I
OKT3 B
. O

As O
judged O
by O
supershifting O
the O
DNA B
- I
protein I
complexes I
with O
Abs B
recognizing O
specific O
components O
of O
the O
NF B
- I
kappa I
B I
/ I
Rel I
protein I
family I
, O
the O
p50 B
/ I
p65 I
( O
Rel B
A I
) O
heterodimeric O
form O
of O
NF B
- I
kappa I
B I
is O
primarily O
affected O
. O

Expression O
of O
ATF B
- I
2 I
in O
S O
. O
cerevisiae O
did O
not O
activate O
TRE B
- I
1 I
in O
the O
presence O
of O
Tax B
. O

This O
shows O
that O
in O
a O
eukaryotic O
nucleus O
, O
Tax B
specifically O
interacts O
with O
the O
basic B
domain I
- I
leucine I
zipper I
region I
of O
ATF B
- I
1 I
, O
CREB B
, O
and O
CREM B
. O

This O
shows O
that O
in O
a O
eukaryotic O
nucleus O
, O
Tax B
specifically O
interacts O
with O
the O
basic B
domain I
- I
leucine I
zipper I
region I
of O
ATF B
- I
1 I
, O
CREB B
, O
and O
CREM B
. O

This O
shows O
that O
in O
a O
eukaryotic O
nucleus O
, O
Tax B
specifically O
interacts O
with O
the O
basic B
domain I
- I
leucine I
zipper I
region I
of O
ATF B
- I
1 I
, O
CREB B
, O
and O
CREM B
. O

Trapoxin O
is O
a O
microbially O
derived O
cyclotetrapeptide O
that O
inhibits O
histone B
deacetylation O
in O
vivo O
and O
causes O
mammalian O
cells O
to O
arrest O
in O
the O
cell O
cycle O
. O

Phorbol O
ester O
treatment O
of O
monocytes O
inhibited O
IFN O
alpha O
- O
stimulated O
tyrosine O
phosphorylation O
of O
the O
transcription B
factors I
Stat1alpha B
, O
Stat2 B
, O
and O
Stat3 B
and O
of O
the O
tyrosine B
kinase I
Tyk2 B
but O
had O
no O
effect O
on O
IFN B
- I
gamma I
activation O
of O
Stat1alpha B
. O

Phorbol O
ester O
treatment O
of O
monocytes O
inhibited O
IFN O
alpha O
- O
stimulated O
tyrosine O
phosphorylation O
of O
the O
transcription B
factors I
Stat1alpha B
, O
Stat2 B
, O
and O
Stat3 B
and O
of O
the O
tyrosine B
kinase I
Tyk2 B
but O
had O
no O
effect O
on O
IFN B
- I
gamma I
activation O
of O
Stat1alpha B
. O

Phorbol O
ester O
treatment O
of O
monocytes O
inhibited O
IFN O
alpha O
- O
stimulated O
tyrosine O
phosphorylation O
of O
the O
transcription B
factors I
Stat1alpha B
, O
Stat2 B
, O
and O
Stat3 B
and O
of O
the O
tyrosine B
kinase I
Tyk2 B
but O
had O
no O
effect O
on O
IFN B
- I
gamma I
activation O
of O
Stat1alpha B
. O

Phorbol O
ester O
treatment O
of O
monocytes O
inhibited O
IFN O
alpha O
- O
stimulated O
tyrosine O
phosphorylation O
of O
the O
transcription B
factors I
Stat1alpha B
, O
Stat2 B
, O
and O
Stat3 B
and O
of O
the O
tyrosine B
kinase I
Tyk2 B
but O
had O
no O
effect O
on O
IFN B
- I
gamma I
activation O
of O
Stat1alpha B
. O

Phorbol O
ester O
treatment O
of O
monocytes O
inhibited O
IFN O
alpha O
- O
stimulated O
tyrosine O
phosphorylation O
of O
the O
transcription B
factors I
Stat1alpha B
, O
Stat2 B
, O
and O
Stat3 B
and O
of O
the O
tyrosine B
kinase I
Tyk2 B
but O
had O
no O
effect O
on O
IFN B
- I
gamma I
activation O
of O
Stat1alpha B
. O

Pretreatment O
of O
cells O
with O
vanadate O
prevented O
the O
effects O
of O
PMA O
with O
regard O
to O
PMA O
- O
induced O
Tyk2 B
dephosphorylation O
. O

At O
this O
concentration O
, O
Ro O
13 O
- O
7410 O
potently O
inhibited O
G B
- I
CSF I
- O
stimulated O
myeloid O
as O
well O
as O
SCF B
+ O
Epo B
- O
induced O
erythroid O
colony O
growth O
. O

At O
this O
concentration O
, O
Ro O
13 O
- O
7410 O
potently O
inhibited O
G B
- I
CSF I
- O
stimulated O
myeloid O
as O
well O
as O
SCF B
+ O
Epo B
- O
induced O
erythroid O
colony O
growth O
. O

At O
the O
same O
concentration O
, O
Ro O
25 O
- O
6603 O
and O
Ro O
25 O
- O
7386 O
had O
little O
or O
no O
effect O
on O
G B
- I
CSF I
- O
induced O
colony O
formation O
, O
whereas O
they O
inhibited O
75 O
% O
and O
53 O
% O
, O
respectively O
, O
of O
SCF B
+ O
Epo B
- O
stimulated O
BFU O
- O
E O
colony O
growth O
. O

At O
the O
same O
concentration O
, O
Ro O
25 O
- O
6603 O
and O
Ro O
25 O
- O
7386 O
had O
little O
or O
no O
effect O
on O
G B
- I
CSF I
- O
induced O
colony O
formation O
, O
whereas O
they O
inhibited O
75 O
% O
and O
53 O
% O
, O
respectively O
, O
of O
SCF B
+ O
Epo B
- O
stimulated O
BFU O
- O
E O
colony O
growth O
. O

In O
NB4 O
cells O
, O
two O
other O
synthetic O
nonselective O
RAR O
ligands O
are O
capable O
of O
inducing O
LAP B
as O
much O
as O
AM580 O
, O
whereas O
RAR O
beta O
- O
or O
RAR O
gamma O
- O
specific O
ligands O
are O
totally O
ineffective O
. O

In O
addition O
, O
vitamin O
D O
- O
resistant O
cell O
nuclear O
extract O
contained O
a O
protein O
( O
s O
) O
which O
was O
bound O
specifically O
to O
the O
VDRE B
and O
was O
capable O
of O
completely O
inhibiting O
VDR B
- I
RXR I
- I
VDRE I
complex I
formation O
; O
these O
effects O
were O
not O
demonstrated O
with O
nuclear O
extract O
from O
the O
wild O
type O
cell O
line O
or O
with O
the O
post O
- O
nuclear O
extract O
of O
the O
vitamin O
D O
- O
resistant O
cell O
line O
. O

We O
conclude O
that O
a O
VDRE B
- I
binding I
protein I
( O
s O
) O
, O
distinct O
from O
IDBP B
and O
present O
in O
nuclear O
extract O
of O
cells O
from O
a O
prototypical O
vitamin O
D O
- O
resistant O
NWP O
, O
is O
capable O
of O
inhibiting O
normal O
VDR B
- I
RXR I
heterodimer O
binding O
to O
the O
VDRE B
. O

We O
conclude O
that O
a O
VDRE B
- I
binding I
protein I
( O
s O
) O
, O
distinct O
from O
IDBP B
and O
present O
in O
nuclear O
extract O
of O
cells O
from O
a O
prototypical O
vitamin O
D O
- O
resistant O
NWP O
, O
is O
capable O
of O
inhibiting O
normal O
VDR B
- I
RXR I
heterodimer O
binding O
to O
the O
VDRE B
. O

Finally O
, O
the O
activation O
- O
induced O
changes O
in O
one O
set O
of O
phosphoproteins B
were O
dramatically O
inhibited O
by O
cyclosporin O
A O
. O

Like O
IkappaBalpha B
, O
Tax B
- O
mediated O
breakdown O
of O
IkappaBbeta B
in O
transfected O
T O
lymphocytes O
is O
blocked O
either O
by O
cell O
- O
permeable O
proteasome O
inhibitors O
or O
by O
mutation O
Of O
IkappaBbeta B
at O
two O
serine O
residues O
present O
within O
its O
N B
- I
terminal I
region I
. O

Like O
IkappaBalpha B
, O
Tax B
- O
mediated O
breakdown O
of O
IkappaBbeta B
in O
transfected O
T O
lymphocytes O
is O
blocked O
either O
by O
cell O
- O
permeable O
proteasome O
inhibitors O
or O
by O
mutation O
Of O
IkappaBbeta B
at O
two O
serine O
residues O
present O
within O
its O
N B
- I
terminal I
region I
. O

Like O
IkappaBalpha B
, O
Tax B
- O
mediated O
breakdown O
of O
IkappaBbeta B
in O
transfected O
T O
lymphocytes O
is O
blocked O
either O
by O
cell O
- O
permeable O
proteasome O
inhibitors O
or O
by O
mutation O
Of O
IkappaBbeta B
at O
two O
serine O
residues O
present O
within O
its O
N B
- I
terminal I
region I
. O

Like O
IkappaBalpha B
, O
Tax B
- O
mediated O
breakdown O
of O
IkappaBbeta B
in O
transfected O
T O
lymphocytes O
is O
blocked O
either O
by O
cell O
- O
permeable O
proteasome O
inhibitors O
or O
by O
mutation O
Of O
IkappaBbeta B
at O
two O
serine O
residues O
present O
within O
its O
N B
- I
terminal I
region I
. O

Although O
a O
role O
of O
p16 B
in O
this O
regulation O
has O
been O
presumed O
, O
there O
is O
no O
proof O
so O
far O
that O
loss O
of O
this O
tumor B
suppressor I
gene I
really O
affects O
E2F B
- O
mediated O
regulations O
. O

Although O
a O
role O
of O
p16 B
in O
this O
regulation O
has O
been O
presumed O
, O
there O
is O
no O
proof O
so O
far O
that O
loss O
of O
this O
tumor B
suppressor I
gene I
really O
affects O
E2F B
- O
mediated O
regulations O
. O

We O
have O
isolated O
a O
novel B
cDNA I
clone I
encoding O
interferon B
( I
IFN I
) I
consensus I
sequence I
- I
binding I
protein I
in O
adult O
T O
- O
cell O
leukemia O
cell O
line O
or O
activated O
T O
cells O
( O
ICSAT B
) O
; O
this O
protein O
is O
the O
human O
homolog O
of O
the O
recently O
cloned O
Pip B
/ I
LSIRF I
. O

Here O
, O
we O
describe O
the O
effect O
of O
383 B
- I
bp I
( I
delta383 I
) I
and I
99 I
- I
bp I
( I
delta99 I
) I
sequences I
containing O
the O
PYBF B
- I
binding I
site I
on O
transcription O
from O
various O
globin O
and O
non O
- O
globin O
promoters O
, O
using O
a O
transient O
assay O
with O
the O
cat B
reporter I
gene I
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
, O
a O
cell O
line O
with O
abundant O
PYBF B
activity O
. O

Translocation B
breakpoints I
in O
three O
patients O
with O
campomelic O
dysplasia O
and O
autosomal O
sex O
reversal O
map O
more O
than O
130 O
kb O
from O
SOX9 B
. O

Campomelic O
dysplasia O
( O
CMPD1 O
) O
and O
autosomal O
XY O
sex O
reversal O
( O
SRA1 O
) O
are O
caused O
by O
mutations O
in O
the O
SRY B
- I
related I
gene I
SOX9 B
on O
17q B
. O

Campomelic O
dysplasia O
( O
CMPD1 O
) O
and O
autosomal O
XY O
sex O
reversal O
( O
SRA1 O
) O
are O
caused O
by O
mutations O
in O
the O
SRY B
- I
related I
gene I
SOX9 B
on O
17q B
. O

Unexpectedly O
, O
the O
17q B
breakpoints I
in O
four O
CMPD1 O
translocation O
cases O
previously O
analyzed O
by O
us O
and O
others O
map O
50 O
kb O
or O
more O
from O
SOX9 B
. O

Both O
CIITA B
and O
Bob1 B
increase O
the O
expression O
from O
the O
DRA B
promoter I
, O
which O
is O
a O
prototypic O
class B
II I
promoter I
. O

Both O
CIITA B
and O
Bob1 B
increase O
the O
expression O
from O
the O
DRA B
promoter I
, O
which O
is O
a O
prototypic O
class B
II I
promoter I
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB B
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB B
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB B
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB B
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB B
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB B
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB B
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB B
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB B
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB B
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB B
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

Ca2 B
+ I
- I
modulating I
cyclophilin I
ligand I
( O
CAML B
) O
was O
originally O
described O
as O
a O
cyclophilin B
B I
- I
binding I
protein I
whose O
overexpression O
in O
T O
cells O
causes O
a O
rise O
in O
intracellular O
calcium O
, O
thus O
activating O
transcription B
factors I
responsible O
for O
the O
early O
immune O
response O
. O

The O
chromosome B
17 I
breakpoint I
was O
localized O
to O
intron B
2 I
of O
RARA B
by O
Southern O
blotting O
, O
and O
there O
was O
no O
evidence O
at O
the O
molecular O
level O
for O
rearrangement O
at O
PML B
locus I
. O

Mutation O
of O
the O
consensus B
AP I
- I
1 I
/ I
CRE I
site I
within O
ZII B
abolished O
the O
inducibility O
of O
Zp B
by O
HHV O
- O
6 O
, O
whereas O
positioning O
of O
the O
ZII B
domain I
upstream O
of O
the O
beta B
- I
globin I
minimal I
promoter I
conferred O
responsiveness O
following O
HHV O
- O
6 O
infection O
. O

Mutation O
of O
the O
consensus B
AP I
- I
1 I
/ I
CRE I
site I
within O
ZII B
abolished O
the O
inducibility O
of O
Zp B
by O
HHV O
- O
6 O
, O
whereas O
positioning O
of O
the O
ZII B
domain I
upstream O
of O
the O
beta B
- I
globin I
minimal I
promoter I
conferred O
responsiveness O
following O
HHV O
- O
6 O
infection O
. O

Antibodies O
against O
CRE B
- I
binding I
( I
CREB I
) I
protein I
but O
not O
against O
c B
- I
Fos I
or O
c B
- I
Jun I
were O
able O
to O
supershift O
the O
DNA B
- I
protein I
complex I
, O
identifying O
the O
nature O
of O
the O
transcription B
factor I
which O
binds O
to O
ZII B
as O
a O
member O
of O
the O
CREB B
family I
of I
proteins I
. O

Although O
there O
have O
been O
a O
number O
of O
reports O
demonstrating O
that O
glucocorticoids O
( O
in O
particular O
dexamethasone O
) O
antagonize O
the O
eosinophil O
life O
- O
prolonging O
effects O
of O
hemopoietins B
, O
direct O
effects O
of O
dexamethasone O
on O
eosinophil O
apoptosis O
have O
not O
been O
documented O
. O

In O
an O
attempt O
to O
identify O
changes O
in O
gene O
expression O
that O
accompany O
the O
T O
- O
cell O
stimulation O
defects O
associated O
with O
the O
loss O
of O
Rel B
, O
we O
have O
examined O
the O
expression O
of O
cell B
surface I
activation I
markers I
and O
cytokine O
production O
in O
mitogen O
- O
stimulated O
Rel O
- O
/ O
- O
T O
cells O
. O

These O
findings O
establish O
that O
Rel B
can O
function O
as O
an O
activator O
or O
repressor O
of O
gene O
expression O
and O
is O
required O
by O
T O
lymphocytes O
for O
production O
of O
IL B
- I
3 I
and O
GM B
- I
CSF I
. O

Severe O
skewing O
of O
X O
inactivation O
resulting O
in O
inactivity O
of O
the O
intact O
X B
was O
found O
in O
blood O
and O
cultures O
of O
both O
types O
of O
skin O
, O
but O
analysis O
of O
DNA O
prepared O
directly O
from O
hypopigmented O
skin O
showed O
significant O
inactivation O
of O
the O
translocated O
X B
, O
inconsistent O
with O
the O
usual O
mechanism O
of O
phenotypic O
expression O
in O
X B
; I
autosome I
translocations I
. O

Severe O
skewing O
of O
X O
inactivation O
resulting O
in O
inactivity O
of O
the O
intact O
X B
was O
found O
in O
blood O
and O
cultures O
of O
both O
types O
of O
skin O
, O
but O
analysis O
of O
DNA O
prepared O
directly O
from O
hypopigmented O
skin O
showed O
significant O
inactivation O
of O
the O
translocated O
X B
, O
inconsistent O
with O
the O
usual O
mechanism O
of O
phenotypic O
expression O
in O
X B
; I
autosome I
translocations I
. O

While O
partial O
variable O
monosomy O
of O
loci O
on O
chromosome B
17p I
can O
not O
be O
excluded O
as O
contributing O
to O
the O
phenotype O
in O
this O
patient O
, O
it O
is O
argued O
that O
the O
major O
likely O
factor O
is O
partial O
functional O
disomy O
of O
sequences O
on O
Xp B
in O
cell O
lineages O
that O
have O
failed O
to O
inactivate O
the O
intact O
X B
chromosome I
. O

After O
several O
round O
of O
subcloning O
followed O
by O
transfection O
, O
oriP B
was O
mapped O
to O
a O
1 B
. I
955 I
- I
kb I
viral I
segment I
. O

Fas B
ligation O
induces O
apoptosis O
and O
Jun B
kinase I
activation O
independently O
of O
CD45 B
and O
Lck B
in O
human O
T O
cells O
. O

Fas B
ligation O
induces O
apoptosis O
and O
Jun B
kinase I
activation O
independently O
of O
CD45 B
and O
Lck B
in O
human O
T O
cells O
. O

Fas B
ligation O
induces O
apoptosis O
and O
Jun B
kinase I
activation O
independently O
of O
CD45 B
and O
Lck B
in O
human O
T O
cells O
. O

More O
is O
known O
regarding O
signal O
transduction O
events O
that O
occur O
after O
ligation O
of O
the O
T B
- I
cell I
antigen I
receptor I
( O
TCR B
) O
. O

Although O
prior O
studies O
suggest O
a O
role O
for O
protein B
tyrosine I
kinases I
and O
phosphatases O
in O
Fas B
signaling O
, O
we O
report O
here O
that O
Fas O
ligation O
induces O
apoptosis O
in O
T O
cells O
deficient O
in O
either O
CD45 B
or O
Lck B
. O

Although O
prior O
studies O
suggest O
a O
role O
for O
protein B
tyrosine I
kinases I
and O
phosphatases O
in O
Fas B
signaling O
, O
we O
report O
here O
that O
Fas O
ligation O
induces O
apoptosis O
in O
T O
cells O
deficient O
in O
either O
CD45 B
or O
Lck B
. O

Although O
prior O
studies O
suggest O
a O
role O
for O
protein B
tyrosine I
kinases I
and O
phosphatases O
in O
Fas B
signaling O
, O
we O
report O
here O
that O
Fas O
ligation O
induces O
apoptosis O
in O
T O
cells O
deficient O
in O
either O
CD45 B
or O
Lck B
. O

These O
data O
indicate O
that O
, O
in O
contrast O
to O
most O
LPS O
effects O
, O
AP B
- I
1 I
, O
but O
not O
nuclear B
factor I
- I
kappaB I
, O
mediates O
LPS O
induction O
of O
collagenase B
transcription O
in O
macrophagelike O
cells O
. O

LPS O
treatment O
of O
RAW O
264 O
. O
7 O
cells O
, O
murine O
bone O
marrow O
- O
derived O
macrophages O
, O
and O
the O
human O
monocyte O
cell O
line O
THP O
- O
1 O
resulted O
in O
rapid O
activation O
of O
the O
p46 B
and I
p54 I
isoforms I
of O
JNK B
. O

These O
results O
suggest O
that O
LPS O
activation O
of O
JNK B
in O
monocyte O
/ O
macrophage O
cells O
is O
a O
CD14 O
- O
and O
protein O
tyrosine O
phosphorylation O
- O
dependent O
event O
that O
may O
mediate O
the O
early O
activation O
of O
AP B
- I
1 I
in O
regulating O
LPS O
- O
triggered O
gene O
induction O
. O

Recombinant O
c B
- I
Jun I
and O
c B
- I
Fos I
were O
ubiquitinylated O
by O
the O
ubiquitin B
carrier I
enzymes I
E214K B
, O
E220K B
, O
or O
E232K B
in O
the O
presence O
of O
the O
ubiquitin B
- I
activating I
enzyme I
, O
E1 B
. O

Recombinant O
c B
- I
Jun I
and O
c B
- I
Fos I
were O
ubiquitinylated O
by O
the O
ubiquitin B
carrier I
enzymes I
E214K B
, O
E220K B
, O
or O
E232K B
in O
the O
presence O
of O
the O
ubiquitin B
- I
activating I
enzyme I
, O
E1 B
. O

Recombinant O
c B
- I
Jun I
and O
c B
- I
Fos I
were O
ubiquitinylated O
by O
the O
ubiquitin B
carrier I
enzymes I
E214K B
, O
E220K B
, O
or O
E232K B
in O
the O
presence O
of O
the O
ubiquitin B
- I
activating I
enzyme I
, O
E1 B
. O

Recombinant O
c B
- I
Jun I
and O
c B
- I
Fos I
were O
ubiquitinylated O
by O
the O
ubiquitin B
carrier I
enzymes I
E214K B
, O
E220K B
, O
or O
E232K B
in O
the O
presence O
of O
the O
ubiquitin B
- I
activating I
enzyme I
, O
E1 B
. O

mBob1 B
interacts O
with O
the O
octamer B
transcription I
factors I
Oct B
- I
1 I
and O
Oct B
- I
2 I
and O
stimulates O
transcription O
mediated O
by O
these O
factors O
. O

Moreover O
, O
gp120 B
induces O
tyrosine O
phosphorylation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
( O
STAT B
- I
1 I
alpha I
) O
as O
well O
as O
the O
Janus B
kinase I
( O
JAK2 B
) O
in O
glial O
cells O
. O

Moreover O
, O
gp120 B
induces O
tyrosine O
phosphorylation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
( O
STAT B
- I
1 I
alpha I
) O
as O
well O
as O
the O
Janus B
kinase I
( O
JAK2 B
) O
in O
glial O
cells O
. O

Northern O
blot O
analysis O
as O
well O
as O
Ab O
blocking O
and O
cytokine B
secretion O
studies O
indicated O
that O
the O
induction O
of O
either O
endogenous B
TNF I
- I
alpha I
or O
IL B
- I
10 I
was O
not O
involved O
in O
the O
cooperativity O
, O
nor O
was O
an O
up O
- O
regulation O
of O
TNF B
- I
alpha I
receptors I
. O

We O
identified O
a O
physical O
interaction O
between O
Tax B
and O
the O
HsN3 B
subunit I
of O
the O
human B
proteasome I
. O

This O
raises O
the O
intriguing O
possibility O
that O
physical O
association O
of O
the O
HsN3 B
proteasome I
subunit I
with O
HTLV B
- I
I I
Tax I
coupled O
with O
the O
independent O
interaction O
of O
Tax B
with O
either O
p100 O
or O
p65 O
- O
I B
kappa I
B I
alpha I
targets O
these O
cytoplasmic B
NF I
- I
kappa I
B I
/ I
Rel I
complexes I
to O
the O
proteasome B
for O
processing O
. O

This O
raises O
the O
intriguing O
possibility O
that O
physical O
association O
of O
the O
HsN3 B
proteasome I
subunit I
with O
HTLV B
- I
I I
Tax I
coupled O
with O
the O
independent O
interaction O
of O
Tax B
with O
either O
p100 O
or O
p65 O
- O
I B
kappa I
B I
alpha I
targets O
these O
cytoplasmic B
NF I
- I
kappa I
B I
/ I
Rel I
complexes I
to O
the O
proteasome B
for O
processing O
. O

Basement O
membrane O
immunoreactivity O
for O
type B
IV I
collagen I
and O
laminin B
was O
discontinuous O
in O
most O
examples O
of O
IDC O
regardless O
of O
type O
, O
with O
a O
trend O
toward O
more O
intense O
staining O
in O
comedo O
than O
in O
noncomedo O
carcinomas O
. O

We O
have O
focused O
on O
the O
study O
of O
the O
signal O
transduction O
pathways O
triggered O
by O
CD23 B
in O
human O
monocytes O
and O
the O
promonocytic O
cell O
line O
U937 O
. O

IkappaBalpha B
phosphorylation O
and O
degradation O
was O
analyzed O
by O
Western O
blot O
. O

Paclitaxel O
and O
other O
drugs O
that O
disturb O
microtubule B
dynamics O
kill O
cells O
in O
a O
Fas B
/ B
Fas I
ligand I
( O
FasL B
) O
- O
dependent O
manner O
; O
antibody O
to O
FasL B
inhibits O
paclitaxel O
- O
induced O
apoptosis O
. O

Paclitaxel O
and O
other O
drugs O
that O
disturb O
microtubule B
dynamics O
kill O
cells O
in O
a O
Fas B
/ B
Fas I
ligand I
( O
FasL B
) O
- O
dependent O
manner O
; O
antibody O
to O
FasL B
inhibits O
paclitaxel O
- O
induced O
apoptosis O
. O

Paclitaxel O
and O
other O
drugs O
that O
disturb O
microtubule B
dynamics O
kill O
cells O
in O
a O
Fas B
/ B
Fas I
ligand I
( O
FasL B
) O
- O
dependent O
manner O
; O
antibody O
to O
FasL B
inhibits O
paclitaxel O
- O
induced O
apoptosis O
. O

Paclitaxel O
and O
other O
drugs O
that O
disturb O
microtubule B
dynamics O
kill O
cells O
in O
a O
Fas B
/ B
Fas I
ligand I
( O
FasL B
) O
- O
dependent O
manner O
; O
antibody O
to O
FasL B
inhibits O
paclitaxel O
- O
induced O
apoptosis O
. O

Without O
NFAT B
nuclear O
translocation O
, O
the O
FasL B
gene O
is O
not O
transcribed O
. O

Without O
NFAT B
nuclear O
translocation O
, O
the O
FasL B
gene O
is O
not O
transcribed O
. O

Recently O
, O
we O
and O
others O
have O
shown O
that O
thrombopoietin B
induces O
rapid O
tyrosine O
phosphorylation O
of O
Jak2 B
and O
other O
proteins O
in O
human O
platelets O
and O
BaF3 O
cells O
, O
genetically O
engineered O
to O
express O
c B
- I
Mpl I
, O
a O
receptor O
for O
thrombopoietin B
. O

Recently O
, O
we O
and O
others O
have O
shown O
that O
thrombopoietin B
induces O
rapid O
tyrosine O
phosphorylation O
of O
Jak2 B
and O
other O
proteins O
in O
human O
platelets O
and O
BaF3 O
cells O
, O
genetically O
engineered O
to O
express O
c B
- I
Mpl I
, O
a O
receptor O
for O
thrombopoietin B
. O

Recently O
, O
we O
and O
others O
have O
shown O
that O
thrombopoietin B
induces O
rapid O
tyrosine O
phosphorylation O
of O
Jak2 B
and O
other O
proteins O
in O
human O
platelets O
and O
BaF3 O
cells O
, O
genetically O
engineered O
to O
express O
c B
- I
Mpl I
, O
a O
receptor O
for O
thrombopoietin B
. O

Thus O
, O
our O
data O
indicate O
that O
Stat3 B
and O
Stat5 B
may O
be O
involved O
in O
signal O
transduction O
after O
ligand O
binding O
to O
c B
- I
Mpl I
and O
that O
this O
event O
may O
have O
a O
role O
in O
megakaryopoiesis O
/ O
thrombopoiesis O
or O
possibly O
a O
mature O
platelet O
function O
such O
as O
aggregation O
. O

Thus O
, O
our O
data O
indicate O
that O
Stat3 B
and O
Stat5 B
may O
be O
involved O
in O
signal O
transduction O
after O
ligand O
binding O
to O
c B
- I
Mpl I
and O
that O
this O
event O
may O
have O
a O
role O
in O
megakaryopoiesis O
/ O
thrombopoiesis O
or O
possibly O
a O
mature O
platelet O
function O
such O
as O
aggregation O
. O

One O
such O
example O
is O
the O
excessive O
expression O
of O
` B
` I
normal I
' I
' I
lymphokines I
of O
cytokines B
which O
accompanies O
many O
lymphoproliferative O
diseases O
. O

The O
dysregulated O
expression O
of O
cytokines B
during O
malignancy O
can O
result O
in O
the O
augmentation O
of O
growth O
of O
transformed O
lymphocytes O
, O
as O
well O
as O
an O
alteration O
of O
the O
anti O
- O
tumor O
immune O
response O
. O

IL B
- I
4 I
activates O
gene O
expression O
by O
inducing O
tyrosine O
phosphorylation O
, O
homodimerization O
, O
and O
nuclear O
translocation O
of O
the O
latent B
transcription I
factor I
, O
STAT6 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
6 I
) O
. O

Because O
STAT6 B
activation O
is O
essential O
for O
IL B
- I
4 I
- O
induced O
gene O
expression O
, O
we O
examined O
the O
ability O
of O
type O
I O
and O
type O
II O
IFNs B
to O
regulate O
activation O
of O
STAT6 B
by O
IL B
- I
4 I
in O
primary O
human O
monocytes O
. O

Because O
STAT6 B
activation O
is O
essential O
for O
IL B
- I
4 I
- O
induced O
gene O
expression O
, O
we O
examined O
the O
ability O
of O
type O
I O
and O
type O
II O
IFNs B
to O
regulate O
activation O
of O
STAT6 B
by O
IL B
- I
4 I
in O
primary O
human O
monocytes O
. O

Because O
STAT6 B
activation O
is O
essential O
for O
IL B
- I
4 I
- O
induced O
gene O
expression O
, O
we O
examined O
the O
ability O
of O
type O
I O
and O
type O
II O
IFNs B
to O
regulate O
activation O
of O
STAT6 B
by O
IL B
- I
4 I
in O
primary O
human O
monocytes O
. O

In O
this O
study O
, O
we O
analyzed O
the O
binding O
activity O
of O
IL B
- I
10 I
- I
and I
IFN I
- I
gamma I
- I
activated I
STAT I
molecules I
to O
two O
kinds O
of O
GAS B
- O
motif O
sequences O
. O

A O
recent O
sib O
- O
pair O
analysis O
revealed O
a O
tight O
linkage O
between O
markers O
on O
5q31 B
. I
1 I
and O
a O
major B
susceptibility I
gene I
controlling O
total O
serum O
IgE B
levels O
. O

Since O
CLs O
can O
induce O
either O
apoptotic O
or O
necrotic O
cell O
death O
, O
we O
asked O
whether O
E1A B
sensitization O
to O
injury O
- O
induced O
apoptosis O
is O
sufficient O
to O
explain O
E1A B
- O
induced O
cytolytic O
susceptibility O
. O

Since O
CLs O
can O
induce O
either O
apoptotic O
or O
necrotic O
cell O
death O
, O
we O
asked O
whether O
E1A B
sensitization O
to O
injury O
- O
induced O
apoptosis O
is O
sufficient O
to O
explain O
E1A B
- O
induced O
cytolytic O
susceptibility O
. O

We O
find O
that O
TCL1 B
is O
expressed O
in O
the O
majority O
of O
AIDS O
IBLP O
tumors O
examined O
. O

They O
also O
indicate O
that O
abundant O
TCL1 B
expression O
in O
quiescent O
mantle O
zone O
B O
cells O
is O
down O
- O
regulated O
in O
activated O
germinal O
center O
follicular O
B O
cells O
in O
parallel O
to O
the O
known O
expression O
pattern O
of O
BCL B
- I
2 I
. O

High O
- O
level O
expression O
in O
nonproliferating O
B O
cells O
suggests O
that O
TCL1 B
may O
function O
in O
protecting O
naive O
preactivated O
B O
cells O
from O
apoptosis O
. O

Here O
, O
we O
report O
a O
model O
of O
CD28 B
costimulation O
using O
PMA O
plus O
the O
natural B
ligand I
CD80 I
that O
resulted O
in O
very O
limited O
stimulation O
of O
IL B
- I
2 I
, O
as O
evidenced O
by O
both O
cytokine B
production O
and O
IL B
- I
2 I
promoter I
stimulation O
. O

Here O
, O
we O
report O
a O
model O
of O
CD28 B
costimulation O
using O
PMA O
plus O
the O
natural B
ligand I
CD80 I
that O
resulted O
in O
very O
limited O
stimulation O
of O
IL B
- I
2 I
, O
as O
evidenced O
by O
both O
cytokine B
production O
and O
IL B
- I
2 I
promoter I
stimulation O
. O

We O
have O
determined O
that O
the O
JAK B
/ B
STAT I
pathway O
positively O
regulates O
Qp B
activity O
. O

We O
have O
determined O
that O
the O
JAK B
/ B
STAT I
pathway O
positively O
regulates O
Qp B
activity O
. O

In O
transient O
- O
transfection O
assays O
, O
a O
Qp B
- I
CAT I
reporter I
was O
activated O
by O
cotransfected O
JAK B
- I
1 I
and O
by O
treatment O
of O
cells O
with O
the O
cytokine B
IL B
- I
6 I
. O

Consistent O
with O
a O
role O
for O
STATs B
in O
Qp B
function O
, O
Qp B
using O
Burkitt O
' O
s O
lymphoma O
Rael O
cells O
and O
cultured O
nasopharyngeal O
carcinoma O
( O
NPC O
) O
cells O
contained O
nuclear O
STAT B
protein I
. O

Consistent O
with O
a O
role O
for O
STATs B
in O
Qp B
function O
, O
Qp B
using O
Burkitt O
' O
s O
lymphoma O
Rael O
cells O
and O
cultured O
nasopharyngeal O
carcinoma O
( O
NPC O
) O
cells O
contained O
nuclear O
STAT B
protein I
. O

Consistent O
with O
a O
role O
for O
STATs B
in O
Qp B
function O
, O
Qp B
using O
Burkitt O
' O
s O
lymphoma O
Rael O
cells O
and O
cultured O
nasopharyngeal O
carcinoma O
( O
NPC O
) O
cells O
contained O
nuclear O
STAT B
protein I
. O

This O
negative O
regulation O
required O
Zta B
DNA O
- O
binding O
activity O
. O

We O
provide O
evidence O
that O
Zta B
up O
- O
regulation O
of O
p53 B
leads O
to O
p53 B
- O
mediated O
interference O
with O
JAK B
/ B
STAT I
activation O
of O
Qp B
. O

We O
provide O
evidence O
that O
Zta B
up O
- O
regulation O
of O
p53 B
leads O
to O
p53 B
- O
mediated O
interference O
with O
JAK B
/ B
STAT I
activation O
of O
Qp B
. O

We O
provide O
evidence O
that O
Zta B
up O
- O
regulation O
of O
p53 B
leads O
to O
p53 B
- O
mediated O
interference O
with O
JAK B
/ B
STAT I
activation O
of O
Qp B
. O

We O
provide O
evidence O
that O
Zta B
up O
- O
regulation O
of O
p53 B
leads O
to O
p53 B
- O
mediated O
interference O
with O
JAK B
/ B
STAT I
activation O
of O
Qp B
. O

We O
provide O
evidence O
that O
Zta B
up O
- O
regulation O
of O
p53 B
leads O
to O
p53 B
- O
mediated O
interference O
with O
JAK B
/ B
STAT I
activation O
of O
Qp B
. O

We O
show O
here O
that O
the O
response O
of O
the O
HIV O
- O
1 O
long O
terminal O
repeat O
( O
LTR B
) O
to O
mitogenic O
or O
Tat B
- O
mediated O
activation O
is O
sensitive O
to O
the O
suppressive O
action O
of O
a O
Herpesvirus O
saimiri O
( O
HVS O
) O
- O
transformed O
CD8 O
+ O
T O
cell O
clone O
from O
an O
HIV O
- O
infected O
individual O
and O
supernatants O
from O
CD8 O
+ O
T O
cells O
of O
HIV O
- O
1 O
- O
infected O
asymptomatic O
subjects O
( O
CD4 B
+ I
> O
350 O
/ O
microliters O
) O
. O

We O
show O
here O
that O
the O
response O
of O
the O
HIV O
- O
1 O
long O
terminal O
repeat O
( O
LTR B
) O
to O
mitogenic O
or O
Tat B
- O
mediated O
activation O
is O
sensitive O
to O
the O
suppressive O
action O
of O
a O
Herpesvirus O
saimiri O
( O
HVS O
) O
- O
transformed O
CD8 O
+ O
T O
cell O
clone O
from O
an O
HIV O
- O
infected O
individual O
and O
supernatants O
from O
CD8 O
+ O
T O
cells O
of O
HIV O
- O
1 O
- O
infected O
asymptomatic O
subjects O
( O
CD4 B
+ I
> O
350 O
/ O
microliters O
) O
. O

Mutagenesis O
of O
NF B
kappa I
B I
or I
Sp I
- I
1 I
elements I
within O
the O
LTR B
resulted O
in O
no O
change O
in O
the O
ability O
of O
CD8 O
+ O
T O
cell O
supernatants O
to O
inhibit O
Tat O
- O
or O
mitogen O
- O
mediated O
LTR O
transcription O
. O

Taken O
together O
, O
these O
observations O
suggest O
that O
mitogenic O
activation O
, O
mediated O
primarily O
through O
the O
NF B
kappa I
B I
enhancer I
, O
is O
susceptible O
to O
CD8 B
- O
mediated O
inhibition O
, O
however O
, O
inhibition O
of O
Tat B
- O
mediated O
activation O
may O
rely O
upon O
a O
different O
pathway O
that O
is O
NFAT B
- I
1 I
dependent O
. O

Taken O
together O
, O
these O
observations O
suggest O
that O
mitogenic O
activation O
, O
mediated O
primarily O
through O
the O
NF B
kappa I
B I
enhancer I
, O
is O
susceptible O
to O
CD8 B
- O
mediated O
inhibition O
, O
however O
, O
inhibition O
of O
Tat B
- O
mediated O
activation O
may O
rely O
upon O
a O
different O
pathway O
that O
is O
NFAT B
- I
1 I
dependent O
. O

Induction O
of O
endothelial B
adhesion I
molecules I
by O
the O
cytokine B
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
can O
occur O
independently O
of O
protein B
kinase I
C I
and O
activation O
of O
a O
protein B
tyrosine I
kinase I
( O
PTK B
) O
has O
recently O
been O
implicated O
in O
the O
upregulation O
of O
vascular B
cell I
adhesion I
molecule I
1 I
( O
VCAM B
- I
1 I
) O
by O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
endothelial O
cells O
. O

Induction O
of O
endothelial B
adhesion I
molecules I
by O
the O
cytokine B
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
can O
occur O
independently O
of O
protein B
kinase I
C I
and O
activation O
of O
a O
protein B
tyrosine I
kinase I
( O
PTK B
) O
has O
recently O
been O
implicated O
in O
the O
upregulation O
of O
vascular B
cell I
adhesion I
molecule I
1 I
( O
VCAM B
- I
1 I
) O
by O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
endothelial O
cells O
. O

Induction O
of O
endothelial B
adhesion I
molecules I
by O
the O
cytokine B
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
can O
occur O
independently O
of O
protein B
kinase I
C I
and O
activation O
of O
a O
protein B
tyrosine I
kinase I
( O
PTK B
) O
has O
recently O
been O
implicated O
in O
the O
upregulation O
of O
vascular B
cell I
adhesion I
molecule I
1 I
( O
VCAM B
- I
1 I
) O
by O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
endothelial O
cells O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
constitutive O
expression O
of O
bcl B
- I
xl I
but O
not O
bcl B
- I
2 I
, O
bcl B
- I
xs I
, O
bak B
, O
bad B
, O
or O
bax B
was O
associated O
with O
apoptosis O
resistance O
after O
IL B
- I
2 I
deprivation O
in O
CTLL O
- O
2 O
cells O
that O
expressed O
Tax B
. O

In O
this O
study O
, O
we O
demonstrate O
that O
constitutive O
expression O
of O
bcl B
- I
xl I
but O
not O
bcl B
- I
2 I
, O
bcl B
- I
xs I
, O
bak B
, O
bad B
, O
or O
bax B
was O
associated O
with O
apoptosis O
resistance O
after O
IL B
- I
2 I
deprivation O
in O
CTLL O
- O
2 O
cells O
that O
expressed O
Tax B
. O

In O
this O
study O
, O
we O
demonstrate O
that O
constitutive O
expression O
of O
bcl B
- I
xl I
but O
not O
bcl B
- I
2 I
, O
bcl B
- I
xs I
, O
bak B
, O
bad B
, O
or O
bax B
was O
associated O
with O
apoptosis O
resistance O
after O
IL B
- I
2 I
deprivation O
in O
CTLL O
- O
2 O
cells O
that O
expressed O
Tax B
. O

In O
this O
study O
, O
we O
demonstrate O
that O
constitutive O
expression O
of O
bcl B
- I
xl I
but O
not O
bcl B
- I
2 I
, O
bcl B
- I
xs I
, O
bak B
, O
bad B
, O
or O
bax B
was O
associated O
with O
apoptosis O
resistance O
after O
IL B
- I
2 I
deprivation O
in O
CTLL O
- O
2 O
cells O
that O
expressed O
Tax B
. O

We O
find O
that O
recruitment O
of O
EKLF B
to O
5 B
' I
HS2 I
requires O
the O
TATA B
box I
, O
but O
recruitment O
to O
5 B
' I
HS3 I
depends O
on O
the O
CACCC O
and O
TATA B
boxes I
of O
the O
beta B
- I
globin I
promoter I
. O

We O
have O
found O
that O
the O
recruitment O
of O
EKLF B
to O
5 B
' I
HS3 I
depends O
on O
the O
presence O
of O
5 B
' I
HS2 I
in O
cis O
, O
but O
the O
recruitment O
to O
5 B
' I
HS2 I
does O
not O
depend O
on O
5 B
' I
HS3 I
. O

Based O
on O
these O
results O
, O
we O
present O
a O
model O
that O
illustrates O
how O
EKLF B
may O
be O
recruited O
to O
the O
beta B
- I
globin I
locus I
. O

We O
also O
report O
that O
in O
RAW O
264 O
. O
7 O
cells O
, O
an O
E O
( O
2 O
) O
receptor O
- O
positive O
murine O
monocytic O
line O
, O
E O
( O
2 O
) O
downregulates O
cytokine O
- O
induced O
TNF B
gene O
expression O
by O
decreasing O
the O
activity O
of O
the O
Jun B
NH I
( I
2 I
) I
- I
terminal I
kinase I
( O
JNK B
) O
. O

We O
also O
report O
that O
in O
RAW O
264 O
. O
7 O
cells O
, O
an O
E O
( O
2 O
) O
receptor O
- O
positive O
murine O
monocytic O
line O
, O
E O
( O
2 O
) O
downregulates O
cytokine O
- O
induced O
TNF B
gene O
expression O
by O
decreasing O
the O
activity O
of O
the O
Jun B
NH I
( I
2 I
) I
- I
terminal I
kinase I
( O
JNK B
) O
. O

The O
resulting O
diminished O
phosphorylation O
of O
c B
- I
Jun I
and O
JunD B
at O
their O
NH B
( I
2 I
) I
- I
termini I
decreases O
the O
ability O
of O
these O
nuclear O
proteins O
to O
autostimulate O
the O
expression O
of O
the O
c B
- I
Jun I
and I
JunD I
genes I
, O
thus O
leading O
to O
lower O
production O
of O
c B
- I
Jun I
and O
JunD B
. O

The O
resulting O
diminished O
phosphorylation O
of O
c B
- I
Jun I
and O
JunD B
at O
their O
NH B
( I
2 I
) I
- I
termini I
decreases O
the O
ability O
of O
these O
nuclear O
proteins O
to O
autostimulate O
the O
expression O
of O
the O
c B
- I
Jun I
and I
JunD I
genes I
, O
thus O
leading O
to O
lower O
production O
of O
c B
- I
Jun I
and O
JunD B
. O

Recent O
data O
show O
that O
TCR B
/ I
CD3 I
stimulation O
induces O
activation O
of O
Stat5 B
in O
murine O
T O
cells O
. O

In O
conclusion O
, O
we O
show O
that O
CD3 B
ligation O
by O
mAb B
and O
SE O
triggers O
a O
rapid O
, O
PP1 B
- O
sensitive O
tyrosine O
and O
serine O
phosphorylation O
of O
Stat3 B
in O
human O
CD4 O
+ O
T O
cells O
. O

In O
conclusion O
, O
we O
show O
that O
CD3 B
ligation O
by O
mAb B
and O
SE O
triggers O
a O
rapid O
, O
PP1 B
- O
sensitive O
tyrosine O
and O
serine O
phosphorylation O
of O
Stat3 B
in O
human O
CD4 O
+ O
T O
cells O
. O

In O
conclusion O
, O
we O
show O
that O
CD3 B
ligation O
by O
mAb B
and O
SE O
triggers O
a O
rapid O
, O
PP1 B
- O
sensitive O
tyrosine O
and O
serine O
phosphorylation O
of O
Stat3 B
in O
human O
CD4 O
+ O
T O
cells O
. O

In O
conclusion O
, O
we O
show O
that O
CD3 B
ligation O
by O
mAb B
and O
SE O
triggers O
a O
rapid O
, O
PP1 B
- O
sensitive O
tyrosine O
and O
serine O
phosphorylation O
of O
Stat3 B
in O
human O
CD4 O
+ O
T O
cells O
. O

Clusters O
of O
genes B
expressed O
by O
stromal O
cells O
and O
lymphocytes O
in O
the O
breast O
tumors O
also O
were O
identified O
in O
this O
analysis O
. O

Stimulation O
of O
T O
cells O
with O
calcium O
ionophore O
induced O
a O
shift O
in O
the O
molecular O
weight O
of O
NFATp B
that O
is O
due O
to O
its O
dephosphorylation O
. O

The O
B B
cell I
- I
associated I
surface I
molecule I
CD40 B
plays O
a O
key O
role O
in O
T O
cell O
- O
dependent O
B O
cell O
maturation O
, O
as O
individuals O
with O
defects O
in O
either O
CD40 B
or O
its O
ligand O
are O
impaired O
in O
immunoglobulin B
isotype O
class O
switching O
and O
germinal O
center O
formation O
. O

The O
B B
cell I
- I
associated I
surface I
molecule I
CD40 B
plays O
a O
key O
role O
in O
T O
cell O
- O
dependent O
B O
cell O
maturation O
, O
as O
individuals O
with O
defects O
in O
either O
CD40 B
or O
its O
ligand O
are O
impaired O
in O
immunoglobulin B
isotype O
class O
switching O
and O
germinal O
center O
formation O
. O

The O
B B
cell I
- I
associated I
surface I
molecule I
CD40 B
plays O
a O
key O
role O
in O
T O
cell O
- O
dependent O
B O
cell O
maturation O
, O
as O
individuals O
with O
defects O
in O
either O
CD40 B
or O
its O
ligand O
are O
impaired O
in O
immunoglobulin B
isotype O
class O
switching O
and O
germinal O
center O
formation O
. O

CD40 B
signaling O
activates O
downstream B
effectors I
, O
including O
the O
tyrosine B
protein I
kinase I
, O
Lyn B
, O
the O
phosphatidylinositol B
- I
3 I
- I
kinase I
( O
PI B
- I
3 I
kinase I
) O
, O
and O
the O
transcription O
factor O
, O
NF B
- I
kappa I
B I
. O

CD40 B
signaling O
activates O
downstream B
effectors I
, O
including O
the O
tyrosine B
protein I
kinase I
, O
Lyn B
, O
the O
phosphatidylinositol B
- I
3 I
- I
kinase I
( O
PI B
- I
3 I
kinase I
) O
, O
and O
the O
transcription O
factor O
, O
NF B
- I
kappa I
B I
. O

In O
this O
study O
, O
we O
demonstrate O
that O
stress B
- I
activated I
protein I
kinases I
( O
SAPK B
) O
are O
activated O
after O
CD40 B
cross O
- O
linking O
on O
various O
B O
cell O
lines O
or O
human O
tonsillar O
B O
cells O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
stress B
- I
activated I
protein I
kinases I
( O
SAPK B
) O
are O
activated O
after O
CD40 B
cross O
- O
linking O
on O
various O
B O
cell O
lines O
or O
human O
tonsillar O
B O
cells O
. O

In O
summary O
, O
CD40 B
signaling O
preferentially O
induces O
SAPK B
but O
not O
MAPK B
. O

In O
summary O
, O
CD40 B
signaling O
preferentially O
induces O
SAPK B
but O
not O
MAPK B
. O

In O
summary O
, O
CD40 B
signaling O
preferentially O
induces O
SAPK B
but O
not O
MAPK B
. O

Using O
CD45 O
- O
or O
CD3 O
- O
negative O
variants O
of O
the O
Jurkat O
leukemic O
T O
- O
cell O
line O
we O
show O
that O
the O
different O
biochemical O
events O
induced O
by O
pervanadate O
appeared O
to O
be O
dependent O
on O
the O
presence O
at O
the O
cell O
surface O
of O
either O
CD45 B
or O
CD3 B
. O

Using O
CD45 O
- O
or O
CD3 O
- O
negative O
variants O
of O
the O
Jurkat O
leukemic O
T O
- O
cell O
line O
we O
show O
that O
the O
different O
biochemical O
events O
induced O
by O
pervanadate O
appeared O
to O
be O
dependent O
on O
the O
presence O
at O
the O
cell O
surface O
of O
either O
CD45 B
or O
CD3 B
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

Previously O
, O
the O
action O
of O
MC903 O
and O
KH1060 O
was O
presumed O
to O
be O
mediated O
by O
the O
nuclear B
vitamin I
D I
receptor I
( O
VDRnuc B
) O
. O

These O
data O
suggest O
that O
although O
MC903 O
and O
KH1060 O
may O
bind O
the O
VDRnuc B
, O
that O
the O
differentiative O
activities O
of O
these O
agents O
requires O
nongenomic O
signaling O
pathways O
. O

Tax B
has O
been O
shown O
to O
transactivate O
several O
cellular B
genes I
. O

The O
other O
major O
subpopulation O
expressing O
the O
CD4 B
receptor I
, O
namely O
, O
the O
double O
- O
positive O
( O
DP O
) O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
CD3 O
( O
+ O
/ O
- O
) O
thymocytes O
, O
despite O
the O
entry O
of O
the O
virus O
, O
do O
not O
produce O
a O
significant O
level O
of O
virus O
, O
presumably O
because O
they O
are O
unresponsive O
to O
TNF B
and O
IL B
- I
7 I
. O

Activation O
of O
CD40 B
is O
essential O
for O
thymus O
- O
dependent O
humoral O
immune O
responses O
and O
rescuing O
B O
cells O
from O
apoptosis O
. O

MBP B
over O
the O
concentration O
range O
of O
0 O
. O
1 O
to O
10 O
microM O
stimulated O
the O
release O
of O
up O
to O
approximately O
8 O
ng O
/ O
ml O
IL B
- I
8 I
. O

MBP B
also O
induced O
transient O
increases O
in O
mRNA B
for O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
- I
1alpha I
and O
MIP B
- I
1beta I
, O
but O
did O
not O
stimulate O
the O
release O
of O
either O
chemokine B
. O

MBP B
also O
induced O
transient O
increases O
in O
mRNA B
for O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
- I
1alpha I
and O
MIP B
- I
1beta I
, O
but O
did O
not O
stimulate O
the O
release O
of O
either O
chemokine B
. O

MBP B
also O
induced O
transient O
increases O
in O
mRNA B
for O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
- I
1alpha I
and O
MIP B
- I
1beta I
, O
but O
did O
not O
stimulate O
the O
release O
of O
either O
chemokine B
. O

A O
high O
- O
affinity O
calcineurin B
- O
binding O
peptide O
was O
selected O
from O
combinatorial O
peptide O
libraries O
based O
on O
the O
calcineurin B
docking I
motif I
of O
NFAT B
. O

A O
high O
- O
affinity O
calcineurin B
- O
binding O
peptide O
was O
selected O
from O
combinatorial O
peptide O
libraries O
based O
on O
the O
calcineurin B
docking I
motif I
of O
NFAT B
. O

Substitution O
of O
the O
optimized O
peptide O
sequence O
into O
the O
natural O
calcineurin B
docking I
site I
increased O
the O
calcineurin B
responsiveness O
of O
NFAT B
. O

Substitution O
of O
the O
optimized O
peptide O
sequence O
into O
the O
natural O
calcineurin B
docking I
site I
increased O
the O
calcineurin B
responsiveness O
of O
NFAT B
. O

Compounds O
that O
interfere O
selectively O
with O
the O
calcineurin B
- B
NFAT I
interaction O
without O
affecting O
calcineurin B
phosphatase B
activity O
may O
be O
useful O
as O
therapeutic O
agents O
that O
are O
less O
toxic O
than O
current O
drugs O
. O

Compounds O
that O
interfere O
selectively O
with O
the O
calcineurin B
- B
NFAT I
interaction O
without O
affecting O
calcineurin B
phosphatase B
activity O
may O
be O
useful O
as O
therapeutic O
agents O
that O
are O
less O
toxic O
than O
current O
drugs O
. O

Compounds O
that O
interfere O
selectively O
with O
the O
calcineurin B
- B
NFAT I
interaction O
without O
affecting O
calcineurin B
phosphatase B
activity O
may O
be O
useful O
as O
therapeutic O
agents O
that O
are O
less O
toxic O
than O
current O
drugs O
. O

Thus O
, O
both O
copies O
of O
BRCA1 B
were O
retained O
in O
tumor O
. O

Therefore O
, O
we O
investigated O
whether O
IVS1 O
- O
10T O
- O
- O
> O
C O
deleteriously O
affected O
BRCA1 B
splicing O
or O
expression O
, O
and O
thereby O
inactivated O
the O
other O
BRCA1 B
allele I
. O

We O
have O
investigated O
mechanisms O
and O
consequences O
of O
STAT5 B
activation O
through O
the O
human B
IL I
- I
4 I
receptor I
( O
IL B
- I
4R I
) O
. O

By O
functionally O
expressing O
receptor B
mutants I
in O
the O
murine O
pro O
- O
B O
cell O
line O
Ba O
/ O
F3 O
, O
we O
could O
show O
that O
phosphorylated O
tyrosine O
residues O
within O
the O
IL B
- I
4R I
alpha I
chain I
are O
dispensable O
for O
IL B
- I
4 I
- O
induced O
STAT5 B
activity O
. O

RNA B
was O
extracted O
by O
phenol O
/ O
chloroform O
and O
c B
- I
fos I
expression O
was O
analyzed O
by O
PCR O
assisted O
mRNA O
assay O
. O

MNDA B
was O
not O
detected O
in O
normal O
tissue O
histiocytes O
but O
was O
found O
in O
activated O
macrophages O
and O
foreign O
body O
giant O
cells O
associated O
with O
inflammation O
. O

Flow O
cytometric O
cell O
sorting O
of O
normal O
bone O
marrow O
established O
that O
MNDA B
is O
initially O
expressed O
in O
myeloid O
blast O
cells O
. O

Peroxisome B
proliferator I
- I
activated I
receptors I
( O
PPARs B
) O
, O
members O
of O
the O
nuclear B
receptor I
superfamily I
of O
transcription B
factors I
, O
are O
activated O
by O
fatty O
acid O
metabolites O
, O
peroxisome O
proliferators O
, O
and O
thiazolidinediones O
and O
are O
now O
recognized O
as O
important O
mediators O
in O
the O
inflammatory O
response O
. O

Expression O
of O
wild B
- I
type I
SHP1 I
had O
a O
very O
small O
effect O
on O
the O
TCR O
- O
induced O
tyrosine O
phosphorylation O
of O
ZAP B
- I
70 I
and O
Syk B
, O
even O
when O
SHP1 B
was O
overexpressed O
20 O
- O
100 O
- O
fold O
over O
endogenous B
SHP1 I
. O

Expression O
of O
wild B
- I
type I
SHP1 I
had O
a O
very O
small O
effect O
on O
the O
TCR O
- O
induced O
tyrosine O
phosphorylation O
of O
ZAP B
- I
70 I
and O
Syk B
, O
even O
when O
SHP1 B
was O
overexpressed O
20 O
- O
100 O
- O
fold O
over O
endogenous B
SHP1 I
. O

However O
, O
the O
two O
SH2 B
domains I
of O
SHP1 B
did O
not O
facilitate O
its O
recognition O
of O
ZAP B
- I
70 I
and O
Syk B
as O
substrates O
in O
intact O
cells O
. O

However O
, O
the O
two O
SH2 B
domains I
of O
SHP1 B
did O
not O
facilitate O
its O
recognition O
of O
ZAP B
- I
70 I
and O
Syk B
as O
substrates O
in O
intact O
cells O
. O

Eosinophil B
granule I
major I
basic I
protein I
( O
MBP B
) O
is O
expressed O
exclusively O
in O
eosinophils O
and O
basophils O
in O
hematopoietic O
cells O
. O

Extracellular O
signal O
- O
regulated O
protein O
kinase O
( O
ERK O
) O
- O
dependent O
and O
ERK O
- O
independent O
pathways O
target O
STAT3 B
on O
serine O
- O
727 O
in O
human O
neutrophils O
stimulated O
by O
chemotactic B
factors I
and O
cytokines B
. O

Extracellular O
signal O
- O
regulated O
protein O
kinase O
( O
ERK O
) O
- O
dependent O
and O
ERK O
- O
independent O
pathways O
target O
STAT3 B
on O
serine O
- O
727 O
in O
human O
neutrophils O
stimulated O
by O
chemotactic B
factors I
and O
cytokines B
. O

( O
2 O
- O
Amino O
- O
3 O
' O
- O
methoxyphenyl O
) O
oxanaphthalen O
- O
4 O
- O
one O
( O
PD O
98059 O
) O
, O
an O
inhibitor O
of O
extracellular O
signal B
- I
regulated I
protein I
kinase I
( O
ERK B
) O
activation O
, O
blocked O
the O
serine O
phosphorylation O
of O
STAT3 B
induced O
by O
chemotactic B
factors I
or O
PMA O
. O

( O
2 O
- O
Amino O
- O
3 O
' O
- O
methoxyphenyl O
) O
oxanaphthalen O
- O
4 O
- O
one O
( O
PD O
98059 O
) O
, O
an O
inhibitor O
of O
extracellular O
signal B
- I
regulated I
protein I
kinase I
( O
ERK B
) O
activation O
, O
blocked O
the O
serine O
phosphorylation O
of O
STAT3 B
induced O
by O
chemotactic B
factors I
or O
PMA O
. O

After O
exercise O
following O
placebo O
administration O
we O
observed O
increases O
in O
concentrations O
of O
blood O
substrates O
, O
plasma B
adrenocorticotropin I
( O
ACTH B
) O
, O
growth O
hormone O
and O
cortisol O
and O
in O
the O
number O
of O
glucocorticoid B
receptors I
in O
lymphocytes O
without O
changes O
in O
the O
dissociation O
constant O
. O

Intravenous O
PCr O
injection O
led O
to O
smaller O
changes O
in O
ACTH B
and O
cortisol O
concentrations O
as O
well O
as O
to O
a O
lower O
activation O
of O
glucocorticoid O
binding O
in O
lymphocytes O
. O

In O
this O
study O
, O
we O
investigate O
the O
role O
of O
TNFalpha B
- O
inducible O
reactive O
oxygen O
species O
( O
ROS O
) O
in O
IL B
- I
8 I
expression O
by O
` O
` O
monocyte O
- O
like O
' O
' O
U937 O
histiocytic O
lymphoma O
cells O
. O

These O
data O
indicate O
that O
TNFalpha B
induces O
a O
delayed O
ROS O
- O
dependent O
signalling O
pathway O
that O
is O
required O
for O
NF B
- I
kappaB I
transcriptional O
activation O
and O
is O
separable O
from O
that O
required O
for O
its O
nuclear O
translocation O
. O

Protein B
kinase I
C I
and O
calcineurin B
synergize O
to O
activate O
IkappaB B
kinase I
and O
NF B
- I
kappaB I
in O
T O
lymphocytes O
. O

We O
also O
demonstrate O
that O
the O
IKK B
complex I
, O
but O
not O
p90 B
( I
rsk I
) I
, O
is O
responsible O
for O
the O
in O
vivo O
phosphorylation O
of O
IkappaBalpha B
mediated O
by O
the O
co O
- O
activation O
of O
PKC B
and O
calcineurin B
. O

We O
also O
demonstrate O
that O
the O
IKK B
complex I
, O
but O
not O
p90 B
( I
rsk I
) I
, O
is O
responsible O
for O
the O
in O
vivo O
phosphorylation O
of O
IkappaBalpha B
mediated O
by O
the O
co O
- O
activation O
of O
PKC B
and O
calcineurin B
. O

We O
also O
demonstrate O
that O
the O
IKK B
complex I
, O
but O
not O
p90 B
( I
rsk I
) I
, O
is O
responsible O
for O
the O
in O
vivo O
phosphorylation O
of O
IkappaBalpha B
mediated O
by O
the O
co O
- O
activation O
of O
PKC B
and O
calcineurin B
. O

The O
p53 B
paradox O
in O
the O
pathogenesis O
of O
tumor O
progression O
. O

Additional O
upstream O
gene O
segments O
dramatically O
affected O
B29 B
minimal B
promoter I
activity O
. O

A O
factor O
in O
bovine O
colostrum O
( O
colostrum B
inhibitory I
factor I
, O
CIF B
) O
inhibits O
interleukin B
2 I
( O
IL2 B
) O
production O
in O
activated O
T O
helper O
cells O
by O
blocking O
the O
accumulation O
of O
IL2 B
mRNA I
. O

A O
factor O
in O
bovine O
colostrum O
( O
colostrum B
inhibitory I
factor I
, O
CIF B
) O
inhibits O
interleukin B
2 I
( O
IL2 B
) O
production O
in O
activated O
T O
helper O
cells O
by O
blocking O
the O
accumulation O
of O
IL2 B
mRNA I
. O

To O
determine O
whether O
CIF B
blocks O
at O
the O
level O
of O
IL2 B
transcription O
, O
we O
introduced O
reporter O
plasmids O
into O
the O
human O
T O
leukemia O
cell O
line O
Jurkat O
by O
transient O
transfection O
. O

To O
determine O
whether O
CIF B
blocks O
at O
the O
level O
of O
IL2 B
transcription O
, O
we O
introduced O
reporter O
plasmids O
into O
the O
human O
T O
leukemia O
cell O
line O
Jurkat O
by O
transient O
transfection O
. O

The O
NFAT B
- I
controlled I
luciferase I
gene I
system I
distinguishes O
CIF B
from O
other O
T O
cell O
inhibitory O
activities O
present O
in O
colostrum O
, O
in O
particular O
, O
TGF B
beta I
1 I
and O
TGF B
beta I
2 I
and O
the O
glucocorticoids O
. O

The O
NFAT B
- O
luc O
assay O
is O
a O
useful O
technique O
for O
the O
rapid O
, O
sensitive O
measurement O
of O
CIF B
or O
other O
immunosuppressants O
with O
a O
similar O
mode O
of O
action O
. O

The O
NFAT B
- O
luc O
assay O
is O
a O
useful O
technique O
for O
the O
rapid O
, O
sensitive O
measurement O
of O
CIF B
or O
other O
immunosuppressants O
with O
a O
similar O
mode O
of O
action O
. O

To O
propel O
itself O
in O
infected O
cells O
, O
the O
pathogen O
Shigella O
flexneri O
subverts O
the O
Cdc42 B
- O
controlled O
machinery O
responsible O
for O
actin B
assembly O
during O
filopodia O
formation O
. O

To O
propel O
itself O
in O
infected O
cells O
, O
the O
pathogen O
Shigella O
flexneri O
subverts O
the O
Cdc42 B
- O
controlled O
machinery O
responsible O
for O
actin B
assembly O
during O
filopodia O
formation O
. O

Using O
a O
combination O
of O
bacterial O
motility O
assays O
in O
platelet O
extracts O
with O
Escherichia O
coli O
expressing O
the O
Shigella B
IcsA I
protein I
and O
in O
vitro O
analysis O
of O
reconstituted O
systems O
from O
purified B
proteins I
, O
we O
show O
here O
that O
the O
bacterial B
protein I
IcsA I
binds O
N B
- I
WASP I
and O
activates O
it O
in O
a O
Cdc42 B
- O
like O
fashion O
. O

VASP O
is O
not O
involved O
in O
Shigella O
movement O
, O
and O
the O
function O
of O
profilin B
does O
not O
require O
its O
binding O
to O
proline B
- I
rich I
regions I
. O

We O
have O
examined O
the O
effect O
of O
Rb B
expression O
on O
the O
activation O
of O
the O
promoter O
for O
HLA B
- I
DRA I
, O
the O
prototype B
class I
II I
gene I
. O

Activation O
of O
NF B
- I
kappa I
B I
is O
induced O
by O
prooxidants O
and O
several O
stimuli O
eliciting O
oxidative O
stress O
, O
such O
as O
cytokines B
, O
lipopolysaccharide O
, O
UV O
irradiation O
and O
other O
mediators O
. O

To O
better O
understand O
the O
assembly O
mechanism O
for O
the O
progesterone B
receptor I
( O
PR B
) O
, O
we O
have O
developed O
cell O
- O
free O
systems O
for O
studying O
interactions O
of O
PR B
, O
hsp90 B
, O
and O
other O
associated B
proteins I
. O

To O
better O
understand O
the O
assembly O
mechanism O
for O
the O
progesterone B
receptor I
( O
PR B
) O
, O
we O
have O
developed O
cell O
- O
free O
systems O
for O
studying O
interactions O
of O
PR B
, O
hsp90 B
, O
and O
other O
associated B
proteins I
. O

To O
better O
understand O
the O
assembly O
mechanism O
for O
the O
progesterone B
receptor I
( O
PR B
) O
, O
we O
have O
developed O
cell O
- O
free O
systems O
for O
studying O
interactions O
of O
PR B
, O
hsp90 B
, O
and O
other O
associated B
proteins I
. O

These O
interactions O
require O
ATP O
/ O
Mg2 O
+ O
and O
when O
ATP O
is O
limiting O
the O
PR B
complex O
is O
altered O
to O
one O
containing O
the O
proteins O
p60 B
and O
p48 B
, O
but O
lacking O
immunophilins B
and O
p23 B
. O

These O
interactions O
require O
ATP O
/ O
Mg2 O
+ O
and O
when O
ATP O
is O
limiting O
the O
PR B
complex O
is O
altered O
to O
one O
containing O
the O
proteins O
p60 B
and O
p48 B
, O
but O
lacking O
immunophilins B
and O
p23 B
. O

These O
interactions O
require O
ATP O
/ O
Mg2 O
+ O
and O
when O
ATP O
is O
limiting O
the O
PR B
complex O
is O
altered O
to O
one O
containing O
the O
proteins O
p60 B
and O
p48 B
, O
but O
lacking O
immunophilins B
and O
p23 B
. O

These O
interactions O
require O
ATP O
/ O
Mg2 O
+ O
and O
when O
ATP O
is O
limiting O
the O
PR B
complex O
is O
altered O
to O
one O
containing O
the O
proteins O
p60 B
and O
p48 B
, O
but O
lacking O
immunophilins B
and O
p23 B
. O

These O
interactions O
require O
ATP O
/ O
Mg2 O
+ O
and O
when O
ATP O
is O
limiting O
the O
PR B
complex O
is O
altered O
to O
one O
containing O
the O
proteins O
p60 B
and O
p48 B
, O
but O
lacking O
immunophilins B
and O
p23 B
. O

One O
contains O
hsp90 B
bound O
to O
hsp70 B
and O
p60 B
and O
this O
complex O
forms O
spontaneously O
in O
the O
absence O
of O
ATP O
. O

One O
contains O
hsp90 B
bound O
to O
hsp70 B
and O
p60 B
and O
this O
complex O
forms O
spontaneously O
in O
the O
absence O
of O
ATP O
. O

One O
contains O
hsp90 B
bound O
to O
hsp70 B
and O
p60 B
and O
this O
complex O
forms O
spontaneously O
in O
the O
absence O
of O
ATP O
. O

Since O
NF O
- O
kappaB O
/ O
IkappaB B
system O
regulates O
the O
transcription O
of O
proinflammatory B
genes I
, O
including O
those O
responsible O
for O
ROS O
generation O
, O
we O
tested O
the O
hypothesis O
that O
hydrocortisone O
may O
stimulate O
IkappaB B
production O
thus O
inhibiting O
NF B
- I
kappaB I
translocation O
from O
the O
cytosol O
into O
the O
nucleus O
in O
MNC O
, O
in O
vivo O
. O

Since O
NF O
- O
kappaB O
/ O
IkappaB B
system O
regulates O
the O
transcription O
of O
proinflammatory B
genes I
, O
including O
those O
responsible O
for O
ROS O
generation O
, O
we O
tested O
the O
hypothesis O
that O
hydrocortisone O
may O
stimulate O
IkappaB B
production O
thus O
inhibiting O
NF B
- I
kappaB I
translocation O
from O
the O
cytosol O
into O
the O
nucleus O
in O
MNC O
, O
in O
vivo O
. O

The O
total O
protein O
content O
of O
NF B
- I
kappaB I
subunit I
( O
P65 B
) O
in O
MNC O
lysates O
also O
showed O
a O
decrease O
following O
hydrocortisone O
injection O
. O

Our O
data O
demonstrate O
that O
hydrocortisone O
induces O
IkappaB B
and O
suppresses O
NF B
- I
kappaB I
expression O
in O
MNC O
in O
parallel O
. O

The O
inflammatory O
mediators O
lipopolysaccharide O
( O
LPS O
) O
and O
tumor B
necrosis I
factor I
( O
TNF B
) O
are O
potent O
activators O
of O
NF B
- I
kappaB I
. O

Kinase O
assays O
showed O
that O
TNF B
elicited O
a O
rapid O
but O
short O
- O
lived O
induction O
of O
IKK B
activity O
with O
a O
3 O
- O
fold O
greater O
effect O
on O
IKK B
- I
alpha I
than O
on O
IKK B
- I
beta I
, O
peaking O
at O
5 O
min O
. O

Kinase O
assays O
showed O
that O
TNF B
elicited O
a O
rapid O
but O
short O
- O
lived O
induction O
of O
IKK B
activity O
with O
a O
3 O
- O
fold O
greater O
effect O
on O
IKK B
- I
alpha I
than O
on O
IKK B
- I
beta I
, O
peaking O
at O
5 O
min O
. O

Furthermore O
, O
our O
studies O
showed O
association O
of O
the O
IKK B
- I
alpha I
/ I
beta I
heterodimer I
with O
NIK B
, O
IkappaB B
- I
alpha I
and O
- B
epsilon I
in O
unstimulated O
cells O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
ability O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
, O
a O
proinflammatory B
cytokine I
) O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
an O
anti B
- I
inflammatory I
cytokine I
) O
to O
differentially O
regulate O
the O
sensitivity O
of O
human O
monocytes O
/ O
macrophages O
to O
glucocorticoids O
. O

TNFalpha B
decreased O
( O
P O
< O
0 O
. O
001 O
) O
, O
while O
IL B
- I
10 I
increased O
( O
P O
< O
0 O
. O
001 O
) O
, O
the O
concentration O
of O
dexamethasone O
binding O
sites O
in O
these O
cells O
, O
with O
no O
discernible O
effect O
on O
their O
binding O
affinity O
. O

We O
conclude O
that O
glucocorticoids O
differentially O
modulate O
TNFalpha B
and O
IL B
- I
10 I
secretion O
by O
human O
monocytes O
in O
a O
LPS O
dose O
- O
dependent O
fashion O
and O
that O
the O
sensitivity O
of O
these O
cells O
to O
glucocorticoids O
is O
altered O
by O
TNFalpha B
or O
IL B
- I
10 I
pretreatment O
; O
TNFalpha B
blocks O
their O
effects O
, O
whereas O
IL B
- I
10 I
acts O
synergistically O
with O
glucocorticoids O
. O

We O
conclude O
that O
glucocorticoids O
differentially O
modulate O
TNFalpha B
and O
IL B
- I
10 I
secretion O
by O
human O
monocytes O
in O
a O
LPS O
dose O
- O
dependent O
fashion O
and O
that O
the O
sensitivity O
of O
these O
cells O
to O
glucocorticoids O
is O
altered O
by O
TNFalpha B
or O
IL B
- I
10 I
pretreatment O
; O
TNFalpha B
blocks O
their O
effects O
, O
whereas O
IL B
- I
10 I
acts O
synergistically O
with O
glucocorticoids O
. O

We O
conclude O
that O
glucocorticoids O
differentially O
modulate O
TNFalpha B
and O
IL B
- I
10 I
secretion O
by O
human O
monocytes O
in O
a O
LPS O
dose O
- O
dependent O
fashion O
and O
that O
the O
sensitivity O
of O
these O
cells O
to O
glucocorticoids O
is O
altered O
by O
TNFalpha B
or O
IL B
- I
10 I
pretreatment O
; O
TNFalpha B
blocks O
their O
effects O
, O
whereas O
IL B
- I
10 I
acts O
synergistically O
with O
glucocorticoids O
. O

Here O
, O
we O
investigate O
further O
the O
events O
triggered O
by O
TLR2 B
in O
response O
to O
LPS O
. O

Intracellular O
deletion O
variants O
of O
TLR2 B
lacking O
C O
- O
terminal O
13 O
or O
141 O
aa O
fail O
to O
recruit O
IRAK B
, O
which O
is O
consistent O
with O
the O
inability O
of O
these O
mutants O
to O
transmit O
LPS O
cellular O
signaling O
. O

Intracellular O
deletion O
variants O
of O
TLR2 B
lacking O
C O
- O
terminal O
13 O
or O
141 O
aa O
fail O
to O
recruit O
IRAK B
, O
which O
is O
consistent O
with O
the O
inability O
of O
these O
mutants O
to O
transmit O
LPS O
cellular O
signaling O
. O

Here O
we O
provide O
novel O
evidence O
that O
AG O
- O
490 O
potently O
inhibits O
the O
autokinase O
activity O
of O
JAK3 B
and O
tyrosine O
phosphorylation O
and O
DNA O
binding O
of O
signal B
transducer I
and I
activator I
of I
transcription I
5a I
and I
5b I
( I
STAT5a I
/ I
b I
) I
. O

Taken O
together O
, O
these O
findings O
suggest O
that O
AG O
- O
490 O
inhibits O
the O
JAK3 B
- O
mediated O
Type O
II O
signaling O
pathway O
but O
not O
the O
T O
cell O
receptor O
- O
derived O
Type O
I O
pathway O
and O
possesses O
therapeutic O
potential O
for O
T O
cell O
- O
derived O
pathologies O
such O
as O
graft O
- O
versus O
- O
host O
disease O
, O
allergy O
, O
and O
autoimmune O
disorders O
. O

Therefore O
, O
IRF B
- I
1 I
may O
be O
an O
important O
contributor O
to O
IL B
- I
12 I
signaling O
, O
and O
we O
speculate O
that O
the O
defective O
IL B
- I
12 I
responses O
seen O
in O
IRF B
- O
1 O
- O
/ O
- O
mice O
might O
be O
attributable O
, O
in O
part O
, O
to O
the O
absence O
of O
this O
transcription B
factor I
. O

To O
determine O
whether O
it O
is O
possible O
to O
artificially O
enhance O
the O
opening O
of O
the O
chromatin O
structure O
of O
a O
minimal B
beta I
- I
globin I
promoter I
, O
we O
placed O
a O
101bp O
, O
erythroid B
- I
specific I
DNase I
1 I
hypersensitive I
site I
- I
forming I
element I
( O
HSFE B
) O
immediately O
upstream O
of O
the O
beta B
- I
globin I
promoter I
and I
gene I
. O

Nuclear B
factor I
- I
90 I
of O
activated O
T O
- O
cells O
: O
A O
double B
- I
stranded I
RNA I
- O
binding O
protein O
and O
substrate O
for O
the O
double B
- I
stranded I
RNA I
- I
dependent I
protein I
kinase I
, O
PKR B
. O

Using O
in O
vitro O
translated O
polypeptides O
, O
we O
have O
demonstrated O
that O
NF90 B
specifically O
binds O
to O
double B
- I
stranded I
RNA I
. O

CD40 B
/ B
CD40 I
ligand O
interactions O
play O
a O
key O
role O
in O
the O
immune O
responses O
of O
B O
lymphocytes O
, O
monocytes O
, O
and O
dendritic O
cells O
. O

However O
, O
the O
components O
of O
the O
NF B
- I
kappaB I
complexes I
were O
different O
in O
monocytes O
and O
B O
cells O
, O
because O
p50 B
is O
part O
of O
the O
NF B
- I
kappaB I
complex I
induced O
by O
CD40 B
triggering O
in O
both O
monocytes O
and O
B O
cells O
, O
whereas O
p65 B
was O
only O
induced O
in O
B O
cells O
. O
In O
contrast O
, O
although O
the O
Janus B
kinase I
3 I
tyrosine I
kinase I
was O
associated O
with O
CD40 B
molecules O
in O
both O
monocytes O
and O
resting O
B O
cells O
, O
Janus B
kinase I
3 I
phosphorylation O
induction O
was O
observed O
only O
in O
CD40 O
- O
activated O
monocytes O
, O
with O
subsequent O
induction O
of O
STAT5a B
DNA O
binding O
activity O
in O
the O
nucleus O
. O

However O
, O
the O
components O
of O
the O
NF B
- I
kappaB I
complexes I
were O
different O
in O
monocytes O
and O
B O
cells O
, O
because O
p50 B
is O
part O
of O
the O
NF B
- I
kappaB I
complex I
induced O
by O
CD40 B
triggering O
in O
both O
monocytes O
and O
B O
cells O
, O
whereas O
p65 B
was O
only O
induced O
in O
B O
cells O
. O
In O
contrast O
, O
although O
the O
Janus B
kinase I
3 I
tyrosine I
kinase I
was O
associated O
with O
CD40 B
molecules O
in O
both O
monocytes O
and O
resting O
B O
cells O
, O
Janus B
kinase I
3 I
phosphorylation O
induction O
was O
observed O
only O
in O
CD40 O
- O
activated O
monocytes O
, O
with O
subsequent O
induction O
of O
STAT5a B
DNA O
binding O
activity O
in O
the O
nucleus O
. O

However O
, O
the O
components O
of O
the O
NF B
- I
kappaB I
complexes I
were O
different O
in O
monocytes O
and O
B O
cells O
, O
because O
p50 B
is O
part O
of O
the O
NF B
- I
kappaB I
complex I
induced O
by O
CD40 B
triggering O
in O
both O
monocytes O
and O
B O
cells O
, O
whereas O
p65 B
was O
only O
induced O
in O
B O
cells O
. O
In O
contrast O
, O
although O
the O
Janus B
kinase I
3 I
tyrosine I
kinase I
was O
associated O
with O
CD40 B
molecules O
in O
both O
monocytes O
and O
resting O
B O
cells O
, O
Janus B
kinase I
3 I
phosphorylation O
induction O
was O
observed O
only O
in O
CD40 O
- O
activated O
monocytes O
, O
with O
subsequent O
induction O
of O
STAT5a B
DNA O
binding O
activity O
in O
the O
nucleus O
. O

However O
, O
the O
components O
of O
the O
NF B
- I
kappaB I
complexes I
were O
different O
in O
monocytes O
and O
B O
cells O
, O
because O
p50 B
is O
part O
of O
the O
NF B
- I
kappaB I
complex I
induced O
by O
CD40 B
triggering O
in O
both O
monocytes O
and O
B O
cells O
, O
whereas O
p65 B
was O
only O
induced O
in O
B O
cells O
. O
In O
contrast O
, O
although O
the O
Janus B
kinase I
3 I
tyrosine I
kinase I
was O
associated O
with O
CD40 B
molecules O
in O
both O
monocytes O
and O
resting O
B O
cells O
, O
Janus B
kinase I
3 I
phosphorylation O
induction O
was O
observed O
only O
in O
CD40 O
- O
activated O
monocytes O
, O
with O
subsequent O
induction O
of O
STAT5a B
DNA O
binding O
activity O
in O
the O
nucleus O
. O

However O
, O
the O
components O
of O
the O
NF B
- I
kappaB I
complexes I
were O
different O
in O
monocytes O
and O
B O
cells O
, O
because O
p50 B
is O
part O
of O
the O
NF B
- I
kappaB I
complex I
induced O
by O
CD40 B
triggering O
in O
both O
monocytes O
and O
B O
cells O
, O
whereas O
p65 B
was O
only O
induced O
in O
B O
cells O
. O
In O
contrast O
, O
although O
the O
Janus B
kinase I
3 I
tyrosine I
kinase I
was O
associated O
with O
CD40 B
molecules O
in O
both O
monocytes O
and O
resting O
B O
cells O
, O
Janus B
kinase I
3 I
phosphorylation O
induction O
was O
observed O
only O
in O
CD40 O
- O
activated O
monocytes O
, O
with O
subsequent O
induction O
of O
STAT5a B
DNA O
binding O
activity O
in O
the O
nucleus O
. O

Interestingly O
, O
when O
we O
fused O
HT O
- O
2 O
cells O
expressing O
the O
EPOR B
with O
Ba O
/ O
F3 O
cells O
in O
a O
complementation O
assay O
, O
the O
resulting O
hybridomas O
proliferated O
and O
potently O
activated O
STAT B
- I
5 I
and O
MAPK B
in O
response O
to O
EPO B
. O

Interestingly O
, O
when O
we O
fused O
HT O
- O
2 O
cells O
expressing O
the O
EPOR B
with O
Ba O
/ O
F3 O
cells O
in O
a O
complementation O
assay O
, O
the O
resulting O
hybridomas O
proliferated O
and O
potently O
activated O
STAT B
- I
5 I
and O
MAPK B
in O
response O
to O
EPO B
. O

Interestingly O
, O
when O
we O
fused O
HT O
- O
2 O
cells O
expressing O
the O
EPOR B
with O
Ba O
/ O
F3 O
cells O
in O
a O
complementation O
assay O
, O
the O
resulting O
hybridomas O
proliferated O
and O
potently O
activated O
STAT B
- I
5 I
and O
MAPK B
in O
response O
to O
EPO B
. O

Moreover O
, O
Ba O
/ O
F3 O
cells O
apparently O
express O
this O
factor O
( O
s O
) O
and O
somatic O
fusions O
can O
, O
therefore O
, O
confer O
EPO B
- O
responsiveness O
to O
HT O
- O
2 O
cells O
that O
lack O
this O
factor O
. O

Selection O
and O
long O
- O
term O
persistence O
of O
reactive O
CTL O
clones O
during O
an O
EBV O
chronic O
response O
are O
determined O
by O
avidity O
, O
CD8 B
variable O
contribution O
compensating O
for O
differences O
in O
TCR B
affinities O
. O

Selection O
and O
long O
- O
term O
persistence O
of O
reactive O
CTL O
clones O
during O
an O
EBV O
chronic O
response O
are O
determined O
by O
avidity O
, O
CD8 B
variable O
contribution O
compensating O
for O
differences O
in O
TCR B
affinities O
. O

We O
found O
a O
wide O
range O
of O
TCR B
affinities O
among O
the O
different O
clonotypes O
that O
segregated O
with O
Vbeta O
usage O
. O

Packaging O
of O
viral O
particles O
, O
integration O
into O
the O
target O
genome O
, O
and O
stability O
of O
the O
integrated O
provirus O
are O
not O
affected O
by O
the O
LTR B
modification O
. O

These O
results O
indicate O
that O
ALG B
- I
4 I
is O
necessary O
and O
sufficient O
for O
FasL B
expression O
. O

We O
now O
find O
that O
LMP1 B
signaling O
through O
TRADD B
differs O
from O
TNFR1 B
signaling O
through O
TRADD B
. O

We O
now O
find O
that O
LMP1 B
signaling O
through O
TRADD B
differs O
from O
TNFR1 B
signaling O
through O
TRADD B
. O

We O
now O
find O
that O
LMP1 B
signaling O
through O
TRADD B
differs O
from O
TNFR1 B
signaling O
through O
TRADD B
. O

We O
now O
find O
that O
LMP1 B
signaling O
through O
TRADD B
differs O
from O
TNFR1 B
signaling O
through O
TRADD B
. O

Among O
upstream B
signaling I
molecules I
of O
ERK B
, O
Shc B
was O
constitutively O
associated O
with O
Grb2 O
and O
was O
not O
tyrosine O
- O
phosphorylated O
by O
GM B
- I
CSF I
and O
FMLP O
, O
and O
Sos1 B
and O
c B
- I
Raf I
- I
1 I
were O
not O
phosphorylated O
by O
GM B
- I
CSF I
, O
IL O
- O
3 O
, O
TNF O
, O
and O
FMLP O
in O
monocytes O
, O
whereas O
all O
these O
signaling O
molecules O
were O
affected O
and O
/ O
or O
utilized O
by O
GM B
- I
CSF I
in O
MO7e O
cells O
. O

Among O
upstream B
signaling I
molecules I
of O
ERK B
, O
Shc B
was O
constitutively O
associated O
with O
Grb2 O
and O
was O
not O
tyrosine O
- O
phosphorylated O
by O
GM B
- I
CSF I
and O
FMLP O
, O
and O
Sos1 B
and O
c B
- I
Raf I
- I
1 I
were O
not O
phosphorylated O
by O
GM B
- I
CSF I
, O
IL O
- O
3 O
, O
TNF O
, O
and O
FMLP O
in O
monocytes O
, O
whereas O
all O
these O
signaling O
molecules O
were O
affected O
and O
/ O
or O
utilized O
by O
GM B
- I
CSF I
in O
MO7e O
cells O
. O

Among O
upstream B
signaling I
molecules I
of O
ERK B
, O
Shc B
was O
constitutively O
associated O
with O
Grb2 O
and O
was O
not O
tyrosine O
- O
phosphorylated O
by O
GM B
- I
CSF I
and O
FMLP O
, O
and O
Sos1 B
and O
c B
- I
Raf I
- I
1 I
were O
not O
phosphorylated O
by O
GM B
- I
CSF I
, O
IL O
- O
3 O
, O
TNF O
, O
and O
FMLP O
in O
monocytes O
, O
whereas O
all O
these O
signaling O
molecules O
were O
affected O
and O
/ O
or O
utilized O
by O
GM B
- I
CSF I
in O
MO7e O
cells O
. O

In O
contrast O
to O
neutrophils O
, O
p38 B
was O
constitutively O
phosphorylated O
and O
agonist O
- O
dependent O
phosphorylation O
and O
activation O
was O
not O
detected O
in O
human O
monocytes O
. O

Functional O
analysis O
indicates O
that O
the O
BRs B
are O
involved O
in O
control O
of O
hIL B
- I
5 I
promoter I
activity O
. O

PNU156804 O
action O
is O
restricted O
to O
some O
signaling O
pathways O
; O
it O
does O
not O
affect O
NF B
- I
kappa I
B I
activation O
by O
PMA O
in O
T O
cells O
but O
blocks O
that O
induced O
by O
CD40 B
cross O
- O
linking O
in O
B O
lymphocytes O
. O

The O
expression O
of O
STAT1 B
and O
STAT5 B
in O
a O
human O
T O
- O
cell O
line O
was O
induced O
by O
Tax B
. O

The O
expression O
of O
STAT1 B
and O
STAT5 B
in O
a O
human O
T O
- O
cell O
line O
was O
induced O
by O
Tax B
. O

The O
expression O
of O
STAT1 B
and O
STAT5 B
in O
a O
human O
T O
- O
cell O
line O
was O
induced O
by O
Tax B
. O

We O
used O
an O
adenoviral O
technique O
of O
blocking O
NF B
- I
kappaB I
through O
overexpression O
of O
the O
inhibitory B
subunit I
IkappaBalpha B
, O
which O
has O
the O
advantage O
that O
it O
can O
be O
used O
in O
the O
diseased O
tissue O
itself O
, O
with O
> O
90 O
% O
of O
the O
synovial O
macrophages O
, O
fibroblasts O
, O
and O
T O
cells O
infected O
. O

Of O
even O
more O
interest O
, O
IkappaBalpha B
overexpression O
inhibited O
the O
production O
of O
matrix B
metalloproteinases I
1 I
and I
3 I
while O
not O
affecting O
their O
tissue O
inhibitor O
. O

A O
high O
expression O
of O
WT1 B
has O
been O
detected O
in O
a O
range O
of O
acute O
leukemias O
, O
and O
WT1 B
is O
downregulated O
during O
induced O
differentiation O
of O
some O
leukemic O
cell O
lines O
. O

A O
high O
expression O
of O
WT1 B
has O
been O
detected O
in O
a O
range O
of O
acute O
leukemias O
, O
and O
WT1 B
is O
downregulated O
during O
induced O
differentiation O
of O
some O
leukemic O
cell O
lines O
. O

K562 O
cells O
express O
endogenous O
WT1 B
, O
which O
is O
downregulated O
as O
a O
response O
to O
induced O
differentiation O
along O
the O
erythroid O
and O
megakaryocytic O
pathways O
. O

However O
, O
activation O
of O
STAT6 B
, O
CD23 B
expression O
, O
and O
IgE B
synthesis O
induced O
by O
IL B
- I
4 I
were O
not O
affected O
in O
p47phox O
- O
deficient O
patients O
, O
which O
raises O
the O
possibility O
that O
p47phox O
may O
be O
important O
in O
other O
signaling O
activities O
as O
well O
in O
B O
cells O
. O

However O
, O
activation O
of O
STAT6 B
, O
CD23 B
expression O
, O
and O
IgE B
synthesis O
induced O
by O
IL B
- I
4 I
were O
not O
affected O
in O
p47phox O
- O
deficient O
patients O
, O
which O
raises O
the O
possibility O
that O
p47phox O
may O
be O
important O
in O
other O
signaling O
activities O
as O
well O
in O
B O
cells O
. O

However O
, O
activation O
of O
STAT6 B
, O
CD23 B
expression O
, O
and O
IgE B
synthesis O
induced O
by O
IL B
- I
4 I
were O
not O
affected O
in O
p47phox O
- O
deficient O
patients O
, O
which O
raises O
the O
possibility O
that O
p47phox O
may O
be O
important O
in O
other O
signaling O
activities O
as O
well O
in O
B O
cells O
. O

METHODS O
: O
Protein O
production O
in O
supernatants O
was O
assessed O
by O
ELISA O
, O
and O
mRNA B
expression O
was O
evaluated O
by O
semiquantitative O
RT O
- O
PCR O
. O

Messenger B
RNA I
production O
coding O
for O
IL B
- I
8 I
, O
RANTES B
, O
and O
MCP B
- I
1 I
showed O
parallel O
variations O
to O
the O
production O
of O
the O
correspondent B
proteins I
. O

Furthermore O
, O
SLP B
- I
76 I
and O
Vav B
have O
a O
synergistic O
effect O
on O
interleukin B
( I
IL I
) I
- I
2 I
promoter I
activity O
in O
T O
cells O
. O

Surprisingly O
, O
we O
find O
also O
that O
the O
interaction O
between O
SLP B
- I
76 I
and O
Vav B
is O
not O
required O
for O
their O
cooperation O
in O
augmenting O
IL B
- I
2 I
promoter I
activity O
, O
as O
the O
two O
molecules O
appear O
to O
function O
in O
different O
signaling O
pathways O
upstream O
of O
IL B
- I
2 I
gene I
expression O
. O

In O
contrast O
, O
overexpression O
of O
Vav B
leads O
to O
enhanced O
nuclear B
factor I
of I
activated I
T I
cells I
activity O
without O
affecting O
AP B
- I
1 I
. O

Additionally O
, O
overexpression O
of O
Vav B
, O
but O
not O
SLP B
- I
76 I
, O
augments O
CD28 O
- O
induced O
IL B
- I
2 I
promoter I
activity O
. O

Here O
, O
we O
show O
that O
Jagged1 B
is O
a O
Rel B
/ I
NF I
- I
kappaB I
- I
responsive I
gene I
. O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

inhibited O
by O
dominant O
negative O
c B
- I
Fos I
; O
and O
( O
iv O
) O
PGN O
- O
induced O
activation O
of O
CREB B
/ I
ATF I
and O
AP B
- I
1 I
was O
mediated O
through O
CD14 B
. O

In O
contrast O
to O
these O
findings O
, O
mucosal O
hGR B
levels O
were O
significantly O
decreased O
in O
both O
steroid O
- O
treated O
( O
18 O
. O
0 O
+ O
/ O
- O
15 O
. O
5 O
) O
and O
not O
steroid O
- O
treated O
( O
37 O
. O
8 O
+ O
/ O
- O
30 O
. O
5 O
) O
patients O
compared O
with O
control O
subjects O
( O
125 O
. O
6 O
+ O
/ O
- O
97 O
. O
1 O
; O
P O
= O
0 O
. O
00009 O
and O
P O
= O
0 O
. O
0008 O
respectively O
) O
. O

In O
this O
study O
, O
we O
created O
transgenic O
mice O
overexpressing O
ICSAT B
in O
lymphocytes O
. O

Repression O
by O
Ikaros B
and O
Aiolos B
is O
mediated O
through O
histone B
deacetylase I
complexes I
. O

Repression O
by O
Ikaros B
and O
Aiolos B
is O
mediated O
through O
histone B
deacetylase I
complexes I
. O

To O
better O
understand O
signals O
controlling O
proliferation O
and O
viability O
, O
erythroid O
cells O
that O
resist O
apoptosis O
in O
the O
absence O
of O
EPO B
were O
subcloned O
and O
characterized O
( O
HCD57 O
- O
SREI O
cells O
) O
. O

Enforced O
expression O
of O
Id3 B
, O
which O
has O
the O
capacity O
to O
inhibit O
many O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
transcription I
factors I
, O
in O
human O
CD34 O
( O
+ O
) O
hematopoietic O
progenitor O
cells O
that O
have O
not O
undergone O
T B
cell I
receptor I
( I
TCR I
) I
gene I
rearrangements I
inhibits O
development O
of O
the O
transduced O
cells O
into O
TCRalpha O
beta O
and O
gamma O
delta O
cells O
in O
a O
fetal O
thymic O
organ O
culture O
( O
FTOC O
) O
. O

HIV O
- O
1 O
reactivation O
in O
resting O
peripheral O
blood O
mononuclear O
cells O
of O
infected O
adults O
upon O
in O
vitro O
CD4 B
cross O
- O
linking O
by O
ligands O
of O
the O
CDR2 B
- I
loop I
in O
extracellular B
domain I
1 I
. O

Additionally O
, O
virus O
reactivation O
in O
resting O
PBMCs O
infected O
in O
vitro O
with O
HIV O
- O
1 O
was O
found O
to O
be O
specifically O
induced O
by O
ligands O
of O
the O
CDR2 B
- I
loop I
in O
domain B
1 I
( O
D1 B
) O
of O
CD4 B
( O
virus B
envelope I
and I
anti I
- I
CD4 I
monoclonal I
antibodies I
) O
. O

Additionally O
, O
virus O
reactivation O
in O
resting O
PBMCs O
infected O
in O
vitro O
with O
HIV O
- O
1 O
was O
found O
to O
be O
specifically O
induced O
by O
ligands O
of O
the O
CDR2 B
- I
loop I
in O
domain B
1 I
( O
D1 B
) O
of O
CD4 B
( O
virus B
envelope I
and I
anti I
- I
CD4 I
monoclonal I
antibodies I
) O
. O

In O
contrast O
, O
virus O
reactivation O
was O
not O
observed O
following O
CD4 B
oligomerization O
by O
antibodies B
that O
bind O
other O
epitopes O
in O
D1 B
, O
including O
the O
D1 B
/ I
CDR3 I
- I
loop I
. O

In O
contrast O
, O
virus O
reactivation O
was O
not O
observed O
following O
CD4 B
oligomerization O
by O
antibodies B
that O
bind O
other O
epitopes O
in O
D1 B
, O
including O
the O
D1 B
/ I
CDR3 I
- I
loop I
. O

In O
contrast O
, O
virus O
reactivation O
was O
not O
observed O
following O
CD4 B
oligomerization O
by O
antibodies B
that O
bind O
other O
epitopes O
in O
D1 B
, O
including O
the O
D1 B
/ I
CDR3 I
- I
loop I
. O

Our O
results O
indicate O
that O
the O
signaling O
events O
initiated O
in O
PBMCs O
by O
oligomerization O
of O
CD4 B
at O
the O
D1 B
/ I
CDR2 I
- I
loop I
can O
trigger O
HIV O
- O
1 O
upregulation O
in O
infected O
individuals O
. O

The O
mAECA B
, O
but O
not O
normal B
human I
IgG I
, O
had O
anti O
- O
human O
aortic O
EC O
activity O
. O

Four O
of O
the O
6 O
mAECA B
activated O
EC O
, O
manifested O
by O
increased O
IL B
- I
6 I
and O
vWF O
secretion O
. O

Both O
PPARalpha B
activators O
decreased O
cytokine O
- O
induced O
VCAM B
- I
1 I
mRNA O
expression O
without O
altering O
its O
mRNA O
half O
- O
life O
. O

Such O
findings O
also O
have O
implications O
regarding O
the O
clinical O
use O
of O
lipid O
- O
lowering O
agents O
, O
like O
fibric O
acids O
, O
which O
can O
activate O
PPARalpha B
. O

CBP B
/ I
p300 I
integrates O
Raf B
/ O
Rac B
- O
signaling O
pathways O
in O
the O
transcriptional O
induction O
of O
NF B
- I
ATc I
during O
T O
cell O
activation O
. O

CBP B
/ I
p300 I
integrates O
Raf B
/ O
Rac B
- O
signaling O
pathways O
in O
the O
transcriptional O
induction O
of O
NF B
- I
ATc I
during O
T O
cell O
activation O
. O

The O
effect O
of O
oestrogens O
on O
oestrogen O
- O
receptive O
organs O
and O
cells O
is O
mediated O
via O
intracellular B
receptors I
( O
ERalpha B
and O
ERbeta B
) O
. O

The O
effect O
of O
oestrogens O
on O
oestrogen O
- O
receptive O
organs O
and O
cells O
is O
mediated O
via O
intracellular B
receptors I
( O
ERalpha B
and O
ERbeta B
) O
. O

USF B
/ I
c I
- I
Myc I
enhances O
, O
while O
Yin B
- I
Yang I
1 I
suppresses O
, O
the O
promoter O
activity O
of O
CXCR4 B
, O
a O
coreceptor B
for O
HIV O
- O
1 O
entry O
. O

USF B
/ I
c I
- I
Myc I
enhances O
, O
while O
Yin B
- I
Yang I
1 I
suppresses O
, O
the O
promoter O
activity O
of O
CXCR4 B
, O
a O
coreceptor B
for O
HIV O
- O
1 O
entry O
. O

RCC O
- O
S O
did O
not O
alter O
the O
cytoplasmic O
levels O
of O
RelA B
and O
NF B
- I
kappaB1 I
but O
did O
suppress O
their O
nuclear O
localization O
and O
inhibited O
the O
activation O
of O
RelA B
/ I
NF I
- I
kappaB1 I
binding I
complexes I
. O

We O
investigated O
the O
involvement O
of O
signal B
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
factors I
in O
this O
phenomenon O
and O
reported O
the O
specific O
, O
time O
- O
dependent O
, O
activation O
of O
STAT1 B
protein O
starting O
at O
day O
0 O
/ O
1 O
of O
cultivation O
and O
maximally O
expressed O
at O
day O
5 O
. O

STAT1 B
activity O
was O
evident O
on O
the O
STAT B
binding I
sequences I
( O
SBE B
) O
present O
in O
the O
promoters B
of O
genes O
which O
are O
up O
- O
regulated O
during O
monocyte O
to O
macrophage O
maturation O
such O
as O
FcgammaRI B
and O
ICAM B
- I
1 I
, O
and O
in O
the O
promoter O
of O
the O
transcription B
factor I
IFN I
regulatory I
factor I
- I
1 I
. O

STAT1 B
activity O
was O
evident O
on O
the O
STAT B
binding I
sequences I
( O
SBE B
) O
present O
in O
the O
promoters B
of O
genes O
which O
are O
up O
- O
regulated O
during O
monocyte O
to O
macrophage O
maturation O
such O
as O
FcgammaRI B
and O
ICAM B
- I
1 I
, O
and O
in O
the O
promoter O
of O
the O
transcription B
factor I
IFN I
regulatory I
factor I
- I
1 I
. O

STAT1 B
activity O
was O
evident O
on O
the O
STAT B
binding I
sequences I
( O
SBE B
) O
present O
in O
the O
promoters B
of O
genes O
which O
are O
up O
- O
regulated O
during O
monocyte O
to O
macrophage O
maturation O
such O
as O
FcgammaRI B
and O
ICAM B
- I
1 I
, O
and O
in O
the O
promoter O
of O
the O
transcription B
factor I
IFN I
regulatory I
factor I
- I
1 I
. O

STAT1 B
activity O
was O
evident O
on O
the O
STAT B
binding I
sequences I
( O
SBE B
) O
present O
in O
the O
promoters B
of O
genes O
which O
are O
up O
- O
regulated O
during O
monocyte O
to O
macrophage O
maturation O
such O
as O
FcgammaRI B
and O
ICAM B
- I
1 I
, O
and O
in O
the O
promoter O
of O
the O
transcription B
factor I
IFN I
regulatory I
factor I
- I
1 I
. O

Compared O
with O
monocytes O
adherent O
on O
plastic O
surfaces O
, O
freshly O
isolated O
cells O
allowed O
to O
adhere O
either O
to O
fibronectin O
- O
or O
laminin O
- O
coated O
flasks O
exhibited O
an O
increased O
STAT1 B
binding O
activity O
both O
in O
control O
and O
in O
IFN O
- O
gamma O
- O
treated O
cells O
. O

Thereafter O
, O
PML B
is O
downmodulated O
in O
late O
granulocytic O
maturation O
, O
whereas O
it O
is O
sustainably O
expressed O
through O
the O
erythroid O
pathway O
. O

Furthermore O
, O
PML B
and O
pRb B
105 I
were O
co O
- O
immunoprecipitated O
in O
cellular O
lysates O
derived O
from O
erythroid O
precursors O
indicating O
that O
this O
functional O
interaction O
may O
have O
a O
biochemical O
basis O
. O

Treatment O
of O
cells O
with O
PD98059 O
, O
a O
specific O
inhibitor O
of O
mitogen B
- I
activated I
protein I
kinase I
kinase I
( O
MEK B
) O
, O
inhibited O
TPA O
- O
induced O
ERK2 B
activity O
. O

Treatment O
of O
cells O
with O
PD98059 O
, O
a O
specific O
inhibitor O
of O
mitogen B
- I
activated I
protein I
kinase I
kinase I
( O
MEK B
) O
, O
inhibited O
TPA O
- O
induced O
ERK2 B
activity O
. O

In O
addition O
, O
sodium O
salicylate O
and O
additional O
NSAIDs O
used O
at O
concentrations O
that O
activate O
HSF1 B
also O
inhibited O
the O
expression O
of O
other O
monocytic B
genes I
( O
TNF B
- I
alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
IL B
- I
10 I
, O
ICAM B
- I
1 I
) O
activated O
by O
exposure O
to O
a O
pro O
- O
inflammatory O
stimulus O
( O
lipopolysaccharide O
, O
LPS O
) O
. O

Fibroblast B
growth I
factors I
( O
FGFs B
) O
are O
heparin B
- I
binding I
proteins I
crucial O
to O
embryogenesis O
, O
angiogenesis O
, O
and O
wound O
healing O
. O

In O
this O
paper O
, O
we O
show O
that O
HCMV O
down O
regulates O
gamma O
interferon O
( O
IFN B
- I
gamma I
) O
- O
induced O
HLA B
- I
DR I
expression O
in O
U373 O
MG O
astrocytoma O
cells O
due O
to O
a O
defect O
downstream O
of O
STAT1 B
phosphorylation O
and O
nuclear O
translocation O
. O

Inhibition O
of O
NF B
- I
kappaB I
transcriptional O
activity O
and O
promotion O
of O
IkappaBalpha B
degradation O
. O

DZA O
inhibits O
the O
transcriptional O
activity O
of O
NF B
- I
kappaB I
through O
the O
hindrance O
of O
p65 B
( O
Rel B
- I
A I
) O
phosphorylation O
without O
reduction O
of O
its O
nuclear O
translocation O
and O
DNA O
binding O
activity O
. O

Decidual O
gammadelta O
T O
cells O
, O
which O
significantly O
increase O
in O
number O
during O
pregnancy O
, O
might O
play O
a O
role O
in O
recognition O
of O
fetal B
antigens I
and O
also O
in O
determining O
the O
quality O
of O
the O
response O
to O
these O
antigens B
. O

Here O
, O
we O
investigate O
the O
role O
of O
Rho B
in O
regulating O
the O
distribution O
of O
the O
monocyte B
- I
binding I
receptors I
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
in O
human O
endothelial O
cells O
. O

Similarly O
, O
N19RhoA B
inhibited O
receptor O
clustering O
. O

CD28 B
costimulation O
augments O
IL B
- I
2 I
secretion O
of O
activated O
lamina O
propria O
T O
cells O
by O
increasing O
mRNA O
stability O
without O
enhancing O
IL B
- I
2 I
gene O
transactivation O
. O

Previous O
studies O
have O
characterized O
the O
CD28 B
augmentation O
of O
TCR B
- O
mediated O
signaling O
in O
peripheral O
blood O
T O
cells O
through O
transcriptional O
activation O
of O
an O
IL B
- I
2 I
promoter O
CD28 B
response I
element I
( O
CD28RE B
) O
, O
along O
with O
enhanced O
mRNA O
stability O
. O

Previous O
studies O
have O
characterized O
the O
CD28 B
augmentation O
of O
TCR B
- O
mediated O
signaling O
in O
peripheral O
blood O
T O
cells O
through O
transcriptional O
activation O
of O
an O
IL B
- I
2 I
promoter O
CD28 B
response I
element I
( O
CD28RE B
) O
, O
along O
with O
enhanced O
mRNA O
stability O
. O

Previous O
studies O
have O
characterized O
the O
CD28 B
augmentation O
of O
TCR B
- O
mediated O
signaling O
in O
peripheral O
blood O
T O
cells O
through O
transcriptional O
activation O
of O
an O
IL B
- I
2 I
promoter O
CD28 B
response I
element I
( O
CD28RE B
) O
, O
along O
with O
enhanced O
mRNA O
stability O
. O

LPMC O
exhibited O
increased O
IL B
- I
2 I
production O
in O
response O
to O
CD28 B
costimulation O
, O
compared O
with O
cells O
activated O
through O
CD2 B
alone O
. O

LPMC O
exhibited O
increased O
IL B
- I
2 I
production O
in O
response O
to O
CD28 B
costimulation O
, O
compared O
with O
cells O
activated O
through O
CD2 B
alone O
. O

In O
conclusion O
, O
production O
of O
a O
Th1 B
cytokine I
, O
IFN B
- I
gamma I
, O
by O
HBsAg B
- O
reactive O
cells O
was O
associated O
with O
hepatocyte O
damage O
in O
chronic O
hepatitis O
B O
, O
while O
no O
counteracting O
effect O
of O
Th2 B
cytokines I
produced O
by O
those O
cells O
was O
observed O
. O

As2O3 O
induced O
PML O
( O
promyelocytic O
leukemia O
) O
protein O
degradation O
but O
did O
not O
modulate O
expression O
of O
cell B
cycle I
- I
related I
proteins I
, O
including O
c B
- I
myc I
, O
retinoblastoma B
protein I
, O
cyclin B
- I
dependent I
kinase I
4 I
, O
cyclin B
D1 I
, O
and O
p53 B
, O
or O
expression O
of O
differentiation B
- I
related I
antigens I
. O

CTLA B
- I
4 I
ligation O
inhibited O
CD3 O
/ O
CD28 B
- O
induced O
IL B
- I
2 I
mRNA I
accumulation O
by O
inhibiting O
IL B
- I
2 I
transcription O
, O
which O
appears O
to O
be O
mediated O
in O
part O
through O
decreasing O
NF B
- I
AT I
accumulation O
in O
the O
nuclei O
. O

Further O
, O
CTLA B
- I
4 I
engagement O
inhibited O
progression O
through O
the O
cell O
cycle O
by O
inhibiting O
the O
production O
of O
cyclin B
D3 I
, O
cyclin B
- I
dependent I
kinase I
( B
cdk I
) I
4 I
, O
and O
cdk6 B
when O
the O
T O
cells O
were O
stimulated O
with O
anti B
- I
CD3 I
/ I
CD28 I
and O
with O
anti B
- I
CD3 I
alone O
. O

Dexamethasone O
( O
Dex O
) O
, O
a O
synthetic O
glucocorticoid O
hormone O
, O
cooperated O
with O
Epo B
and O
stem B
cell I
factor I
to O
induce O
erythroid O
progenitors O
to O
undergo O
15 O
to O
22 O
cell O
divisions O
, O
corresponding O
to O
a O
10 O
( O
5 O
) O
- O
to O
10 O
( O
6 O
) O
- O
fold O
amplification O
of O
erythroid O
cells O
. O

SOCS B
- I
3 I
protein O
was O
detectable O
as O
early O
as O
30 O
min O
following O
IL B
- I
2 I
stimulation O
, O
while O
CIS B
was O
seen O
only O
at O
low O
levels O
after O
2 O
h O
. O

Tyrosine O
phosphorylation O
of O
SOCS B
- I
3 I
was O
observed O
upon O
coexpression O
with O
Jak1 B
and O
Jak2 B
but O
only O
weakly O
with O
Jak3 B
. O

Tyrosine O
phosphorylation O
of O
SOCS B
- I
3 I
was O
observed O
upon O
coexpression O
with O
Jak1 B
and O
Jak2 B
but O
only O
weakly O
with O
Jak3 B
. O

Tyrosine O
phosphorylation O
of O
SOCS B
- I
3 I
was O
observed O
upon O
coexpression O
with O
Jak1 B
and O
Jak2 B
but O
only O
weakly O
with O
Jak3 B
. O

There O
was O
, O
however O
, O
a O
significant O
difference O
in O
the O
amounts O
of O
the O
nuclear B
protein I
, O
REF B
- I
1 I
( O
which O
regulates O
AP B
- I
1 I
DNA O
binding O
by O
altering O
the O
redox O
status O
of O
FOS B
and O
JUN B
proteins I
) O
, O
in O
alveolar O
macrophages O
compared O
with O
monocytes O
. O

The O
costimulatory B
molecule I
CD28 B
has O
a O
restricted O
tissue O
distribution O
and O
is O
expressed O
on O
T O
cells O
and O
some O
plasmacytoma O
cells O
. O

In O
vivo O
, O
CD8 O
+ O
T O
cells O
and O
, O
less O
frequently O
, O
CD4 O
+ O
T O
cells O
may O
completely O
lose O
CD28 B
surface O
expression O
during O
chronic O
infections O
and O
with O
aging O
. O

A O
role O
for O
RanBP1 B
in O
the O
release O
of O
CRM1 B
from O
the O
nuclear B
pore I
complex I
in O
a O
terminal O
step O
of O
nuclear O
export O
. O

A O
role O
for O
RanBP1 B
in O
the O
release O
of O
CRM1 B
from O
the O
nuclear B
pore I
complex I
in O
a O
terminal O
step O
of O
nuclear O
export O
. O

It O
also O
stimulates O
nuclear O
export O
in O
cells O
that O
have O
not O
been O
preincubated O
with O
RanQ69L B
. O

In O
a O
model O
where O
foreign O
cells O
( O
rat O
fibroblasts O
) O
were O
cocultured O
with O
human O
IL O
- O
2 O
activated O
NK O
cells O
, O
we O
observed O
that O
NK O
cells O
were O
capable O
of O
efficiently O
killing O
their O
targets O
only O
if O
the O
cells O
overexpressed O
the O
oncogene O
c B
- I
Myc I
or O
E1A B
. O

These O
results O
provided O
evidence O
that O
c B
- I
Myc I
and O
E1A B
activated O
the O
NK O
cell O
induced O
cytolysis O
at O
a O
post O
- O
triggering O
stage O
of O
NK O
cell O
- O
target O
cell O
interaction O
. O

In O
the O
culture O
system O
reported O
here O
, O
( O
1 O
) O
the O
growth B
factor I
( O
GF B
) O
stimulus O
induces O
cord O
blood O
( O
CB O
) O
progenitor O
cells O
to O
proliferate O
and O
differentiate O
/ O
mature O
exclusively O
along O
the O
erythroid O
lineage O
; O
( O
2 O
) O
this O
erythropoietic O
wave O
is O
characterized O
by O
less O
than O
4 O
% O
apoptotic O
cells O
; O
( O
3 O
) O
asymmetric O
divisions O
are O
virtually O
absent O
, O
ie O
, O
nonresponsive O
hematopoietic O
progenitors O
with O
no O
erythropoietic O
potential O
are O
forced O
into O
apoptosis O
; O
( O
4 O
) O
the O
system O
is O
cell O
division O
controlled O
( O
cdc O

Single O
- O
cell O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
was O
applied O
to O
this O
culture O
system O
to O
investigate O
gene O
expression O
of O
diverse O
receptors B
, O
markers B
of I
differentiation I
, O
and O
transcription B
factors I
( O
EKLF B
, O
GATA B
- I
1 I
, O
GATA B
- I
2 I
, O
p45 B
NF I
- I
E2 I
, O
PU B
. I
1 I
, O
and O
SCL B
/ I
Tal1 I
) O
at O
discrete O
stages O
of O
erythropoietic O
development O
. O

Single O
- O
cell O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
was O
applied O
to O
this O
culture O
system O
to O
investigate O
gene O
expression O
of O
diverse O
receptors B
, O
markers B
of I
differentiation I
, O
and O
transcription B
factors I
( O
EKLF B
, O
GATA B
- I
1 I
, O
GATA B
- I
2 I
, O
p45 B
NF I
- I
E2 I
, O
PU B
. I
1 I
, O
and O
SCL B
/ I
Tal1 I
) O
at O
discrete O
stages O
of O
erythropoietic O
development O
. O

However O
, O
stimulation O
with O
IL B
- I
2 I
resulted O
in O
Jak3 B
and O
STAT5 B
phosphorylation O
in O
both O
leukemic O
ATLL O
cells O
and O
IL O
- O
2 O
- O
dependent O
lines O
. O

However O
, O
stimulation O
with O
IL B
- I
2 I
resulted O
in O
Jak3 B
and O
STAT5 B
phosphorylation O
in O
both O
leukemic O
ATLL O
cells O
and O
IL O
- O
2 O
- O
dependent O
lines O
. O

A O
skewed O
XCI O
pattern O
with O
greater O
than O
75 O
% O
amplification O
of O
1 O
allele B
( O
allele B
ratio O
> O
3 O
: O
1 O
) O
was O
found O
in O
22 O
( O
9 O
. O
1 O
% O
) O
of O
242 O
control O
subjects O
. O

A O
skewed O
XCI O
pattern O
with O
greater O
than O
75 O
% O
amplification O
of O
1 O
allele B
( O
allele B
ratio O
> O
3 O
: O
1 O
) O
was O
found O
in O
22 O
( O
9 O
. O
1 O
% O
) O
of O
242 O
control O
subjects O
. O

In O
T O
lymphocytes O
, O
the O
hematopoietic B
cytokine I
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
uses O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
- O
induced O
signaling O
pathways O
to O
regulate O
E2F B
transcriptional O
activity O
, O
a O
critical O
cell O
cycle O
checkpoint O
. O

Moreover O
, O
the O
effects O
of O
rapamycin O
on O
, O
and O
the O
role O
of O
p70 B
( I
s6k I
) I
in O
, O
IL B
- I
2 I
and O
PI B
3 I
- I
kinase I
activation O
of O
E2Fs B
have O
not O
been O
characterized O
. O

Our O
present O
results O
show O
that O
IL B
- I
2 I
- O
and O
PI B
3 I
- I
kinase I
- O
induced O
pathways O
for O
the O
regulation O
of O
E2F B
transcriptional O
activity O
include O
both O
rapamycin O
- O
resistant O
and O
rapamycin O
- O
sensitive O
components O
. O

Thus O
, O
the O
rapamycin O
- O
controlled O
processes O
involved O
in O
E2F B
regulation O
appear O
to O
be O
mediated O
by O
p70 B
( I
s6k I
) I
. O

These O
include O
the O
Ikaros B
, O
LKLF B
, O
and O
GATA3 B
zinc I
- I
finger I
proteins I
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF B
- I
kappa I
B I
/ I
Rel I
/ I
NFAT I
transcription I
factors I
; O
the O
Stat B
proteins I
; O
and O
HMG B
box I
transcription I
factors I
such O
as O
LEF1 B
, O
TCF1 B
, O
and O
Sox4 B
. O

These O
include O
the O
Ikaros B
, O
LKLF B
, O
and O
GATA3 B
zinc I
- I
finger I
proteins I
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF B
- I
kappa I
B I
/ I
Rel I
/ I
NFAT I
transcription I
factors I
; O
the O
Stat B
proteins I
; O
and O
HMG B
box I
transcription I
factors I
such O
as O
LEF1 B
, O
TCF1 B
, O
and O
Sox4 B
. O

These O
include O
the O
Ikaros B
, O
LKLF B
, O
and O
GATA3 B
zinc I
- I
finger I
proteins I
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF B
- I
kappa I
B I
/ I
Rel I
/ I
NFAT I
transcription I
factors I
; O
the O
Stat B
proteins I
; O
and O
HMG B
box I
transcription I
factors I
such O
as O
LEF1 B
, O
TCF1 B
, O
and O
Sox4 B
. O

These O
include O
the O
Ikaros B
, O
LKLF B
, O
and O
GATA3 B
zinc I
- I
finger I
proteins I
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF B
- I
kappa I
B I
/ I
Rel I
/ I
NFAT I
transcription I
factors I
; O
the O
Stat B
proteins I
; O
and O
HMG B
box I
transcription I
factors I
such O
as O
LEF1 B
, O
TCF1 B
, O
and O
Sox4 B
. O

These O
include O
the O
Ikaros B
, O
LKLF B
, O
and O
GATA3 B
zinc I
- I
finger I
proteins I
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF B
- I
kappa I
B I
/ I
Rel I
/ I
NFAT I
transcription I
factors I
; O
the O
Stat B
proteins I
; O
and O
HMG B
box I
transcription I
factors I
such O
as O
LEF1 B
, O
TCF1 B
, O
and O
Sox4 B
. O

These O
include O
the O
Ikaros B
, O
LKLF B
, O
and O
GATA3 B
zinc I
- I
finger I
proteins I
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF B
- I
kappa I
B I
/ I
Rel I
/ I
NFAT I
transcription I
factors I
; O
the O
Stat B
proteins I
; O
and O
HMG B
box I
transcription I
factors I
such O
as O
LEF1 B
, O
TCF1 B
, O
and O
Sox4 B
. O

Paradoxical O
priming O
effects O
of O
IL B
- I
10 I
on O
cytokine B
production O
. O

Interestingly O
, O
an O
enhanced O
frequency O
of O
CD16 B
and O
CD68 O
( O
+ O
) O
cells O
among O
the O
CD14 O
( O
+ O
) O
cells O
was O
observed O
in O
the O
presence O
of O
IL B
- I
10 I
, O
independently O
of O
the O
pre O
- O
culture O
conditions O
of O
the O
PBMC O
. O

Transcription B
factors I
Sp1 B
and O
AP B
- I
2 I
mediate O
induction O
of O
acid B
sphingomyelinase I
during O
monocytic O
differentiation O
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- B
319 I
and I
- I
219 I
bp I
upstream I
of O
the O
initiation O
codon O
and O
co O
- O
transfections O
with O
transcription B
factor I
expression I
plasmids I
for O
AP B
- I
2 I
and O
Sp1 B
resulted O
in O
augmented O
ASM O
promoter O
activity O
, O
which O
was O
abolished O
when O
the O
binding B
sites I
for O
these O
two O
factors O
were O
deleted O
. O

Direct O
activation O
of O
PKC B
with O
PMA O
induced O
both O
NF B
- I
kappaB I
activation O
and O
TNF B
- I
alpha I
production O
by O
human O
monocytes O
. O

Furthermore O
, O
our O
results O
provide O
evidence O
that O
PTK B
plays O
a O
role O
in O
LPS O
- O
induced O
NF B
- I
kappaB I
activation O
and O
TNF B
- I
alpha I
release O
in O
human O
monocytes O
and O
thus O
could O
be O
a O
potential O
therapeutic O
target O
in O
inflammatory O
states O
. O

Characterization O
of O
expression O
of O
the O
gene O
for O
human B
pterin I
carbinolamine I
dehydratase I
/ I
dimerization I
cofactor I
of O
HNF1 B
. O

In O
the O
nucleus O
, O
it O
functions O
as O
a O
dimerization B
cofactor I
of O
HNF1 B
and O
increases O
the O
transcriptional O
activity O
of O
HNF1 B
. O

In O
the O
nucleus O
, O
it O
functions O
as O
a O
dimerization B
cofactor I
of O
HNF1 B
and O
increases O
the O
transcriptional O
activity O
of O
HNF1 B
. O

Transfection O
of O
Jurkat O
cells O
with O
the O
NF B
- I
kappaB I
subunits I
p50 B
and O
p65 B
confers O
resistance O
against O
Fas O
- O
mediated O
apoptosis O
. O

Transfection O
of O
Jurkat O
cells O
with O
the O
NF B
- I
kappaB I
subunits I
p50 B
and O
p65 B
confers O
resistance O
against O
Fas O
- O
mediated O
apoptosis O
. O

Capacitance O
would O
simply O
involve O
expression O
of O
IL B
- I
12R I
beta I
1 I
and I
beta I
2 I
subunits I
, O
regulated O
by O
TCR O
, O
IL B
- I
4 I
and O
IFNs B
. O

The O
activation O
of O
STAT3 B
was O
not O
found O
in O
human O
eosinophils O
, O
monocytes O
, O
and O
HL O
- O
60 O
cells O
, O
although O
the O
STAT3 B
protein I
was O
expressed O
in O
these O
cells O
. O

The O
transcription B
factor I
NF B
- I
ATc I
is O
synthesized O
in O
three O
prominent O
isoforms B
. O

Together O
, O
these O
results O
demonstrate O
that O
ER B
and O
PR B
can O
be O
activated O
by O
endogenous O
or O
exogenous O
ligands O
to O
induce O
a O
genetic O
response O
that O
impairs O
TNF B
- I
alpha I
- O
induced O
apoptosis O
in O
U937 O
cells O
. O

Together O
, O
these O
results O
demonstrate O
that O
ER B
and O
PR B
can O
be O
activated O
by O
endogenous O
or O
exogenous O
ligands O
to O
induce O
a O
genetic O
response O
that O
impairs O
TNF B
- I
alpha I
- O
induced O
apoptosis O
in O
U937 O
cells O
. O

Inhibition O
of O
T O
cell O
signaling O
by O
mitogen B
- I
activated I
protein I
kinase I
- I
targeted I
hematopoietic I
tyrosine I
phosphatase I
( O
HePTP B
) O
. O

Activation O
of O
T O
lymphocytes O
to O
produce O
cytokines B
is O
regulated O
by O
the O
counterbalance O
of O
protein B
- I
tyrosine I
kinases I
and O
protein O
- O
tyrosine O
phosphatases O
, O
many O
of O
which O
have O
a O
high O
degree O
of O
substrate O
specificity O
because O
of O
physical O
association O
with O
their O
targets O
. O

In O
contrast O
, O
HePTP B
had O
no O
effects O
on O
N B
- I
terminal I
c I
- I
Jun I
kinase I
or O
on O
events O
upstream O
of O
the O
MAP O
kinases O
. O

However O
, O
p38 B
MAPK I
is O
activated O
strongly O
and O
synergistically O
by O
either O
CD3 B
/ I
CD28 I
coligation O
or O
PMA O
/ O
Ca2 O
+ O
ionophore O
stimulation O
, O
which O
mimics O
TCR B
- O
CD3 B
/ I
CD28 I
- O
mediated O
signaling O
. O

We O
have O
compared O
the O
effects O
of O
Epo B
and O
the O
chemical O
inducers O
, O
delta O
- O
aminolaevulinic O
acid O
( O
delta O
- O
ALA O
) O
and O
haemin O
on O
the O
differentiation O
capacity O
of O
UT O
- O
7 O
cells O
. O

Epo B
alone O
promoted O
relatively O
early O
events O
in O
erythroid O
maturation O
, O
without O
significant O
changes O
in O
haemoglobin O
production O
or O
morphology O
. O

Epo B
caused O
an O
increase O
in O
the O
proportion O
of O
cells O
expressing O
cell O
surface O
glycophorin B
A I
( O
GPA B
) O
and O
up O
- O
regulated O
beta B
- I
and I
gamma I
- I
globin I
by O
several O
fold O
. O

Epo B
caused O
an O
increase O
in O
the O
proportion O
of O
cells O
expressing O
cell O
surface O
glycophorin B
A I
( O
GPA B
) O
and O
up O
- O
regulated O
beta B
- I
and I
gamma I
- I
globin I
by O
several O
fold O
. O

Gel O
supershift O
assays O
demonstrated O
that O
thrombin B
induced O
binding O
of O
NF B
- I
kappa I
Bp65 I
( O
Rel B
A I
) O
to O
downstream O
NF B
- I
kappa I
B I
site I
of O
the O
ICAM B
- I
1 I
promoter I
. O

Thrombin B
receptor O
activation O
peptide O
, O
a O
14 O
- O
amino O
- O
acid O
peptide O
representing O
the O
new O
NH2 B
terminus I
of O
proteolytically O
activated O
receptor B
- I
1 I
, O
mimicked O
thrombin B
' O
s O
action O
in O
inducing O
ICAM B
- I
1 I
expression O
. O

Thrombin B
receptor O
activation O
peptide O
, O
a O
14 O
- O
amino O
- O
acid O
peptide O
representing O
the O
new O
NH2 B
terminus I
of O
proteolytically O
activated O
receptor B
- I
1 I
, O
mimicked O
thrombin B
' O
s O
action O
in O
inducing O
ICAM B
- I
1 I
expression O
. O

These O
data O
indicate O
that O
thrombin B
activates O
endothelial O
ICAM B
- I
1 I
expression O
and O
polymorphonuclear O
leukocyte O
adhesion O
by O
NF B
- I
kappa I
Bp65 I
binding O
to O
the O
downstream O
NF B
- I
kappa I
B I
site I
of O
ICAM B
- I
1 I
promoter I
after O
proteolytically O
activated O
receptor O
- O
1 O
activation O
. O

Here O
we O
demonstrate O
that O
both O
Smad6 B
and O
Smad7 B
are O
human B
bone I
morphogenetic I
protein I
- I
2 I
( O
hBMP B
- I
2 I
) O
- O
inducible O
antagonists O
of O
hBMP B
- I
2 I
- O
induced O
growth O
arrest O
and O
apoptosis O
in O
mouse O
B O
cell O
hybridoma O
HS O
- O
72 O
cells O
. O

Here O
we O
demonstrate O
that O
both O
Smad6 B
and O
Smad7 B
are O
human B
bone I
morphogenetic I
protein I
- I
2 I
( O
hBMP B
- I
2 I
) O
- O
inducible O
antagonists O
of O
hBMP B
- I
2 I
- O
induced O
growth O
arrest O
and O
apoptosis O
in O
mouse O
B O
cell O
hybridoma O
HS O
- O
72 O
cells O
. O

CONCLUSION O
: O
Our O
results O
show O
that O
the O
tested O
agents O
( O
except O
indomethacin O
) O
are O
inhibitors O
of O
the O
T O
cell O
- O
mediated O
immune O
response O
, O
as O
expected O
, O
that O
aspirin O
is O
an O
effective O
suppressor O
of O
adhesion B
molecule I
expression O
, O
and O
that O
all O
three O
agents O
can O
induce O
Hsp60 B
in O
HUVECs O
. O

However O
, O
the O
mechanism O
by O
which O
IFNs B
mediate O
this O
inhibition O
has O
not O
been O
defined O
. O

Because O
STAT6 B
activation O
plays O
an O
essential O
role O
in O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
induced O
gene O
expression O
, O
the O
ability O
of O
IFN B
- I
beta I
and O
IFN B
- I
gamma I
to O
inhibit O
STAT6 B
activity O
provides O
an O
explanation O
for O
how O
IFNs B
can O
suppress O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
inducible O
gene O
expression O
. O

Because O
STAT6 B
activation O
plays O
an O
essential O
role O
in O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
induced O
gene O
expression O
, O
the O
ability O
of O
IFN B
- I
beta I
and O
IFN B
- I
gamma I
to O
inhibit O
STAT6 B
activity O
provides O
an O
explanation O
for O
how O
IFNs B
can O
suppress O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
inducible O
gene O
expression O
. O

Because O
STAT6 B
activation O
plays O
an O
essential O
role O
in O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
induced O
gene O
expression O
, O
the O
ability O
of O
IFN B
- I
beta I
and O
IFN B
- I
gamma I
to O
inhibit O
STAT6 B
activity O
provides O
an O
explanation O
for O
how O
IFNs B
can O
suppress O
IL B
- I
4 I
/ O
IL B
- I
13 I
- O
inducible O
gene O
expression O
. O

A O
cdk2 O
inhibitor O
, O
Olomoucine O
, O
as O
well O
as O
a O
dominant B
- I
negative I
cdk2 I
construct I
prevented O
HLA B
class I
I I
- O
mediated O
inactivation O
of O
Rb B
; O
in O
contrast O
, O
dominant B
- I
negative I
cdk4 I
and I
cdk6 I
constructs I
had O
no O
effect O
. O

PG490 O
inhibits O
interleukin B
( I
IL I
) I
- I
2 I
expression O
by O
normal O
human O
peripheral O
blood O
lymphocytes O
stimulated O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
and O
antibody O
to O
CD3 B
( O
IC50 O
of O
10 O
ng O
/ O
ml O
) O
, O
and O
with O
PMA O
and O
ionomycin O
( O
Iono O
, O
IC50 O
of O
40 O
ng O
/ O
ml O
) O
. O

PG490 O
also O
inhibits O
PMA O
- O
stimulated O
activation O
of O
a O
chimeric B
transcription I
factor I
in O
which O
the O
C B
- I
terminal I
TA1 I
transactivation I
domain I
of O
NF B
- I
kappaB I
p65 I
is O
fused O
to O
the O
DNA B
binding I
domain I
of O
GAL4 B
. O

Fludarabine O
- O
induced O
immunosuppression O
is O
associated O
with O
inhibition O
of O
STAT1 B
signaling O
. O

STAT1 B
, O
which O
is O
activated O
in O
response O
to O
many O
lymphocyte B
- I
activating I
cytokines I
including O
the O
interferons B
, O
is O
essential O
for O
cell O
- O
mediated O
immunity O
, O
as O
the O
absence O
of O
this O
protein O
is O
associated O
with O
prominent O
defects O
in O
the O
ability O
to O
control O
viral O
infections O
. O

STAT1 B
, O
which O
is O
activated O
in O
response O
to O
many O
lymphocyte B
- I
activating I
cytokines I
including O
the O
interferons B
, O
is O
essential O
for O
cell O
- O
mediated O
immunity O
, O
as O
the O
absence O
of O
this O
protein O
is O
associated O
with O
prominent O
defects O
in O
the O
ability O
to O
control O
viral O
infections O
. O

Here O
we O
show O
that O
fludarabine O
, O
but O
not O
the O
immunosuppressant O
cyclosporine O
A O
, O
inhibits O
the O
cytokine B
- O
induced O
activation O
of O
STAT1 B
and O
STAT1 B
- O
dependent O
gene O
transcription O
in O
normal O
resting O
or O
activated O
lymphocytes O
. O

Here O
we O
show O
that O
fludarabine O
, O
but O
not O
the O
immunosuppressant O
cyclosporine O
A O
, O
inhibits O
the O
cytokine B
- O
induced O
activation O
of O
STAT1 B
and O
STAT1 B
- O
dependent O
gene O
transcription O
in O
normal O
resting O
or O
activated O
lymphocytes O
. O

Here O
we O
show O
that O
fludarabine O
, O
but O
not O
the O
immunosuppressant O
cyclosporine O
A O
, O
inhibits O
the O
cytokine B
- O
induced O
activation O
of O
STAT1 B
and O
STAT1 B
- O
dependent O
gene O
transcription O
in O
normal O
resting O
or O
activated O
lymphocytes O
. O

Fludarabine O
caused O
a O
specific O
depletion O
of O
STAT1 B
protein I
( O
and O
mRNA O
) O
but O
not O
of O
other O
STATs B
. O

This O
loss O
of O
STAT1 B
was O
also O
seen O
in O
cells O
from O
patients O
treated O
with O
fludarabine O
in O
vivo O
. O

Thus O
, O
STAT1 B
may O
be O
a O
useful O
target O
in O
the O
development O
of O
new O
immunosuppressive O
and O
antineoplastic O
agents O
. O

Furthermore O
, O
it O
demonstrates O
that O
aging O
does O
not O
influence O
the O
sensitivity O
of O
this O
phosphatase B
. O

The O
viral B
protein I
Tax B
induces O
the O
activation O
and O
nuclear O
translocalization O
of O
transcription B
factor I
NF B
- I
kappaB I
, O
which O
is O
proposed O
to O
play O
a O
crucial O
role O
in O
the O
transformation O
of O
T O
cells O
by O
HTLV O
- O
I O
. O

However O
, O
the O
HTLV B
- I
I I
genes I
including O
Tax B
are O
not O
expressed O
significantly O
in O
primary O
leukemic O
cells O
from O
ATL O
patients O
. O

We O
found O
that O
leukemic O
cells O
from O
ATL O
patients O
, O
like O
HTLV O
- O
I O
- O
infected O
T O
- O
cell O
lines O
, O
display O
constitutive O
NF B
- I
kappaB I
DNA O
binding O
activity O
and O
increased O
degradation O
of O
IkappaBalpha B
( O
an O
inhibitor O
of O
NF B
- I
kappaB I
) O
. O

One O
T O
- O
cell O
line O
derived O
from O
ATL O
leukemic O
cells O
, O
TL O
- O
Om1 O
, O
displayed O
constitutive O
NF B
- I
kappaB I
activity O
, O
as O
well O
as O
enhanced O
degradation O
of O
IkappaBalpha B
, O
despite O
the O
lack O
of O
detectable O
Tax B
expression O
. O

One O
T O
- O
cell O
line O
derived O
from O
ATL O
leukemic O
cells O
, O
TL O
- O
Om1 O
, O
displayed O
constitutive O
NF B
- I
kappaB I
activity O
, O
as O
well O
as O
enhanced O
degradation O
of O
IkappaBalpha B
, O
despite O
the O
lack O
of O
detectable O
Tax B
expression O
. O

The O
most O
characterized O
pathway O
is O
via O
JAK B
- B
STAT I
signaling O
. O

Therefore O
, O
this O
study O
was O
designed O
to O
analyze O
the O
role O
of O
Lck B
in O
IFN B
- I
alpha I
signaling O
by O
using O
the O
Jurkat O
, O
JCam O
( O
an O
Lck O
- O
defective O
cell O
line O
derived O
from O
Jurkat O
) O
, O
and O
JCam O
/ O
Lck O
( O
JCam O
cells O
with O
Lck B
restored O
) O
. O

Therefore O
, O
this O
study O
was O
designed O
to O
analyze O
the O
role O
of O
Lck B
in O
IFN B
- I
alpha I
signaling O
by O
using O
the O
Jurkat O
, O
JCam O
( O
an O
Lck O
- O
defective O
cell O
line O
derived O
from O
Jurkat O
) O
, O
and O
JCam O
/ O
Lck O
( O
JCam O
cells O
with O
Lck B
restored O
) O
. O

We O
investigated O
the O
MAPk B
kinase I
( O
MKK B
) O
that O
activates O
p38 B
MAPk I
in O
response O
to O
LPS O
, O
the O
p38 B
MAPk I
isoforms I
that O
are O
activated O
as O
part O
of O
this O
pathway O
, O
and O
the O
functional O
responses O
affected O
by O
p38 B
MAPk I
activation O
. O

Although O
MKK3 B
, O
MKK4 B
, O
and O
MKK6 B
all O
activated O
p38 B
MAPk I
in O
experimental O
models O
, O
only O
MKK3 B
was O
found O
to O
activate O
recombinant O
p38 B
MAPk I
in O
LPS O
- O
treated O
neutrophils O
. O

Although O
MKK3 B
, O
MKK4 B
, O
and O
MKK6 B
all O
activated O
p38 B
MAPk I
in O
experimental O
models O
, O
only O
MKK3 B
was O
found O
to O
activate O
recombinant O
p38 B
MAPk I
in O
LPS O
- O
treated O
neutrophils O
. O

Although O
MKK3 B
, O
MKK4 B
, O
and O
MKK6 B
all O
activated O
p38 B
MAPk I
in O
experimental O
models O
, O
only O
MKK3 B
was O
found O
to O
activate O
recombinant O
p38 B
MAPk I
in O
LPS O
- O
treated O
neutrophils O
. O

Although O
MKK3 B
, O
MKK4 B
, O
and O
MKK6 B
all O
activated O
p38 B
MAPk I
in O
experimental O
models O
, O
only O
MKK3 B
was O
found O
to O
activate O
recombinant O
p38 B
MAPk I
in O
LPS O
- O
treated O
neutrophils O
. O

The O
I B
gamma I
3 I
ECS B
lies O
upstream O
of O
the O
major B
I I
gamma I
3 I
transcription I
initiation I
site I
and O
displays O
more O
than O
90 O
% O
identity O
with O
the O
corresponding O
human B
I I
gamma I
1 I
, O
I B
gamma I
2 I
, O
and O
I B
gamma I
4 I
regions O
. O

In O
these O
transfected O
CL O
- O
01 O
cells O
, O
CD40 O
: O
CD40L B
engagement O
and O
exposure O
to O
IL B
- I
4 I
synergistically O
induced O
gamma O
3 O
ECS O
- O
dependent O
luciferase B
reporter I
gene I
activation O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
p50 B
/ I
p65 I
/ I
c I
- I
Rel I
and O
STAT B
- I
6 I
are O
effectively O
induced O
by O
CD40L B
and O
IL B
- I
4 I
, O
respectively O
, O
and O
bind O
to O
specific O
DNA B
motifs I
within O
the O
ECS B
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
p50 B
/ I
p65 I
/ I
c I
- I
Rel I
and O
STAT B
- I
6 I
are O
effectively O
induced O
by O
CD40L B
and O
IL B
- I
4 I
, O
respectively O
, O
and O
bind O
to O
specific O
DNA B
motifs I
within O
the O
ECS B
. O

CIITA B
- O
induced O
occupation O
of O
MHC B
class I
II I
promoters I
is O
independent O
of O
the O
cooperative O
stabilization O
of O
the O
promoter B
- I
bound I
multi I
- I
protein I
complexes I
. O

Activation O
of O
MHC B
class I
II I
promoters I
requires O
binding O
of O
at O
least O
three O
distinct O
multi B
- I
protein I
complexes I
( O
RFX B
, O
X2BP B
and O
NF B
- I
Y I
) O
. O

Activation O
of O
MHC B
class I
II I
promoters I
requires O
binding O
of O
at O
least O
three O
distinct O
multi B
- I
protein I
complexes I
( O
RFX B
, O
X2BP B
and O
NF B
- I
Y I
) O
. O

We O
show O
, O
however O
, O
that O
the O
presence O
of O
CIITA B
does O
not O
affect O
the O
stability O
of O
the O
higher O
- O
order O
protein O
complex O
formed O
on O
DNA O
by O
RFX B
, O
X2BP B
and O
NF B
- I
Y I
. O

We O
show O
, O
however O
, O
that O
the O
presence O
of O
CIITA B
does O
not O
affect O
the O
stability O
of O
the O
higher O
- O
order O
protein O
complex O
formed O
on O
DNA O
by O
RFX B
, O
X2BP B
and O
NF B
- I
Y I
. O

We O
show O
, O
however O
, O
that O
the O
presence O
of O
CIITA B
does O
not O
affect O
the O
stability O
of O
the O
higher O
- O
order O
protein O
complex O
formed O
on O
DNA O
by O
RFX B
, O
X2BP B
and O
NF B
- I
Y I
. O

Finally O
, O
we O
conclude O
that O
this O
effect O
of O
CIITA B
is O
cell O
- O
type O
specific O
, O
since O
expression O
of O
CIITA B
is O
not O
required O
for O
normal O
occupation O
of O
MHC B
class I
II I
promoters I
in O
B O
lymphocytes O
. O

Finally O
, O
we O
conclude O
that O
this O
effect O
of O
CIITA B
is O
cell O
- O
type O
specific O
, O
since O
expression O
of O
CIITA B
is O
not O
required O
for O
normal O
occupation O
of O
MHC B
class I
II I
promoters I
in O
B O
lymphocytes O
. O

SH2 B
domain I
- I
containing I
protein I
76 I
( O
SLP B
- I
76 I
) O
interacts O
with O
the O
guanine B
nucleotide I
exchange I
factor I
Vav B
to O
activate O
the O
nuclear B
factor I
of I
activated I
cells I
( O
NF B
- I
AT I
) O
, O
and O
its O
expression O
is O
required O
for O
normal O
T O
cell O
development O
. O

In O
contrast O
, O
another O
inducible O
gene O
expression O
of O
monocyte B
chemotactic I
protein I
- I
1 I
( O
a O
CC B
chemokine I
) O
and O
the O
activation O
of O
the O
transcriptional B
factor I
( O
FcRFgamma B
) O
bound O
to O
the O
gamma B
response I
region I
were O
similarly O
or O
less O
abundantly O
induced O
by O
IFNgamma B
treatment O
in O
PMA O
- O
or O
RA O
- O
differentiated O
U937 O
cells O
, O
indicating O
that O
increased O
IP B
- I
10 I
mRNA I
induction O
was O
not O
due O
to O
the O
augmented O
ability O
of O
the O
cells O
to O
respond O
to O
the O
presence O
of O
IFNgamma B
. O

In O
contrast O
, O
another O
inducible O
gene O
expression O
of O
monocyte B
chemotactic I
protein I
- I
1 I
( O
a O
CC B
chemokine I
) O
and O
the O
activation O
of O
the O
transcriptional B
factor I
( O
FcRFgamma B
) O
bound O
to O
the O
gamma B
response I
region I
were O
similarly O
or O
less O
abundantly O
induced O
by O
IFNgamma B
treatment O
in O
PMA O
- O
or O
RA O
- O
differentiated O
U937 O
cells O
, O
indicating O
that O
increased O
IP B
- I
10 I
mRNA I
induction O
was O
not O
due O
to O
the O
augmented O
ability O
of O
the O
cells O
to O
respond O
to O
the O
presence O
of O
IFNgamma B
. O

In O
contrast O
, O
another O
inducible O
gene O
expression O
of O
monocyte B
chemotactic I
protein I
- I
1 I
( O
a O
CC B
chemokine I
) O
and O
the O
activation O
of O
the O
transcriptional B
factor I
( O
FcRFgamma B
) O
bound O
to O
the O
gamma B
response I
region I
were O
similarly O
or O
less O
abundantly O
induced O
by O
IFNgamma B
treatment O
in O
PMA O
- O
or O
RA O
- O
differentiated O
U937 O
cells O
, O
indicating O
that O
increased O
IP B
- I
10 I
mRNA I
induction O
was O
not O
due O
to O
the O
augmented O
ability O
of O
the O
cells O
to O
respond O
to O
the O
presence O
of O
IFNgamma B
. O

Role O
of O
cellular B
tumor I
necrosis I
factor I
receptor I
- I
associated I
factors I
in O
NF B
- I
kappaB I
activation O
and O
lymphocyte O
transformation O
by O
herpesvirus O
Saimiri O
STP B
. O

In O
addition O
, O
a O
somewhat O
divergent O
region O
of O
STP B
- I
C488 I
is O
critical O
for O
TRAF B
association O
. O

In O
contrast O
, O
caspase O
1 O
( O
ICE O
) O
did O
not O
cleave O
SP1 B
in O
vitro O
. O

Comparison O
of O
tumor O
specimen O
from O
MM O
precursor O
lesions O
, O
primary O
tumors O
, O
and O
metastases O
revealed O
that O
CD40 B
surface O
expression O
is O
down O
- O
regulated O
during O
tumor O
progression O
. O

CD40 B
expression O
was O
confirmed O
in O
7 O
human O
MM O
cell O
lines O
established O
from O
immunogenic O
primary O
tumors O
or O
metastases O
, O
whereas O
11 O
cell O
lines O
established O
from O
advanced O
stages O
were O
CD40 B
negative O
. O

CD40 B
expression O
was O
confirmed O
in O
7 O
human O
MM O
cell O
lines O
established O
from O
immunogenic O
primary O
tumors O
or O
metastases O
, O
whereas O
11 O
cell O
lines O
established O
from O
advanced O
stages O
were O
CD40 B
negative O
. O

Furthermore O
, O
CD40 B
ligation O
of O
a O
HLA O
- O
A2 O
+ O
, O
MelanA O
/ O
MART1 O
+ O
MM O
cell O
line O
enhanced O
its O
susceptibility O
to O
specific O
lysis O
by O
a O
HLA O
- O
A2 O
- O
restricted O
, O
MelanA O
/ O
MART O
- O
1 O
- O
specific O
CTL O
clone O
. O

This O
fusion O
protein O
contains O
the O
DNA B
- I
binding I
domain I
of O
the O
transcription B
factor I
AML1 B
fused O
in O
- O
frame O
to O
the O
entire O
MDS1 B
/ I
EVI1 I
with O
the O
exclusion O
of O
its O
first O
12 O
amino O
acids O
. O

By O
using O
the O
yeast O
two O
- O
hybrid O
system O
, O
we O
also O
show O
that O
EVI1 B
( O
contained O
in O
its O
entirety O
in O
MDS1 B
/ I
EVI1 I
and O
AML1 B
/ I
MDS1 I
/ I
EVI1 I
) O
physically O
interacts O
with O
SMAD3 B
, O
which O
is O
an O
intracellular O
mediator O
of O
TGF B
- I
beta1 I
signaling O
. O

By O
using O
the O
yeast O
two O
- O
hybrid O
system O
, O
we O
also O
show O
that O
EVI1 B
( O
contained O
in O
its O
entirety O
in O
MDS1 B
/ I
EVI1 I
and O
AML1 B
/ I
MDS1 I
/ I
EVI1 I
) O
physically O
interacts O
with O
SMAD3 B
, O
which O
is O
an O
intracellular O
mediator O
of O
TGF B
- I
beta1 I
signaling O
. O

The O
levels O
of O
cAMP B
- I
dependent I
protein I
kinase I
and O
Rap1 B
were O
assessed O
by O
Western O
blot O
analysis O
, O
immunostaining O
, O
and O
computer O
- O
assisted O
imaging O
. O

Beta O
- O
catenin O
is O
the O
vertebrate O
homolog O
of O
the O
Drosophila B
segment I
polarity I
gene I
Armadillo B
and O
plays O
roles O
in O
both O
cell O
- O
cell O
adhesion O
and O
transduction O
of O
the O
Wnt O
signaling O
cascade O
. O

Overexpression O
of O
SIT B
in O
Jurkat O
cells O
downmodulates O
T O
cell O
receptor O
- O
and O
phytohemagglutinin O
- O
mediated O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
by O
interfering O
with O
signaling O
processes O
that O
are O
probably O
located O
upstream O
of O
activation O
of O
phospholipase B
C I
. O

However O
, O
binding O
of O
SHP2 B
to O
SIT B
is O
not O
required O
for O
inhibition O
of O
NF B
- I
AT I
induction O
, O
suggesting O
that O
SIT B
not O
only O
regulates O
NF B
- I
AT I
activity O
but O
also O
controls O
NF B
- I
AT I
unrelated O
pathways O
of O
T O
cell O
activation O
involving O
SHP2 B
. O

However O
, O
binding O
of O
SHP2 B
to O
SIT B
is O
not O
required O
for O
inhibition O
of O
NF B
- I
AT I
induction O
, O
suggesting O
that O
SIT B
not O
only O
regulates O
NF B
- I
AT I
activity O
but O
also O
controls O
NF B
- I
AT I
unrelated O
pathways O
of O
T O
cell O
activation O
involving O
SHP2 B
. O

However O
, O
binding O
of O
SHP2 B
to O
SIT B
is O
not O
required O
for O
inhibition O
of O
NF B
- I
AT I
induction O
, O
suggesting O
that O
SIT B
not O
only O
regulates O
NF B
- I
AT I
activity O
but O
also O
controls O
NF B
- I
AT I
unrelated O
pathways O
of O
T O
cell O
activation O
involving O
SHP2 B
. O

However O
, O
binding O
of O
SHP2 B
to O
SIT B
is O
not O
required O
for O
inhibition O
of O
NF B
- I
AT I
induction O
, O
suggesting O
that O
SIT B
not O
only O
regulates O
NF B
- I
AT I
activity O
but O
also O
controls O
NF B
- I
AT I
unrelated O
pathways O
of O
T O
cell O
activation O
involving O
SHP2 B
. O

We O
investigated O
the O
function O
of O
conditionally O
expressed O
EBNA2 B
in O
the O
context O
of O
the O
IFN B
response O
in O
Burkitt O
' O
s O
lymphoma O
cell O
lines O
. O

We O
investigated O
the O
function O
of O
conditionally O
expressed O
EBNA2 B
in O
the O
context O
of O
the O
IFN B
response O
in O
Burkitt O
' O
s O
lymphoma O
cell O
lines O
. O

Expression O
of O
EBNA2 B
led O
to O
the O
transcriptional O
activation O
of O
both O
endogenous O
or O
transfected O
IFN B
- I
stimulated I
genes I
( O
ISGs B
) O
, O
genes O
which O
contain O
within O
their O
promoters B
either O
the O
interferon B
- I
stimulated I
response I
element I
( O
ISRE B
) O
or O
the O
gamma B
interferon I
activation I
site I
( O
GAS B
) O
. O

Expression O
of O
EBNA2 B
led O
to O
the O
transcriptional O
activation O
of O
both O
endogenous O
or O
transfected O
IFN B
- I
stimulated I
genes I
( O
ISGs B
) O
, O
genes O
which O
contain O
within O
their O
promoters B
either O
the O
interferon B
- I
stimulated I
response I
element I
( O
ISRE B
) O
or O
the O
gamma B
interferon I
activation I
site I
( O
GAS B
) O
. O

Expression O
of O
EBNA2 B
led O
to O
the O
transcriptional O
activation O
of O
both O
endogenous O
or O
transfected O
IFN B
- I
stimulated I
genes I
( O
ISGs B
) O
, O
genes O
which O
contain O
within O
their O
promoters B
either O
the O
interferon B
- I
stimulated I
response I
element I
( O
ISRE B
) O
or O
the O
gamma B
interferon I
activation I
site I
( O
GAS B
) O
. O

Expression O
of O
EBNA2 B
led O
to O
the O
transcriptional O
activation O
of O
both O
endogenous O
or O
transfected O
IFN B
- I
stimulated I
genes I
( O
ISGs B
) O
, O
genes O
which O
contain O
within O
their O
promoters B
either O
the O
interferon B
- I
stimulated I
response I
element I
( O
ISRE B
) O
or O
the O
gamma B
interferon I
activation I
site I
( O
GAS B
) O
. O

Expression O
of O
EBNA2 B
led O
to O
the O
transcriptional O
activation O
of O
both O
endogenous O
or O
transfected O
IFN B
- I
stimulated I
genes I
( O
ISGs B
) O
, O
genes O
which O
contain O
within O
their O
promoters B
either O
the O
interferon B
- I
stimulated I
response I
element I
( O
ISRE B
) O
or O
the O
gamma B
interferon I
activation I
site I
( O
GAS B
) O
. O

ANG B
II I
, O
like O
TNFalpha B
, O
caused O
rapid O
activation O
of O
NF B
- I
kappaB I
in O
human O
mononuclear O
cells O
isolated O
from O
peripheral O
blood O
by O
Ficoll O
density O
gradient O
. O

Increased O
mRNA B
and O
surface O
expression O
of O
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
were O
noted O
within O
hours O
. O

Markedly O
impaired O
binding O
was O
observed O
, O
consistent O
with O
both O
the O
use O
of O
different O
anchor O
residues O
and O
with O
changes O
in O
levels O
of O
DQ O
cis O
- O
dimer B
availability O
for O
peptide O
binding O
interactions O
. O

SERCA B
activity O
was O
measured O
as O
the O
thapsigargin O
sensitive O
, O
Ca2 O
+ O
dependent O
and O
ouabain O
resistant O
, O
ATP O
hydrolyses O
in O
platelet O
membranes O
. O

LPS O
- O
induced O
NF B
- I
kappaB I
activation O
was O
not O
inhibited O
by O
a O
dominant O
negative O
mutant O
of O
TRAF2 B
that O
is O
involved O
in O
TNF B
signaling O
. O

LPS O
- O
induced O
NF B
- I
kappaB I
activation O
was O
not O
inhibited O
by O
a O
dominant O
negative O
mutant O
of O
TRAF2 B
that O
is O
involved O
in O
TNF B
signaling O
. O

Tyrosine O
phosphorylation O
of O
IFN B
- I
gammaR I
, O
Jak1 B
, O
Jak2 B
, O
and O
Stat1alpha B
was O
examined O
by O
immunoblotting O
. O

Tyrosine O
phosphorylation O
of O
IFN B
- I
gammaR I
, O
Jak1 B
, O
Jak2 B
, O
and O
Stat1alpha B
was O
examined O
by O
immunoblotting O
. O

Tyrosine O
phosphorylation O
of O
IFN B
- I
gammaR I
, O
Jak1 B
, O
Jak2 B
, O
and O
Stat1alpha B
was O
examined O
by O
immunoblotting O
. O

In O
addition O
, O
IFN B
- I
gamma I
enhanced O
the O
DNA O
- O
binding O
activity O
of O
Stat1alpha B
. O

This O
RXR B
agonist O
activity O
is O
blocked O
by O
RAR B
- O
specific O
antagonists O
, O
suggesting O
extensive O
cross O
- O
talk O
between O
the O
partners O
of O
the O
RXR B
- I
RARalpha403 I
heterodimer I
. O

This O
RXR B
agonist O
activity O
is O
blocked O
by O
RAR B
- O
specific O
antagonists O
, O
suggesting O
extensive O
cross O
- O
talk O
between O
the O
partners O
of O
the O
RXR B
- I
RARalpha403 I
heterodimer I
. O

Similarly O
, O
IL B
- I
2 I
neither O
activates O
JNK B
nor O
increases O
AP B
- I
1 I
binding O
activity O
to O
a O
consensus O
o B
- I
tetradecanoylphorbol I
13 I
- I
acetate I
( I
TPA I
) I
response I
element I
. O

The O
phosphorylation O
appears O
to O
be O
related O
to O
the O
signaling O
events O
that O
are O
activated O
by O
TRAF2 B
under O
these O
circumstances O
, O
since O
two O
nonfunctional O
mutants O
were O
found O
to O
be O
phosphorylated O
significantly O
less O
than O
the O
wild B
- I
type I
protein I
. O

We O
conclude O
from O
these O
studies O
that O
the O
phosphorylation O
of O
TRAF2 B
is O
likely O
to O
play O
an O
important O
role O
in O
regulating O
signaling O
by O
virtue O
of O
its O
ability O
to O
influence O
the O
CD40 B
- B
TRAF2 I
interaction O
. O

We O
conclude O
from O
these O
studies O
that O
the O
phosphorylation O
of O
TRAF2 B
is O
likely O
to O
play O
an O
important O
role O
in O
regulating O
signaling O
by O
virtue O
of O
its O
ability O
to O
influence O
the O
CD40 B
- B
TRAF2 I
interaction O
. O

Unlike O
the O
proposed O
role O
of O
Cbl B
as O
a O
negative O
regulator O
, O
our O
results O
suggest O
that O
the O
Cbl B
homologue O
Cbl B
- I
b I
has O
a O
positive O
role O
in O
T O
- O
cell O
signaling O
, O
most O
likely O
via O
a O
direct O
interaction O
with O
the O
upstream B
kinase I
Zap B
- I
70 I
. O

Unlike O
the O
proposed O
role O
of O
Cbl B
as O
a O
negative O
regulator O
, O
our O
results O
suggest O
that O
the O
Cbl B
homologue O
Cbl B
- I
b I
has O
a O
positive O
role O
in O
T O
- O
cell O
signaling O
, O
most O
likely O
via O
a O
direct O
interaction O
with O
the O
upstream B
kinase I
Zap B
- I
70 I
. O

Grf40 B
, O
A O
novel O
Grb2 B
family I
member I
, O
is O
involved O
in O
T O
cell O
signaling O
through O
interaction O
with O
SLP B
- I
76 I
and O
LAT B
. O

Grf40 B
, O
A O
novel O
Grb2 B
family I
member I
, O
is O
involved O
in O
T O
cell O
signaling O
through O
interaction O
with O
SLP B
- I
76 I
and O
LAT B
. O

This O
review O
will O
discuss O
the O
mechanisms O
by O
which O
Ras B
expressing O
tumors O
are O
able O
to O
evade O
destruction O
by O
the O
immune O
system O
and O
enhance O
their O
growth O
and O
metastatic O
potential O
. O

Though O
the O
levels O
of O
DP1 B
and I
- I
2 I
increase O
when O
cells O
progress O
from O
G0 O
to O
S O
, O
the O
proportion O
of O
DP1 B
to O
DP2 B
remains O
relatively O
constant O
during O
the O
cell O
cycle O
. O

Though O
the O
levels O
of O
DP1 B
and I
- I
2 I
increase O
when O
cells O
progress O
from O
G0 O
to O
S O
, O
the O
proportion O
of O
DP1 B
to O
DP2 B
remains O
relatively O
constant O
during O
the O
cell O
cycle O
. O

We O
also O
observed O
an O
increase O
in O
electrophoretic O
mobility O
of O
the O
predominant O
E2F B
components I
, O
DP1 B
and O
E2F4 B
, O
as O
B O
- O
lymphocytes O
progressed O
from O
G0 O
into O
early O
G1 O
. O

We O
also O
observed O
an O
increase O
in O
electrophoretic O
mobility O
of O
the O
predominant O
E2F B
components I
, O
DP1 B
and O
E2F4 B
, O
as O
B O
- O
lymphocytes O
progressed O
from O
G0 O
into O
early O
G1 O
. O

In O
this O
study O
, O
we O
examined O
whether O
gp41 B
- O
induced O
IL B
- I
10 I
up O
- O
regulation O
is O
mediated O
by O
the O
previously O
described O
synergistic O
activation O
of O
cAMP O
and O
NF B
- I
kappaB I
pathways O
. O

Thus O
CTL O
clones O
that O
recognized O
the O
viral O
, O
self O
, O
and O
bacterial O
peptides O
expressed O
a O
highly O
restricted O
alphabeta O
TCR B
phenotype O
. O

Furthermore O
, O
these O
oxidative O
stresses O
inhibited O
activity O
of O
calcineurin O
, O
a O
serine O
/ O
threonine B
phosphatase I
that O
regulates O
NFAT B
activation O
. O

Several O
intracellular O
signaling B
proteins I
, O
such O
as O
CBL B
and O
VAV B
, O
were O
phosphorylated O
on O
tyrosine O
in O
response O
to O
CD80 B
, O
CD86 B
, O
and O
anti B
- I
CD28 I
mAb I
. O

Several O
intracellular O
signaling B
proteins I
, O
such O
as O
CBL B
and O
VAV B
, O
were O
phosphorylated O
on O
tyrosine O
in O
response O
to O
CD80 B
, O
CD86 B
, O
and O
anti B
- I
CD28 I
mAb I
. O

Several O
intracellular O
signaling B
proteins I
, O
such O
as O
CBL B
and O
VAV B
, O
were O
phosphorylated O
on O
tyrosine O
in O
response O
to O
CD80 B
, O
CD86 B
, O
and O
anti B
- I
CD28 I
mAb I
. O

Several O
intracellular O
signaling B
proteins I
, O
such O
as O
CBL B
and O
VAV B
, O
were O
phosphorylated O
on O
tyrosine O
in O
response O
to O
CD80 B
, O
CD86 B
, O
and O
anti B
- I
CD28 I
mAb I
. O

In O
addition O
, O
the O
association O
of O
phosphoinositide B
3 I
- I
kinase I
with O
CD28 B
and O
enhanced O
tyrosine O
phosphorylation O
of O
phospholipase O
Cgamma O
were O
seen O
after O
anti O
- O
CD28 O
mAb O
and O
CHO O
- O
CD80 O
stimulation O
but O
to O
a O
much O
lesser O
extent O
after O
CHO B
- I
CD86 I
stimulation O
. O

However O
, O
CD80 B
and O
CD86 B
also O
induce O
distinct O
signal O
transduction O
pathways O
including O
the O
tyrosine O
phosphorylation O
of O
CD28 B
and O
phospholipase B
Cgamma1 I
and O
the O
SH2 B
- O
dependent O
association O
of O
phosphoinositide B
3 I
- I
kinase I
with O
CD28 B
. O

However O
, O
CD80 B
and O
CD86 B
also O
induce O
distinct O
signal O
transduction O
pathways O
including O
the O
tyrosine O
phosphorylation O
of O
CD28 B
and O
phospholipase B
Cgamma1 I
and O
the O
SH2 B
- O
dependent O
association O
of O
phosphoinositide B
3 I
- I
kinase I
with O
CD28 B
. O

However O
, O
CD80 B
and O
CD86 B
also O
induce O
distinct O
signal O
transduction O
pathways O
including O
the O
tyrosine O
phosphorylation O
of O
CD28 B
and O
phospholipase B
Cgamma1 I
and O
the O
SH2 B
- O
dependent O
association O
of O
phosphoinositide B
3 I
- I
kinase I
with O
CD28 B
. O

However O
, O
CD80 B
and O
CD86 B
also O
induce O
distinct O
signal O
transduction O
pathways O
including O
the O
tyrosine O
phosphorylation O
of O
CD28 B
and O
phospholipase B
Cgamma1 I
and O
the O
SH2 B
- O
dependent O
association O
of O
phosphoinositide B
3 I
- I
kinase I
with O
CD28 B
. O

However O
, O
CD80 B
and O
CD86 B
also O
induce O
distinct O
signal O
transduction O
pathways O
including O
the O
tyrosine O
phosphorylation O
of O
CD28 B
and O
phospholipase B
Cgamma1 I
and O
the O
SH2 B
- O
dependent O
association O
of O
phosphoinositide B
3 I
- I
kinase I
with O
CD28 B
. O

The O
master O
switch O
for O
the O
expression O
of O
these O
genes O
is O
the O
class B
II I
transactivator I
( O
CIITA B
) O
. O

In O
contrast O
, O
overexpression O
of O
CREB B
inhibited O
GAL4 B
- O
p65 O
( O
286 O
- O
551 O
) O
- O
mediated O
transcription O
. O

In O
contrast O
, O
overexpression O
of O
CREB B
inhibited O
GAL4 B
- O
p65 O
( O
286 O
- O
551 O
) O
- O
mediated O
transcription O
. O

We O
measured O
the O
number O
of O
glucocorticoid B
receptors I
( O
GR B
) O
in O
cord O
blood O
lymphocytes O
and O
the O
binding O
affinity O
( O
Kd O
) O
in O
15 O
term O
and O
in O
20 O
preterm O
babies O
. O

The O
number O
of O
GR B
and O
the O
Kd O
were O
similar O
in O
the O
term O
and O
preterm O
( O
with O
and O
without O
NRDS O
) O
babies O
. O

Apart O
from O
clear O
- O
cut O
defects O
in O
the O
synthesis O
of O
mRNAs B
for O
Th2 B
- I
type I
lymphokines I
, O
such O
as O
IL B
- I
4 I
, O
IL B
- I
5 I
, O
IL B
- I
10 I
and O
IL B
- I
13 I
, O
in O
primary O
and O
secondary O
stimulations O
of O
spleen O
cells O
in O
vitro O
, O
of O
a O
distinct O
impaired O
deletion O
of O
V O
beta O
11 O
+ O
/ O
CD4 O
+ O
T O
lymphocytes O
from O
these O
mice O
was O
detected O
after O
superantigen O
injection O
. O

Our O
data O
constitute O
a O
starting O
point O
for O
studies O
to O
elucidate O
the O
molecular O
mechanism O
by O
which O
TGF B
- I
beta I
regulates O
IgA B
production O
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

The O
aberrant O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
T O
cells O
from O
lpr O
/ O
lpr O
and O
gld O
/ O
gld O
mice O
, O
which O
have O
mutations O
in O
the O
genes O
encoding O
Fas B
and O
FasL B
, O
respectively O
, O
have O
an O
activated O
phenotype O
and O
constitutively O
express O
high O
levels O
of O
fasL B
mRNA I
, O
prompting O
us O
to O
ask O
what O
role O
if O
any O
the O
FLRE B
and O
Egr B
family I
proteins I
have O
in O
this O
aberrant O
expression O
of O
fasL B
. O

The O
aberrant O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
T O
cells O
from O
lpr O
/ O
lpr O
and O
gld O
/ O
gld O
mice O
, O
which O
have O
mutations O
in O
the O
genes O
encoding O
Fas B
and O
FasL B
, O
respectively O
, O
have O
an O
activated O
phenotype O
and O
constitutively O
express O
high O
levels O
of O
fasL B
mRNA I
, O
prompting O
us O
to O
ask O
what O
role O
if O
any O
the O
FLRE B
and O
Egr B
family I
proteins I
have O
in O
this O
aberrant O
expression O
of O
fasL B
. O

The O
aberrant O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
T O
cells O
from O
lpr O
/ O
lpr O
and O
gld O
/ O
gld O
mice O
, O
which O
have O
mutations O
in O
the O
genes O
encoding O
Fas B
and O
FasL B
, O
respectively O
, O
have O
an O
activated O
phenotype O
and O
constitutively O
express O
high O
levels O
of O
fasL B
mRNA I
, O
prompting O
us O
to O
ask O
what O
role O
if O
any O
the O
FLRE B
and O
Egr B
family I
proteins I
have O
in O
this O
aberrant O
expression O
of O
fasL B
. O

The O
aberrant O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
T O
cells O
from O
lpr O
/ O
lpr O
and O
gld O
/ O
gld O
mice O
, O
which O
have O
mutations O
in O
the O
genes O
encoding O
Fas B
and O
FasL B
, O
respectively O
, O
have O
an O
activated O
phenotype O
and O
constitutively O
express O
high O
levels O
of O
fasL B
mRNA I
, O
prompting O
us O
to O
ask O
what O
role O
if O
any O
the O
FLRE B
and O
Egr B
family I
proteins I
have O
in O
this O
aberrant O
expression O
of O
fasL B
. O

Differential O
induction O
of O
DNA B
- I
binding I
activities I
following O
CD19 B
cross O
- O
linking O
in O
human O
B O
lineage O
cells O
. O

The O
B B
cell I
- I
specific I
cell I
surface I
molecule I
CD19 B
is O
expressed O
at O
all O
stages O
of O
B O
cell O
development O
, O
including O
normal O
plasma O
cells O
, O
and O
mediates O
signal O
transduction O
via O
interaction O
with O
cytoplasmic B
effector I
proteins I
. O

The O
regulatory B
regions I
of O
several O
genes O
specifically O
expressed O
in O
B O
cells O
contain O
functional B
binding I
sites I
for O
Oct2 B
. O

These O
target B
genes I
show O
quite O
distinct O
expression O
patterns O
demonstrating O
that O
transcription B
factors I
in O
addition O
to O
Oct2 B
are O
involved O
in O
their O
regulation O
. O

Fas B
( O
CD95 B
) O
and O
Fas B
ligand I
( O
CD95L B
) O
are O
an O
interacting O
receptor O
- O
ligand O
pair O
required O
for O
immune O
homeostasis O
. O

Fas B
( O
CD95 B
) O
and O
Fas B
ligand I
( O
CD95L B
) O
are O
an O
interacting O
receptor O
- O
ligand O
pair O
required O
for O
immune O
homeostasis O
. O

Fas B
( O
CD95 B
) O
and O
Fas B
ligand I
( O
CD95L B
) O
are O
an O
interacting O
receptor O
- O
ligand O
pair O
required O
for O
immune O
homeostasis O
. O

Although O
resting O
Jurkat O
cells O
express O
Fas B
, O
Fas B
mRNA I
was O
induced O
approximately O
10 O
- O
fold O
in O
2 O
h O
upon O
P O
/ O
I O
stimulation O
. O

The O
functional O
contribution O
of O
the O
kappaB B
- I
Sp1 I
composite I
site I
in O
P B
/ I
I I
- I
inducible I
fas I
promoter I
activation O
was O
verified O
by O
using O
kappaB O
- O
Sp1 B
concatamers O
( O
- B
295 I
to I
- I
286 I
) O
in O
a O
thymidine B
kinase I
promoter I
- I
driven I
reporter I
construct I
and O
native B
promoter I
constructs I
in O
Jurkat O
cells O
overexpressing O
IkappaB B
- I
alpha I
. O

However O
, O
while O
HUVECs O
contained O
endothelial O
NOS B
protein I
, O
no O
inducible O
NOS B
was O
detected O
in O
either O
tolerant O
or O
nontolerant O
cells O
. O

The O
inhibition O
of O
IL B
- I
2 I
production O
was O
observed O
in O
the O
CD3 B
( O
+ O
) O
T O
- O
lymphocyte O
cytoplasm O
as O
early O
as O
4 O
h O
after O
activation O
by O
PMA O
+ O
ionomycin O
. O

These O
cells O
, O
stimulated O
by O
an O
agonistic O
monoclonal O
antibody O
against O
CD40 B
or O
by O
transfection O
with O
a O
CD40L B
expression I
vector I
, O
secreted O
p40 B
and O
showed O
enhanced O
p40 B
mRNA I
expression O
. O

These O
cells O
, O
stimulated O
by O
an O
agonistic O
monoclonal O
antibody O
against O
CD40 B
or O
by O
transfection O
with O
a O
CD40L B
expression I
vector I
, O
secreted O
p40 B
and O
showed O
enhanced O
p40 B
mRNA I
expression O
. O

The O
3 B
' I
- I
CAGGTG I
E I
- I
box I
could O
bind O
USF B
proteins I
, O
the O
ubiquitous B
repressor I
ZEB B
, O
or O
the O
basic B
helix I
- I
loop I
- I
helix I
proteins I
E2A B
and O
HEB B
, O
and O
we O
showed O
that O
a O
competition O
between O
ZEB B
and O
E2A B
/ I
HEB I
proteins I
is O
involved O
in O
the O
silencer O
activity O
. O

The O
3 B
' I
- I
CAGGTG I
E I
- I
box I
could O
bind O
USF B
proteins I
, O
the O
ubiquitous B
repressor I
ZEB B
, O
or O
the O
basic B
helix I
- I
loop I
- I
helix I
proteins I
E2A B
and O
HEB B
, O
and O
we O
showed O
that O
a O
competition O
between O
ZEB B
and O
E2A B
/ I
HEB I
proteins I
is O
involved O
in O
the O
silencer O
activity O
. O

The O
3 B
' I
- I
CAGGTG I
E I
- I
box I
could O
bind O
USF B
proteins I
, O
the O
ubiquitous B
repressor I
ZEB B
, O
or O
the O
basic B
helix I
- I
loop I
- I
helix I
proteins I
E2A B
and O
HEB B
, O
and O
we O
showed O
that O
a O
competition O
between O
ZEB B
and O
E2A B
/ I
HEB I
proteins I
is O
involved O
in O
the O
silencer O
activity O
. O

The O
3 B
' I
- I
CAGGTG I
E I
- I
box I
could O
bind O
USF B
proteins I
, O
the O
ubiquitous B
repressor I
ZEB B
, O
or O
the O
basic B
helix I
- I
loop I
- I
helix I
proteins I
E2A B
and O
HEB B
, O
and O
we O
showed O
that O
a O
competition O
between O
ZEB B
and O
E2A B
/ I
HEB I
proteins I
is O
involved O
in O
the O
silencer O
activity O
. O

Stimulation O
of O
lymphoid O
cells O
with O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
led O
to O
ROI O
production O
and O
NF B
- I
kappaB I
activation O
, O
which O
could O
both O
be O
blocked O
by O
antioxidants O
or O
FLAP B
inhibitors O
, O
confirming O
that O
5 B
- I
LOX I
was O
the O
source O
of O
ROIs O
and O
was O
required O
for O
NF B
- I
kappaB I
activation O
in O
these O
cells O
. O

Cutting O
edge O
: O
dominant O
effect O
of O
Ile50Val B
variant I
of O
the O
human B
IL I
- I
4 I
receptor I
alpha I
- I
chain I
in O
IgE B
synthesis O
. O

Regulation O
of O
IL B
- I
4 I
expression O
by O
the O
transcription B
factor I
JunB B
during O
T O
helper O
cell O
differentiation O
. O

Here O
we O
show O
that O
JunB B
, O
but O
not O
the O
other O
Jun B
family I
members I
, O
was O
selectively O
induced O
in O
Th2 O
cells O
and O
not O
in O
Th1 O
cells O
during O
differentiation O
. O

The O
finding O
of O
Tax B
mutants O
segregating O
these O
two O
pathways O
suggested O
that O
the O
NF B
- I
kappaB I
pathway O
was O
essential O
for O
IL B
- I
2 I
- O
independent O
growth O
of O
CTLL O
- O
2 O
cells O
while O
the O
CRE B
pathway O
was O
unnecessary O
. O

The O
finding O
of O
Tax B
mutants O
segregating O
these O
two O
pathways O
suggested O
that O
the O
NF B
- I
kappaB I
pathway O
was O
essential O
for O
IL B
- I
2 I
- O
independent O
growth O
of O
CTLL O
- O
2 O
cells O
while O
the O
CRE B
pathway O
was O
unnecessary O
. O

Our O
results O
show O
that O
Tax B
has O
at O
least O
two O
distinct O
activities O
on O
T O
cells O
, O
and O
suggest O
that O
Tax B
plays O
a O
crucial O
role O
in O
IL B
- I
2 I
- O
independent O
T O
- O
cell O
transformation O
induced O
by O
HTLV O
- O
1 O
, O
in O
addition O
to O
its O
well O
- O
known O
IL B
- I
2 I
- O
dependent O
cell O
transformation O
. O

Our O
results O
show O
that O
Tax B
has O
at O
least O
two O
distinct O
activities O
on O
T O
cells O
, O
and O
suggest O
that O
Tax B
plays O
a O
crucial O
role O
in O
IL B
- I
2 I
- O
independent O
T O
- O
cell O
transformation O
induced O
by O
HTLV O
- O
1 O
, O
in O
addition O
to O
its O
well O
- O
known O
IL B
- I
2 I
- O
dependent O
cell O
transformation O
. O

Furthermore O
, O
GRbeta B
did O
not O
antagonize O
the O
repressive O
effects O
of O
GRalpha B
on O
IL B
- I
2 I
promoter I
activity O
. O

Furthermore O
, O
GRbeta B
did O
not O
antagonize O
the O
repressive O
effects O
of O
GRalpha B
on O
IL B
- I
2 I
promoter I
activity O
. O

Surprisingly O
, O
overexpression O
of O
GRbeta B
in O
Jurkat O
cells O
did O
not O
cause O
significant O
inhibition O
of O
GRalpha B
- O
induced O
transactivation O
of O
a O
GRE B
- I
dependent I
luciferase I
reporter I
gene I
either O
. O

Surprisingly O
, O
overexpression O
of O
GRbeta B
in O
Jurkat O
cells O
did O
not O
cause O
significant O
inhibition O
of O
GRalpha B
- O
induced O
transactivation O
of O
a O
GRE B
- I
dependent I
luciferase I
reporter I
gene I
either O
. O

Evidence O
for O
suppressed O
activity O
of O
the O
transcription B
factor I
NFAT1 B
at O
its O
proximal B
binding I
element I
P0 B
in O
the O
IL B
- I
4 I
promoter I
associated O
with O
enhanced O
IL B
- I
4 I
gene I
transcription O
in O
T O
cells O
of O
atopic O
patients O
. O

Evidence O
for O
suppressed O
activity O
of O
the O
transcription B
factor I
NFAT1 B
at O
its O
proximal B
binding I
element I
P0 B
in O
the O
IL B
- I
4 I
promoter I
associated O
with O
enhanced O
IL B
- I
4 I
gene I
transcription O
in O
T O
cells O
of O
atopic O
patients O
. O

In O
a O
series O
of O
electrophoretic O
mobility O
shift O
assays O
with O
protein O
extracts O
of O
highly O
polarized O
Th2 O
clones O
from O
atopics O
and O
Th1 O
clones O
from O
controls O
we O
compared O
DNA O
- O
binding O
activities O
at O
the O
two O
NFAT B
- I
binding I
elements I
P0 B
and O
P1 B
of O
the O
crucial O
proximal O
human O
IL B
- I
4 I
promoter I
. O

In O
a O
series O
of O
electrophoretic O
mobility O
shift O
assays O
with O
protein O
extracts O
of O
highly O
polarized O
Th2 O
clones O
from O
atopics O
and O
Th1 O
clones O
from O
controls O
we O
compared O
DNA O
- O
binding O
activities O
at O
the O
two O
NFAT B
- I
binding I
elements I
P0 B
and O
P1 B
of O
the O
crucial O
proximal O
human O
IL B
- I
4 I
promoter I
. O

At O
the O
most O
proximal O
P0 B
site O
, O
NFAT O
- O
containing O
complexes O
devoid O
of O
NFAT2 B
were O
readily O
inducible O
in O
the O
Th1 O
clones O
, O
but O
hardly O
or O
not O
in O
the O
Th2 O
clones O
. O

At O
the O
most O
proximal O
P0 B
site O
, O
NFAT O
- O
containing O
complexes O
devoid O
of O
NFAT2 B
were O
readily O
inducible O
in O
the O
Th1 O
clones O
, O
but O
hardly O
or O
not O
in O
the O
Th2 O
clones O
. O

These O
findings O
suggest O
that O
high O
- O
level O
IL B
- I
4 I
production O
in O
atopic O
Th2 O
cells O
is O
associated O
with O
selective O
reduction O
of O
suppressive O
NFAT1 B
activity O
at O
the O
IL B
- I
4 I
P0 I
element I
and O
that O
some O
patients O
with O
this O
multifactorial O
disease O
may O
have O
a O
putative O
systemic O
disorder O
at O
this O
level O
. O

A O
role O
for O
changes O
in O
immunophilins B
, O
causing O
glucocorticoid O
resistance O
in O
neotropical O
primates O
, O
is O
supported O
by O
the O
following O
: O
the O
changes O
in O
FKBP51 B
and O
FKBP52 B
were O
observed O
in O
cells O
from O
other O
neotropical O
primates O
with O
glucocorticoid O
resistance O
; O
the O
elevated O
level O
of O
FKBP51 B
was O
reflected O
in O
an O
abundance O
of O
FKBP51 B
in O
heat B
shock I
protein I
90 I
complexes I
in O
SML O
; O
when O
cytosols O
of O
SML O
and O
L929 O
cells O
were O
mixed O
, O
the O
decrease O
in O
GR O
binding O
was O
associated O
with O
incorporation O
of O
FKBP51 B
into O

A O
role O
for O
changes O
in O
immunophilins B
, O
causing O
glucocorticoid O
resistance O
in O
neotropical O
primates O
, O
is O
supported O
by O
the O
following O
: O
the O
changes O
in O
FKBP51 B
and O
FKBP52 B
were O
observed O
in O
cells O
from O
other O
neotropical O
primates O
with O
glucocorticoid O
resistance O
; O
the O
elevated O
level O
of O
FKBP51 B
was O
reflected O
in O
an O
abundance O
of O
FKBP51 B
in O
heat B
shock I
protein I
90 I
complexes I
in O
SML O
; O
when O
cytosols O
of O
SML O
and O
L929 O
cells O
were O
mixed O
, O
the O
decrease O
in O
GR O
binding O
was O
associated O
with O
incorporation O
of O
FKBP51 B
into O

A O
role O
for O
changes O
in O
immunophilins B
, O
causing O
glucocorticoid O
resistance O
in O
neotropical O
primates O
, O
is O
supported O
by O
the O
following O
: O
the O
changes O
in O
FKBP51 B
and O
FKBP52 B
were O
observed O
in O
cells O
from O
other O
neotropical O
primates O
with O
glucocorticoid O
resistance O
; O
the O
elevated O
level O
of O
FKBP51 B
was O
reflected O
in O
an O
abundance O
of O
FKBP51 B
in O
heat B
shock I
protein I
90 I
complexes I
in O
SML O
; O
when O
cytosols O
of O
SML O
and O
L929 O
cells O
were O
mixed O
, O
the O
decrease O
in O
GR O
binding O
was O
associated O
with O
incorporation O
of O
FKBP51 B
into O

A O
role O
for O
changes O
in O
immunophilins B
, O
causing O
glucocorticoid O
resistance O
in O
neotropical O
primates O
, O
is O
supported O
by O
the O
following O
: O
the O
changes O
in O
FKBP51 B
and O
FKBP52 B
were O
observed O
in O
cells O
from O
other O
neotropical O
primates O
with O
glucocorticoid O
resistance O
; O
the O
elevated O
level O
of O
FKBP51 B
was O
reflected O
in O
an O
abundance O
of O
FKBP51 B
in O
heat B
shock I
protein I
90 I
complexes I
in O
SML O
; O
when O
cytosols O
of O
SML O
and O
L929 O
cells O
were O
mixed O
, O
the O
decrease O
in O
GR O
binding O
was O
associated O
with O
incorporation O
of O
FKBP51 B
into O

A O
role O
for O
changes O
in O
immunophilins B
, O
causing O
glucocorticoid O
resistance O
in O
neotropical O
primates O
, O
is O
supported O
by O
the O
following O
: O
the O
changes O
in O
FKBP51 B
and O
FKBP52 B
were O
observed O
in O
cells O
from O
other O
neotropical O
primates O
with O
glucocorticoid O
resistance O
; O
the O
elevated O
level O
of O
FKBP51 B
was O
reflected O
in O
an O
abundance O
of O
FKBP51 B
in O
heat B
shock I
protein I
90 I
complexes I
in O
SML O
; O
when O
cytosols O
of O
SML O
and O
L929 O
cells O
were O
mixed O
, O
the O
decrease O
in O
GR O
binding O
was O
associated O
with O
incorporation O
of O
FKBP51 B
into O

A O
role O
for O
changes O
in O
immunophilins B
, O
causing O
glucocorticoid O
resistance O
in O
neotropical O
primates O
, O
is O
supported O
by O
the O
following O
: O
the O
changes O
in O
FKBP51 B
and O
FKBP52 B
were O
observed O
in O
cells O
from O
other O
neotropical O
primates O
with O
glucocorticoid O
resistance O
; O
the O
elevated O
level O
of O
FKBP51 B
was O
reflected O
in O
an O
abundance O
of O
FKBP51 B
in O
heat B
shock I
protein I
90 I
complexes I
in O
SML O
; O
when O
cytosols O
of O
SML O
and O
L929 O
cells O
were O
mixed O
, O
the O
decrease O
in O
GR O
binding O
was O
associated O
with O
incorporation O
of O
FKBP51 B
into O

GR B
heterocomplexes I
; O
the O
effect O
of O
SML O
cytosol O
on O
GR O
binding O
was O
reproduced O
with O
cytosol O
from O
COS O
cells O
expressing O
squirrel O
monkey O
FKBP51 B
; O
and O
both O
the O
effect O
of O
SML O
cytosol O
on O
GR O
binding O
and O
the O
incorporation O
of O
FKBP51 B
into O
GR B
heterocomplexes I
were O
blocked O
by O
FK506 O
. O

GR B
heterocomplexes I
; O
the O
effect O
of O
SML O
cytosol O
on O
GR O
binding O
was O
reproduced O
with O
cytosol O
from O
COS O
cells O
expressing O
squirrel O
monkey O
FKBP51 B
; O
and O
both O
the O
effect O
of O
SML O
cytosol O
on O
GR O
binding O
and O
the O
incorporation O
of O
FKBP51 B
into O
GR B
heterocomplexes I
were O
blocked O
by O
FK506 O
. O

NF B
- I
kappaB I
activity O
is O
tightly O
correlated O
with O
the O
transcriptional O
activity O
of O
a O
long B
terminal I
repeat I
( O
LTR B
) O
of O
HIV O
- O
1 O
transfected O
in O
thymocytes O
. O

Serial O
sectioning O
of O
6 O
micrometer O
was O
performed O
using O
a O
cryostat O
, O
and O
samples O
were O
immunohistochemicall O
stained O
using O
the O
streptoavidin B
- B
biotin I
peroxidase I
method O
and O
a O
monoclonal O
antibody O
against O
c O
- O
fos O
. O

The O
allele O
- O
specific O
expression O
profiles O
of O
other O
imprinted B
genes I
, O
IGF2 B
and O
H19 B
, O
on O
human B
chromosome I
11 I
were O
constant O
and O
consistent O
with O
those O
in O
other O
tissues O
. O

The O
allele O
- O
specific O
expression O
profiles O
of O
other O
imprinted B
genes I
, O
IGF2 B
and O
H19 B
, O
on O
human B
chromosome I
11 I
were O
constant O
and O
consistent O
with O
those O
in O
other O
tissues O
. O

Our O
unexpected O
observations O
of O
paternal O
or O
biallelic O
expression O
of O
WT1 B
in O
fibroblasts O
and O
lymphocytes O
, O
together O
with O
the O
previous O
findings O
of O
maternal O
or O
biallelic O
expression O
in O
placentae O
and O
brains O
, O
suggest O
that O
the O
allele O
- O
specific O
regulatory O
system O
of O
WT1 B
is O
unique O
and O
may O
be O
controlled O
by O
a O
putative O
tissue O
- O
and O
individual O
- O
specific O
modifier O
. O

Our O
unexpected O
observations O
of O
paternal O
or O
biallelic O
expression O
of O
WT1 B
in O
fibroblasts O
and O
lymphocytes O
, O
together O
with O
the O
previous O
findings O
of O
maternal O
or O
biallelic O
expression O
in O
placentae O
and O
brains O
, O
suggest O
that O
the O
allele O
- O
specific O
regulatory O
system O
of O
WT1 B
is O
unique O
and O
may O
be O
controlled O
by O
a O
putative O
tissue O
- O
and O
individual O
- O
specific O
modifier O
. O

T O
cell O
responses O
to O
some O
nuclear O
antigens O
, O
particularly O
U1RNP B
, O
have O
been O
detected O
in O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
and O
in O
healthy O
subjects O
. O

Six O
of O
20 O
patients O
with O
SS O
and O
10 O
/ O
19 O
controls O
proliferated O
to O
La O
( O
rSSB B
) O
. O

Tumor B
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
- O
induced O
HIV O
- O
1 O
replication O
in O
OM10 O
. O
1 O
or O
Ach2 O
cells O
was O
significantly O
inhibited O
by O
non O
- O
cytotoxic O
doses O
of O
AuTG O
( O
> O
10 O
microM O
in O
OM10 O
. O
1 O
cells O
and O
> O
25 O
F O
. O
M O
in O
Ach2 O
cells O
) O
, O
while O
25 O
microM O
of O
the O
counter B
- I
anion I
thioglucose I
( O
TG B
) O
or O
gold O
compound O
containing O
divalent O
gold O
ion O
, O
HAuCl3 O
, O
had O
no O
effect O
. O

A O
Taq B
I I
polymorphism I
was O
identified O
which O
enabled O
chicken O
IL2 B
to O
be O
mapped O
to O
chromosome B
4 I
, O
linked O
to O
ANX5 B
, O
with O
synteny O
with O
mouse B
chromosome I
3 I
and O
human B
chromosome I
4 I
. O

A O
Taq B
I I
polymorphism I
was O
identified O
which O
enabled O
chicken O
IL2 B
to O
be O
mapped O
to O
chromosome B
4 I
, O
linked O
to O
ANX5 B
, O
with O
synteny O
with O
mouse B
chromosome I
3 I
and O
human B
chromosome I
4 I
. O

Transcriptional O
regulation O
of O
the O
alpha2 B
integrin I
gene I
in O
cells O
undergoing O
megakaryocytic O
differentiation O
requires O
a O
core B
promoter I
between O
bp O
- O
30 O
and O
- O
92 O
, O
a O
silencer B
between O
bp O
- O
92 O
and O
- O
351 O
, O
and O
megakaryocytic B
enhancers I
in O
the O
distal B
5 I
' I
flank I
. O

Therefore O
, O
our O
data O
not O
only O
reveal O
that O
Nmi B
can O
potentiate O
STAT B
- O
dependent O
transcription O
, O
but O
also O
suggest O
that O
it O
can O
augment O
coactivator O
protein O
recruitment O
to O
at O
least O
some O
members O
of O
a O
group O
of O
sequence B
- I
specific I
transcription I
factors I
. O

Therefore O
, O
our O
data O
not O
only O
reveal O
that O
Nmi B
can O
potentiate O
STAT B
- O
dependent O
transcription O
, O
but O
also O
suggest O
that O
it O
can O
augment O
coactivator O
protein O
recruitment O
to O
at O
least O
some O
members O
of O
a O
group O
of O
sequence B
- I
specific I
transcription I
factors I
. O

In O
contrast O
, O
activation O
in O
THP B
- I
1 I
cells I
occurred O
in O
the O
absence O
of O
vanadate O
and O
was O
unaffected O
by O
catalase B
. O

These O
findings O
suggest O
the O
presence O
in O
vaginal O
fluid O
of O
agent O
( O
s O
) O
derived O
from O
indigenous O
bacteria O
that O
can O
activate O
the O
HIV B
- I
1 I
LTR I
, O
cytokine B
production O
, O
and O
NF B
- I
kappaB I
in O
cells O
of O
macrophage O
lineage O
, O
with O
possible O
influence O
on O
vaginal O
physiology O
and O
host O
defense O
. O

Activated O
primed O
CD4 O
T O
cells O
contain O
more O
NFAT1 B
and O
support O
greater O
NFAT B
- O
directed O
transcription O
than O
unprimed O
CD4 O
T O
cells O
, O
while O
activator B
protein I
1 I
binding O
and O
activator B
protein I
1 I
- O
mediated O
transcription O
by O
both O
cell O
types O
is O
similar O
. O

Activated O
primed O
CD4 O
T O
cells O
contain O
more O
NFAT1 B
and O
support O
greater O
NFAT B
- O
directed O
transcription O
than O
unprimed O
CD4 O
T O
cells O
, O
while O
activator B
protein I
1 I
binding O
and O
activator B
protein I
1 I
- O
mediated O
transcription O
by O
both O
cell O
types O
is O
similar O
. O

These O
agents O
also O
significantly O
decreased O
TNF B
- O
and O
LPS O
- O
stimulated O
increases O
in O
HUVEC B
surface I
VCAM I
- I
1 I
. O

TNF B
stimulated O
expression O
of O
both O
intercellular B
adhesion I
molecule I
- I
1 I
and O
E B
- I
selectin I
in O
HUVECs O
, O
but O
in O
HUAECs O
, O
only O
intercellular B
adhesion I
molecule I
- I
1 I
was O
increased O
. O

AR B
can O
be O
visualized O
with O
the O
anti B
- I
AR I
antibodies I
in O
the O
cytoplasm O
of O
permeabilized O
T O
cells O
by O
using O
CLSM O
, O
though O
AR B
are O
not O
detectable O
in O
cytosol O
fractions O
when O
using O
the O
charcoal O
binding O
assay O
with O
3H O
- O
R1881 O
as O
ligand O
. O

AR B
can O
be O
visualized O
with O
the O
anti B
- I
AR I
antibodies I
in O
the O
cytoplasm O
of O
permeabilized O
T O
cells O
by O
using O
CLSM O
, O
though O
AR B
are O
not O
detectable O
in O
cytosol O
fractions O
when O
using O
the O
charcoal O
binding O
assay O
with O
3H O
- O
R1881 O
as O
ligand O
. O

B O
lymphocytes O
from O
patients O
with O
chronic O
lymphocytic O
leukemia O
contain O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
1 I
and O
STAT3 B
constitutively O
phosphorylated O
on O
serine O
residues O
. O

In O
summary O
, O
the O
constitutive O
serine O
phosphorylation O
of O
STAT1 B
and O
STAT3 B
is O
present O
in O
all O
CLL O
samples O
tested O
to O
date O
, O
although O
the O
physiologic O
significance O
of O
this O
modification O
remains O
to O
be O
determined O
. O

In O
summary O
, O
the O
constitutive O
serine O
phosphorylation O
of O
STAT1 B
and O
STAT3 B
is O
present O
in O
all O
CLL O
samples O
tested O
to O
date O
, O
although O
the O
physiologic O
significance O
of O
this O
modification O
remains O
to O
be O
determined O
. O

Highly O
purified O
monocytes O
were O
incubated O
with O
IL B
- I
10 I
for O
60 O
to O
90 O
minutes O
before O
the O
addition O
of O
IFNgamma B
or O
IFNalpha B
. O

Highly O
purified O
monocytes O
were O
incubated O
with O
IL B
- I
10 I
for O
60 O
to O
90 O
minutes O
before O
the O
addition O
of O
IFNgamma B
or O
IFNalpha B
. O

IL B
- I
10 I
preincubation O
resulted O
in O
the O
inhibition O
of O
gene O
expression O
for O
several O
IFN B
- I
induced I
genes I
, O
such O
as O
IP B
- I
10 I
, O
ISG54 B
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
. O

Associated O
with O
the O
inhibition O
of O
the O
cell O
cycle O
, O
IL B
- I
10 I
suppressed O
SEB B
induction O
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

In O
both O
cell O
types O
, O
the O
cytokine B
that O
inhibits O
the O
induction O
of O
IkappaBalpha B
by O
DEX O
, O
also O
rescues O
these O
cells O
from O
DEX O
- O
induced O
apoptosis O
, O
although O
the O
rescue O
cytokine O
is O
different O
in O
Th1 O
and O
Th2 O
cells O
. O

In O
both O
cell O
types O
, O
the O
cytokine B
that O
inhibits O
the O
induction O
of O
IkappaBalpha B
by O
DEX O
, O
also O
rescues O
these O
cells O
from O
DEX O
- O
induced O
apoptosis O
, O
although O
the O
rescue O
cytokine O
is O
different O
in O
Th1 O
and O
Th2 O
cells O
. O

Infection O
of O
human O
monocytes O
with O
influenza O
A O
virus O
induces O
a O
broad O
range O
of O
proinflammatory B
cytokines I
and O
mononuclear O
cell O
attracting O
chemokines B
before O
the O
infected O
cells O
undergo O
apoptosis O
. O

The O
importance O
of O
BCL2 B
and O
Stat3 B
on O
IL B
- I
6 I
- O
induced O
macrophage O
- O
differentiation O
and O
apoptosis O
was O
studied O
with O
1A9 O
- O
M O
cells O
expressing O
human B
BCL2 I
or O
a O
dominant O
- O
negative O
form O
of O
Stat3 B
, O
respectively O
. O

The O
importance O
of O
BCL2 B
and O
Stat3 B
on O
IL B
- I
6 I
- O
induced O
macrophage O
- O
differentiation O
and O
apoptosis O
was O
studied O
with O
1A9 O
- O
M O
cells O
expressing O
human B
BCL2 I
or O
a O
dominant O
- O
negative O
form O
of O
Stat3 B
, O
respectively O
. O

The O
importance O
of O
BCL2 B
and O
Stat3 B
on O
IL B
- I
6 I
- O
induced O
macrophage O
- O
differentiation O
and O
apoptosis O
was O
studied O
with O
1A9 O
- O
M O
cells O
expressing O
human B
BCL2 I
or O
a O
dominant O
- O
negative O
form O
of O
Stat3 B
, O
respectively O
. O

IL B
- I
6 I
- O
induced O
apoptosis O
, O
but O
not O
macrophage O
- O
differentiation O
, O
was O
blocked O
by O
continuously O
expressed O
BCL2 B
. O

Interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
is O
a O
chemokine B
that O
belongs O
to O
the O
alpha B
- I
chemokine I
or O
CXC B
subfamily I
and O
is O
produced O
by O
a O
wide O
variety O
of O
human O
cells O
, O
including O
monocytes O
and O
polymorphonuclear O
cells O
( O
PMN O
) O
. O

In O
this O
report O
, O
we O
show O
that O
Mycoplasma B
fermentans I
lipid I
- I
associated I
membrane I
proteins I
( O
LAMPf B
) O
induce O
the O
production O
of O
high O
levels O
of O
IL B
- I
8 I
by O
THP O
- O
1 O
( O
human O
monocyte O
) O
cells O
and O
PMN O
at O
the O
same O
extent O
as O
LPS O
. O

In O
this O
study O
we O
investigated O
the O
effects O
of O
C3a B
and O
C3a B
( I
desArg I
) I
on O
gene O
expression O
and O
protein O
secretion O
of O
IL B
- I
6 I
in O
human O
PBMCs O
, O
either O
alone O
or O
in O
combination O
with O
LPS O
or O
IL B
- I
1beta I
. O

Furthermore O
, O
we O
investigated O
the O
effects O
of O
C3a B
and O
C3a B
( I
desArg I
) I
on O
induction O
of O
NF B
- I
kappaB I
and O
activating B
protein I
- I
1 I
binding O
. O

These O
results O
demonstrate O
the O
capacity O
of O
intact O
C3a B
and O
its O
circulating O
des B
- I
Arg I
form I
to O
exert O
immunmodulatory O
effects O
in O
vitro O
. O

Therefore O
we O
investigated O
the O
properties O
and O
function O
of O
the O
glucocorticoid B
receptors I
( O
GR B
) O
in O
FMS O
patients O
and O
compared O
the O
results O
with O
those O
of O
healthy O
persons O
and O
patients O
with O
chronic O
low O
back O
pain O
( O
LBP O
a O
localized O
pain O
condition O
) O
. O

The O
suggested O
roles O
of O
the O
downstream B
3 I
' I
regions I
acting O
as O
a O
Locus B
Control I
Region I
( O
LCR B
) O
, O
have O
allowed O
comparisons O
to O
be O
made O
between O
the O
regulation O
of O
the O
IgH B
locus I
with O
other O
model O
systems O
whose O
gene O
expression O
is O
governed O
by O
LCR B
activity O
. O

The O
suggested O
roles O
of O
the O
downstream B
3 I
' I
regions I
acting O
as O
a O
Locus B
Control I
Region I
( O
LCR B
) O
, O
have O
allowed O
comparisons O
to O
be O
made O
between O
the O
regulation O
of O
the O
IgH B
locus I
with O
other O
model O
systems O
whose O
gene O
expression O
is O
governed O
by O
LCR B
activity O
. O

OCA B
- I
B I
is O
a O
functional O
analog O
of O
VP16 B
but O
targets O
a O
separate O
surface O
of O
the O
Oct B
- I
1 I
POU I
domain I
[ O
published O
erratum O
appears O
in O
Mol O
Cell O
Biol O
1998 O
Apr O
; O
18 O
( O
4 O
) O
: O
2430 O
] O

Phosphatidylinositol B
3 I
- I
kinase I
couples O
the O
interleukin B
- I
2 I
receptor I
to O
the O
cell B
cycle I
regulator I
E2F B
. O

We O
eliminate O
both O
Stat5 B
and O
Raf B
/ B
MEK I
pathways O
from O
E2F B
regulation O
. O

We O
eliminate O
both O
Stat5 B
and O
Raf B
/ B
MEK I
pathways O
from O
E2F B
regulation O
. O

We O
eliminate O
both O
Stat5 B
and O
Raf B
/ B
MEK I
pathways O
from O
E2F B
regulation O
. O

TRADD B
was O
the O
only O
protein O
that O
interacted O
with O
wild B
- I
type I
TES2 I
and O
not O
with O
isoleucine B
- I
mutated I
TES2 I
. O

In O
transfection O
assays O
, O
TRADD B
and O
TES2 B
synergistically O
mediated O
high O
- O
level O
NF B
- I
kappaB I
activation O
. O

In O
transfection O
assays O
, O
TRADD B
and O
TES2 B
synergistically O
mediated O
high O
- O
level O
NF B
- I
kappaB I
activation O
. O

Core B
- I
specific I
mAb I
inhibited O
mCD14 B
- O
mediated O
uptake O
of O
homologous O
and O
heterologous O
LPS O
, O
while O
producing O
less O
concurrent O
enhancement O
of O
non O
- O
mCD14 B
- O
mediated O
LPS O
uptake O
. O

Core B
- I
specific I
mAb I
inhibited O
mCD14 B
- O
mediated O
uptake O
of O
homologous O
and O
heterologous O
LPS O
, O
while O
producing O
less O
concurrent O
enhancement O
of O
non O
- O
mCD14 B
- O
mediated O
LPS O
uptake O
. O

Transfection O
of O
EL O
- O
4 O
cells O
with O
the O
IL B
- I
4 I
promoter I
- I
reporter I
constructs I
carrying O
mutated B
P I
- I
like I
elements I
showed O
that O
four O
P B
- I
like I
elements I
, O
CLE0 B
, O
P B
, O
P2 B
and O
P4 B
, O
but O
not O
P3 B
, O
were O
required O
for O
optimal O
activation O
of O
the O
IL B
- I
4 I
promoter I
. O

Transfection O
of O
EL O
- O
4 O
cells O
with O
the O
IL B
- I
4 I
promoter I
- I
reporter I
constructs I
carrying O
mutated B
P I
- I
like I
elements I
showed O
that O
four O
P B
- I
like I
elements I
, O
CLE0 B
, O
P B
, O
P2 B
and O
P4 B
, O
but O
not O
P3 B
, O
were O
required O
for O
optimal O
activation O
of O
the O
IL B
- I
4 I
promoter I
. O

Transfection O
of O
EL O
- O
4 O
cells O
with O
the O
IL B
- I
4 I
promoter I
- I
reporter I
constructs I
carrying O
mutated B
P I
- I
like I
elements I
showed O
that O
four O
P B
- I
like I
elements I
, O
CLE0 B
, O
P B
, O
P2 B
and O
P4 B
, O
but O
not O
P3 B
, O
were O
required O
for O
optimal O
activation O
of O
the O
IL B
- I
4 I
promoter I
. O

Transfection O
of O
EL O
- O
4 O
cells O
with O
the O
IL B
- I
4 I
promoter I
- I
reporter I
constructs I
carrying O
mutated B
P I
- I
like I
elements I
showed O
that O
four O
P B
- I
like I
elements I
, O
CLE0 B
, O
P B
, O
P2 B
and O
P4 B
, O
but O
not O
P3 B
, O
were O
required O
for O
optimal O
activation O
of O
the O
IL B
- I
4 I
promoter I
. O

Transfection O
of O
EL O
- O
4 O
cells O
with O
the O
IL B
- I
4 I
promoter I
- I
reporter I
constructs I
carrying O
mutated B
P I
- I
like I
elements I
showed O
that O
four O
P B
- I
like I
elements I
, O
CLE0 B
, O
P B
, O
P2 B
and O
P4 B
, O
but O
not O
P3 B
, O
were O
required O
for O
optimal O
activation O
of O
the O
IL B
- I
4 I
promoter I
. O

Strikingly O
, O
Western O
blotting O
and O
immunocytochemical O
experiments O
indicated O
that O
PDTC O
promoted O
a O
transient O
and O
rapid O
shuttling O
of O
NFATp B
and O
NFATc B
, O
leading O
to O
their O
accelerated O
export O
from O
the O
nucleus O
of O
activated O
T O
cells O
. O

Strikingly O
, O
Western O
blotting O
and O
immunocytochemical O
experiments O
indicated O
that O
PDTC O
promoted O
a O
transient O
and O
rapid O
shuttling O
of O
NFATp B
and O
NFATc B
, O
leading O
to O
their O
accelerated O
export O
from O
the O
nucleus O
of O
activated O
T O
cells O
. O

We O
recently O
identified O
the O
winged B
- I
helix I
transcription I
factor I
Trident B
and O
described O
its O
expression O
pattern O
in O
synchronized O
fibroblasts O
. O

The O
estrogen B
receptor I
( O
ER B
) O
repressed O
erythroid O
differentiation O
and O
erythroid B
- I
specific I
gene I
expression O
. O

Recently O
, O
cyclin O
E O
- O
Cdk2 O
- O
and O
cyclin O
A O
- O
Cdk2 O
- O
dependent O
phosphorylation O
of O
a O
single O
conserved O
serine O
residue O
( O
Ser5 O
) O
in O
Id2 B
has O
been O
shown O
to O
occur O
during O
late O
G1 O
- O
to O
- O
S O
phase O
transition O
of O
the O
cell O
cycle O
, O
and O
this O
neutralizes O
the O
function O
of O
Id2 B
in O
abrogating O
E B
- I
box I
- I
dependent I
bHLH I
homo O
- O
or O
heterodimer O
complex O
formation O
in O
vitro O
( O
E O
. O
Hara O
, O
M O
. O
Hall O
, O
and O
G O
. O
Peters O
, O
EMBO O
J O
. O
16 O
: O
332 O
- O

Recently O
, O
cyclin O
E O
- O
Cdk2 O
- O
and O
cyclin O
A O
- O
Cdk2 O
- O
dependent O
phosphorylation O
of O
a O
single O
conserved O
serine O
residue O
( O
Ser5 O
) O
in O
Id2 B
has O
been O
shown O
to O
occur O
during O
late O
G1 O
- O
to O
- O
S O
phase O
transition O
of O
the O
cell O
cycle O
, O
and O
this O
neutralizes O
the O
function O
of O
Id2 B
in O
abrogating O
E B
- I
box I
- I
dependent I
bHLH I
homo O
- O
or O
heterodimer O
complex O
formation O
in O
vitro O
( O
E O
. O
Hara O
, O
M O
. O
Hall O
, O
and O
G O
. O
Peters O
, O
EMBO O
J O
. O
16 O
: O
332 O
- O

In O
the O
mouse O
embryo O
, O
mNFATc B
transcript I
was O
strongly O
expressed O
in O
thymus O
, O
lung O
and O
submandibular O
gland O
and O
weakly O
in O
skeletal O
muscle O
and O
heart O
suggesting O
that O
mNFATc B
may O
have O
a O
role O
both O
in O
embryogenesis O
and O
in O
mature O
T O
cells O
. O

These O
data O
indicate O
that O
the O
TRE B
- I
like I
cAMP I
- I
responsive I
DSE I
sites I
within O
the O
5 B
' I
- I
untranslated I
leader I
can O
mediate O
the O
transcriptional O
cooperativity O
between O
TNFalpha B
and O
the O
cAMP O
/ B
PKA I
pathway O
. O

Furthermore O
, O
we O
show O
that O
patients O
with O
GC O
- O
insensitive O
asthma O
have O
cytokine O
- O
induced O
abnormalities O
in O
the O
DNA O
binding O
capability O
of O
the O
GCR B
. O

Mutation O
of O
the O
CBF1 B
/ I
RBP I
- I
Jkappa I
binding I
site I
in O
EBNA3C B
abrogated O
repression O
, O
strongly O
suggesting O
that O
CBF1 B
/ I
RBP I
- I
Jkappa I
is O
necessary O
for O
targeting O
the O
viral O
protein O
to O
Cp B
. O

Mutation O
of O
the O
CBF1 B
/ I
RBP I
- I
Jkappa I
binding I
site I
in O
EBNA3C B
abrogated O
repression O
, O
strongly O
suggesting O
that O
CBF1 B
/ I
RBP I
- I
Jkappa I
is O
necessary O
for O
targeting O
the O
viral O
protein O
to O
Cp B
. O

Cooperation O
of O
binding B
sites I
for O
STAT6 B
and O
NF B
kappa I
B I
/ I
rel I
in O
the O
IL B
- I
4 I
- O
induced O
up O
- O
regulation O
of O
the O
human B
IgE I
germline I
promoter I
. O

Cyclosporin O
A O
inhibits O
early O
mRNA O
expression O
of O
G0 B
/ I
G1 I
switch I
gene I
2 I
( O
G0S2 B
) O
in O
cultured O
human O
blood O
mononuclear O
cells O
. O

YY1 B
, O
a O
widely O
distributed O
human B
transcription I
factor I
, O
is O
known O
to O
inhibit O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
transcription O
and O
virus O
production O
. O

YY1 B
, O
a O
widely O
distributed O
human B
transcription I
factor I
, O
is O
known O
to O
inhibit O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
transcription O
and O
virus O
production O
. O

LSF B
( O
also O
known O
as O
LBP B
- I
1 I
, O
UBP B
, O
and O
CP B
- I
2 I
) O
has O
been O
shown O
to O
repress O
LTR O
transcription O
in O
vitro O
, O
but O
transient O
expression O
of O
LSF B
has O
no O
effect O
on O
LTR B
activity O
in O
vivo O
. O

LSF B
( O
also O
known O
as O
LBP B
- I
1 I
, O
UBP B
, O
and O
CP B
- I
2 I
) O
has O
been O
shown O
to O
repress O
LTR O
transcription O
in O
vitro O
, O
but O
transient O
expression O
of O
LSF B
has O
no O
effect O
on O
LTR B
activity O
in O
vivo O
. O

LSF B
( O
also O
known O
as O
LBP B
- I
1 I
, O
UBP B
, O
and O
CP B
- I
2 I
) O
has O
been O
shown O
to O
repress O
LTR O
transcription O
in O
vitro O
, O
but O
transient O
expression O
of O
LSF B
has O
no O
effect O
on O
LTR B
activity O
in O
vivo O
. O

LSF B
( O
also O
known O
as O
LBP B
- I
1 I
, O
UBP B
, O
and O
CP B
- I
2 I
) O
has O
been O
shown O
to O
repress O
LTR O
transcription O
in O
vitro O
, O
but O
transient O
expression O
of O
LSF B
has O
no O
effect O
on O
LTR B
activity O
in O
vivo O
. O

The O
effect O
of O
Tax B
on O
VCAM B
- I
1 I
gene O
transcription O
was O
next O
confirmed O
in O
JPX O
- O
9 O
cells O
, O
a O
subclone O
of O
Jurkat O
cells O
, O
carrying O
the O
tax B
sequences I
under O
the O
control O
of O
an O
inducible B
promoter I
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B
- I
1 I
promoter I
performed O
with O
chloramphenicol B
acetyltransferase I
constructs I
revealed O
that O
Tax B
was O
trans O
activating O
the O
VCAM B
- I
1 I
promoter I
via O
two O
NF B
- I
kappaB I
sites I
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM B
- I
1 I
gene I
promoter I
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B
- O
induced O
expression O
of O
this O
adhesion B
molecule I
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B
- I
1 I
promoter I
performed O
with O
chloramphenicol B
acetyltransferase I
constructs I
revealed O
that O
Tax B
was O
trans O
activating O
the O
VCAM B
- I
1 I
promoter I
via O
two O
NF B
- I
kappaB I
sites I
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM B
- I
1 I
gene I
promoter I
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B
- O
induced O
expression O
of O
this O
adhesion B
molecule I
. O

We O
have O
investigated O
the O
effects O
of O
Vpr B
on O
host O
cell O
activation O
and O
confirm O
that O
it O
influences O
cellular O
proliferation O
. O

In O
the O
absence O
of O
TCR B
- O
mediated O
activation O
, O
Vpr B
induces O
apoptosis O
whereas O
in O
its O
presence O
, O
Vpr B
interrupts O
the O
expected O
induction O
of O
apoptosis O
. O

In O
the O
absence O
of O
TCR B
- O
mediated O
activation O
, O
Vpr B
induces O
apoptosis O
whereas O
in O
its O
presence O
, O
Vpr B
interrupts O
the O
expected O
induction O
of O
apoptosis O
. O

In O
the O
absence O
of O
TCR B
- O
mediated O
activation O
, O
Vpr B
induces O
apoptosis O
whereas O
in O
its O
presence O
, O
Vpr B
interrupts O
the O
expected O
induction O
of O
apoptosis O
. O

Our O
finding O
that O
Vpr B
can O
regulate O
NF B
- I
kappa I
B I
supports O
the O
hypothesis O
that O
some O
aspects O
of O
viral O
pathogenesis O
are O
the O
consequence O
of O
cell O
dysregulation O
by O
Vpr B
. O

Our O
finding O
that O
Vpr B
can O
regulate O
NF B
- I
kappa I
B I
supports O
the O
hypothesis O
that O
some O
aspects O
of O
viral O
pathogenesis O
are O
the O
consequence O
of O
cell O
dysregulation O
by O
Vpr B
. O

In O
fact O
, O
by O
employing O
a O
novel O
haptenized O
lysis O
synthetic O
substrate O
which O
allows O
the O
isolation O
of O
glutaminyl O
- O
tTG O
substrates O
in O
vivo O
, O
we O
identified O
pRB B
as O
a O
potential O
tTG O
substrate O
in O
U937 O
cells O
undergoing O
apoptosis O
. O

IL B
- I
2 I
and O
T B
cell I
antigen I
receptor I
complex I
induction O
of O
STAT3alpha B
serine O
727 O
phosphorylation O
is O
dependent O
on O
the O
activity O
of O
the O
MEK B
/ B
ERK I
pathway O
. O

IL B
- I
2 I
and O
T B
cell I
antigen I
receptor I
complex I
induction O
of O
STAT3alpha B
serine O
727 O
phosphorylation O
is O
dependent O
on O
the O
activity O
of O
the O
MEK B
/ B
ERK I
pathway O
. O

In O
addition O
, O
both O
RelA B
and O
c B
- I
Rel I
, O
but O
not O
NF B
- I
kappa I
B1 I
, O
were O
shown O
to O
transactivate O
an O
ICAM B
- I
1 I
kappa I
B I
- I
reporter I
construct I
. O

Patients O
with O
renin B
values O
less O
than O
0 O
. O
13 O
ng O
angiotensin O
I O
/ O
L O
per O
second O
were O
markedly O
less O
sensitive O
to O
cortisol O
than O
those O
with O
higher O
values O
. O

The O
composite B
PU I
. I
1 I
and I
Pip I
site I
likely O
accounts O
for O
both O
lineage O
and O
stage O
- O
specific O
expression O
of O
CD20 B
whereas O
the O
CD20 B
E I
box I
binding I
proteins I
enhance O
overall O
promoter O
activity O
and O
may O
link O
the O
promoter O
to O
a O
distant B
enhancer I
. O

Furthermore O
, O
the O
degree O
of O
CN B
inhibition O
was O
reflected O
by O
a O
similar O
degree O
of O
reduction O
in O
lymphocyte O
proliferation O
and O
IFN B
- I
gamma I
production O
in O
the O
allogeneic O
mixed O
lymphocyte O
cultures O
. O

Thus O
, O
the O
reduction O
of O
CN B
activity O
observed O
in O
CsA O
- O
treated O
patients O
is O
accompanied O
by O
a O
similar O
degree O
of O
reduction O
in O
lymphocyte B
gene I
activation O
, O
and O
accounts O
for O
the O
immunosuppression O
observed O
. O

G28 B
- I
5 I
sFv I
was O
a O
more O
potent O
agonist O
than O
G28 B
- I
5 I
IgG I
and O
was O
able O
to O
stimulate O
CD40 B
responses O
by O
B O
cells O
and O
monocytes O
. O

Increased O
CRH B
promoter O
activity O
following O
phorbol O
ester O
treatment O
was O
inhibited O
by O
a O
dominant O
negative O
NF B
- I
IL6 I
mutant I
, O
showing O
that O
the O
effects O
of O
phorbol O
ester O
were O
principally O
mediated O
by O
C B
/ I
EBP I
. O

We O
screened O
TSG101 B
for O
somatic O
mutations O
in O
DNA O
and O
RNA O
samples O
isolated O
from O
a O
variety O
of O
common O
human O
malignancies O
, O
EBV O
- O
immortalised O
B O
- O
cells O
, O
and O
normal O
lung O
parenchyma O
. O

Intragenic O
TSG101 B
deletions O
in O
RNA B
transcripts I
were O
frequently O
found O
in O
all O
types O
of O
samples O
. O

A O
similar O
spectrum O
of O
transcript O
deletions O
has O
previously O
been O
described O
in O
the O
putative B
tumour I
suppressor I
gene I
FHIT B
. O

CD40 B
ligation O
leads O
to O
B O
cell O
activation O
events O
such O
as O
proliferation O
, O
Ig O
secretion O
, O
isotype O
switching O
, O
and O
up O
- O
regulation O
of O
cell B
surface I
molecules I
, O
as O
well O
as O
the O
generation O
of O
memory O
B O
cells O
. O

Many O
of O
these O
events O
are O
dependent O
upon O
the O
ability O
of O
CD40 B
to O
activate O
the O
transcription O
factor O
NF B
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
. O

To O
define O
the O
CD40 B
signaling O
components O
upstream O
of O
NF B
- I
kappa I
B I
activation O
and O
the O
functional O
consequences O
downstream O
of O
NF B
- I
kappa I
B I
activation O
, O
we O
examined O
mouse O
B O
cell O
transfectants O
expressing O
wild B
- I
type I
or I
mutant I
human I
CD40 I
. O

A O
threonine O
residue O
at O
position B
234 I
, O
previously O
shown O
to O
be O
important O
for O
CD40 B
association O
with O
TNF B
receptor I
- I
associated I
factor I
2 I
( O
TRAF2 B
) O
, O
TRAF3 B
, O
and O
TRAF5 B
, O
was O
not O
required O
for O
NF B
- I
kappa I
B I
activation O
. O

A O
threonine O
residue O
at O
position B
234 I
, O
previously O
shown O
to O
be O
important O
for O
CD40 B
association O
with O
TNF B
receptor I
- I
associated I
factor I
2 I
( O
TRAF2 B
) O
, O
TRAF3 B
, O
and O
TRAF5 B
, O
was O
not O
required O
for O
NF B
- I
kappa I
B I
activation O
. O

A O
threonine O
residue O
at O
position B
234 I
, O
previously O
shown O
to O
be O
important O
for O
CD40 B
association O
with O
TNF B
receptor I
- I
associated I
factor I
2 I
( O
TRAF2 B
) O
, O
TRAF3 B
, O
and O
TRAF5 B
, O
was O
not O
required O
for O
NF B
- I
kappa I
B I
activation O
. O

A O
threonine O
residue O
at O
position B
234 I
, O
previously O
shown O
to O
be O
important O
for O
CD40 B
association O
with O
TNF B
receptor I
- I
associated I
factor I
2 I
( O
TRAF2 B
) O
, O
TRAF3 B
, O
and O
TRAF5 B
, O
was O
not O
required O
for O
NF B
- I
kappa I
B I
activation O
. O

NF B
- I
kappa I
B I
activation O
was O
independent O
of O
the O
transmembrane B
domain I
of O
CD40 B
, O
suggesting O
that O
it O
is O
independent O
of O
p23 B
, O
a O
molecule O
that O
associates O
with O
CD40 B
in O
a O
region O
other O
than O
the O
cytoplasmic B
domain I
. O

NF B
- I
kappa I
B I
activation O
was O
independent O
of O
the O
transmembrane B
domain I
of O
CD40 B
, O
suggesting O
that O
it O
is O
independent O
of O
p23 B
, O
a O
molecule O
that O
associates O
with O
CD40 B
in O
a O
region O
other O
than O
the O
cytoplasmic B
domain I
. O

NF B
- I
kappa I
B I
activation O
was O
independent O
of O
the O
transmembrane B
domain I
of O
CD40 B
, O
suggesting O
that O
it O
is O
independent O
of O
p23 B
, O
a O
molecule O
that O
associates O
with O
CD40 B
in O
a O
region O
other O
than O
the O
cytoplasmic B
domain I
. O

NF B
- I
kappa I
B I
activation O
correlated O
with O
the O
ability O
of O
CD40 B
to O
induce O
Ab O
secretion O
and O
the O
up O
- O
regulation O
of O
ICAM B
- I
1 I
and O
LFA B
- I
1 I
. O

The O
induction O
of O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
, O
and O
ELAM B
- I
1 I
by O
TNF B
in O
MVEC O
occurred O
within O
6 O
h O
and O
was O
also O
completely O
down O
- O
regulated O
by O
PAO O
in O
a O
dose O
- O
dependent O
manner O
. O

Further O
, O
M O
. O
tuberculosis O
and O
its O
tuberculin B
, O
purified B
protein I
derivative I
, O
induced O
the O
degradation O
of O
I B
kappa I
B I
- I
alpha I
and O
the O
expression O
of O
I B
kappa I
B I
- I
alpha I
mRNA I
, O
and O
purified O
protein O
derivative O
induced O
the O
activation O
of O
NF B
- I
kappa I
B I
in O
monocytes O
. O

Inhibition O
of O
TF B
induction O
in O
the O
presence O
of O
high O
CsA O
blood O
concentrations O
was O
also O
observed O
when O
stimulation O
of O
cells O
was O
performed O
with O
interferon B
- I
gamma I
or O
interleukin B
- I
1beta I
. O

Inhibition O
of O
monocyte O
TF B
induction O
by O
CsA O
may O
contribute O
to O
its O
successful O
use O
in O
cardiac O
transplant O
medicine O
and O
might O
be O
useful O
in O
managing O
further O
settings O
of O
vascular O
pathology O
also O
known O
to O
involve O
TF B
expression O
and O
NF B
- I
kappaB I
activation O
. O

Inhibition O
of O
monocyte O
TF B
induction O
by O
CsA O
may O
contribute O
to O
its O
successful O
use O
in O
cardiac O
transplant O
medicine O
and O
might O
be O
useful O
in O
managing O
further O
settings O
of O
vascular O
pathology O
also O
known O
to O
involve O
TF B
expression O
and O
NF B
- I
kappaB I
activation O
. O

Both O
cytokines B
induced O
assembly O
of O
STAT5A B
and O
STAT5B B
containing O
complexes O
capable O
of O
binding O
to O
the O
interferon B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
, O
and O
these O
complexes O
rapidly O
translocated O
( O
within O
1 O
min O
) O
into O
the O
nucleus O
of O
IL O
- O
2 O
- O
or O
IL O
- O
7 O
- O
treated O
cells O
. O

Both O
cytokines B
induced O
assembly O
of O
STAT5A B
and O
STAT5B B
containing O
complexes O
capable O
of O
binding O
to O
the O
interferon B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
, O
and O
these O
complexes O
rapidly O
translocated O
( O
within O
1 O
min O
) O
into O
the O
nucleus O
of O
IL O
- O
2 O
- O
or O
IL O
- O
7 O
- O
treated O
cells O
. O

Both O
cytokines B
induced O
assembly O
of O
STAT5A B
and O
STAT5B B
containing O
complexes O
capable O
of O
binding O
to O
the O
interferon B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
, O
and O
these O
complexes O
rapidly O
translocated O
( O
within O
1 O
min O
) O
into O
the O
nucleus O
of O
IL O
- O
2 O
- O
or O
IL O
- O
7 O
- O
treated O
cells O
. O

Both O
cytokines B
induced O
assembly O
of O
STAT5A B
and O
STAT5B B
containing O
complexes O
capable O
of O
binding O
to O
the O
interferon B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
, O
and O
these O
complexes O
rapidly O
translocated O
( O
within O
1 O
min O
) O
into O
the O
nucleus O
of O
IL O
- O
2 O
- O
or O
IL O
- O
7 O
- O
treated O
cells O
. O

IL B
- I
2 I
and O
IL B
- I
7 I
were O
equivalent O
in O
their O
ability O
to O
induce O
tyrosine O
phosphorylation O
of O
STAT5A B
and O
STAT5B B
and O
to O
facilitate O
binding O
of O
these O
STATs B
to O
an O
immobilized B
GAS I
element I
. O

IL B
- I
2 I
and O
IL B
- I
7 I
were O
equivalent O
in O
their O
ability O
to O
induce O
tyrosine O
phosphorylation O
of O
STAT5A B
and O
STAT5B B
and O
to O
facilitate O
binding O
of O
these O
STATs B
to O
an O
immobilized B
GAS I
element I
. O

IL B
- I
2 I
and O
IL B
- I
7 I
were O
equivalent O
in O
their O
ability O
to O
induce O
tyrosine O
phosphorylation O
of O
STAT5A B
and O
STAT5B B
and O
to O
facilitate O
binding O
of O
these O
STATs B
to O
an O
immobilized B
GAS I
element I
. O

These O
data O
suggest O
that O
IL B
- I
2 I
and O
IL B
- I
7 I
induce O
assembly O
of O
STAT B
heterodimers I
in O
a O
similar O
manner O
and O
that O
subsequent O
cellular O
responses O
may O
be O
driven O
by O
induction O
of O
similar O
sets O
of O
genes B
. O

The O
class B
II I
trans I
- I
activator I
( O
CIITA B
) O
is O
a O
bi B
- I
or I
multi I
- I
functional I
domain I
protein I
which O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

Rather O
, O
helenalin O
modifies O
the O
NF B
- I
kappaB I
/ I
IkappaB I
complex I
, O
preventing O
the O
release O
of O
IkappaB B
. O

The O
tax B
protein I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
mediates O
the O
transactivation O
of O
the O
c B
- I
sis I
/ I
platelet I
- I
derived I
growth I
factor I
- I
B I
promoter I
through O
interactions O
with O
the O
zinc B
finger I
transcription I
factors I
Sp1 B
and O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

In O
the O
present O
work O
, O
we O
have O
investigated O
the O
mechanism O
( O
s O
) O
whereby O
Tax B
transactivates O
the O
c B
- I
sis I
/ I
PDGF I
- I
B I
proto I
- I
oncogene I
. O

Interestingly O
, O
co O
- O
immunoprecipitation O
analysis O
also O
revealed O
that O
Tax B
mutant O
IEXC29S B
is O
unable O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
, O
whereas O
Tax B
mutant O
IEXL320G B
is O
able O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

Interestingly O
, O
co O
- O
immunoprecipitation O
analysis O
also O
revealed O
that O
Tax B
mutant O
IEXC29S B
is O
unable O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
, O
whereas O
Tax B
mutant O
IEXL320G B
is O
able O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

Interestingly O
, O
co O
- O
immunoprecipitation O
analysis O
also O
revealed O
that O
Tax B
mutant O
IEXC29S B
is O
unable O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
, O
whereas O
Tax B
mutant O
IEXL320G B
is O
able O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

Interestingly O
, O
co O
- O
immunoprecipitation O
analysis O
also O
revealed O
that O
Tax B
mutant O
IEXC29S B
is O
unable O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
, O
whereas O
Tax B
mutant O
IEXL320G B
is O
able O
to O
interact O
with O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

Immunohistochemical O
staining O
demonstrated O
RelB B
within O
the O
differentiated O
lymph O
node O
interdigitating O
DC O
and O
follicular O
DC O
, O
but O
not O
undifferentiated O
DC O
in O
normal O
skin O
. O

NF B
- I
AT I
activation O
induced O
by O
a O
CAML B
- O
interacting O
member O
of O
the O
tumor B
necrosis I
factor I
receptor I
superfamily I
. O

These O
results O
suggest O
that O
coordination O
of O
NF B
- I
kappaB I
and O
STAT6 B
may O
be O
required O
for O
induction O
of O
germline B
Cepsilon O
transcription O
by O
IL B
- I
4 I
, O
and O
that O
CD40 B
- O
mediated O
NF B
- I
kappaB I
activation O
may O
be O
important O
in O
regulating O
both O
enhancement O
of O
germline B
Cepsilon O
transcription O
and O
class O
switching O
to O
IgE B
. O

These O
results O
suggest O
that O
coordination O
of O
NF B
- I
kappaB I
and O
STAT6 B
may O
be O
required O
for O
induction O
of O
germline B
Cepsilon O
transcription O
by O
IL B
- I
4 I
, O
and O
that O
CD40 B
- O
mediated O
NF B
- I
kappaB I
activation O
may O
be O
important O
in O
regulating O
both O
enhancement O
of O
germline B
Cepsilon O
transcription O
and O
class O
switching O
to O
IgE B
. O

These O
results O
suggest O
that O
coordination O
of O
NF B
- I
kappaB I
and O
STAT6 B
may O
be O
required O
for O
induction O
of O
germline B
Cepsilon O
transcription O
by O
IL B
- I
4 I
, O
and O
that O
CD40 B
- O
mediated O
NF B
- I
kappaB I
activation O
may O
be O
important O
in O
regulating O
both O
enhancement O
of O
germline B
Cepsilon O
transcription O
and O
class O
switching O
to O
IgE B
. O

These O
results O
suggest O
that O
coordination O
of O
NF B
- I
kappaB I
and O
STAT6 B
may O
be O
required O
for O
induction O
of O
germline B
Cepsilon O
transcription O
by O
IL B
- I
4 I
, O
and O
that O
CD40 B
- O
mediated O
NF B
- I
kappaB I
activation O
may O
be O
important O
in O
regulating O
both O
enhancement O
of O
germline B
Cepsilon O
transcription O
and O
class O
switching O
to O
IgE B
. O

These O
results O
suggest O
that O
coordination O
of O
NF B
- I
kappaB I
and O
STAT6 B
may O
be O
required O
for O
induction O
of O
germline B
Cepsilon O
transcription O
by O
IL B
- I
4 I
, O
and O
that O
CD40 B
- O
mediated O
NF B
- I
kappaB I
activation O
may O
be O
important O
in O
regulating O
both O
enhancement O
of O
germline B
Cepsilon O
transcription O
and O
class O
switching O
to O
IgE B
. O

Proteins O
of O
the O
ATF O
/ O
CREB B
class O
of O
transcription B
factors I
stimulate O
gene O
expression O
of O
several O
cell B
growth I
- I
related I
genes I
through O
protein B
kinase I
A I
- I
related I
cAMP I
response I
elements I
. O

Neither O
the O
PLC B
gamma I
1 I
overexpression O
induced O
by O
IFN B
nor O
the O
increased O
hydrolytic O
activity O
of O
the O
enzyme B
appear O
to O
be O
affected O
by O
pretreatment O
of O
the O
cells O
with O
the O
protein O
tyrosine B
kinase I
inhibitor O
genistein O
, O
which O
is O
known O
to O
prevent O
the O
association O
of O
ISGF3 B
components O
. O

Neither O
the O
PLC B
gamma I
1 I
overexpression O
induced O
by O
IFN B
nor O
the O
increased O
hydrolytic O
activity O
of O
the O
enzyme B
appear O
to O
be O
affected O
by O
pretreatment O
of O
the O
cells O
with O
the O
protein O
tyrosine B
kinase I
inhibitor O
genistein O
, O
which O
is O
known O
to O
prevent O
the O
association O
of O
ISGF3 B
components O
. O

Neither O
the O
PLC B
gamma I
1 I
overexpression O
induced O
by O
IFN B
nor O
the O
increased O
hydrolytic O
activity O
of O
the O
enzyme B
appear O
to O
be O
affected O
by O
pretreatment O
of O
the O
cells O
with O
the O
protein O
tyrosine B
kinase I
inhibitor O
genistein O
, O
which O
is O
known O
to O
prevent O
the O
association O
of O
ISGF3 B
components O
. O

These O
results O
suggest O
that O
in O
human O
T O
lymphocytes O
IFN B
- I
beta I
can O
activate O
other O
transcription B
factor I
( O
s O
) O
distinct O
from O
ISGF3 B
to O
regulate O
PLC B
gamma I
1 I
expression O
. O

Moreover O
, O
anti B
- I
TNF I
- I
alpha I
inhibited O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
- O
driven O
transcription O
of O
a O
reporter B
gene I
in O
primary O
T O
cells O
in O
response O
to O
activation O
, O
either O
in O
the O
presence O
or O
the O
absence O
of O
HIV B
- I
1 I
Tat I
. O

These O
results O
indicate O
that O
JAK2 B
/ B
STAT5 I
activation O
is O
a O
common O
JAK B
/ B
STAT I
pathway O
for O
hIL B
- I
5 I
- O
mediated O
signal O
in O
these O
cells O
. O

These O
results O
indicate O
that O
JAK2 B
/ B
STAT5 I
activation O
is O
a O
common O
JAK B
/ B
STAT I
pathway O
for O
hIL B
- I
5 I
- O
mediated O
signal O
in O
these O
cells O
. O

This O
activation O
of O
NF B
- I
kappa I
B I
was O
inhibited O
by O
the O
antioxidant O
and O
H2O2 O
scavenger O
pyrrolidine O
dithiocarbamate O
and O
the O
proteasome B
inhibitor O
PSI O
. O

The O
oxLDL B
- O
induced O
NF B
- I
kappa I
B I
activation O
was O
accompanied O
by O
an O
initial O
depletion O
of O
I B
kappa I
B I
- I
alpha I
followed O
by O
a O
slight O
transient O
increase O
in O
the O
level O
of O
this O
inhibitor O
protein O
. O

These O
observations O
provide O
additional O
evidence O
that O
oxLDL B
is O
a O
potent O
modulator O
of O
gene O
expression O
and O
suggest O
that O
( O
dys O
) O
regulation O
of O
NF B
- I
kappa I
B I
/ I
Rel I
is O
likely O
to O
play O
an O
important O
role O
in O
atherogenesis O
. O

PURPOSE O
: O
To O
demonstrate O
that O
leukocyte O
adhesion O
to O
cultured O
corneal O
endothelial O
cells O
is O
mediated O
by O
the O
CD18 B
antigen I
, O
and O
to O
determine O
whether O
dexamethasone O
directly O
suppresses O
adhesion O
by O
inhibiting O
activation O
of O
nuclear B
factor I
kappa I
B I
( O
NFkappaB B
) O
. O

RESULTS O
: O
Neutrophil O
adhesion O
to O
cultured O
corneal O
endothelial O
cells O
increased O
significantly O
on O
exposure O
to O
TNFalpha B
( O
451 O
. O
4 O
+ O
/ O
- O
45 O
. O
4 O
cells O
/ O
mm2 O
, O
n O
= O
16 O
) O
compared O
to O
control O
( O
156 O
. O
7 O
+ O
/ O
- O
27 O
. O
3 O
cells O
/ O
mm2 O
, O
n O
= O
16 O
, O
P O
< O
0 O
. O
01 O
) O
. O

The O
transcriptional B
start I
sites I
were O
identified O
by O
an O
RNase B
protection O
assay O
. O

Since O
GH B
stimulates O
the O
development O
and O
function O
of O
granulocytes O
, O
we O
investigated O
the O
expression O
of O
GH B
in O
granulocyte O
subsets O
. O

Since O
GH B
stimulates O
the O
development O
and O
function O
of O
granulocytes O
, O
we O
investigated O
the O
expression O
of O
GH B
in O
granulocyte O
subsets O
. O

In O
addition O
, O
BHRF1 B
protected O
these O
cells O
from O
monocyte O
- O
mediated O
killing O
but O
failed O
to O
protect O
them O
from O
killing O
mediated O
by O
lymphokine O
- O
activated O
killer O
cells O
. O

Eotaxin B
is O
an O
eosinophil B
specific I
beta I
- I
chemokine I
assumed O
to O
be O
involved O
in O
eosinophilic O
inflammatory O
diseases O
such O
as O
atopic O
dermatitis O
, O
allergic O
rhinitis O
, O
asthma O
and O
parasitic O
infections O
. O

The O
class B
II I
- I
specific I
transcription I
factors I
RFX B
and O
CIITA B
are O
also O
required O
for O
expression O
, O
as O
cell O
lines O
deficient O
in O
these O
factors O
failed O
to O
allow O
transcription O
from O
the O
DM B
promoters I
. O

The O
class B
II I
- I
specific I
transcription I
factors I
RFX B
and O
CIITA B
are O
also O
required O
for O
expression O
, O
as O
cell O
lines O
deficient O
in O
these O
factors O
failed O
to O
allow O
transcription O
from O
the O
DM B
promoters I
. O

Critical O
cytoplasmic B
domains I
of O
human B
interleukin I
- I
9 I
receptor I
alpha I
chain I
in O
interleukin B
- O
9 O
- O
mediated O
cell O
proliferation O
and O
signal O
transduction O
. O

In O
a O
previous O
study O
, O
we O
demonstrated O
that O
bufalin O
, O
which O
is O
an O
active O
principle O
of O
Chinese O
medicine O
, O
chan O
' O
su O
, O
caused O
apoptosis O
in O
human O
leukemia O
U937 O
cells O
by O
anomalous O
activation O
of O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
via O
the O
signaling O
pathway O
of O
Ras B
, O
Raf B
- I
1 I
, O
and O
MAPK B
kinase I
- I
1 I
. O

In O
a O
previous O
study O
, O
we O
demonstrated O
that O
bufalin O
, O
which O
is O
an O
active O
principle O
of O
Chinese O
medicine O
, O
chan O
' O
su O
, O
caused O
apoptosis O
in O
human O
leukemia O
U937 O
cells O
by O
anomalous O
activation O
of O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
via O
the O
signaling O
pathway O
of O
Ras B
, O
Raf B
- I
1 I
, O
and O
MAPK B
kinase I
- I
1 I
. O

Decreased O
transcriptional O
activation O
by O
N B
- I
terminal I
deletions I
of O
CIITA B
is O
correlated O
directly O
with O
their O
reduced O
binding O
to O
TAFII32 B
. O

Decreased O
transcriptional O
activation O
by O
N B
- I
terminal I
deletions I
of O
CIITA B
is O
correlated O
directly O
with O
their O
reduced O
binding O
to O
TAFII32 B
. O

Ligand O
binding O
and O
activation O
of O
the O
IL B
- I
10 I
receptor I
expressed O
on O
B O
- O
CLL O
cells O
results O
in O
the O
phosphorylation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
and O
STAT3 B
proteins O
. O

Ligand O
binding O
and O
activation O
of O
the O
IL B
- I
10 I
receptor I
expressed O
on O
B O
- O
CLL O
cells O
results O
in O
the O
phosphorylation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
and O
STAT3 B
proteins O
. O

When O
18C7 B
was O
incubated O
with O
MR B
before O
aldosterone O
or O
progesterone O
, O
the O
antibody O
inhibited O
75 O
- O
80 O
% O
of O
the O
binding O
. O

When O
18C7 B
was O
incubated O
with O
MR B
before O
aldosterone O
or O
progesterone O
, O
the O
antibody O
inhibited O
75 O
- O
80 O
% O
of O
the O
binding O
. O

c B
- I
Myb I
and O
Ets B
proteins I
synergize O
to O
overcome O
transcriptional O
repression O
by O
ZEB B
. O

IL B
- I
4 I
- O
dependent O
activation O
of O
Stat6 B
was O
also O
observed O
in O
HC11 O
mammary O
epithelial O
cells O
. O

In O
these O
cells O
, O
Stat6 B
activation O
led O
to O
the O
induction O
of O
the O
beta B
- I
casein I
gene I
promoter I
. O

In O
pre O
- O
B O
cells O
( O
Ba O
/ O
F3 O
) O
, O
the O
transactivation O
domain O
of O
Stat6 B
was O
IL B
- I
4 I
regulated O
, O
independently O
from O
its O
DNA O
binding O
function O
. O

Activation O
of O
helper O
T O
cells O
results O
in O
coordinate O
expression O
of O
a O
number O
of O
cytokines B
involved O
in O
differentiation O
, O
proliferation O
and O
activation O
of O
the O
haematopoietic O
system O
. O

Granulocyte B
- I
macrophage I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
is O
one O
such O
cytokine B
, O
whose O
increased O
expression O
results O
mostly O
from O
increases O
in O
transcription O
. O

ETS1 B
is O
a O
transcription B
factor I
of O
the O
ETS B
family I
that O
is O
expressed O
in O
T O
cells O
. O

We O
have O
previously O
shown O
that O
ETS1 B
can O
transactivate O
GM B
- I
CSF I
in O
Jurkat O
T O
cells O
, O
but O
only O
after O
the O
cells O
have O
been O
stimulated O
by O
treatment O
with O
PMA O
and O
ionomycin O
, O
agents O
that O
mimic O
T O
cell O
activation O
. O

CD40 B
is O
an O
important O
signaling O
and O
activation O
Ag O
found O
on O
certain O
bone O
marrow O
- O
derived O
cells O
. O

Recently O
, O
CD40 B
also O
has O
been O
shown O
to O
be O
expressed O
by O
mesenchymal O
cells O
, O
including O
human O
fibroblasts O
. O

Little O
is O
known O
about O
the O
role O
of O
CD40 B
in O
fibroblasts O
. O

The O
current O
study O
investigates O
the O
hypothesis O
that O
CD40 B
expressed O
on O
lung O
fibroblasts O
is O
an O
activation O
structure O
and O
mechanism O
for O
interaction O
with O
hemopoietic O
cells O
. O

Signaling O
through O
CD40 B
with O
soluble O
CD40 B
ligand O
stimulated O
fibroblast O
activation O
, O
as O
evidenced O
by O
mobilization O
of O
nuclear O
factor O
- O
kappaB O
and O
by O
induction O
of O
the O
proinflammatory O
and O
chemoattractant O
cytokines B
IL B
- I
6 I
and O
IL B
- I
8 I
. O

Signaling O
through O
CD40 B
with O
soluble O
CD40 B
ligand O
stimulated O
fibroblast O
activation O
, O
as O
evidenced O
by O
mobilization O
of O
nuclear O
factor O
- O
kappaB O
and O
by O
induction O
of O
the O
proinflammatory O
and O
chemoattractant O
cytokines B
IL B
- I
6 I
and O
IL B
- I
8 I
. O

Signaling O
through O
CD40 B
with O
soluble O
CD40 B
ligand O
stimulated O
fibroblast O
activation O
, O
as O
evidenced O
by O
mobilization O
of O
nuclear O
factor O
- O
kappaB O
and O
by O
induction O
of O
the O
proinflammatory O
and O
chemoattractant O
cytokines B
IL B
- I
6 I
and O
IL B
- I
8 I
. O

Fusion O
proteins O
involving O
the O
retinoic O
acid O
receptor B
alpha I
( O
RAR B
alpha I
) O
and O
the O
PML B
or O
PLZF B
nuclear I
protein I
are O
the O
genetic O
markers O
of O
acute O
promyelocytic O
leukemias O
( O
APLs O
) O
. O

Interleukin B
- I
12 I
( O
IL B
- I
12 I
) O
is O
a O
cytokine B
that O
exhibits O
pleiotropic O
effects O
on O
lymphocytes O
and O
natural O
killer O
cells O
and O
has O
been O
shown O
to O
have O
promise O
for O
the O
immunotherapy O
of O
cancer O
. O

Plasma O
sialyltransferase B
levels O
in O
psychiatric O
disorders O
as O
a O
possible O
indicator O
of O
HPA O
axis O
function O
. O

While O
there O
was O
a O
significant O
increase O
in O
plasma O
cortisol O
levels O
in O
the O
depressed O
group O
, O
there O
were O
no O
changes O
in O
the O
lymphocyte O
GR B
binding O
parameters O
( O
K O
( O
m O
) O
and O
Bmax O
) O
. O

Using O
a O
previously O
described O
mutant O
of O
the O
Jurkat O
T O
cell O
line O
, O
we O
show O
that O
proximal O
signaling O
events O
dependent O
on O
the O
presence O
of O
the O
CD45 B
tyrosine I
phosphatase I
are O
required O
for O
TCR B
- O
stimulated O
CD95 B
ligand I
expression O
. O

Together O
, O
these O
studies O
begin O
a O
dissection O
of O
the O
biochemical O
events O
that O
lead O
to O
expression O
of O
CD95 B
ligand I
, O
a O
required O
step O
for O
TCR B
- O
induced O
apoptosis O
. O

Large O
germline O
deletions O
of O
TSC2 B
occur O
in O
< O
5 O
% O
of O
cases O
, O
and O
a O
number O
of O
small O
intragenic O
mutations O
have O
been O
described O
. O

The O
Eed B
- O
mediated O
transcriptional O
effects O
are O
likely O
to O
reflect O
the O
interaction O
of O
Eed B
with O
multiple O
molecular O
partners O
, O
including O
K B
protein I
. O

The O
Eed B
- O
mediated O
transcriptional O
effects O
are O
likely O
to O
reflect O
the O
interaction O
of O
Eed B
with O
multiple O
molecular O
partners O
, O
including O
K B
protein I
. O

The O
human B
C I
/ I
EBPepsilon I
gene I
is O
transcribed O
by O
two O
alternative O
promoters B
, O
Palpha B
and O
Pbeta B
. O

The O
human B
C I
/ I
EBPepsilon I
gene I
is O
transcribed O
by O
two O
alternative O
promoters B
, O
Palpha B
and O
Pbeta B
. O

The O
human B
C I
/ I
EBPepsilon I
gene I
is O
transcribed O
by O
two O
alternative O
promoters B
, O
Palpha B
and O
Pbeta B
. O

A O
combination O
of O
differential O
splicing O
and O
alternative O
use O
of O
promoters B
generates O
four O
mRNA B
isoforms I
, O
of O
2 O
. O
6 O
kb O
and O
1 O
. O
3 O
- O
1 O
. O
5 O
kb O
in O
size O
. O

Thus O
, O
Tap B
is O
likely O
to O
be O
an O
important O
cellular O
mediator O
of O
Tip B
function O
in O
T O
cell O
transformation O
by O
herpesvirus O
saimiri O
. O

Thus O
, O
Tap B
is O
likely O
to O
be O
an O
important O
cellular O
mediator O
of O
Tip B
function O
in O
T O
cell O
transformation O
by O
herpesvirus O
saimiri O
. O

Functional O
analysis O
of O
monocytic O
THP O
- O
1 O
cells O
transfected O
with O
plasmids B
containing O
various O
lengths O
of O
TNF B
- I
alpha I
promoter I
localized O
enhancer B
elements I
in O
a O
region O
( O
- B
182 I
to I
- I
37 I
base I
pairs I
( O
bp O
) O
) O
that O
were O
required O
for O
optimal O
transcription O
of O
the O
TNF B
- I
alpha I
gene I
in O
response O
to O
LPS O
. O

The O
other O
, O
CIITA B
, O
encodes O
a O
large O
protein O
with O
a O
defined O
acidic B
transcriptional I
activation I
domain I
; O
this O
protein O
does O
not O
interact O
with O
DNA O
. O

However O
, O
these O
plasmids B
produced O
transcriptional O
activity O
in O
HeLa O
cells O
only O
in O
conjunction O
with O
interferon B
gamma I
stimulation O
, O
a O
condition O
in O
which O
expression O
of O
both O
CIITA B
and O
class B
II I
major I
histocompatibility I
complex I
surface I
proteins I
are O
induced O
. O

However O
, O
these O
plasmids B
produced O
transcriptional O
activity O
in O
HeLa O
cells O
only O
in O
conjunction O
with O
interferon B
gamma I
stimulation O
, O
a O
condition O
in O
which O
expression O
of O
both O
CIITA B
and O
class B
II I
major I
histocompatibility I
complex I
surface I
proteins I
are O
induced O
. O

Thus O
, O
RFX5 B
can O
activate O
transcription O
only O
in O
cooperation O
with O
CIITA B
. O

Thus O
, O
RFX5 B
can O
activate O
transcription O
only O
in O
cooperation O
with O
CIITA B
. O

To O
better O
understand O
the O
AP B
- I
1 I
- O
dependent O
luciferase B
expression O
in O
Jurkat O
T O
cells O
, O
we O
tested O
two O
specific O
inhibitors O
of O
serine B
/ I
threonine I
phosphatases I
- I
1 I
and I
- I
2A I
: O
okadaic O
acid O
and O
calyculin O
A O
. O

In O
Jurkat O
T O
cells O
activated O
by O
phorbol O
- O
12 O
- O
myristate O
- O
13 O
- O
acetate O
and O
phytohemagglutinin B
, O
CCK O
- O
8 O
induced O
IL O
- O
2 O
expression O
. O

While O
the O
activation O
of O
JAK2 B
, O
Shc B
, O
Erk B
, O
and O
STAT5 B
proteins I
correlated O
with O
hGM B
- I
CSF I
- O
mediated O
cell O
growth O
, O
cellular O
differentiation O
occurred O
in O
the O
absence O
of O
activation O
of O
these O
signal O
transduction O
pathways O
. O

While O
the O
activation O
of O
JAK2 B
, O
Shc B
, O
Erk B
, O
and O
STAT5 B
proteins I
correlated O
with O
hGM B
- I
CSF I
- O
mediated O
cell O
growth O
, O
cellular O
differentiation O
occurred O
in O
the O
absence O
of O
activation O
of O
these O
signal O
transduction O
pathways O
. O

While O
the O
activation O
of O
JAK2 B
, O
Shc B
, O
Erk B
, O
and O
STAT5 B
proteins I
correlated O
with O
hGM B
- I
CSF I
- O
mediated O
cell O
growth O
, O
cellular O
differentiation O
occurred O
in O
the O
absence O
of O
activation O
of O
these O
signal O
transduction O
pathways O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
cDNA B
, O
CHEMR1 B
, O
encoding O
a O
chemokine B
receptor I
with O
a O
homology O
to O
the O
human B
C I
- I
C I
chemokine I
receptor I
, O
CCR B
- I
4 I
. O

Molecular O
cloning O
and O
characterization O
of O
a O
cDNA B
, O
CHEMR1 B
, O
encoding O
a O
chemokine B
receptor I
with O
a O
homology O
to O
the O
human B
C I
- I
C I
chemokine I
receptor I
, O
CCR B
- I
4 I
. O

Chemokines B
refer O
to O
a O
rapidly O
expanding O
family O
of O
small O
cytokines B
whose O
primary O
function O
is O
recruitment O
of O
leukocytes O
to O
inflammatory O
sites O
. O

Chemokines B
refer O
to O
a O
rapidly O
expanding O
family O
of O
small O
cytokines B
whose O
primary O
function O
is O
recruitment O
of O
leukocytes O
to O
inflammatory O
sites O
. O

This O
suggests O
that O
CHEMR1 B
may O
be O
a O
receptor O
for O
unidentified O
C B
- I
C I
chemokine I
or O
a O
low O
- O
affinity O
receptor O
for O
MIP B
- I
1alpha I
. O

Human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Tat I
, O
an O
early O
regulatory B
protein I
that O
is O
critical O
for O
viral O
gene O
expression O
and O
replication O
, O
transactivates O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
via O
its O
binding O
to O
the O
transactivation B
response I
element I
( O
TAR B
) O
and O
, O
along O
with O
other O
cellular O
factors O
, O
increases O
viral O
transcription O
initiation O
and O
elongation O
. O

Human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Tat I
, O
an O
early O
regulatory B
protein I
that O
is O
critical O
for O
viral O
gene O
expression O
and O
replication O
, O
transactivates O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
via O
its O
binding O
to O
the O
transactivation B
response I
element I
( O
TAR B
) O
and O
, O
along O
with O
other O
cellular O
factors O
, O
increases O
viral O
transcription O
initiation O
and O
elongation O
. O

In O
this O
study O
, O
a O
combined O
pharmacologic O
and O
genetic O
strategy O
using O
two O
PKC B
( O
NF B
- I
kappa I
B I
) O
inhibitors O
, O
pentoxifylline O
( O
PTX O
) O
and O
Go O
- O
6976 O
, O
and O
a O
stably O
expressed O
anti B
- I
Tat I
single I
- I
chain I
intracellular I
antibody I
( O
sFv B
intrabody I
) O
was O
employed O
to O
obtain O
cooperative O
inhibition O
of O
both O
HIV O
- O
1 O
LTR B
- O
driven O
gene O
expression O
and O
HIV O
- O
1 O
replication O
. O

In O
this O
study O
, O
a O
combined O
pharmacologic O
and O
genetic O
strategy O
using O
two O
PKC B
( O
NF B
- I
kappa I
B I
) O
inhibitors O
, O
pentoxifylline O
( O
PTX O
) O
and O
Go O
- O
6976 O
, O
and O
a O
stably O
expressed O
anti B
- I
Tat I
single I
- I
chain I
intracellular I
antibody I
( O
sFv B
intrabody I
) O
was O
employed O
to O
obtain O
cooperative O
inhibition O
of O
both O
HIV O
- O
1 O
LTR B
- O
driven O
gene O
expression O
and O
HIV O
- O
1 O
replication O
. O

CD28 B
is O
an O
important O
costimulatory B
molecule I
in O
the O
activation O
of O
human O
T O
cells O
. O

These O
data O
indicate O
that O
functional O
complexes O
encompassing O
both O
the O
CD28RE B
and O
the O
AP B
- I
1 I
- I
binding I
sites I
influence O
IL B
- I
2 I
promoter I
activity O
in O
CD28 B
- O
costimulated O
T O
cells O
. O

These O
data O
indicate O
that O
functional O
complexes O
encompassing O
both O
the O
CD28RE B
and O
the O
AP B
- I
1 I
- I
binding I
sites I
influence O
IL B
- I
2 I
promoter I
activity O
in O
CD28 B
- O
costimulated O
T O
cells O
. O

VSMCs O
derived O
from O
human O
coronary O
atherosclerotic O
plaques O
that O
apoptose O
even O
in O
serum O
also O
generated O
thrombin B
( O
AUC O
of O
260 O
+ O
/ O
- O
2 O
nmol O
x O
min O
/ O
L O
; O
PT O
of O
128 O
+ O
/ O
- O
4 O
nmol O
/ O
L O
) O
. O

Patients O
with O
one O
type O
of O
major B
histocompatibility I
complex I
class I
II I
combined O
immunodeficiency O
have O
mutations O
in O
a O
gene O
termed O
class B
II I
transactivator I
( O
CIITA B
) O
, O
which O
coordinately O
controls O
the O
transcription O
of O
the O
three O
major O
human B
class I
II I
genes I
, O
HLA B
- I
DR I
, I
- I
DQ I
, I
and I
- I
DP I
. O

The O
cytokines B
interleukin B
( I
IL I
) I
- I
4 I
and O
IL B
- I
13 I
play O
a O
critical O
role O
in O
inducing O
Cepsilon B
germline I
transcripts I
and O
IgE B
isotype I
switching O
in O
human O
B O
cells O
. O

We O
show O
that O
ligand O
- O
induced O
homodimerization O
of O
chimeric B
surface I
receptors I
consisting O
of O
the O
extracellular B
and I
transmembrane I
domains I
of O
the O
erythropoietin B
receptor I
and O
of O
the O
intracellular B
domain I
of O
IL B
- I
4Ralpha I
induces O
Janus B
kinase I
1 I
( O
Jak1 B
) O
activation O
, O
STAT6 B
activation O
, O
and O
Cepsilon B
germline I
transcripts I
in O
human O
B O
cell O
line O
BJAB O
. O

We O
show O
that O
ligand O
- O
induced O
homodimerization O
of O
chimeric B
surface I
receptors I
consisting O
of O
the O
extracellular B
and I
transmembrane I
domains I
of O
the O
erythropoietin B
receptor I
and O
of O
the O
intracellular B
domain I
of O
IL B
- I
4Ralpha I
induces O
Janus B
kinase I
1 I
( O
Jak1 B
) O
activation O
, O
STAT6 B
activation O
, O
and O
Cepsilon B
germline I
transcripts I
in O
human O
B O
cell O
line O
BJAB O
. O

To O
understand O
the O
molecular O
mechanisms O
controlling O
CD19 B
gene O
expression O
, O
we O
isolated O
and O
functionally O
characterized O
the O
CD19 B
promoter I
using O
in O
vivo O
footprinting O
, O
gel O
shift O
assays O
, O
and O
transfection O
studies O
. O

EBF B
and O
E47 B
collaborate O
to O
induce O
expression O
of O
the O
endogenous B
immunoglobulin I
surrogate I
light I
chain I
genes I
. O

EBF B
and O
E47 B
collaborate O
to O
induce O
expression O
of O
the O
endogenous B
immunoglobulin I
surrogate I
light I
chain I
genes I
. O

Taken O
together O
, O
these O
data O
suggest O
that O
EBF B
and O
E47 B
synergize O
to O
activate O
expression O
of O
a O
subset O
of O
genes O
that O
define O
an O
early O
stage O
of O
the O
B O
cell O
lineage O
. O

Taken O
together O
, O
these O
data O
suggest O
that O
EBF B
and O
E47 B
synergize O
to O
activate O
expression O
of O
a O
subset O
of O
genes O
that O
define O
an O
early O
stage O
of O
the O
B O
cell O
lineage O
. O

Treatment O
of O
cells O
expressing O
the O
chimeric B
receptor I
kit B
/ I
IL I
- I
4R I
alpha I
with O
SCF B
induces O
activation O
of O
the O
IL B
- I
4R I
alpha I
- I
associated I
kinase I
JAK B
- I
1 I
and O
the O
transcription B
factor I
STAT6 B
. O

Treatment O
of O
cells O
expressing O
the O
chimeric B
receptor I
kit B
/ I
IL I
- I
4R I
alpha I
with O
SCF B
induces O
activation O
of O
the O
IL B
- I
4R I
alpha I
- I
associated I
kinase I
JAK B
- I
1 I
and O
the O
transcription B
factor I
STAT6 B
. O

Clonal O
analysis O
revealed O
individual O
responses O
to O
the O
two O
immediate B
early I
proteins I
BZLF1 B
and O
BRLF1 B
, O
and O
to O
three O
( O
BMLF1 B
, O
BMRF1 B
, O
and O
BALF2 B
) O
of O
the O
six O
early B
proteins I
tested O
. O

Clonal O
analysis O
revealed O
individual O
responses O
to O
the O
two O
immediate B
early I
proteins I
BZLF1 B
and O
BRLF1 B
, O
and O
to O
three O
( O
BMLF1 B
, O
BMRF1 B
, O
and O
BALF2 B
) O
of O
the O
six O
early B
proteins I
tested O
. O

Clonal O
analysis O
revealed O
individual O
responses O
to O
the O
two O
immediate B
early I
proteins I
BZLF1 B
and O
BRLF1 B
, O
and O
to O
three O
( O
BMLF1 B
, O
BMRF1 B
, O
and O
BALF2 B
) O
of O
the O
six O
early B
proteins I
tested O
. O

Clonal O
analysis O
revealed O
individual O
responses O
to O
the O
two O
immediate B
early I
proteins I
BZLF1 B
and O
BRLF1 B
, O
and O
to O
three O
( O
BMLF1 B
, O
BMRF1 B
, O
and O
BALF2 B
) O
of O
the O
six O
early B
proteins I
tested O
. O

Clonal O
analysis O
revealed O
individual O
responses O
to O
the O
two O
immediate B
early I
proteins I
BZLF1 B
and O
BRLF1 B
, O
and O
to O
three O
( O
BMLF1 B
, O
BMRF1 B
, O
and O
BALF2 B
) O
of O
the O
six O
early B
proteins I
tested O
. O

To O
identify O
genes O
that O
are O
expressed O
in O
T O
cells O
after O
stimulation O
, O
mRNA O
from O
T O
lymphocytes O
that O
had O
been O
activated O
by O
the O
simultaneous O
stimulation O
of O
the O
CD3 B
and O
CD28 B
trigger O
molecules O
was O
transcribed O
for O
a O
differential O
mRNA O
display O
analysis O
into O
cDNA O
and O
was O
compared O
with O
cDNA O
from O
CD28 B
- O
or O
CD3 B
- O
activated O
or O
resting O
lymphocytes O
. O

To O
identify O
genes O
that O
are O
expressed O
in O
T O
cells O
after O
stimulation O
, O
mRNA O
from O
T O
lymphocytes O
that O
had O
been O
activated O
by O
the O
simultaneous O
stimulation O
of O
the O
CD3 B
and O
CD28 B
trigger O
molecules O
was O
transcribed O
for O
a O
differential O
mRNA O
display O
analysis O
into O
cDNA O
and O
was O
compared O
with O
cDNA O
from O
CD28 B
- O
or O
CD3 B
- O
activated O
or O
resting O
lymphocytes O
. O

To O
identify O
genes O
that O
are O
expressed O
in O
T O
cells O
after O
stimulation O
, O
mRNA O
from O
T O
lymphocytes O
that O
had O
been O
activated O
by O
the O
simultaneous O
stimulation O
of O
the O
CD3 B
and O
CD28 B
trigger O
molecules O
was O
transcribed O
for O
a O
differential O
mRNA O
display O
analysis O
into O
cDNA O
and O
was O
compared O
with O
cDNA O
from O
CD28 B
- O
or O
CD3 B
- O
activated O
or O
resting O
lymphocytes O
. O

To O
identify O
genes O
that O
are O
expressed O
in O
T O
cells O
after O
stimulation O
, O
mRNA O
from O
T O
lymphocytes O
that O
had O
been O
activated O
by O
the O
simultaneous O
stimulation O
of O
the O
CD3 B
and O
CD28 B
trigger O
molecules O
was O
transcribed O
for O
a O
differential O
mRNA O
display O
analysis O
into O
cDNA O
and O
was O
compared O
with O
cDNA O
from O
CD28 B
- O
or O
CD3 B
- O
activated O
or O
resting O
lymphocytes O
. O

The O
predictive B
protein I
- I
coding I
region I
of O
RP1 B
had O
a O
significant O
homology O
to O
members O
of O
the O
recently O
found O
adenomatous B
polyposis I
coli I
( I
APC I
) I
protein I
- I
binding I
EB1 I
gene I
family I
, O
which O
codes O
for O
yet O
unknown O
protein O
( O
s O
) O
. O

We O
show O
for O
human O
Jurkat O
T O
leukemia O
cells O
, O
as O
well O
as O
human O
and O
mouse O
primary O
T O
lymphocytes O
, O
that O
this O
inhibitory O
effect O
is O
accompanied O
by O
an O
impaired O
nuclear O
translocation O
of O
the O
Rel B
proteins I
c B
- I
Rel I
, O
RelA B
/ I
p65 I
and O
NF B
- I
kappa I
B1 I
/ I
p50 I
, O
whereas O
the O
nuclear O
appearance O
of O
RelB B
remains O
unaffected O
. O

Accordingly O
, O
immunoblot O
experiments O
showed O
that O
amongst O
NF B
- I
kappa I
B I
/ B
Rel I
proteins I
, O
RelA B
and O
p50 B
are O
mobilized O
to O
the O
nucleus O
following O
microglial O
cell O
stimulation O
with O
A O
beta O
( O
25 O
- O
35 O
) O
plus O
IFN B
gamma I
. O

Accordingly O
, O
immunoblot O
experiments O
showed O
that O
amongst O
NF B
- I
kappa I
B I
/ B
Rel I
proteins I
, O
RelA B
and O
p50 B
are O
mobilized O
to O
the O
nucleus O
following O
microglial O
cell O
stimulation O
with O
A O
beta O
( O
25 O
- O
35 O
) O
plus O
IFN B
gamma I
. O

We O
have O
generated O
transgenic O
mice O
that O
express O
a O
catalytically B
inactive I
form I
of O
Ca2 B
+ I
/ I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
( O
CaMKIV B
) O
specifically O
in O
thymic O
T O
cells O
. O

Rabbit O
antiserum O
raised O
against O
a O
COOH O
- O
terminal O
polypeptide O
of O
the O
SRG3 B
recognized O
a O
protein O
with O
an O
apparent O
molecular O
mass O
of O
155 O
kD O
. O

It O
has O
been O
recently O
claimed O
that O
polymorphism O
for O
the O
vitamin B
D I
receptor I
( O
VDR B
) O
influences O
several O
aspects O
of O
calcium O
and O
bone O
metabolism O
. O

EMS O
analyses O
utilizing O
a O
series O
of O
mutated B
pp I
repeat I
elements I
demonstrate O
that O
the O
nucleotide O
sequence O
requirements O
for O
U1 B
( O
U1A B
/ I
U1B I
) O
and O
U2 B
formation O
are O
separable O
from O
those O
required O
for O
C1 B
- I
C3 I
formation O
. O

EMS O
analyses O
utilizing O
a O
series O
of O
mutated B
pp I
repeat I
elements I
demonstrate O
that O
the O
nucleotide O
sequence O
requirements O
for O
U1 B
( O
U1A B
/ I
U1B I
) O
and O
U2 B
formation O
are O
separable O
from O
those O
required O
for O
C1 B
- I
C3 I
formation O
. O

EMS O
supershift O
analyses O
have O
demonstrated O
that O
Sp1 B
is O
involved O
in O
U1A O
formation O
while O
Sp3 B
is O
involved O
in O
U1B O
and O
U2 O
formation O
. O

EMS O
supershift O
analyses O
have O
demonstrated O
that O
Sp1 B
is O
involved O
in O
U1A O
formation O
while O
Sp3 B
is O
involved O
in O
U1B O
and O
U2 O
formation O
. O

Signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
( O
STAT3 B
) O
is O
constitutively O
activated O
in O
normal O
, O
self O
- O
renewing O
B O
- O
1 O
cells O
but O
only O
inducibly O
expressed O
in O
conventional O
B O
lymphocytes O
[ O
see O
comments O
] O

Cytokine B
and O
growth B
factor I
receptor I
engagement O
leads O
to O
the O
rapid O
phosphorylation O
and O
activation O
of O
latent O
, O
cytosolic B
signal I
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
proteins I
, O
which O
then O
translocate O
to O
the O
nucleus O
where O
they O
regulate O
transcriptional O
events O
from O
specific B
promoter I
sequences I
. O

Induction O
of O
STAT3 B
is O
inhibited O
by O
both O
the O
serine O
/ O
threonine O
protein O
kinase O
inhibitor O
H O
- O
7 O
and O
the O
immunosuppressive O
drug O
rapamycin O
and O
requires O
de O
novo O
protein O
synthesis O
, O
demonstrating O
novel O
coupling O
between O
sIg B
and O
STAT B
proteins I
that O
differs O
from O
the O
classical O
paradigm O
for O
STAT B
induction O
by O
cytokine B
receptors I
. O

Induction O
of O
STAT3 B
is O
inhibited O
by O
both O
the O
serine O
/ O
threonine O
protein O
kinase O
inhibitor O
H O
- O
7 O
and O
the O
immunosuppressive O
drug O
rapamycin O
and O
requires O
de O
novo O
protein O
synthesis O
, O
demonstrating O
novel O
coupling O
between O
sIg B
and O
STAT B
proteins I
that O
differs O
from O
the O
classical O
paradigm O
for O
STAT B
induction O
by O
cytokine B
receptors I
. O

Induction O
of O
STAT3 B
is O
inhibited O
by O
both O
the O
serine O
/ O
threonine O
protein O
kinase O
inhibitor O
H O
- O
7 O
and O
the O
immunosuppressive O
drug O
rapamycin O
and O
requires O
de O
novo O
protein O
synthesis O
, O
demonstrating O
novel O
coupling O
between O
sIg B
and O
STAT B
proteins I
that O
differs O
from O
the O
classical O
paradigm O
for O
STAT B
induction O
by O
cytokine B
receptors I
. O

This O
effect O
was O
specifically O
due O
to O
Tat B
, O
since O
Jurkat O
and O
U937 O
cells O
cotransfected O
either O
with O
tat B
cDNA I
in O
antisense O
orientation O
( O
tat B
/ I
AS I
) O
, O
tat B
carrying O
a O
mutation O
in O
the O
aminoacid B
cys22 I
- I
gly22 I
( O
tat B
22 I
/ I
S I
) O
or O
with O
the O
backbone B
vector I
alone I
( O
pRPneo B
- I
SL3 I
) O
did O
not O
show O
any O
significant O
difference O
in O
c B
- I
fos I
promoter I
activity O
as O
compared O
to O
cells O
transfected O
with O
FC3 B
plasmid I
alone O
. O

This O
effect O
was O
specifically O
due O
to O
Tat B
, O
since O
Jurkat O
and O
U937 O
cells O
cotransfected O
either O
with O
tat B
cDNA I
in O
antisense O
orientation O
( O
tat B
/ I
AS I
) O
, O
tat B
carrying O
a O
mutation O
in O
the O
aminoacid B
cys22 I
- I
gly22 I
( O
tat B
22 I
/ I
S I
) O
or O
with O
the O
backbone B
vector I
alone I
( O
pRPneo B
- I
SL3 I
) O
did O
not O
show O
any O
significant O
difference O
in O
c B
- I
fos I
promoter I
activity O
as O
compared O
to O
cells O
transfected O
with O
FC3 B
plasmid I
alone O
. O

c B
- I
Fos I
protein O
was O
shown O
essential O
for O
an O
optimal O
transactivation O
of O
the O
HIV O
- O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
by O
Tat B
: O
incubation O
of O
Jurkat O
cells O
with O
antisense O
, O
but O
not O
sense O
, O
c O
- O
fos O
oligonucleotides O
significantly O
reduced O
either O
the O
Tat B
- O
enhanced O
expression O
of O
an O
LTR B
- I
CAT I
reporter I
construct I
or O
the O
levels O
of O
gag B
p24 I
in O
the O
culture O
supernatants O
of O
Jurkat O
cells O
and O
PBMC O
acutely O
infected O
with O
HIV O
- O
1 O
. O

c B
- I
Fos I
protein O
was O
shown O
essential O
for O
an O
optimal O
transactivation O
of O
the O
HIV O
- O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
by O
Tat B
: O
incubation O
of O
Jurkat O
cells O
with O
antisense O
, O
but O
not O
sense O
, O
c O
- O
fos O
oligonucleotides O
significantly O
reduced O
either O
the O
Tat B
- O
enhanced O
expression O
of O
an O
LTR B
- I
CAT I
reporter I
construct I
or O
the O
levels O
of O
gag B
p24 I
in O
the O
culture O
supernatants O
of O
Jurkat O
cells O
and O
PBMC O
acutely O
infected O
with O
HIV O
- O
1 O
. O

c B
- I
Fos I
protein O
was O
shown O
essential O
for O
an O
optimal O
transactivation O
of O
the O
HIV O
- O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
by O
Tat B
: O
incubation O
of O
Jurkat O
cells O
with O
antisense O
, O
but O
not O
sense O
, O
c O
- O
fos O
oligonucleotides O
significantly O
reduced O
either O
the O
Tat B
- O
enhanced O
expression O
of O
an O
LTR B
- I
CAT I
reporter I
construct I
or O
the O
levels O
of O
gag B
p24 I
in O
the O
culture O
supernatants O
of O
Jurkat O
cells O
and O
PBMC O
acutely O
infected O
with O
HIV O
- O
1 O
. O

Role O
of O
AP B
- I
1 I
, O
NF B
- I
kappa I
B I
/ I
Rel I
, O
and O
Sp1 B
proteins O
in O
uninduced O
and O
lipopolysaccharide O
- O
induced O
expression O
. O

The O
human B
TF I
promoter I
contains O
binding O
sites O
for O
the O
transcription O
factors O
AP B
- I
1 I
, O
c B
- I
Rel I
/ I
p65 I
, O
Egr B
- I
1 I
, O
and O
Sp1 B
. O

Immunoblot O
and O
flow O
cytometry O
analysis O
revealed O
a O
limited O
proteolysis O
of O
the O
carboxyl B
terminus I
of O
the O
alphaIIb B
subunit I
heavy I
chain I
( O
alphaIIbH B
) O
, O
as O
judged O
by O
the O
disappearance O
of O
the O
epitope O
for O
the O
monoclonal B
antibody I
PMI I
- I
1 I
. O

Treatment O
by O
NE B
of O
ATP O
- O
depleted O
platelets O
or O
Chinese O
hamster O
ovary O
cells O
expressing O
human B
recombinant I
alphaIIbbeta3 I
clearly O
established O
that O
activation O
of O
the O
integrin B
was O
independent O
of O
signal O
transduction O
events O
and O
was O
concomitant O
with O
the O
proteolysis O
of O
alphaIIbH B
. O

Treatment O
by O
NE B
of O
ATP O
- O
depleted O
platelets O
or O
Chinese O
hamster O
ovary O
cells O
expressing O
human B
recombinant I
alphaIIbbeta3 I
clearly O
established O
that O
activation O
of O
the O
integrin B
was O
independent O
of O
signal O
transduction O
events O
and O
was O
concomitant O
with O
the O
proteolysis O
of O
alphaIIbH B
. O

Treatment O
by O
NE B
of O
ATP O
- O
depleted O
platelets O
or O
Chinese O
hamster O
ovary O
cells O
expressing O
human B
recombinant I
alphaIIbbeta3 I
clearly O
established O
that O
activation O
of O
the O
integrin B
was O
independent O
of O
signal O
transduction O
events O
and O
was O
concomitant O
with O
the O
proteolysis O
of O
alphaIIbH B
. O

These O
studies O
were O
conducted O
with O
highly O
purified O
( O
FACS O
- O
isolated O
) O
subsets O
of O
CD4 O
T O
cells O
identified O
by O
expression O
of O
both O
CD45RA B
and O
CD62L B
. O

These O
studies O
were O
conducted O
with O
highly O
purified O
( O
FACS O
- O
isolated O
) O
subsets O
of O
CD4 O
T O
cells O
identified O
by O
expression O
of O
both O
CD45RA B
and O
CD62L B
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
to O
screen O
for O
proteins O
which O
interact O
with O
Tax1 B
, O
we O
isolated O
the O
B B
subunit I
of O
the O
CCAAT B
binding I
protein I
NF B
- I
Y I
from O
a O
HeLa B
cDNA I
library I
. O

The O
interaction O
of O
Tax1 B
with O
NF B
- I
YB I
was O
specific O
in O
that O
NF B
- I
YB I
did O
not O
interact O
with O
a O
variety O
of O
other O
transcription B
factors I
, O
including O
human B
immunodeficiency I
virus I
Tat I
, O
human B
papillomavirus I
E6 I
, O
and O
Bicoid B
, O
or O
with O
the O
M7 B
( I
amino I
acids I
29CP I
- I
AS I
) I
Tax1 I
mutant I
. O

The O
interaction O
of O
Tax1 B
with O
NF B
- I
YB I
was O
specific O
in O
that O
NF B
- I
YB I
did O
not O
interact O
with O
a O
variety O
of O
other O
transcription B
factors I
, O
including O
human B
immunodeficiency I
virus I
Tat I
, O
human B
papillomavirus I
E6 I
, O
and O
Bicoid B
, O
or O
with O
the O
M7 B
( I
amino I
acids I
29CP I
- I
AS I
) I
Tax1 I
mutant I
. O

However O
, O
NF B
- I
YB I
did O
interact O
with O
the O
C B
- I
terminal I
Tax1 I
mutants I
M22 B
( O
130TL B
- I
AS I
) O
and O
M47 B
( O
319LL B
- I
RS I
) O
. O

However O
, O
NF B
- I
YB I
did O
interact O
with O
the O
C B
- I
terminal I
Tax1 I
mutants I
M22 B
( O
130TL B
- I
AS I
) O
and O
M47 B
( O
319LL B
- I
RS I
) O
. O

Through O
activation O
of O
this O
and O
other O
NF B
- I
Y I
driven O
promoters B
, O
the O
Tax1 B
- B
NF I
- I
Y I
interaction O
may O
play O
a O
critical O
role O
in O
causing O
cellular O
transformation O
and O
HTLV O
- O
1 O
pathogenesis O
. O

Through O
activation O
of O
this O
and O
other O
NF B
- I
Y I
driven O
promoters B
, O
the O
Tax1 B
- B
NF I
- I
Y I
interaction O
may O
play O
a O
critical O
role O
in O
causing O
cellular O
transformation O
and O
HTLV O
- O
1 O
pathogenesis O
. O

In O
murine O
Ba O
/ O
F3 O
cells O
transfected O
with O
the O
human B
G I
- I
CSFR I
and O
NFS O
- O
60 O
cells O
constitutively O
expressing O
the O
murine B
G I
- I
CSFR I
, O
G B
- I
CSF I
induced O
tyrosine O
phosphorylation O
and O
activation O
of O
Jak1 B
, O
Jak2 B
, O
and O
Tyk2 B
. O

In O
murine O
Ba O
/ O
F3 O
cells O
transfected O
with O
the O
human B
G I
- I
CSFR I
and O
NFS O
- O
60 O
cells O
constitutively O
expressing O
the O
murine B
G I
- I
CSFR I
, O
G B
- I
CSF I
induced O
tyrosine O
phosphorylation O
and O
activation O
of O
Jak1 B
, O
Jak2 B
, O
and O
Tyk2 B
. O

In O
murine O
Ba O
/ O
F3 O
cells O
transfected O
with O
the O
human B
G I
- I
CSFR I
and O
NFS O
- O
60 O
cells O
constitutively O
expressing O
the O
murine B
G I
- I
CSFR I
, O
G B
- I
CSF I
induced O
tyrosine O
phosphorylation O
and O
activation O
of O
Jak1 B
, O
Jak2 B
, O
and O
Tyk2 B
. O

Activation O
of O
the O
Jak B
- B
Stat I
pathway O
correlates O
with O
proliferative O
signaling O
by O
the O
G B
- I
CSFR I
and O
requires O
the O
membrane B
- I
proximal I
box I
1 I
PXP I
motif I
, O
which O
is O
conserved O
in O
members O
of O
the O
cytokine B
receptor I
superfamily I
. O

In O
addition O
, O
RNase B
protection O
assays O
revealed O
that O
anti O
- O
CD3 O
/ O
PMA O
- O
stimulated O
T O
cells O
from O
a O
substantial O
proportion O
of O
elderly O
subjects O
exhibited O
decreased O
levels O
of O
c B
- I
fos I
and I
/ I
or I
c I
- I
jun I
mRNA I
compared O
to O
T O
cells O
from O
young O
subjects O
. O

However O
, O
the O
intensity O
of O
p65 B
labeling O
was O
much O
higher O
in O
several O
thymocytes O
from O
the O
medulla O
. O

Overexpression O
of O
ALY B
stimulates O
the O
activity O
of O
the O
TCR B
alpha I
enhancer I
complex I
reconstituted O
in O
transfected O
nonlymphoid O
HeLa O
cells O
, O
whereas O
down O
- O
regulation O
of O
ALY B
by O
anti O
- O
sense O
oligonucleotides O
virtually O
eliminates O
TCR B
alpha I
enhancer I
activity O
in O
T O
cells O
. O

Overexpression O
of O
ALY B
stimulates O
the O
activity O
of O
the O
TCR B
alpha I
enhancer I
complex I
reconstituted O
in O
transfected O
nonlymphoid O
HeLa O
cells O
, O
whereas O
down O
- O
regulation O
of O
ALY B
by O
anti O
- O
sense O
oligonucleotides O
virtually O
eliminates O
TCR B
alpha I
enhancer I
activity O
in O
T O
cells O
. O

AML1 B
may O
play O
a O
role O
in O
growth O
and O
differentiation O
of O
cells O
along O
erythroid O
and O
/ O
or O
megakaryocytic O
lineages O
, O
because O
a O
significant O
level O
of O
the O
AML1 B
gene O
is O
expressed O
in O
these O
cells O
. O

AML1 B
may O
play O
a O
role O
in O
growth O
and O
differentiation O
of O
cells O
along O
erythroid O
and O
/ O
or O
megakaryocytic O
lineages O
, O
because O
a O
significant O
level O
of O
the O
AML1 B
gene O
is O
expressed O
in O
these O
cells O
. O

We O
overexpressed O
AML1a B
( O
without O
the O
transcription B
- I
activating I
domain I
) O
and O
AML1b B
( O
with O
the O
domain O
) O
proteins O
in O
K562 O
leukemia O
cells O
, O
which O
can O
be O
induced O
to O
differentiate O
into O
hemoglobin O
- O
producing O
cells O
and O
megakaryocytes O
. O

We O
overexpressed O
AML1a B
( O
without O
the O
transcription B
- I
activating I
domain I
) O
and O
AML1b B
( O
with O
the O
domain O
) O
proteins O
in O
K562 O
leukemia O
cells O
, O
which O
can O
be O
induced O
to O
differentiate O
into O
hemoglobin O
- O
producing O
cells O
and O
megakaryocytes O
. O

We O
have O
cloned O
and O
sequenced O
a O
portion O
of O
the O
ER B
upstream B
regulatory I
region I
from O
the O
ER O
- O
positive O
MCF O
- O
7 O
and O
the O
ER O
- O
negative O
MDA O
- O
MB O
- O
231 O
breast O
cancer O
cell O
lines O
to O
determine O
if O
sequence O
alterations O
in O
this O
region O
account O
for O
the O
ER B
- O
negative O
phenotype O
of O
some O
tumors O
. O

We O
have O
cloned O
and O
sequenced O
a O
portion O
of O
the O
ER B
upstream B
regulatory I
region I
from O
the O
ER O
- O
positive O
MCF O
- O
7 O
and O
the O
ER O
- O
negative O
MDA O
- O
MB O
- O
231 O
breast O
cancer O
cell O
lines O
to O
determine O
if O
sequence O
alterations O
in O
this O
region O
account O
for O
the O
ER B
- O
negative O
phenotype O
of O
some O
tumors O
. O

The O
influence O
of O
the O
anti O
- O
allergy O
agent O
azelastine O
hydrochloride O
( O
Azeptin O
) O
on O
NF B
- I
kappa I
B I
activation O
associated O
with O
the O
generation O
of O
cytokines B
and O
nitric O
oxide O
( O
NO O
) O
was O
investigated O
in O
various O
kinds O
of O
human O
and O
mouse O
cells O
. O

In O
parallel O
with O
the O
decreased O
cytokine B
generation O
, O
each O
cytokine B
mRNA I
was O
less O
expressed O
in O
the O
presence O
of O
10 O
( O
- O
5 O
) O
M O
Azeptin O
. O

Different O
cytokines B
activate O
transcription O
at O
the O
appropriate O
germline B
promoter I
. O

A O
molecular O
basis O
for O
induction O
of O
antibodies B
to O
DNA O
and O
eukaryotic B
transcription I
factors I
. O

Secondly O
, O
we O
investigated O
whether O
polyomavirus O
reactivation O
occurs O
in O
SLE O
patients O
, O
and O
whether O
antibodies B
to O
T B
- I
antigen I
, O
DNA O
, O
and O
to O
TBP B
and O
CREB B
are O
linked O
to O
such O
events O
. O

Secondly O
, O
we O
investigated O
whether O
polyomavirus O
reactivation O
occurs O
in O
SLE O
patients O
, O
and O
whether O
antibodies B
to O
T B
- I
antigen I
, O
DNA O
, O
and O
to O
TBP B
and O
CREB B
are O
linked O
to O
such O
events O
. O

Secondly O
, O
we O
investigated O
whether O
polyomavirus O
reactivation O
occurs O
in O
SLE O
patients O
, O
and O
whether O
antibodies B
to O
T B
- I
antigen I
, O
DNA O
, O
and O
to O
TBP B
and O
CREB B
are O
linked O
to O
such O
events O
. O

Thus O
, O
gammac B
is O
not O
necessary O
to O
trigger O
IL B
- I
4 I
- O
mediated O
responses O
in O
B O
cells O
, O
but O
its O
presence O
is O
important O
for O
optimal O
IL B
- I
4 I
- O
signaling O
. O

Cell O
- O
to O
- O
cell O
contact O
between O
peripheral O
blood O
lymphocytes O
and O
transfected O
human O
colonic O
carcinoma O
cell O
line O
HT29 O
activates O
transcription O
of O
the O
long B
terminal I
repeats I
( O
LTR B
) O
of O
human O
immunodeficiency O
virus O
. O

Activated O
neutrophils O
have O
the O
ability O
to O
upregulate O
the O
expression O
of O
many O
genes O
, O
in O
particular O
those O
encoding O
cytokines B
and O
chemokines B
, O
and O
to O
subsequently O
release O
the O
corresponding O
proteins O
. O

Activated O
neutrophils O
have O
the O
ability O
to O
upregulate O
the O
expression O
of O
many O
genes O
, O
in O
particular O
those O
encoding O
cytokines B
and O
chemokines B
, O
and O
to O
subsequently O
release O
the O
corresponding O
proteins O
. O

Following O
neutrophil O
stimulation O
with O
proinflammatory O
agonists O
( O
such O
as O
lipopolysaccharide O
[ O
LPS O
] O
, O
tumor B
necrosis I
factor I
- I
alpha I
[ O
TNF B
- I
alpha I
] O
, O
and O
fMet O
- O
Leu O
- O
Phe O
) O
that O
induce O
the O
production O
of O
cytokines B
and O
chemokines B
in O
these O
cells O
, O
NF B
- I
kappaB I
/ I
Rel I
proteins I
translocated O
to O
nuclear O
fractions O
, O
resulting O
in O
a O
transient O
induction O
of O
NF B
- I
kappaB I
DNA O
binding O
activity O
, O
as O
determined O
in O
gel O
mobility O
shift O
assays O
. O

Following O
neutrophil O
stimulation O
with O
proinflammatory O
agonists O
( O
such O
as O
lipopolysaccharide O
[ O
LPS O
] O
, O
tumor B
necrosis I
factor I
- I
alpha I
[ O
TNF B
- I
alpha I
] O
, O
and O
fMet O
- O
Leu O
- O
Phe O
) O
that O
induce O
the O
production O
of O
cytokines B
and O
chemokines B
in O
these O
cells O
, O
NF B
- I
kappaB I
/ I
Rel I
proteins I
translocated O
to O
nuclear O
fractions O
, O
resulting O
in O
a O
transient O
induction O
of O
NF B
- I
kappaB I
DNA O
binding O
activity O
, O
as O
determined O
in O
gel O
mobility O
shift O
assays O
. O

GC O
efficiently O
suppressed O
IL B
- I
5 I
synthesis O
of O
T O
- O
cell O
clones O
activated O
via O
either O
T B
- I
cell I
receptor I
( O
TCR B
) O
or O
IL B
- I
2 I
receptor I
( O
IL B
- I
2R I
) O
. O

Stimulation O
of O
CD2 B
or O
TCR B
/ I
CD3 I
induced O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
, O
the O
binding B
site I
of O
which O
is O
included O
in O
the O
IL B
- I
2 I
gene I
promoter I
. O

Stimulation O
of O
CD2 B
or O
TCR B
/ I
CD3 I
induced O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
, O
the O
binding B
site I
of O
which O
is O
included O
in O
the O
IL B
- I
2 I
gene I
promoter I
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

Interaction O
of O
transcription B
factors I
RFX1 B
and O
MIBP1 B
with O
the O
gamma B
motif I
of O
the O
negative B
regulatory I
element I
of O
the O
hepatitis B
B I
virus I
core I
promoter I
. O

Interaction O
of O
transcription B
factors I
RFX1 B
and O
MIBP1 B
with O
the O
gamma B
motif I
of O
the O
negative B
regulatory I
element I
of O
the O
hepatitis B
B I
virus I
core I
promoter I
. O

The O
negative B
regulatory I
element I
( O
NRE B
) O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
core I
promoter I
contains O
three O
subregions O
which O
act O
synergistically O
to O
suppress O
core O
promoter O
activity O
. O

In O
addition O
, O
RFX1 B
can O
bind O
simultaneously O
, O
most O
likely O
as O
a O
heterodimer B
, O
with O
the O
transcription B
factor I
MIBP1 B
to O
NRE B
gamma I
. O

In O
addition O
, O
RFX1 B
can O
bind O
simultaneously O
, O
most O
likely O
as O
a O
heterodimer B
, O
with O
the O
transcription B
factor I
MIBP1 B
to O
NRE B
gamma I
. O

In O
addition O
, O
RFX1 B
can O
bind O
simultaneously O
, O
most O
likely O
as O
a O
heterodimer B
, O
with O
the O
transcription B
factor I
MIBP1 B
to O
NRE B
gamma I
. O

LR1 B
also O
binds O
Ig B
heavy I
chain I
switch O
region O
sequences O
and O
may O
function O
in O
class O
switch O
recombination O
. O

Both O
of O
these O
parameters O
, O
however O
, O
did O
not O
change O
significantly O
after O
mitogen B
stimulation O
. O

There O
was O
a O
significant O
negative O
correlation O
between O
IC50S O
of O
prednisolone O
and O
increase O
- O
ratios O
( O
post O
/ O
pre O
ratio O
) O
of O
Bmax O
after O
mitogen B
stimulation O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
Bmax O
and O
Kd O
were O
not O
significantly O
changed O
after O
mitogen B
stimulation O
in O
both O
subgroups O
of O
CRF O
. O

Immune O
hyperactivation O
of O
HIV O
- O
1 O
- O
infected O
T O
cells O
mediated O
by O
Tat B
and O
the O
CD28 B
pathway O
. O

Immune O
hyperactivation O
of O
HIV O
- O
1 O
- O
infected O
T O
cells O
mediated O
by O
Tat B
and O
the O
CD28 B
pathway O
. O

Interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
is O
a O
cytokine B
that O
is O
expressed O
primarily O
in O
activated O
T O
cells O
. O

The O
adenovirus B
E1B I
19K I
gene I
plays O
an O
essential O
role O
in O
transformation O
of O
primary O
rodent O
cells O
in O
cooperation O
with O
E1A B
and O
in O
the O
inhibition O
of O
apoptosis O
during O
lytic O
infection O
. O

There O
was O
not O
any O
DNA O
homology O
between O
the O
breakpoints O
in O
the O
second O
exon B
and O
the O
inserting B
sequences I
( O
starting O
at O
nt O
532 O
, O
710 O
, O
or O
792 O
) O
. O

Residues O
432 O
, O
435 O
, O
437 O
, O
438 O
, O
and O
440 O
( O
position B
P1 I
, I
P4 I
, I
P6 I
, I
P7 I
, I
and I
P9 I
) O
contributed O
to O
DQ2 B
binding O
, O
whereas O
residues O
431 O
, O
433 O
, O
434 O
, O
and O
436 O
( O
positions B
P I
1 I
, I
P2 I
, I
P3 I
, I
and I
P5 I
) O
contributed O
to O
TCR B
contact O
. O

Residues O
432 O
, O
435 O
, O
437 O
, O
438 O
, O
and O
440 O
( O
position B
P1 I
, I
P4 I
, I
P6 I
, I
P7 I
, I
and I
P9 I
) O
contributed O
to O
DQ2 B
binding O
, O
whereas O
residues O
431 O
, O
433 O
, O
434 O
, O
and O
436 O
( O
positions B
P I
1 I
, I
P2 I
, I
P3 I
, I
and I
P5 I
) O
contributed O
to O
TCR B
contact O
. O

However O
, O
although O
NFAT B
DNA O
binding O
is O
similarly O
induced O
in O
both O
eTh1 O
and O
eTh2 O
cells O
upon O
antigen O
stimulation O
, O
only O
the O
NFAT B
complexes I
present O
in O
eTh2 O
cells O
are O
able O
to O
mediate O
high O
- O
level O
transcription O
, O
and O
relatively O
little O
NFAT B
transcriptional O
activity O
was O
induced O
in O
eTh1 O
cells O
. O

However O
, O
although O
NFAT B
DNA O
binding O
is O
similarly O
induced O
in O
both O
eTh1 O
and O
eTh2 O
cells O
upon O
antigen O
stimulation O
, O
only O
the O
NFAT B
complexes I
present O
in O
eTh2 O
cells O
are O
able O
to O
mediate O
high O
- O
level O
transcription O
, O
and O
relatively O
little O
NFAT B
transcriptional O
activity O
was O
induced O
in O
eTh1 O
cells O
. O

V3 B
- I
BH10 I
neither O
blocked O
radiolabeled O
IL B
- I
2 I
binding O
to O
IL B
- I
2 I
receptors I
nor O
affected O
tyrosyl O
phosphorylation O
of O
several O
cellular B
proteins I
( O
p120 B
, O
p98 B
, O
p96 B
, O
p54 B
, O
and O
p38 B
) O
, O
which O
is O
immediately O
induced O
by O
IL B
- I
2 I
stimulation O
. O

V3 B
- I
BH10 I
neither O
blocked O
radiolabeled O
IL B
- I
2 I
binding O
to O
IL B
- I
2 I
receptors I
nor O
affected O
tyrosyl O
phosphorylation O
of O
several O
cellular B
proteins I
( O
p120 B
, O
p98 B
, O
p96 B
, O
p54 B
, O
and O
p38 B
) O
, O
which O
is O
immediately O
induced O
by O
IL B
- I
2 I
stimulation O
. O

V3 B
- I
BH10 I
neither O
blocked O
radiolabeled O
IL B
- I
2 I
binding O
to O
IL B
- I
2 I
receptors I
nor O
affected O
tyrosyl O
phosphorylation O
of O
several O
cellular B
proteins I
( O
p120 B
, O
p98 B
, O
p96 B
, O
p54 B
, O
and O
p38 B
) O
, O
which O
is O
immediately O
induced O
by O
IL B
- I
2 I
stimulation O
. O

V3 B
- I
BH10 I
neither O
blocked O
radiolabeled O
IL B
- I
2 I
binding O
to O
IL B
- I
2 I
receptors I
nor O
affected O
tyrosyl O
phosphorylation O
of O
several O
cellular B
proteins I
( O
p120 B
, O
p98 B
, O
p96 B
, O
p54 B
, O
and O
p38 B
) O
, O
which O
is O
immediately O
induced O
by O
IL B
- I
2 I
stimulation O
. O

V3 B
- I
BH10 I
neither O
blocked O
radiolabeled O
IL B
- I
2 I
binding O
to O
IL B
- I
2 I
receptors I
nor O
affected O
tyrosyl O
phosphorylation O
of O
several O
cellular B
proteins I
( O
p120 B
, O
p98 B
, O
p96 B
, O
p54 B
, O
and O
p38 B
) O
, O
which O
is O
immediately O
induced O
by O
IL B
- I
2 I
stimulation O
. O

However O
, O
V3 B
- I
BH10 I
enhanced O
IL B
- I
2 I
- B
induced I
mRNA I
expression O
of O
c B
- I
fos I
but O
not O
c B
- I
myc I
or O
junB B
. O

CONCLUSIONS O
: O
Our O
results O
establish O
that O
PI B
3 I
- I
kinase I
can O
both O
positively O
and O
negatively O
regulate O
T O
- O
cell O
function O
, O
and O
uncover O
a O
previously O
unrecognized O
function O
for O
PI B
3 I
- I
kinase I
in O
T O
cells O
as O
a O
selective O
negative O
regulator O
of O
TCR B
- O
signalling O
events O
and O
therefore O
as O
a O
determinant O
of O
T O
- O
cell O
homeostasis O
. O

The O
two O
related O
protein B
- I
tyrosine I
kinases I
Syk B
and O
Zap B
are O
rapidly O
phosphorylated O
on O
tyrosine O
residues O
and O
enzymatically O
activated O
upon O
crosslinking O
of O
the O
T B
cell I
antigen I
receptor I
. O

The O
two O
related O
protein B
- I
tyrosine I
kinases I
Syk B
and O
Zap B
are O
rapidly O
phosphorylated O
on O
tyrosine O
residues O
and O
enzymatically O
activated O
upon O
crosslinking O
of O
the O
T B
cell I
antigen I
receptor I
. O

One O
means O
of O
understanding O
the O
role O
of O
p38 B
in O
these O
responses O
is O
to O
identify O
proteins O
with O
functions O
regulated O
by O
p38 B
- O
catalysed O
phosphorylation O
. O

One O
means O
of O
understanding O
the O
role O
of O
p38 B
in O
these O
responses O
is O
to O
identify O
proteins O
with O
functions O
regulated O
by O
p38 B
- O
catalysed O
phosphorylation O
. O

The O
predominant O
E2F B
complex I
in O
human O
primary O
haemopoietic O
cells O
and O
in O
AML O
blasts O
contains O
E2F B
- I
4 I
, O
DP B
- I
1 I
and O
p130 B
. O

An O
E2F B
- I
4 I
/ I
p130 I
complex I
was O
detected O
in O
representative O
samples O
of O
all O
FAB B
types O
analysed O
. O

In O
order O
to O
evaluate O
the O
conditions O
for O
optimal O
expression O
and O
immunogenicity O
of O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
proteins I
in O
a O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
) O
vector O
, O
we O
selected O
the O
VZV B
glycoprotein I
E I
( O
gE B
) O
, O
encoded O
by O
ORF B
68 I
and O
the O
VZV B
product I
of O
ORF B
62 I
, O
an O
immediate B
- I
early I
major I
tegument I
protein I
( O
IE62 B
) O
. O

In O
order O
to O
evaluate O
the O
conditions O
for O
optimal O
expression O
and O
immunogenicity O
of O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
proteins I
in O
a O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
) O
vector O
, O
we O
selected O
the O
VZV B
glycoprotein I
E I
( O
gE B
) O
, O
encoded O
by O
ORF B
68 I
and O
the O
VZV B
product I
of O
ORF B
62 I
, O
an O
immediate B
- I
early I
major I
tegument I
protein I
( O
IE62 B
) O
. O

Higher B
- I
molecular I
- I
weight I
species I
of O
NFATc B
( O
of O
110 O
and O
140 O
kDa O
) O
were O
also O
detected O
. O

In O
contrast O
to O
ionomycin O
treatment O
, O
exposure O
of O
cells O
to O
phorbol O
myristate O
acetate O
( O
PMA O
) O
plus O
anti B
- I
CD28 I
did O
not O
induce O
NFATc B
, O
indicating O
that O
under O
these O
conditions O
, O
interleukin B
- I
2 I
synthesis O
by O
these O
cells O
is O
apparently O
independent O
of O
NFATc B
. O

In O
contrast O
to O
ionomycin O
treatment O
, O
exposure O
of O
cells O
to O
phorbol O
myristate O
acetate O
( O
PMA O
) O
plus O
anti B
- I
CD28 I
did O
not O
induce O
NFATc B
, O
indicating O
that O
under O
these O
conditions O
, O
interleukin B
- I
2 I
synthesis O
by O
these O
cells O
is O
apparently O
independent O
of O
NFATc B
. O

The O
requirement O
of O
another O
regulatory B
element I
called O
CLE0 B
, O
which O
lies O
downstream O
of O
the O
- B
70 I
GATA I
site I
, O
was O
also O
demonstrated O
. O

We O
found O
that O
NFATx1 B
DNA O
binding O
activity O
and O
interaction O
with O
AP O
- O
1 O
polypeptides O
were O
dependent O
on O
its O
central B
Rel I
similarity I
region I
and O
that O
transcriptional O
activation O
was O
reduced O
by O
deletions O
of O
either O
its O
N B
- I
terminal I
domain I
or O
its O
C B
- I
terminal I
domain I
, O
suggesting O
the O
presence O
of O
intrinsic B
transcriptional I
activation I
motifs I
in O
both O
regions O
. O

NO O
is O
produced O
from O
at O
least O
three O
different O
NO B
synthase I
( I
NOS I
) I
isoforms I
: O
neuronal B
NOS I
( O
nNOS B
) O
, O
endothelial B
NOS I
, O
and O
immunologic B
NOS I
( O
iNOS B
) O
. O

NO O
is O
produced O
from O
at O
least O
three O
different O
NO B
synthase I
( I
NOS I
) I
isoforms I
: O
neuronal B
NOS I
( O
nNOS B
) O
, O
endothelial B
NOS I
, O
and O
immunologic B
NOS I
( O
iNOS B
) O
. O

In O
astrocytes O
PDTC O
also O
dramatically O
induces O
the O
NF B
kappaB I
- I
dependent I
enzyme I
, O
iNOS B
, O
supporting O
the O
physiologic O
relevance O
of O
endogenous O
NO O
regulation O
of O
NF B
kappaB I
. O

Involvement O
of O
Stat3 B
in O
interleukin B
- I
6 I
- O
induced O
IgM B
production O
in O
a O
human O
B O
- O
cell O
line O
. O

Involvement O
of O
Stat3 B
in O
interleukin B
- I
6 I
- O
induced O
IgM B
production O
in O
a O
human O
B O
- O
cell O
line O
. O

EGF O
treatment O
induced O
IgM B
production O
in O
cells O
transfected O
with O
an O
intact O
gp130 B
cytoplasmic I
tail I
, O
but O
not O
in O
untransfected O
cells O
or O
cells O
transfected O
with O
a O
cytoplasmic B
tail I
lacking O
all O
four O
signal B
transducers I
and I
activators I
of I
transcription I
( I
Stat I
) I
binding I
sites I
. O

Moreover O
, O
EGF O
treatment O
induced O
Stat3 B
phosphorylation O
in O
cells O
transfected O
with O
the O
intact O
chimeric B
EGF I
- I
gp130 I
receptor I
along O
with O
induction O
of O
DNA O
- O
mobility O
shift O
of O
a O
classical B
interferon I
- I
gamma I
- I
activated I
site I
. O

This O
cis B
element I
binds O
a O
protein O
complex O
referred O
to O
as O
HRF B
( O
heme B
- I
responsive I
factor I
) O
, O
which O
is O
greatly O
enhanced O
both O
in O
heme O
- O
treated O
FLCs O
and O
during O
monocyte O
- O
to O
- O
macrophage O
differentiation O
. O

One O
of O
the O
latter O
elements O
, O
the O
IgH B
3 I
' I
enhancer I
, O
is O
of O
particular O
interest O
: O
( O
1 O
) O
it O
is O
B O
cell O
- O
specific O
and O
active O
only O
in O
late O
B O
cell O
development O
; O
( O
2 O
) O
in O
rodent O
plasmacytomas O
and O
in O
some O
human O
Burkitt O
' O
s O
lymphomas O
it O
is O
part O
of O
a O
locus B
control I
region I
( O
LCR B
) O
that O
is O
involved O
in O
deregulation O
of O
the O
c B
- I
myc I
oncogene I
as O
a O
result O
of O
translocation O
into O
the O
IgH B
locus I
; O
and O
( O
3 O
) O
it O
has O
been O
implicated O
in O
the O
mechanisms O
that O
control O
Ig B
gene I
class I
switch O
recombination O

Rap1 B
is O
a O
small O
, O
Ras B
- I
like I
GTPase I
whose O
function O
and O
regulation O
are O
still O
largely O
unknown O
. O

Stimulation O
of O
blood O
platelets O
with O
alpha B
- I
thrombin I
or O
other O
platelet O
activators O
caused O
a O
rapid O
and O
strong O
induction O
of O
Rap1 B
that O
associated O
with O
RBD B
in O
vitro O
. O

Stimulation O
of O
blood O
platelets O
with O
alpha B
- I
thrombin I
or O
other O
platelet O
activators O
caused O
a O
rapid O
and O
strong O
induction O
of O
Rap1 B
that O
associated O
with O
RBD B
in O
vitro O
. O

From O
our O
results O
, O
we O
conclude O
that O
Rap1 B
activation O
in O
platelets O
is O
an O
important O
common O
event O
in O
early O
agonist O
- O
induced O
signalling O
, O
and O
that O
this O
activation O
is O
mediated O
by O
an O
increased O
intracellular O
Ca2 O
+ O
concentration O

From O
AML1 B
gene I
, O
two O
representative O
forms O
of O
proteins O
, O
AML1a B
and O
AML1b B
, O
are O
produced O
by O
an O
alternative O
splicing O
. O

From O
AML1 B
gene I
, O
two O
representative O
forms O
of O
proteins O
, O
AML1a B
and O
AML1b B
, O
are O
produced O
by O
an O
alternative O
splicing O
. O

These O
data O
strongly O
suggest O
that O
a O
transcriptionally O
active O
form O
of O
AML1 B
is O
essential O
for O
the O
myeloid O
cell O
differentiation O
. O

The O
expression O
and O
binding O
activity O
of O
the O
Nfil3 B
protein I
( O
also O
called O
E4bp4 B
) O
, O
but O
not O
of O
Hlf B
, O
Dbp B
, O
or O
Tef B
, O
was O
found O
to O
be O
regulated O
by O
IL B
- I
3 I
in O
mouse O
pro O
- O
B O
cell O
lines O
( O
Baf O
- O
3 O
and O
FL5 O
. O
12 O
) O
. O

The O
expression O
and O
binding O
activity O
of O
the O
Nfil3 B
protein I
( O
also O
called O
E4bp4 B
) O
, O
but O
not O
of O
Hlf B
, O
Dbp B
, O
or O
Tef B
, O
was O
found O
to O
be O
regulated O
by O
IL B
- I
3 I
in O
mouse O
pro O
- O
B O
cell O
lines O
( O
Baf O
- O
3 O
and O
FL5 O
. O
12 O
) O
. O

The O
expression O
and O
binding O
activity O
of O
the O
Nfil3 B
protein I
( O
also O
called O
E4bp4 B
) O
, O
but O
not O
of O
Hlf B
, O
Dbp B
, O
or O
Tef B
, O
was O
found O
to O
be O
regulated O
by O
IL B
- I
3 I
in O
mouse O
pro O
- O
B O
cell O
lines O
( O
Baf O
- O
3 O
and O
FL5 O
. O
12 O
) O
. O

The O
expression O
and O
binding O
activity O
of O
the O
Nfil3 B
protein I
( O
also O
called O
E4bp4 B
) O
, O
but O
not O
of O
Hlf B
, O
Dbp B
, O
or O
Tef B
, O
was O
found O
to O
be O
regulated O
by O
IL B
- I
3 I
in O
mouse O
pro O
- O
B O
cell O
lines O
( O
Baf O
- O
3 O
and O
FL5 O
. O
12 O
) O
. O

Common O
and O
distinct O
intracellular O
signaling O
pathways O
in O
human O
neutrophils O
utilized O
by O
platelet B
activating I
factor I
and O
FMLP B
. O

Stimulation O
of O
human O
neutrophils O
with O
chemoattractants B
FMLP B
or O
platelet B
activating I
factor I
( O
PAF B
) O
results O
in O
different O
but O
overlapping O
functional O
responses O
. O

Stimulation O
of O
human O
neutrophils O
with O
chemoattractants B
FMLP B
or O
platelet B
activating I
factor I
( O
PAF B
) O
results O
in O
different O
but O
overlapping O
functional O
responses O
. O

Stimulation O
of O
human O
neutrophils O
with O
chemoattractants B
FMLP B
or O
platelet B
activating I
factor I
( O
PAF B
) O
results O
in O
different O
but O
overlapping O
functional O
responses O
. O

Stimulation O
with O
either O
PAF B
or O
FMLP B
resulted O
in O
equivalent O
phosphorylation O
and O
activation O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPk I
) I
homologue I
38 B
- I
kD I
murine I
MAP I
kinase I
homologous O
to O
HOG B
- I
1 I
( I
p38 I
) I
MAPk I
. O

Stimulation O
with O
either O
PAF B
or O
FMLP B
resulted O
in O
equivalent O
phosphorylation O
and O
activation O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPk I
) I
homologue I
38 B
- I
kD I
murine I
MAP I
kinase I
homologous O
to O
HOG B
- I
1 I
( I
p38 I
) I
MAPk I
. O

A O
specific O
p38 B
MAPk I
inhibitor O
( O
SK O
& O
F O
86002 O
) O
blocked O
superoxide O
anion O
production O
in O
response O
to O
FMLP B
and O
reduced O
adhesion O
and O
chemotaxis O
in O
response O
to O
PAF B
or O
FMLP B
. O

A O
specific O
p38 B
MAPk I
inhibitor O
( O
SK O
& O
F O
86002 O
) O
blocked O
superoxide O
anion O
production O
in O
response O
to O
FMLP B
and O
reduced O
adhesion O
and O
chemotaxis O
in O
response O
to O
PAF B
or O
FMLP B
. O

A O
specific O
p38 B
MAPk I
inhibitor O
( O
SK O
& O
F O
86002 O
) O
blocked O
superoxide O
anion O
production O
in O
response O
to O
FMLP B
and O
reduced O
adhesion O
and O
chemotaxis O
in O
response O
to O
PAF B
or O
FMLP B
. O

In O
the O
present O
report O
, O
we O
show O
that O
A6H B
costimulated O
cell O
proliferation O
and O
cytokine B
production O
in O
purified O
CD4 O
+ O
T O
cells O
. O

In O
the O
present O
report O
, O
we O
show O
that O
A6H B
costimulated O
cell O
proliferation O
and O
cytokine B
production O
in O
purified O
CD4 O
+ O
T O
cells O
. O

Co O
- O
ligation O
of O
the O
A6H B
antigen O
and O
the O
CD3 B
complex I
induced O
expression O
of O
the O
transcription B
factor I
AP B
- I
1 I
in O
CD4 O
+ O
T O
cells O
, O
whereas O
no O
increase O
in O
NF B
- I
kappa I
B I
and O
octamer B
- I
binding I
( I
Oct I
) I
proteins I
was O
seen O
compared O
to O
T O
cells O
stimulated O
with O
anti B
- I
CD3 I
alone O
. O

Molecular O
differences O
of O
the O
A6H B
molecule I
or O
distinct O
regulation O
of O
the O
A6H B
transduced O
AP B
- I
1 I
activation O
pathway O
may O
exist O
in O
CD4 O
+ O
and O
CD8 O
+ O
T O
cell O
subpopulations O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
and O
AP B
- I
1 I
are O
insufficient O
for O
IL B
- I
2 I
promoter I
activation O
: O
requirement O
for O
CD28 B
up O
- O
regulation O
of O
RE B
/ I
AP I
. O

3BP2 B
was O
selectively O
expressed O
in O
hematopoietic O
/ O
lymphoid O
tissues O
and O
bound O
via O
its O
SH2 B
domain I
activated I
Syk I
- I
family I
kinases I
in O
mammalian O
cells O
, O
including O
in O
antigen O
receptor O
- O
stimulated O
T O
cells O
. O

In O
the O
adult O
, O
however O
, O
lymphoid O
lineages O
rely O
on O
Ikaros B
at O
distinct O
phases O
of O
their O
development O
. O

Furthermore O
, O
Ikaros O
- O
null O
thymocytes O
hyperproliferate O
in O
response O
to O
T B
cell I
receptor I
( O
TCR B
) O
signaling O
; O
within O
days O
after O
their O
appearance O
in O
the O
thymus O
, O
clonally O
expanding O
populations O
are O
detected O
. O

Deregulated O
TCR B
- O
mediated O
responses O
and O
the O
fast O
kinetics O
of O
tumor O
development O
in O
these O
mutant O
thymocytes O
implicate O
Ikaros O
as O
a O
central B
tumor I
suppressor I
gene I
for O
the O
T O
cell O
lineage O
. O

The O
role O
of O
Aiolos B
, O
a O
lymphoid B
- I
restricted I
and I
structurally I
related I
gene I
, O
in O
lymphoid O
differentiation O
is O
discussed O
. O

STAT1 B
pathway O
is O
involved O
in O
activation O
of O
caprine O
arthritis B
- I
encephalitis I
virus I
long I
terminal I
repeat I
in O
monocytes O
. O

No O
correlation O
was O
seen O
between O
VDR B
and O
serum O
calcitriol O
or O
PTH O
levels O
, O
when O
considering O
both O
groups O
of O
patients O
together O
or O
separately O
. O

Conversely O
, O
a O
significant O
negative O
correlation O
was O
found O
between O
VDR B
and O
serum O
creatinine O
values O
when O
A O
- O
CRF O
and O
M O
- O
CRF O
were O
considered O
altogether O
( O
r O
= O
- O
0 O
. O
63 O
; O
p O
< O
0 O
. O
01 O
) O
. O

In O
particular O
, O
TRAF6 B
interacted O
with O
membrane B
- I
proximal I
determinants I
distinct O
from O
those O
binding O
TRAFs B
1 I
, I
2 I
, I
3 I
, I
and I
5 I
. O

The O
molecular O
mechanisms O
by O
which O
IL B
- I
4 I
induces O
expression O
of O
the O
IL B
- I
4 I
gene I
are O
not O
known O
, O
although O
the O
IL B
- I
4 I
- I
activated I
transcription I
factor I
signal I
transducer I
and I
activator I
of I
transcription I
6 I
( O
Stat6 B
) O
is O
required O
for O
this O
effect O
. O

The O
triptolide O
- O
induced O
apoptosis O
is O
accompanied O
by O
increase O
of O
DEVD O
- O
cleavable O
caspases B
activity O
and O
degradation O
of O
caspase B
substrate I
poly I
( I
ADP I
- I
ribose I
) I
polymerase I
( O
PARP B
) O
. O

The O
triptolide O
- O
induced O
apoptosis O
is O
accompanied O
by O
increase O
of O
DEVD O
- O
cleavable O
caspases B
activity O
and O
degradation O
of O
caspase B
substrate I
poly I
( I
ADP I
- I
ribose I
) I
polymerase I
( O
PARP B
) O
. O

A O
specific O
inhibitor O
of O
caspases B
, O
zVAD O
- O
FMK O
, O
prevents O
triptolide O
- O
induced O
PARP B
degradation O
and O
DNA O
fragmentation O
but O
not O
growth O
arrest O
. O

A O
specific O
inhibitor O
of O
caspases B
, O
zVAD O
- O
FMK O
, O
prevents O
triptolide O
- O
induced O
PARP B
degradation O
and O
DNA O
fragmentation O
but O
not O
growth O
arrest O
. O

It O
has O
been O
shown O
that O
eosinophil O
stimulation O
by O
these O
cytokines B
is O
associated O
with O
increases O
in O
tyrosine O
phosphorylation O
of O
several O
cellular O
substrates O
. O

The O
upstream O
regions O
UAS3 B
( O
- B
1168 I
to I
- I
440 I
) O
and O
UAS2 B
( O
- B
352 I
to I
- I
264 I
) O
both O
functioned O
in O
a O
cell O
lineage O
- O
independent O
manner O
and O
were O
together O
responsible O
for O
the O
bulk O
of O
Wp O
activity O
in O
non O
- O
B O
cells O
; O
mutational O
analysis O
indicated O
the O
importance O
of O
a O
YY1 B
binding I
site I
in O
UAS2 B
in O
that O
context O
. O

The O
upstream O
regions O
UAS3 B
( O
- B
1168 I
to I
- I
440 I
) O
and O
UAS2 B
( O
- B
352 I
to I
- I
264 I
) O
both O
functioned O
in O
a O
cell O
lineage O
- O
independent O
manner O
and O
were O
together O
responsible O
for O
the O
bulk O
of O
Wp O
activity O
in O
non O
- O
B O
cells O
; O
mutational O
analysis O
indicated O
the O
importance O
of O
a O
YY1 B
binding I
site I
in O
UAS2 B
in O
that O
context O
. O

The O
upstream O
regions O
UAS3 B
( O
- B
1168 I
to I
- I
440 I
) O
and O
UAS2 B
( O
- B
352 I
to I
- I
264 I
) O
both O
functioned O
in O
a O
cell O
lineage O
- O
independent O
manner O
and O
were O
together O
responsible O
for O
the O
bulk O
of O
Wp O
activity O
in O
non O
- O
B O
cells O
; O
mutational O
analysis O
indicated O
the O
importance O
of O
a O
YY1 B
binding I
site I
in O
UAS2 B
in O
that O
context O
. O

By O
contrast O
, O
UAS1 B
( O
- B
140 I
to I
- I
87 I
) O
was O
B O
cell O
specific O
and O
was O
the O
key O
determinant O
of O
the O
promoter O
' O
s O
increased O
activity O
in O
B O
cell O
lines O
. O

The O
first O
step O
in O
the O
nuclear O
import O
process O
is O
recognition O
of O
a O
nuclear B
localization I
sequence I
( O
NLS B
) O
within O
the O
karyophilic B
protein I
by O
a O
cytoplasmic B
receptor I
such O
as O
the O
importin B
( I
karyopherin I
) I
- I
alpha I
subunit I
. O

NLS B
peptide O
- O
mediated O
disruption O
of O
the O
nuclear O
import O
of O
these O
transcription B
factors I
results O
in O
inhibition O
of O
I O
kappa O
B O
alpha O
and O
IL O
- O
2 O
gene O
expression O
, O
processes O
dependent O
on O
NF B
- I
kappa I
B I
or O
the O
combination O
of O
NF B
- I
kappa I
B I
, O
AP B
- I
1 I
, O
and O
NFAT B
. O

NLS B
peptide O
- O
mediated O
disruption O
of O
the O
nuclear O
import O
of O
these O
transcription B
factors I
results O
in O
inhibition O
of O
I O
kappa O
B O
alpha O
and O
IL O
- O
2 O
gene O
expression O
, O
processes O
dependent O
on O
NF B
- I
kappa I
B I
or O
the O
combination O
of O
NF B
- I
kappa I
B I
, O
AP B
- I
1 I
, O
and O
NFAT B
. O

Further O
, O
we O
show O
that O
inhibitory O
NLS B
peptide O
interacts O
in O
vitro O
with O
a O
cytoplasmic B
NLS I
receptor I
complex I
comprised O
of O
the O
Rch1 B
/ I
importin I
( I
karyopherin I
) I
- I
beta I
heterodimer I
expressed O
in O
Jurkat O
T O
cells O
. O

Forty O
- O
eight O
hours O
after O
transfection O
, O
EC O
were O
stimulated O
with O
NK O
cells O
or O
NK O
cell O
membrane O
extracts O
for O
7 O
hr O
and O
activation O
was O
measured O
by O
a O
luciferase B
assay O
. O

CONCLUSIONS O
: O
Human O
NK O
cell O
membrane O
- O
bound O
LT O
signals O
across O
species O
via O
TNFRI B
, O
leading O
to O
NF B
- I
kappaB I
nuclear O
translocation O
and O
transcription O
of O
E B
- I
selectin I
and O
IL B
- I
8 I
, O
which O
results O
in O
EC O
activation O
. O

Ras B
- O
dependent O
, O
Ca2 O
+ O
- O
stimulated O
activation O
of O
nuclear B
factor I
of I
activated I
T I
cells I
by O
a O
constitutively O
active O
Cbl B
mutant I
in O
T O
cells O
. O

Blood O
monocytes O
spontaneously O
activate O
endothelial O
cells O
in O
culture O
, O
leading O
to O
adhesion O
of O
monocytic O
cells O
onto O
the O
endothelial O
surface O
and O
overproduction O
of O
endothelial O
proteins O
such O
as O
von B
Willebrand I
factor I
( O
vWf B
) O
and O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
. O

CD2 B
cross O
- O
linking O
concurrently O
increased O
phosphorylation O
of O
CREB B
detected O
by O
immunoblot O
assay O
eightfold O
. O

CD2 B
cross O
- O
linking O
concurrently O
increased O
phosphorylation O
of O
CREB B
detected O
by O
immunoblot O
assay O
eightfold O
. O

These O
data O
indicate O
specific O
modulation O
of O
the O
CREB B
/ I
ATF I
- I
1 I
family I
of O
transcription B
factors I
by O
the O
CD2 B
signalling O
pathway O
and O
suggest O
CD2 B
receptor O
modulation O
of O
CRE B
- O
mediated O
transcription O
following O
ligand O
engagement O
( O
e O
. O
g O
. O
cell O
- O
to O
- O
cell O
contact O
) O
. O

These O
data O
indicate O
specific O
modulation O
of O
the O
CREB B
/ I
ATF I
- I
1 I
family I
of O
transcription B
factors I
by O
the O
CD2 B
signalling O
pathway O
and O
suggest O
CD2 B
receptor O
modulation O
of O
CRE B
- O
mediated O
transcription O
following O
ligand O
engagement O
( O
e O
. O
g O
. O
cell O
- O
to O
- O
cell O
contact O
) O
. O

These O
data O
indicate O
specific O
modulation O
of O
the O
CREB B
/ I
ATF I
- I
1 I
family I
of O
transcription B
factors I
by O
the O
CD2 B
signalling O
pathway O
and O
suggest O
CD2 B
receptor O
modulation O
of O
CRE B
- O
mediated O
transcription O
following O
ligand O
engagement O
( O
e O
. O
g O
. O
cell O
- O
to O
- O
cell O
contact O
) O
. O

Restoration O
of O
the O
CCAAT B
box I
at O
- B
70 I
bp I
, O
or O
insertion O
of O
an O
EKLF B
binding I
site I
at O
- B
85 I
bp I
or O
- B
95 I
bp I
in O
the O
promoter B
significantly O
increased O
delta O
globin O
gene O
expression O
in O
hAEC O
. O

Constitutive O
association O
of O
JAK1 B
and O
STAT5 B
in O
pro O
- O
B O
cells O
is O
dissolved O
by O
interleukin B
- I
4 I
- O
induced O
tyrosine O
phosphorylation O
of O
both O
proteins O
. O

Constitutive O
association O
of O
JAK1 B
and O
STAT5 B
in O
pro O
- O
B O
cells O
is O
dissolved O
by O
interleukin B
- I
4 I
- O
induced O
tyrosine O
phosphorylation O
of O
both O
proteins O
. O

Based O
on O
the O
high O
specificity O
of O
this O
compound O
for O
PKC B
, O
we O
conclude O
that O
PKC B
is O
necessary O
for O
FN B
- O
induced O
IL B
- I
1beta I
protein O
production O
. O

Based O
on O
the O
high O
specificity O
of O
this O
compound O
for O
PKC B
, O
we O
conclude O
that O
PKC B
is O
necessary O
for O
FN B
- O
induced O
IL B
- I
1beta I
protein O
production O
. O

Based O
on O
the O
high O
specificity O
of O
this O
compound O
for O
PKC B
, O
we O
conclude O
that O
PKC B
is O
necessary O
for O
FN B
- O
induced O
IL B
- I
1beta I
protein O
production O
. O

A O
novel O
member O
of O
the O
tumor B
necrosis I
factor I
( I
TNF I
) I
receptor I
family I
, O
designated O
TRAMP B
, O
has O
been O
identified O
. O

Overexpression O
of O
TRAMP B
leads O
to O
two O
major O
responses O
, O
NF B
- I
kappaB I
activation O
and O
apoptosis O
. O

Conversely O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
markedly O
and O
significantly O
inhibited O
HIV O
replication O
at O
the O
transcriptional O
level O
in O
monocyte O
- O
derived O
macrophages O
, O
and O
this O
occurred O
whether O
these O
cytokines B
were O
added O
before O
or O
after O
HIV O
infection O
. O

Cells O
were O
stimulated O
with O
endotoxin B
( O
LPS O
, O
100 O
ng O
/ O
mL O
) O
with O
and O
without O
human O
IL B
- I
10 I
( O
10 O
ng O
/ O
mL O
) O
. O

Therefore O
in O
this O
study O
, O
we O
have O
examined O
the O
role O
of O
glucocorticoid B
receptor I
/ I
s I
( O
GR B
) O
characteristics O
in O
the O
developing O
of O
these O
abnormalities O
in O
patients O
with O
PCOS O
. O

Immuno O
- O
histochemical O
analysis O
confirmed O
the O
presence O
of O
NGAL B
within O
breast O
carcinoma O
cells O
but O
detected O
only O
low O
levels O
of O
this O
protein O
in O
normal O
ductal O
epithelium O
. O

In O
contrast O
, O
a O
significant O
correlation O
between O
NGAL B
expression O
in O
breast O
cancer O
was O
found O
with O
several O
other O
markers O
of O
poor O
prognosis O
, O
including O
estrogen O
and O
progesterone B
receptor I
- O
negative O
status O
and O
high O
proliferation O
( O
S O
- O
phase O
fraction O
) O
. O

BASH B
, O
a O
novel B
signaling I
molecule I
preferentially O
expressed O
in O
B O
cells O
of O
the O
bursa O
of O
Fabricius O
. O

The O
gene O
encodes O
an O
85 B
- I
kDa I
protein I
, O
designated O
BASH B
( O
B B
cell I
adaptor I
containing I
SH2 I
domain I
) O
, O
that O
contains O
N B
- I
terminal I
acidic I
domains I
with O
SH2 B
domain I
- I
binding I
phosphotyrosine I
- I
based I
motifs I
, O
a O
proline B
- I
rich I
domain I
, O
and O
a O
C B
- I
terminal I
SH2 I
domain I
. O

These O
studies O
revealed O
that O
the O
major B
protein I
in O
extracts O
of O
PMN O
activated O
by O
G B
- I
CSF I
to O
bind O
the O
high B
- I
affinity I
serum I
- I
inducible I
element I
( O
hSIE B
) O
is O
a O
72 B
- I
kDa I
protein I
that O
cross O
- O
reacts O
with O
Stat3 B
monoclonal I
antibody I
, O
which O
we O
have O
designated O
Stat3gamma B
. O

These O
studies O
revealed O
that O
the O
major B
protein I
in O
extracts O
of O
PMN O
activated O
by O
G B
- I
CSF I
to O
bind O
the O
high B
- I
affinity I
serum I
- I
inducible I
element I
( O
hSIE B
) O
is O
a O
72 B
- I
kDa I
protein I
that O
cross O
- O
reacts O
with O
Stat3 B
monoclonal I
antibody I
, O
which O
we O
have O
designated O
Stat3gamma B
. O

Our O
data O
show O
that O
IFNs B
and O
IL B
- I
1 I
upregulate O
PML O
transcript O
and O
protein O
expression O
in O
a O
time O
and O
dose O
- O
dependent O
manner O
. O

Glucocorticoid B
receptors I
( O
GR B
) O
and O
3 O
- O
O O
- O
methyl O
- O
D O
glucose O
( O
3 O
- O
O O
- O
MG O
) O
transport O
were O
determined O
in O
mononuclear O
leukocytes O
( O
MNL O
) O
from O
11 O
abdominal O
obese O
subjects O
, O
10 O
pituitary O
- O
dependent O
Cushing O
' O
s O
syndrome O
( O
Cushing O
' O
s O
disease O
) O
and O
10 O
healthy O
controls O
. O

Interleukin B
- I
10 I
( O
IL B
- I
10 I
) O
and O
transforming B
growth I
factor I
beta I
( O
TGF B
- I
beta I
) O
are O
inhibitory O
for O
B O
and O
T O
cells O
, O
IgE B
production O
, O
and O
mast O
cell O
proliferation O
, O
and O
they O
induce O
apoptosis O
in O
eosinophils O
. O

The O
IL B
- I
10 I
gene O
polymorphism O
was O
a O
C O
- O
to O
- O
A O
exchange O
571 B
base I
pairs I
upstream I
from O
the O
translation B
start I
site I
and O
was O
present O
between O
consensus B
binding I
sequences I
for O
Sp1 B
and O
elevated O
total O
serum O
. O

Since O
the O
protein O
has O
a O
homeodomain B
and O
can O
activate O
transcription O
, O
it O
probably O
exerts O
at O
least O
some O
of O
its O
effects O
in O
vivo O
by O
regulation O
of O
target B
genes I
. O

We O
investigated O
the O
function O
of O
the O
evolutionary O
conserved O
X2 B
box I
in O
the O
promoter B
of O
the O
HLA B
- I
DRA I
gene I
from O
the O
human B
major I
histocompatibility I
complex I
( O
MHC B
) O
in O
resting O
and O
activated O
B O
cells O
. O

We O
investigated O
the O
function O
of O
the O
evolutionary O
conserved O
X2 B
box I
in O
the O
promoter B
of O
the O
HLA B
- I
DRA I
gene I
from O
the O
human B
major I
histocompatibility I
complex I
( O
MHC B
) O
in O
resting O
and O
activated O
B O
cells O
. O

17beta O
- O
estradiol O
( O
E2 O
) O
markedly O
enhanced O
lipopolysaccharide O
- O
( O
LPS O
) O
induced O
IL B
- I
1beta I
promoter I
- O
driven O
CAT B
activity O
in O
a O
dose O
- O
dependent O
manner O
. O

In O
order O
to O
elucidate O
possible O
mechanisms O
underlying O
endothelial O
cell O
activation O
by O
xenogeneic O
serum O
, O
we O
focussed O
on O
transcription B
factor I
NF I
- I
kappa I
B I
, O
a O
central O
regulator O
for O
the O
induction O
of O
different O
genes O
, O
including O
adhesive B
molecules I
and O
chemoattractants B
. O

Anaphylatoxins B
C5a B
and O
C3a B
induce O
nuclear B
factor I
kappaB I
activation O
in O
human O
peripheral O
blood O
monocytes O
. O

Anaphylatoxins B
C5a B
and O
C3a B
induce O
nuclear B
factor I
kappaB I
activation O
in O
human O
peripheral O
blood O
monocytes O
. O

Anaphylatoxins B
C5a B
and O
C3a B
induce O
nuclear B
factor I
kappaB I
activation O
in O
human O
peripheral O
blood O
monocytes O
. O

These O
results O
imply O
a O
potential O
role O
of O
the O
anaphylatoxins B
C5a B
and O
C3a B
in O
regulating O
leukocytes O
gene O
expression O
through O
G O
protein O
- O
coupled O
transcription O
factor O
activation O
. O

These O
results O
imply O
a O
potential O
role O
of O
the O
anaphylatoxins B
C5a B
and O
C3a B
in O
regulating O
leukocytes O
gene O
expression O
through O
G O
protein O
- O
coupled O
transcription O
factor O
activation O
. O

These O
results O
imply O
a O
potential O
role O
of O
the O
anaphylatoxins B
C5a B
and O
C3a B
in O
regulating O
leukocytes O
gene O
expression O
through O
G O
protein O
- O
coupled O
transcription O
factor O
activation O
. O

Plasma O
TPO B
levels O
are O
regulated O
by O
the O
platelet O
and O
megakaryocyte O
mass O
through O
Mpl B
receptor I
binding O
, O
internalization O
and O
degradation O
. O

Promoter O
analysis O
revealed O
that O
a O
GATA B
site I
in O
a O
cryptic B
promoter I
in O
the O
second B
intron I
was O
essential O
and O
sufficient O
for O
the O
TAL1 O
- O
and O
LMO O
- O
dependent O
transcriptional O
activation O
, O
and O
GATA3 B
binds O
to O
this O
site O
. O

Several O
neuroendocrine O
- O
immune O
interactions O
could O
be O
responsible O
for O
reduced O
GR B
levels O
with O
age O
and O
sport O
activity O
in O
man O
. O

Unlike O
IL B
- I
12 I
, O
which O
acts O
only O
on O
Th1 O
cells O
, O
IFN B
- I
alpha I
/ I
beta I
can O
activate O
Stat4 B
not O
only O
in O
human O
Th1 O
, O
but O
also O
in O
Th2 O
cells O
. O

The O
mRNA O
levels O
for O
fkhrl1 B
is O
elevated O
in O
T O
helper O
- O
induced O
lymphocytes O
in O
comparison O
to O
PHA O
- O
stimulated O
T O
lymphocytes O
. O

Further O
characterization O
of O
FKHRL1 B
and O
its O
related O
family O
members O
should O
shed O
light O
on O
the O
transcriptional O
mechanisms O
of O
this O
fork B
head I
gene I
subfamily I
and O
their O
role O
in O
T O
helper O
cell O
differentiation O
and O
regulation O
of O
cell O
growth O
. O

These O
motifs O
are O
regulatory B
sequences I
within O
the O
so O
- O
called O
AU B
- I
rich I
elements I
( O
AREs B
) O
often O
found O
in O
3 B
' I
untranslated I
regions I
of O
genes O
such O
as O
cytokines B
, O
proto B
- I
oncogenes I
, O
and O
transcription B
factors I
. O

These O
motifs O
are O
regulatory B
sequences I
within O
the O
so O
- O
called O
AU B
- I
rich I
elements I
( O
AREs B
) O
often O
found O
in O
3 B
' I
untranslated I
regions I
of O
genes O
such O
as O
cytokines B
, O
proto B
- I
oncogenes I
, O
and O
transcription B
factors I
. O

At O
the O
same O
time O
there O
was O
no O
change O
in O
the O
level O
of O
expression O
of O
the O
cell B
surface I
antigenes I
CD33 B
, O
CD34 B
, O
CD45 B
, O
CD71 B
and O
glycophorin B
A I
. O

At O
the O
same O
time O
there O
was O
no O
change O
in O
the O
level O
of O
expression O
of O
the O
cell B
surface I
antigenes I
CD33 B
, O
CD34 B
, O
CD45 B
, O
CD71 B
and O
glycophorin B
A I
. O

At O
the O
same O
time O
there O
was O
no O
change O
in O
the O
level O
of O
expression O
of O
the O
cell B
surface I
antigenes I
CD33 B
, O
CD34 B
, O
CD45 B
, O
CD71 B
and O
glycophorin B
A I
. O

At O
the O
same O
time O
there O
was O
no O
change O
in O
the O
level O
of O
expression O
of O
the O
cell B
surface I
antigenes I
CD33 B
, O
CD34 B
, O
CD45 B
, O
CD71 B
and O
glycophorin B
A I
. O

The O
class B
II I
transactivator I
( O
CIITA B
) O
is O
essential O
for O
the O
expression O
of O
major B
histocompatibility I
complex I
( I
MHC I
) I
class I
II I
antigens I
. O

In O
contrast O
, O
luciferase B
expression O
was O
not O
stimulated O
after O
IFN B
- I
gamma I
treatment O
when O
the O
construct O
was O
transfected O
in O
macrophage O
or O
in O
epithelial O
cell O
lines O
. O

CD27 B
/ O
CD70 O
interaction O
augments O
IgE B
secretion O
by O
promoting O
the O
differentiation O
of O
memory O
B O
cells O
into O
plasma O
cells O
. O

CD27 B
/ O
CD70 O
interaction O
augments O
IgE B
secretion O
by O
promoting O
the O
differentiation O
of O
memory O
B O
cells O
into O
plasma O
cells O
. O

The O
induction O
of O
IgE B
switching O
in O
B O
cells O
requires O
several O
signals O
given O
by O
cytokines B
and O
cell O
contact O
- O
delivered O
signals O
. O

The O
induction O
of O
IgE B
switching O
in O
B O
cells O
requires O
several O
signals O
given O
by O
cytokines B
and O
cell O
contact O
- O
delivered O
signals O
. O

Here O
, O
we O
investigated O
the O
role O
of O
CD27 B
/ O
CD70 O
interaction O
in O
B O
cell O
IgE B
synthesis O
. O

Here O
, O
we O
investigated O
the O
role O
of O
CD27 B
/ O
CD70 O
interaction O
in O
B O
cell O
IgE B
synthesis O
. O

In O
turn O
, O
assembly O
of O
this O
complex O
mediates O
the O
enzymatic O
activation O
of O
the O
p21 B
- I
activated I
protein I
kinase I
1 I
and O
facilitates O
actin B
polymerization O
. O

In O
this O
report O
, O
we O
describe O
the O
transcriptional O
regulation O
of O
the O
beta B
- I
casein I
gene I
by O
cytokines B
in O
T O
cells O
. O

In O
addition O
, O
Ras B
( I
G12V I
) I
complemented O
signaling O
by O
an O
erythropoietin B
receptor I
mutant I
defective O
in O
Ras B
activation O
and O
augmented O
the O
activation O
of O
the O
beta B
- I
casein I
promoter I
by O
the O
mutant B
erythropoietin I
receptor I
signaling O
, O
suggesting O
a O
possible O
role O
of O
Ras B
in O
Stat5 B
- O
mediated O
gene O
expression O
. O

In O
addition O
, O
Ras B
( I
G12V I
) I
complemented O
signaling O
by O
an O
erythropoietin B
receptor I
mutant I
defective O
in O
Ras B
activation O
and O
augmented O
the O
activation O
of O
the O
beta B
- I
casein I
promoter I
by O
the O
mutant B
erythropoietin I
receptor I
signaling O
, O
suggesting O
a O
possible O
role O
of O
Ras B
in O
Stat5 B
- O
mediated O
gene O
expression O
. O

In O
addition O
, O
Ras B
( I
G12V I
) I
complemented O
signaling O
by O
an O
erythropoietin B
receptor I
mutant I
defective O
in O
Ras B
activation O
and O
augmented O
the O
activation O
of O
the O
beta B
- I
casein I
promoter I
by O
the O
mutant B
erythropoietin I
receptor I
signaling O
, O
suggesting O
a O
possible O
role O
of O
Ras B
in O
Stat5 B
- O
mediated O
gene O
expression O
. O

Ligation O
of O
CD3 B
also O
induces O
the O
tyrosine O
phosphorylation O
of O
HS1 B
, O
a O
75 B
- I
kDa I
hematopoietic I
cell I
- I
specific I
intracellular I
signaling I
protein I
of O
unknown O
function O
. O

Ligation O
of O
CD3 B
also O
induces O
the O
tyrosine O
phosphorylation O
of O
HS1 B
, O
a O
75 B
- I
kDa I
hematopoietic I
cell I
- I
specific I
intracellular I
signaling I
protein I
of O
unknown O
function O
. O

Costimulation O
through O
CD28 B
and O
/ O
or O
CD2 B
did O
not O
modulate O
the O
CD3 B
- O
dependent O
phosphorylation O
of O
HS1 B
. O

Costimulation O
through O
CD28 B
and O
/ O
or O
CD2 B
did O
not O
modulate O
the O
CD3 B
- O
dependent O
phosphorylation O
of O
HS1 B
. O

Costimulation O
through O
CD28 B
and O
/ O
or O
CD2 B
did O
not O
modulate O
the O
CD3 B
- O
dependent O
phosphorylation O
of O
HS1 B
. O

Costimulation O
through O
CD28 B
and O
/ O
or O
CD2 B
did O
not O
modulate O
the O
CD3 B
- O
dependent O
phosphorylation O
of O
HS1 B
. O

In O
addition O
, O
Northern O
blot O
analysis O
of O
cord O
and O
adult O
samples O
revealed O
similar O
maximal O
increases O
in O
c B
- I
fos I
( O
99 O
+ O
/ O
- O
15 O
and O
126 O
+ O
/ O
- O
11 O
% O
, O
p O
= O
0 O
. O
0126 O
) O
and O
c B
- I
jun I
( I
123 I
+ I
/ I
- I
9 I
and I
185 I
+ I
/ I
- I
38 I
% I
, I
p I
= I
0 I
. I
0291 I
) I
mRNA I
expression O
, O
respectively O
, O
as O
early O
as O
15 O
min O
post O
- O
alphaCD3 B
stimulation O
. O

Receptors O
for O
the O
Fc B
portion I
of O
immunoglobulin B
molecules I
( O
FcR B
) O
present O
on O
leukocyte O
cell O
membranes O
mediate O
a O
large O
number O
of O
cellular O
responses O
that O
are O
very O
important O
in O
host O
defense O
, O
including O
phagocytosis O
, O
cell O
cytotoxicity O
, O
production O
and O
secretion O
of O
inflammatory B
mediators I
, O
and O
modulation O
of O
the O
immune O
response O
. O

Cross O
- O
linking O
of O
FcR B
, O
on O
the O
THP O
- O
1 O
monocytic O
cell O
line O
, O
by O
immune B
complexes I
resulted O
in O
both O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
interleukin B
1 I
production O
. O

Neither O
the O
E12 B
nor O
the O
E47 B
product O
of O
the O
E2A B
gene I
nor O
the O
wild B
- I
type I
HLF I
protein I
was O
able O
to O
protect O
the O
cells O
from O
apoptosis O
induced O
by O
IL B
- I
3 I
deprivation O
. O

Neither O
the O
E12 B
nor O
the O
E47 B
product O
of O
the O
E2A B
gene I
nor O
the O
wild B
- I
type I
HLF I
protein I
was O
able O
to O
protect O
the O
cells O
from O
apoptosis O
induced O
by O
IL B
- I
3 I
deprivation O
. O

Surprisingly O
, O
different O
combinations O
of O
disabling O
mutations O
within O
the O
HLF B
bZIP I
domain I
had O
little O
effect O
on O
the O
antiapoptotic O
property O
of O
the O
chimeric B
protein I
, O
so O
long O
as O
the O
amino O
- O
terminal O
portion O
of O
E2A B
remained O
intact O
. O

These O
results O
suggest O
that O
1 O
) O
lipid O
A O
myristoyl O
fatty O
acid O
, O
although O
it O
is O
important O
for O
the O
induction O
of O
inflammatory B
cytokine I
production O
by O
human O
monocytes O
, O
is O
not O
necessary O
for O
the O
induction O
of O
Mn B
SOD I
, O
2 O
) O
endotoxin B
- O
mediated O
induction O
of O
Mn B
SOD I
and O
inflammatory O
cytokines B
are O
regulated O
, O
at O
least O
in O
part O
, O
through O
different O
signal O
transduction O
pathways O
, O
and O
3 O
) O
failure O
of O
the O
mutant B
endotoxin I
to O
induce O
tumor B
necrosis I
factor I
- I
alpha I
production O
is O
, O
at O
least O
in O
part O
, O
due O
to O
its O
inability O
to O
activate O
mitogen B
- I
activated I
protein I
kinase I
. O

These O
results O
suggest O
that O
1 O
) O
lipid O
A O
myristoyl O
fatty O
acid O
, O
although O
it O
is O
important O
for O
the O
induction O
of O
inflammatory B
cytokine I
production O
by O
human O
monocytes O
, O
is O
not O
necessary O
for O
the O
induction O
of O
Mn B
SOD I
, O
2 O
) O
endotoxin B
- O
mediated O
induction O
of O
Mn B
SOD I
and O
inflammatory O
cytokines B
are O
regulated O
, O
at O
least O
in O
part O
, O
through O
different O
signal O
transduction O
pathways O
, O
and O
3 O
) O
failure O
of O
the O
mutant B
endotoxin I
to O
induce O
tumor B
necrosis I
factor I
- I
alpha I
production O
is O
, O
at O
least O
in O
part O
, O
due O
to O
its O
inability O
to O
activate O
mitogen B
- I
activated I
protein I
kinase I
. O

Characterization O
of O
cytokine B
differential O
induction O
of O
STAT B
complexes I
in O
primary O
human O
T O
and O
NK O
cells O
. O

Finally O
, O
we O
observed O
that O
activated O
STAT5a B
and O
STAT5b B
proteins O
form O
distinct O
Fc O
gamma O
RI O
GAS O
binding O
patterns O
in O
T O
and O
NK O
cells O
, O
suggesting O
that O
they O
might O
have O
different O
roles O
in O
gene O
regulation O
. O

Finally O
, O
we O
observed O
that O
activated O
STAT5a B
and O
STAT5b B
proteins O
form O
distinct O
Fc O
gamma O
RI O
GAS O
binding O
patterns O
in O
T O
and O
NK O
cells O
, O
suggesting O
that O
they O
might O
have O
different O
roles O
in O
gene O
regulation O
. O

A O
regulatory B
element I
in O
the O
CD95 B
( I
APO I
- I
1 I
/ I
Fas I
) I
ligand I
promoter I
is O
essential O
for O
responsiveness O
to O
TCR B
- O
mediated O
activation O
. O

Progesterone O
acts O
distally O
to O
the O
initial O
steps O
of O
T B
cell I
receptor I
( O
TCR B
) O
- O
mediated O
signal O
transduction O
, O
since O
it O
blocks O
sustained O
Ca2 O
+ O
signals O
after O
thapsigargin O
stimulation O
, O
as O
well O
as O
oscillatory O
Ca2 O
+ O
signals O
, O
but O
not O
the O
Ca2 O
+ O
transient O
after O
TCR B
stimulation O
. O

Progesterone O
acts O
distally O
to O
the O
initial O
steps O
of O
T B
cell I
receptor I
( O
TCR B
) O
- O
mediated O
signal O
transduction O
, O
since O
it O
blocks O
sustained O
Ca2 O
+ O
signals O
after O
thapsigargin O
stimulation O
, O
as O
well O
as O
oscillatory O
Ca2 O
+ O
signals O
, O
but O
not O
the O
Ca2 O
+ O
transient O
after O
TCR B
stimulation O
. O

Progesterone O
effectively O
blocked O
a O
broad O
spectrum O
of O
K B
+ I
channels I
, O
reducing O
both O
Kv1 B
. I
3 I
and O
charybdotoxin B
- I
resistant I
components I
of O
KV B
current O
and O
KCa B
current O
in O
T O
cells O
, O
as O
well O
as O
blocking O
several O
cloned B
KV I
channels I
expressed O
in O
cell O
lines O
. O

Progesterone O
effectively O
blocked O
a O
broad O
spectrum O
of O
K B
+ I
channels I
, O
reducing O
both O
Kv1 B
. I
3 I
and O
charybdotoxin B
- I
resistant I
components I
of O
KV B
current O
and O
KCa B
current O
in O
T O
cells O
, O
as O
well O
as O
blocking O
several O
cloned B
KV I
channels I
expressed O
in O
cell O
lines O
. O

The O
chemokine B
receptor I
, O
BLR1 B
, O
is O
a O
major O
regulator O
of O
the O
microenvironmental O
homing O
of O
B O
cells O
in O
lymphoid O
organs O
. O

Both O
Tax B
- O
mediated O
apoptosis O
and O
oxidative O
stress O
can O
be O
potently O
suppressed O
by O
antioxidants O
, O
as O
is O
seen O
with O
the O
administration O
of O
recombinant B
thioredoxin I
( O
adult B
T I
cell I
leukemia I
- I
derived I
factor I
) O
or O
pyrrolidine O
dithiocarbamate O
. O

It O
was O
proposed O
that O
the O
mechanism O
of O
antiviral O
action O
of O
S9a O
was O
on O
the O
host O
cell O
, O
by O
blocking O
TNF B
- I
alpha I
transcription O
via O
a O
Tat B
- O
induced O
tar O
- O
independent O
loop O
, O
which O
decreases O
downstream O
NF B
- I
kappaB I
activation O
of O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
. O

It O
was O
proposed O
that O
the O
mechanism O
of O
antiviral O
action O
of O
S9a O
was O
on O
the O
host O
cell O
, O
by O
blocking O
TNF B
- I
alpha I
transcription O
via O
a O
Tat B
- O
induced O
tar O
- O
independent O
loop O
, O
which O
decreases O
downstream O
NF B
- I
kappaB I
activation O
of O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
. O

We O
determined O
whether O
Hsp70 B
induction O
by O
TS O
was O
mediated O
by O
the O
activation O
of O
the O
HS B
transcription I
factor I
, O
HSF B
. O

We O
determined O
whether O
Hsp70 B
induction O
by O
TS O
was O
mediated O
by O
the O
activation O
of O
the O
HS B
transcription I
factor I
, O
HSF B
. O

Thus O
, O
we O
also O
determined O
the O
effects O
of O
TS O
on O
NFkappaB B
. O

TS O
activated O
HSF B
, O
which O
was O
associated O
with O
Hsp70 B
overexpression O
and O
inhibition O
of O
NFkappaB B
binding O
activity O
and O
TNFalpha B
release O
. O

TS O
activated O
HSF B
, O
which O
was O
associated O
with O
Hsp70 B
overexpression O
and O
inhibition O
of O
NFkappaB B
binding O
activity O
and O
TNFalpha B
release O
. O

TS O
activated O
HSF B
, O
which O
was O
associated O
with O
Hsp70 B
overexpression O
and O
inhibition O
of O
NFkappaB B
binding O
activity O
and O
TNFalpha B
release O
. O

TS O
activated O
HSF B
, O
which O
was O
associated O
with O
Hsp70 B
overexpression O
and O
inhibition O
of O
NFkappaB B
binding O
activity O
and O
TNFalpha B
release O
. O

Activation O
of O
T O
cells O
results O
in O
the O
rapid O
calcineurin B
- O
dependent O
translocation O
of O
NFAT B
transcription B
factors I
from O
the O
cytoplasm O
to O
the O
nucleus O
. O

Activation O
of O
T O
cells O
results O
in O
the O
rapid O
calcineurin B
- O
dependent O
translocation O
of O
NFAT B
transcription B
factors I
from O
the O
cytoplasm O
to O
the O
nucleus O
. O

PDBu O
+ O
iono O
induced O
equally O
high O
IL B
- I
2 I
levels O
in O
both O
groups O
and O
, O
when O
stimulated O
with O
plate O
- O
bound O
anti B
- I
CD3 I
monoclonal I
antibody I
( O
mAb B
) O
, O
the O
IL B
- I
2 I
secretion O
by O
neonatal O
cells O
was O
undetectable O
and O
adult O
cells O
produced O
low O
amounts O
of O
IL B
- I
2 I
( O
mean O
331 O
+ O
/ O
- O
86 O
pg O
/ O
ml O
) O
. O

CL O
- O
01 O
cells O
are O
IgM B
+ O
IgD B
+ O
CD30 B
+ O
and O
switch O
to O
IgG B
, O
IgA B
, O
and O
IgE B
when O
exposed O
to O
CD40L B
and O
IL B
- I
4 I
. O

CL O
- O
01 O
cells O
are O
IgM B
+ O
IgD B
+ O
CD30 B
+ O
and O
switch O
to O
IgG B
, O
IgA B
, O
and O
IgE B
when O
exposed O
to O
CD40L B
and O
IL B
- I
4 I
. O

CL O
- O
01 O
cells O
are O
IgM B
+ O
IgD B
+ O
CD30 B
+ O
and O
switch O
to O
IgG B
, O
IgA B
, O
and O
IgE B
when O
exposed O
to O
CD40L B
and O
IL B
- I
4 I
. O

CL O
- O
01 O
cells O
are O
IgM B
+ O
IgD B
+ O
CD30 B
+ O
and O
switch O
to O
IgG B
, O
IgA B
, O
and O
IgE B
when O
exposed O
to O
CD40L B
and O
IL B
- I
4 I
. O

CL O
- O
01 O
cells O
are O
IgM B
+ O
IgD B
+ O
CD30 B
+ O
and O
switch O
to O
IgG B
, O
IgA B
, O
and O
IgE B
when O
exposed O
to O
CD40L B
and O
IL B
- I
4 I
. O

CL O
- O
01 O
cells O
are O
IgM B
+ O
IgD B
+ O
CD30 B
+ O
and O
switch O
to O
IgG B
, O
IgA B
, O
and O
IgE B
when O
exposed O
to O
CD40L B
and O
IL B
- I
4 I
. O

CL O
- O
01 O
cells O
are O
IgM B
+ O
IgD B
+ O
CD30 B
+ O
and O
switch O
to O
IgG B
, O
IgA B
, O
and O
IgE B
when O
exposed O
to O
CD40L B
and O
IL B
- I
4 I
. O

Switching O
is O
hampered O
by O
CD30 B
coengagement O
, O
possibly O
through O
interference O
with O
the O
CD40 B
- O
mediated O
NF B
- I
kappaB I
- O
dependent O
transcriptional O
activation O
of O
downstream B
C I
( I
H I
) I
genes I
. O

Switching O
is O
hampered O
by O
CD30 B
coengagement O
, O
possibly O
through O
interference O
with O
the O
CD40 B
- O
mediated O
NF B
- I
kappaB I
- O
dependent O
transcriptional O
activation O
of O
downstream B
C I
( I
H I
) I
genes I
. O

Signal B
transducer I
and I
activator I
of I
transcription I
3 I
( O
Stat3 B
) O
has O
recently O
been O
shown O
to O
exist O
in O
two O
alternatively O
spliced O
isoforms O
, O
a O
short O
form O
, O
Stat3beta B
, O
and O
a O
longer O
form O
, O
Stat3alpha B
, O
displaying O
differences O
in O
transcriptional O
activity O
. O

Signal B
transducer I
and I
activator I
of I
transcription I
3 I
( O
Stat3 B
) O
has O
recently O
been O
shown O
to O
exist O
in O
two O
alternatively O
spliced O
isoforms O
, O
a O
short O
form O
, O
Stat3beta B
, O
and O
a O
longer O
form O
, O
Stat3alpha B
, O
displaying O
differences O
in O
transcriptional O
activity O
. O

Signal B
transducer I
and I
activator I
of I
transcription I
3 I
( O
Stat3 B
) O
has O
recently O
been O
shown O
to O
exist O
in O
two O
alternatively O
spliced O
isoforms O
, O
a O
short O
form O
, O
Stat3beta B
, O
and O
a O
longer O
form O
, O
Stat3alpha B
, O
displaying O
differences O
in O
transcriptional O
activity O
. O

Relationship O
between O
IkappaBalpha B
constitutive O
expression O
, O
TNFalpha B
synthesis O
, O
and O
apoptosis O
in O
EBV O
- O
infected O
lymphoblastoid O
cells O
. O

Relationship O
between O
IkappaBalpha B
constitutive O
expression O
, O
TNFalpha B
synthesis O
, O
and O
apoptosis O
in O
EBV O
- O
infected O
lymphoblastoid O
cells O
. O

In O
order O
to O
understand O
the O
role O
of O
NF B
- I
kappaB I
in O
EBV O
transformation O
we O
have O
established O
stably O
transfected O
IkappaBalpha B
into O
lymphoblastoid O
cells O
. O

Our O
results O
suggest O
that O
the O
TNFalpha B
gene I
could O
be O
one O
of O
the O
targets O
of O
NF B
- I
kappaB I
in O
EBV O
infected O
cells O
and O
that O
NF O
- O
kappaB O
protects O
EBV O
- O
infected O
cells O
from O
apoptosis O
induced O
by O
TNFalpha B
, O
which O
may O
favour O
the O
proliferative O
effect O
of O
this O
cytokine B
. O

Our O
results O
suggest O
that O
the O
TNFalpha B
gene I
could O
be O
one O
of O
the O
targets O
of O
NF B
- I
kappaB I
in O
EBV O
infected O
cells O
and O
that O
NF O
- O
kappaB O
protects O
EBV O
- O
infected O
cells O
from O
apoptosis O
induced O
by O
TNFalpha B
, O
which O
may O
favour O
the O
proliferative O
effect O
of O
this O
cytokine B
. O

This O
study O
shows O
that O
expression O
of O
LMP1 B
activates O
transcription O
from O
p50 B
/ I
p65 I
- I
and I
c I
- I
Rel I
- I
responsive I
promoters I
, O
and O
that O
this O
activity O
can O
be O
completely O
inhibited O
by O
expression O
of O
a O
dominant O
inhibitory B
IkappaB I
mutant I
. O

Furthermore O
, O
LMP1 B
- O
induced O
cell O
size O
increase O
of O
primary O
B O
cells O
was O
unaffected O
by O
IkappaB B
expression O
. O

Furthermore O
, O
LMP1 B
- O
induced O
cell O
size O
increase O
of O
primary O
B O
cells O
was O
unaffected O
by O
IkappaB B
expression O
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil B
- I
associated I
granule I
proteins I
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil B
- I
derived I
neurotoxin I
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major B
basic I
protein I
( O
MBP B
) O
, O
and O
for O
the O
Charcot B
- I
Leyden I
crystal I
( I
CLC I
) I
protein I
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil B
- I
associated I
granule I
proteins I
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil B
- I
derived I
neurotoxin I
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major B
basic I
protein I
( O
MBP B
) O
, O
and O
for O
the O
Charcot B
- I
Leyden I
crystal I
( I
CLC I
) I
protein I
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil B
- I
associated I
granule I
proteins I
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil B
- I
derived I
neurotoxin I
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major B
basic I
protein I
( O
MBP B
) O
, O
and O
for O
the O
Charcot B
- I
Leyden I
crystal I
( I
CLC I
) I
protein I
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil B
- I
associated I
granule I
proteins I
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil B
- I
derived I
neurotoxin I
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major B
basic I
protein I
( O
MBP B
) O
, O
and O
for O
the O
Charcot B
- I
Leyden I
crystal I
( I
CLC I
) I
protein I
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil B
- I
associated I
granule I
proteins I
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil B
- I
derived I
neurotoxin I
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major B
basic I
protein I
( O
MBP B
) O
, O
and O
for O
the O
Charcot B
- I
Leyden I
crystal I
( I
CLC I
) I
protein I
. O

To O
examine O
the O
hypothesis O
that O
interleukin B
- I
6 I
( O
IL B
- I
6 I
) O
contributes O
to O
PMN O
infiltration O
and O
lung O
damage O
in O
HS O
, O
we O
examined O
the O
lungs O
of O
rats O
subjected O
to O
unresuscitated O
and O
resuscitated O
HS O
for O
the O
production O
of O
IL B
- I
6 I
and O
activation O
of O
Stat3 B
. O

Electrophoretic O
mobility O
shift O
assay O
of O
protein O
extracts O
from O
shock O
lungs O
exhibited O
an O
increase O
in O
Stat3 B
activation O
with O
kinetics O
similar O
to O
IL B
- I
6 I
mRNA I
. O

The O
MHC B
class I
II I
transactivator I
( O
CIITA B
) O
requires O
conserved O
leucine B
charged I
domains I
for O
interactions O
with O
the O
conserved O
W B
box I
promoter I
element I
. O

Two O
mutants O
displayed O
differential O
activity O
between O
the O
two O
promoters B
, O
activating O
transcription O
with O
the O
W B
- I
X I
- I
Y I
but I
not I
the I
X I
- I
Y I
elements I
. O

All O
mutants O
were O
tested O
for O
their O
ability O
to O
interfere O
with O
wild O
- O
type O
CIITA B
activity O
. O

The O
characterization O
of O
CIITA B
mutants I
that O
are O
able O
to O
discriminate O
between O
promoters O
with O
or O
without O
the O
W B
box I
strongly O
suggests O
that O
CIITA B
requires O
such O
interactions O
for O
function O
. O

Recently O
, O
it O
was O
suggested O
that O
activation O
of O
the O
alpha B
isoform I
of O
PPAR B
by O
the O
potent O
proinflammatory O
mediator O
leukotriene O
B4 O
( O
LTB4 O
) O
enhanced O
degradation O
of O
this O
eicosanoid O
, O
offersuggesting O
a O
new O
aspect O
of O
down O
- O
regulation O
of O
inflammation O
. O

Thus O
, O
this O
study O
provides O
no O
evidence O
indicating O
a O
regulatory O
function O
of O
PPARalpha B
in O
LTB4 O
induced O
adhesive O
interactions O
between O
endothelial O
cells O
and O
neutrophils O

We O
determined O
whether O
the O
interaction O
of O
SS O
RBC O
with O
cultured O
endothelial O
cells O
induced O
cellular O
oxidant O
stress O
that O
would O
culminate O
in O
expression O
of O
cell B
adhesion I
molecules I
( O
CAMs B
) O
involved O
in O
the O
adhesion O
and O
diapedesis O
of O
monocytes O
and O
the O
adherence O
of O
SS O
reticulocytes O
. O

Changes O
in O
these O
signaling O
molecules O
during O
cytokine B
treatment O
were O
also O
investigated O
. O

Correlations O
of O
TCRzeta B
or O
p56 B
( I
lck I
) I
levels O
with O
response O
or O
disease O
variables O
, O
except O
for O
lower O
TCRzeta B
levels O
( O
P O
< O
0 O
. O
001 O
) O
in O
the O
presence O
of O
bone O
metastases O
, O
were O
not O
found O
. O

Correlations O
of O
TCRzeta B
or O
p56 B
( I
lck I
) I
levels O
with O
response O
or O
disease O
variables O
, O
except O
for O
lower O
TCRzeta B
levels O
( O
P O
< O
0 O
. O
001 O
) O
in O
the O
presence O
of O
bone O
metastases O
, O
were O
not O
found O
. O

In O
the O
majority O
of O
patients O
with O
advanced O
RCC O
, O
peripheral O
blood O
T O
cells O
express O
TCRzeta B
and O
p56 B
( I
lck I
) I
, O
and O
in O
a O
subset O
, O
reduced O
levels O
of O
these O
TCRzeta B
associated I
molecules I
are O
seen O
that O
may O
increase O
during O
cytokine B
- O
based O
therapy O
. O

In O
the O
majority O
of O
patients O
with O
advanced O
RCC O
, O
peripheral O
blood O
T O
cells O
express O
TCRzeta B
and O
p56 B
( I
lck I
) I
, O
and O
in O
a O
subset O
, O
reduced O
levels O
of O
these O
TCRzeta B
associated I
molecules I
are O
seen O
that O
may O
increase O
during O
cytokine B
- O
based O
therapy O
. O

Interleukin B
- I
4 I
and I
- I
13 I
induce O
upregulation O
of O
the O
murine O
macrophage O
12 B
/ I
15 I
- I
lipoxygenase I
activity I
: O
evidence O
for O
the O
involvement O
of O
transcription B
factor I
STAT6 B
. O

The O
cytokine B
- O
dependent O
upregulation O
of O
the O
murine B
macrophage I
12 I
- I
lipoxygenase I
and O
its O
induction O
during O
experimental O
anemia O
suggests O
its O
close O
relatedness O
with O
the O
human B
reticulocyte I
- I
type I
15 I
- I
lipoxygenase I
despite O
their O
differences O
in O
the O
positional O
specificity O
of O
arachidonic O
acid O
oxygenation O
. O

Activation O
of O
E2F B
- O
mediated O
transcription O
by O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
Tax I
protein I
in O
a O
p16 O
( O
INK4A O
) O
- O
negative O
T O
- O
cell O
line O
. O

Consequently O
, O
Tax B
can O
activate O
the O
signaling O
pathway O
that O
lead O
to O
the O
release O
of O
E2F B
that O
in O
turn O
induces O
expression O
of O
factors O
required O
for O
cell O
cycle O
progression O
. O

Consequently O
, O
Tax B
can O
activate O
the O
signaling O
pathway O
that O
lead O
to O
the O
release O
of O
E2F B
that O
in O
turn O
induces O
expression O
of O
factors O
required O
for O
cell O
cycle O
progression O
. O

In O
addition O
, O
Tax B
also O
stimulates O
the O
transcription O
of O
the O
E2F B
- I
1 I
gene I
itself O
. O

These O
studies O
indicate O
that O
iNO O
attenuates O
iNOS B
expression O
in O
macrophages O
and O
inhibits O
monocyte O
adhesion O
to O
endothelial O
cells O
, O
and O
suggest O
that O
endogenously O
derived O
iNO O
may O
be O
an O
important O
autoregulatory O
inhibitor O
of O
vascular O
inflammation O

These O
results O
corroborate O
previous O
findings O
that O
the O
presence O
of O
ER B
variants O
is O
not O
a O
characteristic O
of O
breast O
cancer O
. O

p21ras B
initiates O
Rac B
- I
1 I
but O
not O
phosphatidyl B
inositol I
3 I
kinase I
/ I
PKB I
, O
mediated O
signaling O
pathways O
in O
T O
lymphocytes O
. O

Moreover O
, O
neither O
TCR B
or O
Ras B
activation O
of O
AP B
- I
1 I
is O
dependent O
on O
PtdIns B
3 I
- I
kinase I
. O

Moreover O
, O
neither O
TCR B
or O
Ras B
activation O
of O
AP B
- I
1 I
is O
dependent O
on O
PtdIns B
3 I
- I
kinase I
. O

LNCaP O
cells O
treated O
with O
prostaglandin O
E2 O
showed O
neither O
a O
reduction O
in O
proliferation O
nor O
a O
down O
- O
regulation O
of O
AR B
and O
PSA B
levels O
. O

LNCaP O
cells O
treated O
with O
prostaglandin O
E2 O
showed O
neither O
a O
reduction O
in O
proliferation O
nor O
a O
down O
- O
regulation O
of O
AR B
and O
PSA B
levels O
. O

In O
addition O
, O
recombinant O
IL B
- I
1beta I
was O
able O
to O
replace O
MCM O
for O
the O
inhibition O
of O
proliferation O
and O
down O
- O
regulation O
of O
AR B
and O
PSA B
proteins O
. O

In O
addition O
, O
recombinant O
IL B
- I
1beta I
was O
able O
to O
replace O
MCM O
for O
the O
inhibition O
of O
proliferation O
and O
down O
- O
regulation O
of O
AR B
and O
PSA B
proteins O
. O

Antibodies B
to O
Duffy B
antigens I
are O
responsible O
for O
some O
cases O
of O
transfusion O
incompatibility O
and O
newborn O
hemolytic O
disease O
. O

The O
Duffy B
protein I
is O
a O
receptor O
for O
the O
Plasmodium B
vivax I
erythrocyte I
- I
binding I
protein I
and O
is O
also O
a O
receptor O
for O
various O
chemokines B
( O
thus O
renamed O
Duffy B
Antigen I
Receptor I
for I
Chemokines I
[ O
DARC B
] O
) O
. O

The O
Duffy B
protein I
is O
a O
receptor O
for O
the O
Plasmodium B
vivax I
erythrocyte I
- I
binding I
protein I
and O
is O
also O
a O
receptor O
for O
various O
chemokines B
( O
thus O
renamed O
Duffy B
Antigen I
Receptor I
for I
Chemokines I
[ O
DARC B
] O
) O
. O

The O
271C O
- O
- O
> O
T O
substitution O
represents O
a O
considerable O
change O
in O
chemical O
nature O
( O
Arg91 O
- O
- O
> O
Cys O
) O
, O
one O
which O
may O
affect O
the O
antigenic O
determinants O
of O
DARC B
, O
and O
thus O
be O
of O
clinical O
significance O
. O

The O
functions O
of O
NFAT B
proteins I
are O
directly O
controlled O
by O
the O
calcium B
- I
and I
calmodulin I
- I
dependent I
phosphatase I
calcineurin B
. O

Expression O
of O
the O
IL B
- I
2 I
gene I
requires O
activation O
of O
T O
cells O
through O
stimulation O
of O
the O
TCR B
and O
costimulation O
through O
accessory B
receptors I
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
bis O
[ O
4 O
- O
[ O
2 O
, O
4 O
- O
dioxo O
- O
5 O
- O
thiazolidinyl O
) O
methyl O
] O
phenyl O
] O
methane O
( O
YM O
- O
268 O
) O
, O
a O
thiazolidinedione O
derivative O
, O
on O
glucose O
uptake O
, O
adipocyte O
differentiation O
through O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
, O
and O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
activity O
in O
cultured O
cells O
. O

The O
nuclear B
receptor I
PPARgamma B
- O
bigger O
than O
fat O
. O

PPARgamma B
has O
also O
been O
implicated O
recently O
in O
the O
biology O
of O
monocytes O
and O
in O
cell O
- O
cycle O
regulation O
and O
cancer O
. O

We O
have O
determined O
how O
the O
phosphorylation O
of O
the O
retinoblastoma B
family I
( O
pRb B
, O
p107 B
, O
and O
p130 B
) O
is O
governed O
in O
individual O
cell O
cycle O
phases O
of O
Daudi O
B O
- O
cells O
during O
cell O
cycle O
exit O
triggered O
by O
alpha B
- I
interferon I
( O
alpha B
- I
IFN I
) O
. O

We O
have O
determined O
how O
the O
phosphorylation O
of O
the O
retinoblastoma B
family I
( O
pRb B
, O
p107 B
, O
and O
p130 B
) O
is O
governed O
in O
individual O
cell O
cycle O
phases O
of O
Daudi O
B O
- O
cells O
during O
cell O
cycle O
exit O
triggered O
by O
alpha B
- I
interferon I
( O
alpha B
- I
IFN I
) O
. O

We O
have O
determined O
how O
the O
phosphorylation O
of O
the O
retinoblastoma B
family I
( O
pRb B
, O
p107 B
, O
and O
p130 B
) O
is O
governed O
in O
individual O
cell O
cycle O
phases O
of O
Daudi O
B O
- O
cells O
during O
cell O
cycle O
exit O
triggered O
by O
alpha B
- I
interferon I
( O
alpha B
- I
IFN I
) O
. O

alpha B
- I
IFN I
causes O
dephosphorylation O
of O
pRb B
and O
loss O
of O
p130 B
phosphorylated I
Form I
3 I
. O

However O
, O
the O
change O
in O
p130 B
phosphorylation O
in O
response O
to O
alpha B
- I
IFN I
occurs O
before O
dephosphorylation O
of O
pRb B
is O
complete O
because O
loss O
of O
p130 B
Form I
3 I
occurs O
throughout O
the O
cell O
cycle O
prior O
to O
complete O
arrest O
in O
G1 O
, O
whereas O
pRb B
is O
dephosphorylated O
only O
in O
G1 O
. O

However O
, O
the O
change O
in O
p130 B
phosphorylation O
in O
response O
to O
alpha B
- I
IFN I
occurs O
before O
dephosphorylation O
of O
pRb B
is O
complete O
because O
loss O
of O
p130 B
Form I
3 I
occurs O
throughout O
the O
cell O
cycle O
prior O
to O
complete O
arrest O
in O
G1 O
, O
whereas O
pRb B
is O
dephosphorylated O
only O
in O
G1 O
. O

However O
, O
the O
change O
in O
p130 B
phosphorylation O
in O
response O
to O
alpha B
- I
IFN I
occurs O
before O
dephosphorylation O
of O
pRb B
is O
complete O
because O
loss O
of O
p130 B
Form I
3 I
occurs O
throughout O
the O
cell O
cycle O
prior O
to O
complete O
arrest O
in O
G1 O
, O
whereas O
pRb B
is O
dephosphorylated O
only O
in O
G1 O
. O

p130 B
, O
predominantly O
in O
Form O
1 O
, O
and O
hypophosphorylated B
pRb I
bind O
an O
E2F B
DNA I
binding I
site I
; O
p130 B
complexes O
E2F B
- I
4 I
, O
whereas O
pRb B
binds O
both O
E2F O
- O
4 O
and O
E2F B
- I
1 I
. O

p130 B
, O
predominantly O
in O
Form O
1 O
, O
and O
hypophosphorylated B
pRb I
bind O
an O
E2F B
DNA I
binding I
site I
; O
p130 B
complexes O
E2F B
- I
4 I
, O
whereas O
pRb B
binds O
both O
E2F O
- O
4 O
and O
E2F B
- I
1 I
. O

p130 B
, O
predominantly O
in O
Form O
1 O
, O
and O
hypophosphorylated B
pRb I
bind O
an O
E2F B
DNA I
binding I
site I
; O
p130 B
complexes O
E2F B
- I
4 I
, O
whereas O
pRb B
binds O
both O
E2F O
- O
4 O
and O
E2F B
- I
1 I
. O

Northern O
blot O
analysis O
of O
L132 O
cells O
transfected O
with O
the O
C B
/ I
EBP I
alpha I
expression O
vector O
demonstrate O
that O
C B
/ I
EBP I
alpha I
is O
sufficient O
to O
enhance O
MRP14 B
expression O
in O
the O
context O
of O
the O
whole O
genome O
. O

This O
observation O
prompted O
us O
to O
postulate O
that O
signal O
2 O
( O
costimulatory O
signal O
) O
alone O
without O
signal O
1 O
( O
TCR B
signal O
) O
can O
activate O
T O
cells O
. O

This O
pathway O
resulted O
in O
the O
induction O
of O
the O
transcription B
factors I
NF B
- I
kappa I
B I
, O
NF B
- I
AT I
, O
and O
proteins O
binding O
to O
the O
CD28 B
response O
element O
of O
the O
IL B
- I
2 I
promoter I
. O

In O
contrast O
to O
the O
differential O
signaling O
of O
BW B
828 I
and O
9 B
. I
3 I
in O
resting O
T O
cells O
, O
the O
two O
mAbs O
exhibited O
a O
similar O
pattern O
of O
early O
signaling O
events O
in O
activated O
T O
cells O
and O
Jurkat O
cells O
( O
p56 B
( I
lck I
) I
activation O
, O
association O
of O
phosphatidylinositol B
3 I
- I
kinase I
with O
CD28 B
) O
, O
indicating O
that O
the O
signaling O
capacity O
of O
CD28 B
changes O
with O
activation O
. O

In O
contrast O
to O
the O
differential O
signaling O
of O
BW B
828 I
and O
9 B
. I
3 I
in O
resting O
T O
cells O
, O
the O
two O
mAbs O
exhibited O
a O
similar O
pattern O
of O
early O
signaling O
events O
in O
activated O
T O
cells O
and O
Jurkat O
cells O
( O
p56 B
( I
lck I
) I
activation O
, O
association O
of O
phosphatidylinositol B
3 I
- I
kinase I
with O
CD28 B
) O
, O
indicating O
that O
the O
signaling O
capacity O
of O
CD28 B
changes O
with O
activation O
. O

In O
CAT B
reporter I
constructions I
no O
appreciable O
level O
of O
CAT B
activity O
was O
supported O
by O
the O
beta B
globin I
promoter I
, O
and O
only O
low O
level O
activity O
by O
the O
delta B
promoter I
. O

The O
induction O
of O
IgE B
by O
IL B
- I
4 I
and O
IL B
- I
13 I
occurs O
through O
the O
activation O
of O
the O
intracellular B
signal I
- I
transducing I
protein I
Stat6 I
, O
whereas O
the O
inhibition O
of O
IgE B
class O
switching O
by O
interferon B
- I
y I
( O
IFN B
- I
gamma I
) O
occurs O
through O
the O
activation O
of O
Statl B
. O

The O
induction O
of O
IgE B
by O
IL B
- I
4 I
and O
IL B
- I
13 I
occurs O
through O
the O
activation O
of O
the O
intracellular B
signal I
- I
transducing I
protein I
Stat6 I
, O
whereas O
the O
inhibition O
of O
IgE B
class O
switching O
by O
interferon B
- I
y I
( O
IFN B
- I
gamma I
) O
occurs O
through O
the O
activation O
of O
Statl B
. O

The O
induction O
of O
IgE B
by O
IL B
- I
4 I
and O
IL B
- I
13 I
occurs O
through O
the O
activation O
of O
the O
intracellular B
signal I
- I
transducing I
protein I
Stat6 I
, O
whereas O
the O
inhibition O
of O
IgE B
class O
switching O
by O
interferon B
- I
y I
( O
IFN B
- I
gamma I
) O
occurs O
through O
the O
activation O
of O
Statl B
. O

NFAT B
regulates O
transcription O
of O
a O
number O
of O
cytokine O
and O
other O
immunoregulatory B
genes I
. O

We O
also O
report O
three O
additional O
isoforms O
of O
NFATx B
, O
designated O
NFATx2 B
, O
NFATx3 B
, O
and O
NFATx4 B
. O

We O
also O
report O
three O
additional O
isoforms O
of O
NFATx B
, O
designated O
NFATx2 B
, O
NFATx3 B
, O
and O
NFATx4 B
. O

We O
also O
report O
three O
additional O
isoforms O
of O
NFATx B
, O
designated O
NFATx2 B
, O
NFATx3 B
, O
and O
NFATx4 B
. O

We O
also O
report O
three O
additional O
isoforms O
of O
NFATx B
, O
designated O
NFATx2 B
, O
NFATx3 B
, O
and O
NFATx4 B
. O

We O
show O
that O
the O
function O
of O
such O
closely O
related O
proteins O
can O
be O
distinguished O
in O
vivo O
by O
matching O
point O
mutations O
in O
5 B
' I
HS3 I
with O
amino O
acid O
changes O
in O
the O
zinc B
fingers I
of O
Sp1 B
and O
EKLF B
. O

We O
show O
that O
the O
function O
of O
such O
closely O
related O
proteins O
can O
be O
distinguished O
in O
vivo O
by O
matching O
point O
mutations O
in O
5 B
' I
HS3 I
with O
amino O
acid O
changes O
in O
the O
zinc B
fingers I
of O
Sp1 B
and O
EKLF B
. O

The O
transition O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
from O
latency O
into O
the O
lytic O
cycle O
is O
associated O
with O
the O
expression O
of O
two O
immediate B
- I
early I
viral I
genes I
, O
BZLF1 B
and O
BRLF1 B
. O

The O
transition O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
from O
latency O
into O
the O
lytic O
cycle O
is O
associated O
with O
the O
expression O
of O
two O
immediate B
- I
early I
viral I
genes I
, O
BZLF1 B
and O
BRLF1 B
. O

In O
HH514 O
- O
16 O
cells O
, O
transfection O
of O
Rta B
leads O
to O
synthesis O
of O
ZEBRA B
, O
viral O
DNA O
replication O
, O
and O
late O
gene O
expression O
. O

In O
HH514 O
- O
16 O
cells O
, O
transfection O
of O
Rta B
leads O
to O
synthesis O
of O
ZEBRA B
, O
viral O
DNA O
replication O
, O
and O
late O
gene O
expression O
. O

Expression O
of O
either O
BZLF1 B
or O
BRLF1 B
triggers O
expression O
of O
the O
other O
immediate B
- I
early I
factor I
, O
and O
together O
these O
activators O
act O
individually O
or O
in O
synergy O
on O
downstream B
targets I
to O
activate O
the O
viral O
lytic O
cycle O
. O

Expression O
of O
either O
BZLF1 B
or O
BRLF1 B
triggers O
expression O
of O
the O
other O
immediate B
- I
early I
factor I
, O
and O
together O
these O
activators O
act O
individually O
or O
in O
synergy O
on O
downstream B
targets I
to O
activate O
the O
viral O
lytic O
cycle O
. O

We O
first O
demonstrate O
, O
in O
human O
and O
mouse O
intraspecies O
hybrids O
, O
the O
coordinate O
suppression O
of O
MHC B
class I
II I
, O
Ii B
( O
invariant B
chain I
) O
and O
HLA B
- I
DM I
gene I
transcription O
, O
and O
the O
release O
of O
the O
silencing O
by O
the O
addition O
of O
interferon B
gamma I
. O

These O
data O
indicate O
that O
the O
IFN B
- I
gamma I
- O
independent O
component O
of O
the O
target O
cell O
HLA B
- I
DR I
expression O
induced O
by O
lymphocyte O
adhesion O
uses O
a O
signaling O
pathway O
that O
is O
distinct O
from O
the O
IFN B
- I
gamma I
- O
dependent O
mechanism O
and O
also O
suggest O
that O
CIITA B
is O
not O
required O
. O

In O
this O
report O
expression O
profiles O
and O
activation O
of O
PKC B
were O
analyzed O
in O
human O
Raji O
B O
lymphoblastoid O
cells O
. O

Transient O
transfection O
analysis O
with O
target B
plasmids I
containing O
either O
DRA B
promoter I
( O
wild O
- O
type O
or O
mutated O
) O
or O
TPA B
response I
elements I
demonstrated O
that O
pretreatment O
with O
the O
selective O
PKC B
inhibitor O
GF O
109203X O
repressed O
TPA O
- O
mediated O
activation O
. O

Together O
, O
these O
results O
show O
that O
activated O
HLA B
- I
DRA I
expression O
in O
response O
to O
TPA O
treatment O
is O
strictly O
dependent O
on O
PKC B
activation O
acting O
on O
the O
X2 B
box I
of O
the O
DRA B
promoter I
and O
that O
selective O
inhibition O
of O
PKC B
enzymatic O
activity O
does O
not O
influence O
subcellular O
localization O
of O
expressed O
PKC B
isoenzymes I
. O

Together O
, O
these O
results O
show O
that O
activated O
HLA B
- I
DRA I
expression O
in O
response O
to O
TPA O
treatment O
is O
strictly O
dependent O
on O
PKC B
activation O
acting O
on O
the O
X2 B
box I
of O
the O
DRA B
promoter I
and O
that O
selective O
inhibition O
of O
PKC B
enzymatic O
activity O
does O
not O
influence O
subcellular O
localization O
of O
expressed O
PKC B
isoenzymes I
. O

In O
situ O
hybridisation O
revealed O
musculin B
expression O
in O
embryos O
was O
largely O
restricted O
to O
the O
embryonic O
skeletal O
muscle O
lineage O
. O

JNK B
enzymatic O
activity O
was O
blocked O
in O
anergized O
T O
cells O
. O

Although O
bacterial O
lipopolysaccharides O
( O
LPS O
) O
and O
several O
other O
microbial O
agonists O
can O
bind O
to O
mCD14 B
( O
membrane B
CD14 I
) O
, O
a O
cell O
- O
surface O
receptor O
found O
principally O
on O
monocytes O
and O
neutrophils O
, O
host O
- O
derived O
mCD14 B
ligands O
are O
poorly O
defined O
. O

Although O
bacterial O
lipopolysaccharides O
( O
LPS O
) O
and O
several O
other O
microbial O
agonists O
can O
bind O
to O
mCD14 B
( O
membrane B
CD14 I
) O
, O
a O
cell O
- O
surface O
receptor O
found O
principally O
on O
monocytes O
and O
neutrophils O
, O
host O
- O
derived O
mCD14 B
ligands O
are O
poorly O
defined O
. O

We O
report O
here O
that O
phosphatidylinositol O
( O
PtdIns O
) O
, O
phosphatidylinositol O
- O
4 O
- O
phosphate O
, O
and O
other O
phosphatidylinositid O
can O
bind O
to O
mCD14 B
. O

Despite O
progress O
in O
understanding O
the O
death O
signals O
transduced O
from O
Fas B
, O
very O
little O
is O
known O
with O
regard O
to O
the O
mechanisms O
by O
which O
Fas B
expression O
is O
regulated O
. O

Despite O
progress O
in O
understanding O
the O
death O
signals O
transduced O
from O
Fas B
, O
very O
little O
is O
known O
with O
regard O
to O
the O
mechanisms O
by O
which O
Fas B
expression O
is O
regulated O
. O

PKC B
- O
dependent O
Fas B
expression O
was O
also O
observed O
in O
several O
murine O
and O
human O
tumor O
cell O
lines O
. O

PKC B
- O
dependent O
Fas B
expression O
was O
also O
observed O
in O
several O
murine O
and O
human O
tumor O
cell O
lines O
. O

Since O
the O
inhibition O
of O
Ca2 O
+ O
redistribution O
by O
an O
inhibitor O
of O
intracellular O
Ca2 O
+ O
mobilization O
, O
8 O
- O
( O
diethylamino O
) O
- O
octyl O
- O
3 O
, O
4 O
, O
5 O
- O
trimethoxybenzoate O
hydrochloride O
, O
inhibited O
TCR B
- I
induced I
FasL I
but O
not O
Fas B
, O
the O
expression O
of O
Fas B
appears O
to O
be O
independent O
of O
Ca2 O
+ O
mobilization O
. O

Since O
the O
inhibition O
of O
Ca2 O
+ O
redistribution O
by O
an O
inhibitor O
of O
intracellular O
Ca2 O
+ O
mobilization O
, O
8 O
- O
( O
diethylamino O
) O
- O
octyl O
- O
3 O
, O
4 O
, O
5 O
- O
trimethoxybenzoate O
hydrochloride O
, O
inhibited O
TCR B
- I
induced I
FasL I
but O
not O
Fas B
, O
the O
expression O
of O
Fas B
appears O
to O
be O
independent O
of O
Ca2 O
+ O
mobilization O
. O

IgE B
synthesis O
was O
even O
more O
markedly O
inhibited O
by O
RA O
starting O
at O
concentrations O
of O
> O
10 O
( O
- O
14 O
) O
mol O
/ O
L O
for O
B O
cells O
and O
> O
10 O
( O
- O
10 O
) O
mol O
/ O
L O
for O
PBMC O
. O

Low O
concentrations O
of O
RA O
inhibiting O
IgE B
synthesis O
( O
10 O
( O
- O
10 O
) O
mol O
/ O
L O
) O
affected O
neither O
B O
- O
cell O
proliferation O
nor O
the O
production O
of O
IgA B
, O
IgG B
, O
and O
IgM B
. O

Low O
concentrations O
of O
RA O
inhibiting O
IgE B
synthesis O
( O
10 O
( O
- O
10 O
) O
mol O
/ O
L O
) O
affected O
neither O
B O
- O
cell O
proliferation O
nor O
the O
production O
of O
IgA B
, O
IgG B
, O
and O
IgM B
. O

Low O
concentrations O
of O
RA O
inhibiting O
IgE B
synthesis O
( O
10 O
( O
- O
10 O
) O
mol O
/ O
L O
) O
affected O
neither O
B O
- O
cell O
proliferation O
nor O
the O
production O
of O
IgA B
, O
IgG B
, O
and O
IgM B
. O

Low O
concentrations O
of O
RA O
inhibiting O
IgE B
synthesis O
( O
10 O
( O
- O
10 O
) O
mol O
/ O
L O
) O
affected O
neither O
B O
- O
cell O
proliferation O
nor O
the O
production O
of O
IgA B
, O
IgG B
, O
and O
IgM B
. O

To O
differentiate O
whether O
the O
RA O
effect O
was O
mediated O
by O
RA B
receptors I
alpha I
, I
beta I
, I
and I
gamma I
, O
the O
expression O
of O
the O
retinoic B
acid I
receptors I
( O
RAR B
) O
was O
examined O
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
. O

Taken O
together O
, O
this O
study O
shows O
that O
RA O
inhibits O
IgE B
production O
of O
anti O
- O
CD40 O
+ O
IL O
- O
4 O
- O
stimulated O
B O
cells O
in O
vitro O
. O

In O
contrast O
, O
a O
mutant O
of O
Tax B
termed O
M22 B
, O
which O
does O
not O
induce O
NF B
- I
kappaB I
, O
fails O
to O
activate O
either O
IKKalpha B
or O
IKKbeta B
. O

In O
contrast O
, O
a O
mutant O
of O
Tax B
termed O
M22 B
, O
which O
does O
not O
induce O
NF B
- I
kappaB I
, O
fails O
to O
activate O
either O
IKKalpha B
or O
IKKbeta B
. O

In O
contrast O
, O
a O
mutant O
of O
Tax B
termed O
M22 B
, O
which O
does O
not O
induce O
NF B
- I
kappaB I
, O
fails O
to O
activate O
either O
IKKalpha B
or O
IKKbeta B
. O

In O
contrast O
, O
a O
mutant O
of O
Tax B
termed O
M22 B
, O
which O
does O
not O
induce O
NF B
- I
kappaB I
, O
fails O
to O
activate O
either O
IKKalpha B
or O
IKKbeta B
. O

The O
pathological O
alteration O
of O
this O
cytokine O
pathway O
leading O
to O
NF B
- I
kappaB I
activation O
by O
Tax B
may O
play O
a O
central O
role O
in O
HTLV O
- O
1 O
- O
mediated O
transformation O
of O
human O
T O
cells O
, O
clinically O
manifested O
as O
the O
adult O
T O
- O
cell O
leukemia O

Recently O
, O
we O
have O
reported O
that O
the O
tumor B
necrosis I
factor I
and O
interleukin B
1 I
signaling O
pathways O
activate O
two O
kinases O
, O
IKK1 B
and O
IKK2 B
. O

Recently O
, O
we O
have O
reported O
that O
the O
tumor B
necrosis I
factor I
and O
interleukin B
1 I
signaling O
pathways O
activate O
two O
kinases O
, O
IKK1 B
and O
IKK2 B
. O

Here O
, O
we O
report O
that O
LPS O
induces O
IKK B
activity O
in O
human O
monocytes O
and O
THP O
- O
1 O
monocytic O
cells O
. O

In O
contrast O
, O
a O
dominant O
negative O
mutant O
of O
IKK2 B
inhibited O
LPS O
induction O
of O
kappaB B
- O
dependent O
transcription O
in O
a O
dose O
- O
dependent O
manner O
. O

In O
contrast O
, O
a O
dominant O
negative O
mutant O
of O
IKK2 B
inhibited O
LPS O
induction O
of O
kappaB B
- O
dependent O
transcription O
in O
a O
dose O
- O
dependent O
manner O
. O

Functional O
analysis O
of O
the O
promoter O
by O
transient O
transfection O
assays O
indicated O
that O
synergistic O
action O
between O
an O
SP B
- I
1 I
- I
like I
element I
at O
- O
21 O
/ O
- O
12 O
, O
a O
GATA B
site I
at O
- O
59 O
/ O
- O
54 O
, O
and O
a O
novel B
regulatory I
element I
, O
CPRE B
( O
- O
GGACTACAG B
- O
) O
at O
- O
49 O
/ O
- O
41 O
, O
is O
essential O
for O
the O
promoter O
activity O
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
. O

Functional O
analysis O
of O
the O
promoter O
by O
transient O
transfection O
assays O
indicated O
that O
synergistic O
action O
between O
an O
SP B
- I
1 I
- I
like I
element I
at O
- O
21 O
/ O
- O
12 O
, O
a O
GATA B
site I
at O
- O
59 O
/ O
- O
54 O
, O
and O
a O
novel B
regulatory I
element I
, O
CPRE B
( O
- O
GGACTACAG B
- O
) O
at O
- O
49 O
/ O
- O
41 O
, O
is O
essential O
for O
the O
promoter O
activity O
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
. O

Here O
we O
report O
an O
analysis O
of O
the O
transcription O
factor O
families O
AP O
- O
1 O
, O
Sp1 O
, O
NF B
- I
kappaB I
, O
and O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STAT B
) O
in O
cancer O
patients O
' O
lymphocytes O
before O
and O
after O
IL B
- I
2 I
immunotherapy O
, O
as O
assessed O
by O
a O
gel O
- O
shift O
assay O
. O

Here O
we O
investigated O
the O
impact O
of O
retinoid B
X I
receptor I
( O
RXR B
) O
, O
retinoic B
acid I
receptor I
( O
RAR B
) O
, O
and O
of O
the O
c B
- I
erbA I
/ I
thyroid I
hormone I
( I
T3 I
) I
receptor I
( O
c B
- I
erbA I
/ I
TR I
) O
on O
growth O
and O
differentiation O
of O
erythroid O
cells O
using O
an O
in O
vitro O
culture O
system O
of O
stem O
cell O
factor O
- O
dependent O
erythroid O
progenitors O
. O

Here O
we O
investigated O
the O
impact O
of O
retinoid B
X I
receptor I
( O
RXR B
) O
, O
retinoic B
acid I
receptor I
( O
RAR B
) O
, O
and O
of O
the O
c B
- I
erbA I
/ I
thyroid I
hormone I
( I
T3 I
) I
receptor I
( O
c B
- I
erbA I
/ I
TR I
) O
on O
growth O
and O
differentiation O
of O
erythroid O
cells O
using O
an O
in O
vitro O
culture O
system O
of O
stem O
cell O
factor O
- O
dependent O
erythroid O
progenitors O
. O

RXR B
, O
RAR B
, O
and O
c B
- I
erbA I
/ I
TR I
- O
specific O
ligands O
were O
found O
to O
induce O
erythroid B
- I
specific I
gene I
expression O
and O
to O
accelerate O
erythroid O
differentiation O
in O
culture O
, O
with O
T3 O
being O
most O
effective O
. O

RXR B
, O
RAR B
, O
and O
c B
- I
erbA I
/ I
TR I
- O
specific O
ligands O
were O
found O
to O
induce O
erythroid B
- I
specific I
gene I
expression O
and O
to O
accelerate O
erythroid O
differentiation O
in O
culture O
, O
with O
T3 O
being O
most O
effective O
. O

In O
marked O
contrast O
, O
expression O
of O
the O
dominant B
interfering I
deltaDNA I
- I
binding I
domain I
RXR B
, O
containing O
a O
deletion O
of O
the O
entire B
DNA I
- I
binding I
domain I
, O
was O
incompatible O
with O
erythroid O
cell O
growth O
in O
vitro O
, O
suggesting O
a O
pivotal O
role O
of O
RXR B
for O
erythroid O
cell O
development O
. O

In O
marked O
contrast O
, O
expression O
of O
the O
dominant B
interfering I
deltaDNA I
- I
binding I
domain I
RXR B
, O
containing O
a O
deletion O
of O
the O
entire B
DNA I
- I
binding I
domain I
, O
was O
incompatible O
with O
erythroid O
cell O
growth O
in O
vitro O
, O
suggesting O
a O
pivotal O
role O
of O
RXR B
for O
erythroid O
cell O
development O
. O

The O
effect O
of O
Rho B
on O
AP B
- I
1 I
is O
independent O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
pathway O
, O
as O
a O
dominant B
- I
negative I
MEK I
and O
a O
MEK B
inhibitor O
( O
PD98059 O
) O
did O
not O
affect O
Rho B
- O
induced O
AP B
- I
1 I
activity O
. O

The O
effect O
of O
Rho B
on O
AP B
- I
1 I
is O
independent O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
pathway O
, O
as O
a O
dominant B
- I
negative I
MEK I
and O
a O
MEK B
inhibitor O
( O
PD98059 O
) O
did O
not O
affect O
Rho B
- O
induced O
AP B
- I
1 I
activity O
. O

The O
effect O
of O
Rho B
on O
AP B
- I
1 I
is O
independent O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
pathway O
, O
as O
a O
dominant B
- I
negative I
MEK I
and O
a O
MEK B
inhibitor O
( O
PD98059 O
) O
did O
not O
affect O
Rho B
- O
induced O
AP B
- I
1 I
activity O
. O

Using O
mRNA O
differential O
display O
we O
demonstrated O
abnormally O
high O
expression O
of O
the O
signal B
transducer I
and I
activator I
of I
transcription I
( O
STAT1alpha B
) O
in O
monocytes O
from O
the O
proband O
II O
- O
2 O
. O

SLP B
- I
76 I
was O
not O
required O
for O
TCR B
- O
induced O
tyrosine O
phosphorylation O
of O
most O
proteins O
, O
but O
was O
required O
for O
optimal O
tyrosine O
phosphorylation O
and O
activation O
of O
phospholipase B
C I
- I
gamma1 I
( O
PLC B
- I
gamma1 I
) O
, O
as O
well O
as O
Ras B
pathway O
activation O
. O

SLP B
- I
76 I
was O
not O
required O
for O
TCR B
- O
induced O
tyrosine O
phosphorylation O
of O
most O
proteins O
, O
but O
was O
required O
for O
optimal O
tyrosine O
phosphorylation O
and O
activation O
of O
phospholipase B
C I
- I
gamma1 I
( O
PLC B
- I
gamma1 I
) O
, O
as O
well O
as O
Ras B
pathway O
activation O
. O

In O
addition O
, O
we O
have O
shown O
that O
Stat1alpha B
, O
but O
not O
Stat3 B
, O
is O
involved O
in O
EPO B
- O
induced O
cellular O
proliferation O
. O

In O
addition O
, O
we O
have O
shown O
that O
Stat1alpha B
, O
but O
not O
Stat3 B
, O
is O
involved O
in O
EPO B
- O
induced O
cellular O
proliferation O
. O

In O
addition O
, O
we O
have O
shown O
that O
Stat1alpha B
, O
but O
not O
Stat3 B
, O
is O
involved O
in O
EPO B
- O
induced O
cellular O
proliferation O
. O

Dominant O
negative O
forms O
of O
Stat1alpha B
or O
Stat3 B
promoted O
the O
EPO B
- O
induced O
erythroid O
differentiation O
of O
UT O
- O
7 O
/ O
GM O
cells O
, O
even O
in O
the O
presence O
of O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
although O
this O
cytokine O
never O
induced O
erythroid O
differentiation O
of O
the O
parent O
UT O
- O
7 O
/ O
GM O
cells O
with O
or O
without O
EPO B
. O

Dominant O
negative O
forms O
of O
Stat1alpha B
or O
Stat3 B
promoted O
the O
EPO B
- O
induced O
erythroid O
differentiation O
of O
UT O
- O
7 O
/ O
GM O
cells O
, O
even O
in O
the O
presence O
of O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
although O
this O
cytokine O
never O
induced O
erythroid O
differentiation O
of O
the O
parent O
UT O
- O
7 O
/ O
GM O
cells O
with O
or O
without O
EPO B
. O

Dominant O
negative O
forms O
of O
Stat1alpha B
or O
Stat3 B
promoted O
the O
EPO B
- O
induced O
erythroid O
differentiation O
of O
UT O
- O
7 O
/ O
GM O
cells O
, O
even O
in O
the O
presence O
of O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
although O
this O
cytokine O
never O
induced O
erythroid O
differentiation O
of O
the O
parent O
UT O
- O
7 O
/ O
GM O
cells O
with O
or O
without O
EPO B
. O

Dominant O
negative O
forms O
of O
Stat1alpha B
or O
Stat3 B
promoted O
the O
EPO B
- O
induced O
erythroid O
differentiation O
of O
UT O
- O
7 O
/ O
GM O
cells O
, O
even O
in O
the O
presence O
of O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
although O
this O
cytokine O
never O
induced O
erythroid O
differentiation O
of O
the O
parent O
UT O
- O
7 O
/ O
GM O
cells O
with O
or O
without O
EPO B
. O

Taken O
together O
, O
our O
data O
suggest O
that O
Stat1alpha B
and O
Stat3 B
act O
as O
negative O
regulators O
in O
EPO B
- O
induced O
erythroid O
differentiation O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
Stat1alpha B
and O
Stat3 B
act O
as O
negative O
regulators O
in O
EPO B
- O
induced O
erythroid O
differentiation O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
Stat1alpha B
and O
Stat3 B
act O
as O
negative O
regulators O
in O
EPO B
- O
induced O
erythroid O
differentiation O
. O

Data O
obtained O
by O
electrophoretic O
mobility O
shift O
assay O
suggested O
that O
the O
activated B
Stat I
- I
3 I
protein I
associates O
with O
the O
human B
serum I
- I
inducible I
element I
( I
hSIE I
) I
DNA I
- I
probe I
derived O
from O
the O
interferon B
- I
gamma I
activated I
site I
( O
GAS B
) O
in O
the O
c B
- I
fos I
promoter I
, O
a O
common O
DNA O
sequence O
for O
Stat B
protein I
binding O
. O

We O
further O
demonstrate O
that O
0 O
. O
1 O
- O
0 O
. O
5 O
microM O
DMDTC O
inhibits O
intracellular O
IL B
- I
2 I
production O
and O
decreases O
surface O
expression O
of O
CD25 B
( O
the O
alpha B
subunit I
of O
the O
IL B
- I
2 I
receptor I
) O
in O
T O
cells O
stimulated O
with O
phorbol O
ester O
. O

To O
determine O
whether O
the O
acquisition O
of O
antitumor O
function O
during O
ex O
vivo O
activation O
is O
associated O
with O
modifications O
in O
signal O
transduction O
capacity O
, O
the O
protein O
tyrosine B
kinases I
p56lck B
and O
p59fyn B
and O
proteins O
of O
the O
NF B
- I
kappaB I
family I
were O
analyzed O
in O
tumor O
- O
draining O
LN O
T O
cells O
. O

To O
determine O
whether O
the O
acquisition O
of O
antitumor O
function O
during O
ex O
vivo O
activation O
is O
associated O
with O
modifications O
in O
signal O
transduction O
capacity O
, O
the O
protein O
tyrosine B
kinases I
p56lck B
and O
p59fyn B
and O
proteins O
of O
the O
NF B
- I
kappaB I
family I
were O
analyzed O
in O
tumor O
- O
draining O
LN O
T O
cells O
. O

In O
contrast O
, O
the O
cytoplasmic O
levels O
of O
c B
- I
Rel I
and O
Rel B
A I
were O
normal O
in O
freshly O
isolated O
tumor O
- O
draining O
LN O
, O
as O
was O
nuclear O
kappaB B
DNA O
- O
binding O
activity O
induced O
by O
anti B
- I
CD3 I
mAb I
or O
phorbol O
myristate O
acetate O
. O

BACKGROUND O
: O
The O
class B
II I
transactivator I
( O
CIITA B
) O
is O
a O
bi B
- I
or I
multifunctional I
domain I
protein I
that O
acts O
as O
a O
transcriptional B
activator I
and O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

Macrophages O
in O
human O
atheroma O
contain O
PPARgamma B
: O
differentiation B
- I
dependent I
peroxisomal I
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
expression O
and O
reduction O
of O
MMP B
- I
9 I
activity O
through O
PPARgamma B
activation O
in O
mononuclear O
phagocytes O
in O
vitro O
. O

Macrophages O
in O
human O
atheroma O
contain O
PPARgamma B
: O
differentiation B
- I
dependent I
peroxisomal I
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
expression O
and O
reduction O
of O
MMP B
- I
9 I
activity O
through O
PPARgamma B
activation O
in O
mononuclear O
phagocytes O
in O
vitro O
. O

Macrophages O
in O
human O
atheroma O
contain O
PPARgamma B
: O
differentiation B
- I
dependent I
peroxisomal I
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
expression O
and O
reduction O
of O
MMP B
- I
9 I
activity O
through O
PPARgamma B
activation O
in O
mononuclear O
phagocytes O
in O
vitro O
. O

Mononuclear O
phagocytes O
play O
an O
important O
role O
in O
atherosclerosis O
and O
its O
sequela O
plaque O
rupture O
in O
part O
by O
their O
secretion O
of O
matrix B
metalloproteinases I
( O
MMPs B
) O
, O
including O
MMP B
- I
9 I
. O

The O
role O
of O
PPARgamma B
in O
human O
atherosclerosis O
is O
unexplored O
. O

We O
examined O
signaling O
by O
erythropoietin B
in O
highly O
purified O
human O
colony O
forming O
unit O
- O
erythroid O
cells O
, O
generated O
in O
vitro O
from O
CD34 O
( O
+ O
) O
cells O
. O

We O
found O
that O
erythropoietin B
induces O
tyrosine O
phosphorylation O
of O
Jak2 B
, O
STAT5A B
, O
and O
STAT5B B
. O

We O
found O
that O
erythropoietin B
induces O
tyrosine O
phosphorylation O
of O
Jak2 B
, O
STAT5A B
, O
and O
STAT5B B
. O

We O
found O
that O
erythropoietin B
induces O
tyrosine O
phosphorylation O
of O
Jak2 B
, O
STAT5A B
, O
and O
STAT5B B
. O

We O
found O
that O
erythropoietin B
induces O
tyrosine O
phosphorylation O
of O
Jak2 B
, O
STAT5A B
, O
and O
STAT5B B
. O

Tyrosine O
phosphorylation O
of O
Jak2 B
reaches O
a O
peak O
around O
10 O
minutes O
after O
stimulation O
and O
is O
maximum O
at O
5 O
U O
/ O
mL O
of O
erythropoietin B
. O

Tyrosine O
phosphorylation O
of O
Jak2 B
reaches O
a O
peak O
around O
10 O
minutes O
after O
stimulation O
and O
is O
maximum O
at O
5 O
U O
/ O
mL O
of O
erythropoietin B
. O

Eosinophils O
infiltrating O
hamster O
cutaneous O
wounds O
were O
found O
to O
express O
TGFs B
sequentially O
. O

The O
observation O
that O
IL B
- I
4 I
can O
differentially O
regulate O
the O
expression O
of O
TGF B
- I
alpha I
and O
TGF B
- I
beta1 I
suggests O
that O
IL B
- I
4 I
may O
serve O
as O
a O
physiologic O
molecular O
switch O
of O
TGF B
expression O
by O
the O
infiltrating O
eosinophils O
in O
wound O
healing O
and O
carcinogenesis O
. O

A O
recent O
study O
showed O
a O
MLL B
/ I
AF10 I
fusion I
in O
all O
cases O
of O
AML O
with O
t B
( I
10 I
; I
11 I
) I
and O
various O
breakpoints O
on O
chromosome B
11 I
ranging O
from O
q13 B
to O
q23 B
. O

A O
recent O
study O
showed O
a O
MLL B
/ I
AF10 I
fusion I
in O
all O
cases O
of O
AML O
with O
t B
( I
10 I
; I
11 I
) I
and O
various O
breakpoints O
on O
chromosome B
11 I
ranging O
from O
q13 B
to O
q23 B
. O

We O
recently O
cloned O
CALM B
( O
Clathrin B
Assembly I
Lymphoid I
Myeloid I
leukemia I
gene I
) O
, O
the O
fusion O
partner O
of O
AF10 B
at O
11q14 B
in O
the O
monocytic O
cell O
line O
U937 O
. O

We O
recently O
cloned O
CALM B
( O
Clathrin B
Assembly I
Lymphoid I
Myeloid I
leukemia I
gene I
) O
, O
the O
fusion O
partner O
of O
AF10 B
at O
11q14 B
in O
the O
monocytic O
cell O
line O
U937 O
. O

We O
recently O
cloned O
CALM B
( O
Clathrin B
Assembly I
Lymphoid I
Myeloid I
leukemia I
gene I
) O
, O
the O
fusion O
partner O
of O
AF10 B
at O
11q14 B
in O
the O
monocytic O
cell O
line O
U937 O
. O

Dominant B
negative I
mutants I
of O
NIK B
, O
IKKalpha B
, O
or O
IKKbeta B
substantially O
inhibited O
NF B
- I
kappaB I
activation O
by O
LMP1 B
or O
by O
each O
of O
its O
effector B
sites I
. O

Dominant B
negative I
mutants I
of O
NIK B
, O
IKKalpha B
, O
or O
IKKbeta B
substantially O
inhibited O
NF B
- I
kappaB I
activation O
by O
LMP1 B
or O
by O
each O
of O
its O
effector B
sites I
. O

Dominant B
negative I
mutants I
of O
NIK B
, O
IKKalpha B
, O
or O
IKKbeta B
substantially O
inhibited O
NF B
- I
kappaB I
activation O
by O
LMP1 B
or O
by O
each O
of O
its O
effector B
sites I
. O

Dominant B
negative I
mutants I
of O
NIK B
, O
IKKalpha B
, O
or O
IKKbeta B
substantially O
inhibited O
NF B
- I
kappaB I
activation O
by O
LMP1 B
or O
by O
each O
of O
its O
effector B
sites I
. O

MyD88 B
, O
originally O
isolated O
as O
a O
myeloid O
differentiation O
primary B
response I
gene I
, O
is O
shown O
to O
act O
as O
an O
adaptor O
in O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
signaling O
by O
interacting O
with O
both O
the O
IL B
- I
1 I
receptor I
complex I
and O
IL B
- I
1 I
receptor I
- I
associated I
kinase I
( O
IRAK B
) O
. O

MyD88 B
, O
originally O
isolated O
as O
a O
myeloid O
differentiation O
primary B
response I
gene I
, O
is O
shown O
to O
act O
as O
an O
adaptor O
in O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
signaling O
by O
interacting O
with O
both O
the O
IL B
- I
1 I
receptor I
complex I
and O
IL B
- I
1 I
receptor I
- I
associated I
kinase I
( O
IRAK B
) O
. O

Furthermore O
, O
IL B
- I
18 I
- O
induced O
activation O
of O
NF B
- I
kappaB I
and O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
is O
blocked O
in O
MyD88 O
- O
/ O
- O
Th1 O
- O
developing O
cells O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
MyD88 B
is O
a O
critical O
component O
in O
the O
signaling O
cascade O
that O
is O
mediated O
by O
IL B
- I
1 I
receptor I
as O
well O
as O
IL B
- I
18 I
receptor I
. O

In O
addition O
, O
transcriptional O
activity O
of O
IL B
- I
2 I
and O
metallothionein B
enhancer I
and I
promoter I
regions I
and O
transcription B
factors I
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
NF B
- I
AT I
were O
analyzed O
by O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
and O
electrophoretic O
mobility O
shift O
assays O
, O
respectively O
. O

Simple O
activation O
of O
RXRs B
is O
not O
sufficient O
to O
induce O
apoptosis O
of O
the O
cells O
. O

Thrombopoietin B
supports O
in O
vitro O
erythroid O
differentiation O
via O
its O
specific O
receptor O
c B
- I
Mpl I
in O
a O
human O
leukemia O
cell O
line O
. O

More O
than O
50 O
% O
of O
TPO O
- O
treated O
UT O
- O
7 O
/ O
GMT O
cells O
positively O
stained O
for O
Hb B
. O

We O
observed O
that O
Abs O
directed O
against O
unique O
domains O
of O
STAT6 B
have O
differential O
effects O
on O
complexes O
in O
T O
cells O
but O
not O
in O
NK O
cells O
, O
suggesting O
different O
STAT6 B
isoforms I
. O

These O
findings O
show O
that O
IL B
- I
13 I
and O
IL B
- I
4 I
have O
the O
ability O
to O
regulate O
NK O
and O
T O
cell O
activation O
and O
that O
IL B
- I
13 I
is O
a O
potent O
regulator O
of O
STAT6 B
and O
JAK3 B
in O
these O
cell O
types O
. O

These O
findings O
show O
that O
IL B
- I
13 I
and O
IL B
- I
4 I
have O
the O
ability O
to O
regulate O
NK O
and O
T O
cell O
activation O
and O
that O
IL B
- I
13 I
is O
a O
potent O
regulator O
of O
STAT6 B
and O
JAK3 B
in O
these O
cell O
types O
. O

NFkappaB B
activity O
is O
independent O
from O
FADD B
, O
caspases B
, O
and O
apoptosis O
induction O
. O

NFkappaB B
activity O
is O
independent O
from O
FADD B
, O
caspases B
, O
and O
apoptosis O
induction O
. O

NFkappaB B
activity O
is O
independent O
from O
FADD B
, O
caspases B
, O
and O
apoptosis O
induction O
. O

To O
study O
the O
influence O
of O
NFkappaB B
activity O
on O
apoptosis O
mediated O
by O
TRAIL B
, O
CD95 O
, O
TNFalpha B
, O
or O
doxorubicin O
, O
NFkappaB B
activation O
was O
inhibited O
using O
the O
proteasome B
inhibitor O
N O
- O
acetyl O
- O
L O
- O
leucinyl O
- O
L O
- O
leucinyl O
- O
L O
- O
norleucinal O
or O
transient O
overexpression O
of O
mutant B
IkappaBalpha I
. O

To O
study O
the O
influence O
of O
NFkappaB B
activity O
on O
apoptosis O
mediated O
by O
TRAIL B
, O
CD95 O
, O
TNFalpha B
, O
or O
doxorubicin O
, O
NFkappaB B
activation O
was O
inhibited O
using O
the O
proteasome B
inhibitor O
N O
- O
acetyl O
- O
L O
- O
leucinyl O
- O
L O
- O
leucinyl O
- O
L O
- O
norleucinal O
or O
transient O
overexpression O
of O
mutant B
IkappaBalpha I
. O

To O
study O
the O
influence O
of O
NFkappaB B
activity O
on O
apoptosis O
mediated O
by O
TRAIL B
, O
CD95 O
, O
TNFalpha B
, O
or O
doxorubicin O
, O
NFkappaB B
activation O
was O
inhibited O
using O
the O
proteasome B
inhibitor O
N O
- O
acetyl O
- O
L O
- O
leucinyl O
- O
L O
- O
leucinyl O
- O
L O
- O
norleucinal O
or O
transient O
overexpression O
of O
mutant B
IkappaBalpha I
. O

To O
study O
the O
influence O
of O
NFkappaB B
activity O
on O
apoptosis O
mediated O
by O
TRAIL B
, O
CD95 O
, O
TNFalpha B
, O
or O
doxorubicin O
, O
NFkappaB B
activation O
was O
inhibited O
using O
the O
proteasome B
inhibitor O
N O
- O
acetyl O
- O
L O
- O
leucinyl O
- O
L O
- O
leucinyl O
- O
L O
- O
norleucinal O
or O
transient O
overexpression O
of O
mutant B
IkappaBalpha I
. O

To O
study O
the O
influence O
of O
NFkappaB B
activity O
on O
apoptosis O
mediated O
by O
TRAIL B
, O
CD95 O
, O
TNFalpha B
, O
or O
doxorubicin O
, O
NFkappaB B
activation O
was O
inhibited O
using O
the O
proteasome B
inhibitor O
N O
- O
acetyl O
- O
L O
- O
leucinyl O
- O
L O
- O
leucinyl O
- O
L O
- O
norleucinal O
or O
transient O
overexpression O
of O
mutant B
IkappaBalpha I
. O

Loss O
- O
and O
gain O
- O
of O
- O
function O
mutations O
reveal O
an O
important O
role O
of O
BSAP B
( O
Pax B
- I
5 I
) O
at O
the O
start O
and O
end O
of O
B O
cell O
differentiation O
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation B
region I
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation B
region I
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation B
region I
. O

A O
nondegradable O
mutant O
of O
I B
kappa I
B I
blocked O
both O
FasL B
expression O
and O
apoptosis O
induced O
by O
DNA O
damage O
but O
not O
Fas B
ligation O
. O

A O
nondegradable O
mutant O
of O
I B
kappa I
B I
blocked O
both O
FasL B
expression O
and O
apoptosis O
induced O
by O
DNA O
damage O
but O
not O
Fas B
ligation O
. O

These O
stimuli O
also O
induced O
the O
stress O
- O
activated O
kinase O
pathway O
( O
SAPK B
/ B
JNK I
) O
, O
which O
was O
required O
for O
the O
maximal O
induction O
of O
apoptosis O
. O

These O
findings O
suggest O
that O
LTR B
sequence I
changes O
can O
significantly O
affect O
basal O
LTR B
function O
and O
transcription B
factor I
recruitment O
, O
which O
may O
, O
in O
turn O
, O
alter O
the O
course O
of O
viral O
replication O
in O
cells O
of O
CNS O
and O
immune O
system O
origin O
. O

Elf B
- I
1 I
binds O
exclusively O
to O
the O
underphosphorylated O
form O
of O
Rb B
and O
fails O
to O
bind O
to O
Rb B
mutants I
derived O
from O
patients O
with O
retinoblastoma O
. O

Jurkat O
cells O
were O
transfected O
with O
plasmids B
containing O
either O
the O
intact O
IL B
- I
2 I
promoter I
or O
its O
AP B
- I
1 I
, I
NF I
- I
AT I
, I
and I
NF I
- I
kB I
motifs I
. O

Other O
bacterial O
toxins O
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
T B
cell I
mitogens I
, O
UV O
light O
, O
gamma O
rays O
and O
oxidative O
stress O
were O
reported O
to O
induce O
NF B
- I
kappa I
B I
. O

Antisera O
to O
Fos B
inhibits O
NF B
- I
AT I
DNA O
binding O
as O
does O
an O
oligonucleotide O
containing O
a O
binding B
site I
for I
AP1 I
. O

Despite O
a O
wide O
range O
, O
the O
mean O
GR B
count O
and O
affinity O
in O
MNC O
from O
septic O
patients O
did O
not O
differ O
from O
those O
in O
normal O
controls O
, O
suggesting O
that O
glucocorticoids O
could O
still O
be O
effective O
in O
the O
hemodynamic O
compensatory O
phase O
of O
sepsis O
. O

Additionally O
, O
Nef O
expressing O
cells O
were O
transiently O
transfected O
with O
a O
plasmid O
in O
which O
HIV B
- I
1 I
AP I
- I
1 I
DNA I
recognition I
sequences I
were O
cloned O
downstream O
of O
the O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
gene O
. O

The O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
and I
HTLV I
- I
II I
Tax I
proteins I
are O
potent O
transactivators B
of O
viral O
and O
cellular O
gene O
expression O
. O

A O
carboxy B
terminal I
Tax I
deletion I
mutant I
was O
deficient O
in O
transactivation O
of O
both O
the O
PTHrP B
and I
IL2R I
alpha I
promoters I
but O
not O
the O
HTLV B
- I
I I
long I
terminal I
repeat I
( O
LTR B
) O
. O

This O
sequence O
contains O
a O
promoter B
specific O
to O
cells O
of O
hematopoietic O
lineage O
. O

However O
, O
the O
tissue O
specificity O
of O
this O
promoter B
is O
only O
partial O
because O
it O
is O
active O
in O
all O
of O
the O
hematopoietic O
cells O
tested O
here O
, O
regardless O
of O
whether O
they O
constitutively O
express O
Fc O
epsilon O
RI O
- O
gamma B
chain I
transcripts O
. O

ACH O
- O
2 O
can O
be O
converted O
to O
productive O
infection O
by O
stimulation O
of O
the O
cells O
with O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
, O
mitogen O
or O
cytokines B
( O
TNF B
- I
alpha I
) O
, O
or O
infection O
with O
HSV O
. O

Northern O
analysis O
demonstrated O
coordinate O
downregulation O
of O
alpha B
globin I
and O
gamma B
globin I
in O
addition O
to O
the O
two O
lineage O
- O
restricted O
transcription B
factors I
, O
SCL B
and O
GATA B
- I
1 I
. O

Surface O
marker O
analysis O
showed O
that O
HMBA O
- O
induced O
cells O
expressed O
reduced O
levels O
of O
glycophorin B
A I
, O
CD5 B
, O
CD7 B
and O
CD11b B
. O

Surface O
marker O
analysis O
showed O
that O
HMBA O
- O
induced O
cells O
expressed O
reduced O
levels O
of O
glycophorin B
A I
, O
CD5 B
, O
CD7 B
and O
CD11b B
. O

Surface O
marker O
analysis O
showed O
that O
HMBA O
- O
induced O
cells O
expressed O
reduced O
levels O
of O
glycophorin B
A I
, O
CD5 B
, O
CD7 B
and O
CD11b B
. O

In O
addition O
, O
an O
inhibitor O
of O
PKC B
blocked O
both O
activated O
ras B
and O
phorbol O
ester O
stimulation O
, O
suggesting O
a O
role O
for O
ras B
upstream O
of O
PKC B
. O

In O
addition O
, O
an O
inhibitor O
of O
PKC B
blocked O
both O
activated O
ras B
and O
phorbol O
ester O
stimulation O
, O
suggesting O
a O
role O
for O
ras B
upstream O
of O
PKC B
. O

In O
addition O
, O
an O
inhibitor O
of O
PKC B
blocked O
both O
activated O
ras B
and O
phorbol O
ester O
stimulation O
, O
suggesting O
a O
role O
for O
ras B
upstream O
of O
PKC B
. O

In O
addition O
, O
an O
inhibitor O
of O
PKC B
blocked O
both O
activated O
ras B
and O
phorbol O
ester O
stimulation O
, O
suggesting O
a O
role O
for O
ras B
upstream O
of O
PKC B
. O

One O
of O
these O
activities O
was O
found O
to O
be O
a O
novel O
, O
less O
abundant O
, O
Rb O
- O
E2F B
complex O
. O

The O
most O
prominent O
E2F B
activity O
in O
resting O
T O
cells O
( O
termed O
complex O
X O
) O
was O
abundant O
in O
both O
G0 O
and O
G1 O
but O
disappeared O
as O
cells O
entered O
S O
phase O
, O
suggesting O
a O
possible O
role O
in O
negatively O
regulating O
E2F B
function O
. O

The O
most O
prominent O
E2F B
activity O
in O
resting O
T O
cells O
( O
termed O
complex O
X O
) O
was O
abundant O
in O
both O
G0 O
and O
G1 O
but O
disappeared O
as O
cells O
entered O
S O
phase O
, O
suggesting O
a O
possible O
role O
in O
negatively O
regulating O
E2F B
function O
. O

Since O
TPA O
activates O
protein B
kinase I
C I
( O
PKC B
) O
, O
we O
examined O
translocation O
of O
PKC B
from O
the O
cytosol O
to O
the O
membrane O
fraction O
. O

Since O
TPA O
activates O
protein B
kinase I
C I
( O
PKC B
) O
, O
we O
examined O
translocation O
of O
PKC B
from O
the O
cytosol O
to O
the O
membrane O
fraction O
. O

To O
determine O
whether O
the O
defect O
in O
the O
patient O
' O
s O
T O
lymphocytes O
involved O
a O
trans B
- I
acting I
factor I
common O
to O
the O
affected O
lymphokine B
genes I
, O
we O
examined O
the O
ability O
of O
nuclear B
factors I
from O
the O
patient O
' O
s O
T O
lymphocytes O
to O
bind O
response O
elements O
present O
in O
the O
regulatory B
region I
of O
IL2 B
. O

Instead O
, O
they O
form O
tight O
complexes O
with O
two O
different O
classes O
of O
abundant O
cytosolic B
receptors I
called O
immunophilins B
upon O
entering O
the O
cell O
, O
and O
consequently O
inhibit O
their O
peptidyl B
prolyl I
cis I
- I
trans I
isomerase I
activities O
. O

p105 B
and O
p98 B
precursor B
proteins I
play O
an O
active O
role O
in O
NF B
- I
kappa I
B I
- O
mediated O
signal O
transduction O
. O

p105 B
and O
p98 B
precursor B
proteins I
play O
an O
active O
role O
in O
NF B
- I
kappa I
B I
- O
mediated O
signal O
transduction O
. O

Association O
with O
the O
precursors O
is O
sufficient O
for O
cytoplasmic O
retention O
of O
either O
p65 B
or O
c B
- I
Rel I
, O
both O
of O
which O
are O
otherwise O
nuclear O
. O

Expression O
of O
PILOT B
, O
a O
putative O
transcription B
factor I
, O
requires O
two O
signals O
and O
is O
cyclosporin O
A O
sensitive O
in O
T O
cells O
. O

Few O
known O
genes B
( O
IL B
- I
2 I
, O
members O
of O
the O
IL B
- I
8 I
family I
, O
interferon B
- I
gamma I
) O
are O
induced O
in O
T O
cells O
only O
through O
the O
combined O
effect O
of O
phorbol O
myristic O
acetate O
( O
PMA O
) O
and O
a O
Ca O
( O
2 O
+ O
) O
- O
ionophore O
, O
and O
expression O
of O
only O
these O
genes B
can O
be O
fully O
suppressed O
by O
Cyclosporin O
A O
( O
CyA O
) O
. O

Few O
known O
genes B
( O
IL B
- I
2 I
, O
members O
of O
the O
IL B
- I
8 I
family I
, O
interferon B
- I
gamma I
) O
are O
induced O
in O
T O
cells O
only O
through O
the O
combined O
effect O
of O
phorbol O
myristic O
acetate O
( O
PMA O
) O
and O
a O
Ca O
( O
2 O
+ O
) O
- O
ionophore O
, O
and O
expression O
of O
only O
these O
genes B
can O
be O
fully O
suppressed O
by O
Cyclosporin O
A O
( O
CyA O
) O
. O

The O
PILOT B
protein O
has O
a O
calculated O
M O
( O
r O
) O
of O
42 O
. O
6 O
kDa O
and O
contains O
three O
zinc B
fingers I
of O
the O
C2H2 B
- I
type I
at O
the O
carboxyl B
- I
terminus I
which O
are O
highly O
homologous O
to O
the O
zinc B
finger I
regions I
of O
the O
transcription B
factors I
EGR1 B
, O
EGR2 B
, O
and O
pAT B
133 I
. O

The O
PILOT B
protein O
has O
a O
calculated O
M O
( O
r O
) O
of O
42 O
. O
6 O
kDa O
and O
contains O
three O
zinc B
fingers I
of O
the O
C2H2 B
- I
type I
at O
the O
carboxyl B
- I
terminus I
which O
are O
highly O
homologous O
to O
the O
zinc B
finger I
regions I
of O
the O
transcription B
factors I
EGR1 B
, O
EGR2 B
, O
and O
pAT B
133 I
. O

The O
PILOT B
protein O
has O
a O
calculated O
M O
( O
r O
) O
of O
42 O
. O
6 O
kDa O
and O
contains O
three O
zinc B
fingers I
of O
the O
C2H2 B
- I
type I
at O
the O
carboxyl B
- I
terminus I
which O
are O
highly O
homologous O
to O
the O
zinc B
finger I
regions I
of O
the O
transcription B
factors I
EGR1 B
, O
EGR2 B
, O
and O
pAT B
133 I
. O

In O
contrast O
to O
T O
cells O
, O
in O
fibroblasts O
PILOT B
gene O
expression O
requires O
only O
one O
signal O
( O
PMA O
) O
and O
is O
not O
affected O
by O
CyA O
. O

However O
, O
the O
p65 B
antisense O
phosphorothioate O
oligodeoxynucleotide O
had O
no O
significant O
effect O
on O
the O
production O
of O
reactive O
oxygen O
intermediates O
or O
on O
phagocytosis O
by O
these O
cells O
. O

These O
findings O
indicate O
that O
antisense O
oligomers O
to O
p65 B
can O
be O
used O
to O
define O
the O
role O
of O
NF B
- I
kappa I
B I
in O
the O
activation O
pathways O
of O
neutrophils O
. O

Overexpression O
of O
p65 B
increases O
endogenous O
I B
kappa I
B I
protein O
in O
both O
carcinoma O
and O
lymphoid O
cells O
by O
two O
mechanisms O
: O
protein O
stabilization O
and O
increased O
transcription O
of O
I B
kappa I
B I
mRNA I
. O

Transcriptional O
regulation O
of O
interleukin B
3 I
( O
IL3 B
) O
in O
primary O
human O
T O
lymphocytes O
. O

The O
c B
- I
rel I
protooncogene I
product I
represses O
NF B
- I
kappa I
B I
p65 B
- O
mediated O
transcriptional O
activation O
of O
the O
long O
terminal O
repeat O
of O
type O
1 O
human O
immunodeficiency O
virus O
. O

This O
intracellular O
signaling O
complex O
potently O
stimulates O
kappa O
B O
- O
directed O
transcription O
from O
either O
the O
HIV B
- I
1 I
LTR I
or O
the O
IL B
- I
2R I
alpha I
promoter I
via O
the O
strong O
transactivation O
domain O
present O
in O
p65 B
. O

We O
now O
demonstrate O
that O
nuclear O
expression O
of O
human O
c B
- I
Rel I
, O
which O
is O
induced O
by O
either O
phorbol O
ester O
or O
tumor B
necrosis I
factor I
alpha I
with O
delayed O
kinetics O
relative O
to O
p65 B
, O
markedly O
represses O
p65 B
- O
mediated O
activation O
of O
these O
transcription O
units O
. O

We O
now O
demonstrate O
that O
nuclear O
expression O
of O
human O
c B
- I
Rel I
, O
which O
is O
induced O
by O
either O
phorbol O
ester O
or O
tumor B
necrosis I
factor I
alpha I
with O
delayed O
kinetics O
relative O
to O
p65 B
, O
markedly O
represses O
p65 B
- O
mediated O
activation O
of O
these O
transcription O
units O
. O

The O
ras O
- O
transformed O
lymphocytes O
displayed O
a O
fully O
functional O
IL B
- I
2r I
, O
as O
assessed O
by O
c B
- I
fos I
induction O
following O
treatment O
with O
IL B
- I
2 I
; O
nevertheless O
, O
they O
were O
not O
growth O
stimulated O
by O
this O
lymphokine B
. O

Somewhat O
unexpectedly O
, O
the O
constitutive O
p21ras B
activity O
did O
not O
cause O
an O
increased O
DNA O
binding O
of O
transcription B
factors I
PEA1 B
( O
AP1 B
) O
, O
PEA3 B
, O
Oct B
- I
2 I
or O
NF B
- I
kB I

Somewhat O
unexpectedly O
, O
the O
constitutive O
p21ras B
activity O
did O
not O
cause O
an O
increased O
DNA O
binding O
of O
transcription B
factors I
PEA1 B
( O
AP1 B
) O
, O
PEA3 B
, O
Oct B
- I
2 I
or O
NF B
- I
kB I

Somewhat O
unexpectedly O
, O
the O
constitutive O
p21ras B
activity O
did O
not O
cause O
an O
increased O
DNA O
binding O
of O
transcription B
factors I
PEA1 B
( O
AP1 B
) O
, O
PEA3 B
, O
Oct B
- I
2 I
or O
NF B
- I
kB I

Somewhat O
unexpectedly O
, O
the O
constitutive O
p21ras B
activity O
did O
not O
cause O
an O
increased O
DNA O
binding O
of O
transcription B
factors I
PEA1 B
( O
AP1 B
) O
, O
PEA3 B
, O
Oct B
- I
2 I
or O
NF B
- I
kB I

In O
contrast O
to O
the O
decrease O
in O
GR B
mRNA I
seen O
in O
IM O
- O
9 O
cells O
after O
treatment O
with O
1 O
microM O
dexamethasone O
for O
16 O
- O
18 O
h O
, O
treatment O
of O
6TG1 O
. O
1 O
cells O
resulted O
in O
an O
8 O
- O
fold O
increase O
in O
GR B
mRNA I
, O
as O
determined O
by O
Northern O
blot O
and O
RNase B
protection O
analysis O
, O
with O
a O
corresponding O
3 O
- O
to O
4 O
- O
fold O
increase O
in O
GR B
protein I
. O

It O
has O
been O
thought O
that O
the O
virally O
induced O
inhibition O
of O
IFN B
- O
MCP O
is O
secondary O
to O
the O
shutdown O
of O
cellular O
macromolecular O
synthesis O
that O
accompanies O
cytopathic O
virus O
infections O
. O

IFN B
- O
MCP O
was O
not O
inhibited O
by O
infection O
with O
dl343 O
, O
despite O
the O
production O
of O
large O
amounts O
of O
both O
early O
( O
E1B B
, O
p55 B
) O
and O
late O
( O
hexon B
) O
Ad B
proteins I
. O

IFN B
- O
MCP O
was O
not O
inhibited O
by O
infection O
with O
dl343 O
, O
despite O
the O
production O
of O
large O
amounts O
of O
both O
early O
( O
E1B B
, O
p55 B
) O
and O
late O
( O
hexon B
) O
Ad B
proteins I
. O

IFN B
- O
MCP O
was O
not O
inhibited O
by O
infection O
with O
dl343 O
, O
despite O
the O
production O
of O
large O
amounts O
of O
both O
early O
( O
E1B B
, O
p55 B
) O
and O
late O
( O
hexon B
) O
Ad B
proteins I
. O

IFN B
- O
MCP O
was O
not O
inhibited O
by O
infection O
with O
dl343 O
, O
despite O
the O
production O
of O
large O
amounts O
of O
both O
early O
( O
E1B B
, O
p55 B
) O
and O
late O
( O
hexon B
) O
Ad B
proteins I
. O

E1A B
' O
s O
inhibition O
of O
IFN B
- O
MCP O
has O
the O
net O
effect O
of O
promoting O
the O
selective O
NK O
cell O
- O
mediated O
clearance O
of O
Ad O
- O
infected O
or O
Ad O
- O
transformed O
human O
cells O
. O

E1A B
' O
s O
inhibition O
of O
IFN B
- O
MCP O
has O
the O
net O
effect O
of O
promoting O
the O
selective O
NK O
cell O
- O
mediated O
clearance O
of O
Ad O
- O
infected O
or O
Ad O
- O
transformed O
human O
cells O
. O

Serum B
response I
factor I
( O
SRF B
) O
binds O
to O
a O
site O
adjacent O
to O
the O
NF B
- I
kappa I
B I
site I
in O
the O
IL B
- I
2R I
enhancer I
, O
and O
both O
sites O
together O
have O
strong O
transcriptional O
activity O
specifically O
in O
T O
cells O
. O

In O
previous O
transfection O
analyses O
using O
the O
chloramphenicol B
acetyltransferase I
reporter B
gene I
system O
, O
we O
determined O
that O
linker O
substitution O
( O
LS O
) O
mutations O
between O
- B
201 I
and I
- I
130 I
( O
relative O
to O
the O
transcription O
start O
site O
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
caused O
moderate O
decreases O
in O
LTR B
transcriptional O
activity O
in O
a O
T O
- O
cell O
line O
( O
S O
. O
L O
. O
Zeichner O
, O
J O
. O
Y O
. O
H O
. O
Kim O
, O
and O
J O
. O
C O
. O
Alwine O
, O
J O
. O
Virol O
. O
65 O
: O
2436 O
- O
2444 O
, O
1991 O
) O
. O

In O
previous O
transfection O
analyses O
using O
the O
chloramphenicol B
acetyltransferase I
reporter B
gene I
system O
, O
we O
determined O
that O
linker O
substitution O
( O
LS O
) O
mutations O
between O
- B
201 I
and I
- I
130 I
( O
relative O
to O
the O
transcription O
start O
site O
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
caused O
moderate O
decreases O
in O
LTR B
transcriptional O
activity O
in O
a O
T O
- O
cell O
line O
( O
S O
. O
L O
. O
Zeichner O
, O
J O
. O
Y O
. O
H O
. O
Kim O
, O
and O
J O
. O
C O
. O
Alwine O
, O
J O
. O
Virol O
. O
65 O
: O
2436 O
- O
2444 O
, O
1991 O
) O
. O

G0S24 B
is O
a O
member O
of O
a O
set O
of O
genes O
( O
putative B
G0 I
/ I
G1 I
switch I
regulatory I
genes I
) O
that O
are O
expressed O
transiently O
within O
1 O
- O
2 O
hr O
of O
the O
addition O
of O
lectin B
or O
cycloheximide O
to O
human O
blood O
mononuclear O
cells O
. O

G0S24 B
is O
a O
member O
of O
a O
set O
of O
genes O
( O
putative B
G0 I
/ I
G1 I
switch I
regulatory I
genes I
) O
that O
are O
expressed O
transiently O
within O
1 O
- O
2 O
hr O
of O
the O
addition O
of O
lectin B
or O
cycloheximide O
to O
human O
blood O
mononuclear O
cells O
. O

Groups O
1 O
and O
2 O
have O
a O
serine B
- I
rich I
region I
and O
an O
` O
` O
arginine B
element I
` O
` O
( O
RRLPIF B
) O
at O
the O
carboxyl B
terminus I
. O

Comparison O
of O
group O
1 O
human B
and I
mouse I
genomic I
sequences I
shows O
high O
conservation O
in O
the O
5 B
' I
flank I
and O
exons B
. O

PBL O
constitutively O
express O
c B
- I
jun I
transcripts I
, O
and O
the O
level O
of O
c B
- I
jun I
mRNA I
is O
not O
altered O
by O
PHA B
activation O
in O
the O
absence O
or O
presence O
of O
EC O
. O

In O
contrast O
, O
c B
- I
fos I
mRNA I
is O
absent O
from O
resting O
T O
cells O
and O
is O
induced O
on O
PHA B
activation O
. O

Site O
- O
directed O
mutagenesis O
further O
demonstrated O
that O
the O
enhancer B
function O
of O
one O
of O
the O
two O
NF O
- O
E2 O
/ O
AP1 O
motifs O
of O
HS B
- I
40 I
is O
mediated O
through O
its O
binding O
to O
NF B
- I
E2 I
but O
not O
AP1 B
transcription I
factor I
. O

To O
determine O
whether O
these O
different O
X1 O
box O
activities O
represented O
distinct O
DNA B
binding I
proteins I
or O
multimeric O
forms O
of O
the O
same O
factor O
( O
s O
) O
, O
protease B
treatment O
of O
the O
crude O
nuclear O
extracts O
followed O
by O
DNA O
- O
binding O
assays O
were O
carried O
out O
and O
demonstrated O
that O
B O
cell O
extracts O
contain O
at O
least O
two O
X1 B
- I
specific I
factors I
. O

A O
similar O
comparison O
with O
protease O
- O
treated O
extracts O
prepared O
from O
Jurkat O
cells O
demonstrated O
the O
presence O
of O
the O
band O
1pk O
activity O
despite O
an O
absence O
of O
the O
native O
RFX B
activity O
. O

RESULTS O
: O
In O
the O
OM O
- O
10 O
. O
1 O
promyelocytic O
model O
of O
chronic O
infection O
, O
TNF O
- O
alpha O
- O
induced O
HIV O
- O
1 O
expression O
also O
resulted O
in O
a O
substantial O
increase O
in O
75 B
kd I
TNF I
receptor I
( O
TR75 B
) O
expression O
although O
55 B
kD I
TNF I
receptor I
( O
TR55 B
) O
levels O
were O
not O
dramatically O
altered O
. O

RESULTS O
: O
In O
the O
OM O
- O
10 O
. O
1 O
promyelocytic O
model O
of O
chronic O
infection O
, O
TNF O
- O
alpha O
- O
induced O
HIV O
- O
1 O
expression O
also O
resulted O
in O
a O
substantial O
increase O
in O
75 B
kd I
TNF I
receptor I
( O
TR75 B
) O
expression O
although O
55 B
kD I
TNF I
receptor I
( O
TR55 B
) O
levels O
were O
not O
dramatically O
altered O
. O

Enhanced O
TR75 B
expression O
on O
OM O
- O
10 O
. O
1 O
cells O
followed O
the O
same O
TNF B
- I
alpha I
- O
dose O
dependency O
as O
that O
observed O
for O
HIV O
- O
1 O
production O
. O

Although O
TR55 B
expression O
was O
unaltered O
during O
TNF B
- I
alpha I
- O
induced O
HIV O
activation O
, O
this O
receptor O
was O
still O
involved O
in O
the O
viral O
activation O
process O
. O

When O
co O
- O
transfected O
with O
a O
construct O
capable O
of O
overexpressing O
the O
tyrosine B
kinase I
p59fyn B
, O
the O
reporter B
gene I
was O
activated O
by O
PMA B
alone O
. O

When O
co O
- O
transfected O
with O
a O
construct O
capable O
of O
overexpressing O
the O
tyrosine B
kinase I
p59fyn B
, O
the O
reporter B
gene I
was O
activated O
by O
PMA B
alone O
. O

Dependence O
for O
the O
proliferative O
response O
to O
erythropoietin B
on O
an O
established O
erythroid O
differentiation O
program O
in O
a O
human O
hematopoietic O
cell O
line O
, O
UT O
- O
7 O
. O

Globin B
chains I
( O
alpha B
, O
beta B
and O
gamma B
) O
were O
clearly O
detectable O
by O
affinity O
chromatography O
in O
UT B
- I
7 I
Epo I
but O
not O
in O
UT O
- O
7 O
cells O
. O

Globin B
chains I
( O
alpha B
, O
beta B
and O
gamma B
) O
were O
clearly O
detectable O
by O
affinity O
chromatography O
in O
UT B
- I
7 I
Epo I
but O
not O
in O
UT O
- O
7 O
cells O
. O

Globin B
chains I
( O
alpha B
, O
beta B
and O
gamma B
) O
were O
clearly O
detectable O
by O
affinity O
chromatography O
in O
UT B
- I
7 I
Epo I
but O
not O
in O
UT O
- O
7 O
cells O
. O

Target O
antigens O
defined O
by O
autoantibodies B
in O
IDDM O
include O
insulin O
, O
a O
putative O
glycolipid O
that O
reacts O
with O
islet B
cell I
antibodies I
, O
and O
a O
64 B
, I
000 I
- I
M I
( I
r I
) I
protein I
recently O
identified O
as O
glutamic B
acid I
decarboxylase I
. O

Costimulation O
of O
cAMP O
and O
protein B
kinase I
C I
pathways O
inhibits O
the O
CD3 B
- O
dependent O
T O
cell O
activation O
and O
leads O
to O
a O
persistent O
expression O
of O
the O
AP B
- I
1 I
transcription I
factor I
. O

Analysis O
of O
intracellular O
Ca2 O
+ O
mobilization O
suggested O
that O
the O
CD3 B
/ O
TcR B
- O
dependent O
signal O
transduction O
was O
impaired O
in O
PMA O
/ O
Bt2cAMP O
- O
treated O
cells O
. O

Analysis O
of O
intracellular O
Ca2 O
+ O
mobilization O
suggested O
that O
the O
CD3 B
/ O
TcR B
- O
dependent O
signal O
transduction O
was O
impaired O
in O
PMA O
/ O
Bt2cAMP O
- O
treated O
cells O
. O

The O
observation O
that O
a O
mutated B
LT I
- I
kappa I
B I
construct I
( O
M1 B
- I
CAT I
) O
was O
inactive O
in O
C81 O
- O
66 O
- O
45 O
, O
confirmed O
the O
importance O
of O
NF B
- I
kappa I
B I
in O
LT B
gene O
expression O
. O

In O
JM O
T O
cells O
, O
tax B
induced O
LT B
- I
293 I
activity O
by O
two O
- O
to O
four O
- O
fold O
, O
though O
there O
was O
no O
induction O
of O
M1 B
- I
CAT I
. O

This O
paper O
describes O
how O
the O
expression O
of O
the O
monocyte B
- I
macrophage I
Ag I
, O
CD14 B
, O
and O
the O
low O
affinity B
Fc I
receptor I
for O
IgE B
, O
CD23 B
, O
were O
inversely O
regulated O
during O
VitD3 O
- O
and O
RA O
- O
induced O
monocytic O
differentiation O
of O
human O
U O
- O
937 O
monoblasts O
. O

This O
paper O
describes O
how O
the O
expression O
of O
the O
monocyte B
- I
macrophage I
Ag I
, O
CD14 B
, O
and O
the O
low O
affinity B
Fc I
receptor I
for O
IgE B
, O
CD23 B
, O
were O
inversely O
regulated O
during O
VitD3 O
- O
and O
RA O
- O
induced O
monocytic O
differentiation O
of O
human O
U O
- O
937 O
monoblasts O
. O

This O
paper O
describes O
how O
the O
expression O
of O
the O
monocyte B
- I
macrophage I
Ag I
, O
CD14 B
, O
and O
the O
low O
affinity B
Fc I
receptor I
for O
IgE B
, O
CD23 B
, O
were O
inversely O
regulated O
during O
VitD3 O
- O
and O
RA O
- O
induced O
monocytic O
differentiation O
of O
human O
U O
- O
937 O
monoblasts O
. O

Studies O
with O
5 B
' I
deletion I
CD20 I
promoter I
- I
CAT I
constructs I
have O
previously O
revealed O
two O
regions O
of O
the O
promoter B
between O
bases O
- O
186 O
and O
- O
280 O
and O
between O
bases O
- O
280 O
and O
- O
454 O
which O
contained O
positive B
regulatory I
elements I
. O

Control O
peptides O
corresponding O
to O
the O
normal O
pml B
and O
RAR B
alpha I
proteins I
were O
not O
recognized O
. O

Thus O
, O
these O
experiments O
demonstrate O
that O
EBNA2 B
interacts O
with O
an O
EBNA2 B
responsive I
cis I
- I
element I
of O
the O
TP1 B
promoter I

Cotransfection O
of O
an O
hGATA B
- I
3 I
expression I
plasmid I
with O
a O
reporter B
plasmid I
whose O
transcription O
is O
directed O
by O
the O
HIV B
- I
1 I
LTR I
resulted O
in O
6 O
- O
to O
10 O
- O
fold O
stimulation O
of O
LTR B
- O
mediated O
transcription O
, O
whereas O
site O
specific O
mutation O
of O
these O
GATA B
sites I
resulted O
in O
virtual O
abrogation O
of O
the O
activation O
by O
hGATA B
- I
3 I
. O

Conversely O
, O
several O
cytokines B
modulate O
the O
levels O
of O
HIV O
expression O
in O
infected O
cells O
of O
both O
T O
lymphocytic O
and O
mononuclear O
phagocytic O
lineage O
. O

Early B
B I
- I
cell I
factor I
( O
EBF B
) O
was O
identified O
previously O
as O
a O
tissue O
- O
specific O
and O
differentiation O
stage O
- O
specific O
DNA B
- I
binding I
protein I
that O
participates O
in O
the O
regulation O
of O
the O
pre B
- I
B I
and I
B I
lymphocyte I
- I
specific I
mb I
- I
1 I
gene I
. O

Partial O
amino O
acid O
sequences O
obtained O
from O
purified O
EBF B
were O
used O
to O
isolate O
cDNA B
clones I
, O
which O
by O
multiple O
criteria O
encode O
EBF B
. O

Partial O
amino O
acid O
sequences O
obtained O
from O
purified O
EBF B
were O
used O
to O
isolate O
cDNA B
clones I
, O
which O
by O
multiple O
criteria O
encode O
EBF B
. O

DNA O
- O
binding O
assays O
with O
cotranslated O
wild O
- O
type O
and O
truncated O
forms O
of O
EBF B
indicated O
that O
the O
protein O
interacts O
with O
its O
site O
as O
a O
homodimer B
. O

DNA O
- O
binding O
assays O
with O
cotranslated O
wild O
- O
type O
and O
truncated O
forms O
of O
EBF B
indicated O
that O
the O
protein O
interacts O
with O
its O
site O
as O
a O
homodimer B
. O

Furthermore O
, O
we O
evaluated O
the O
mineralocorticoid B
receptor I
( O
MR B
) O
count O
in O
mononuclear O
leukocytes O
in O
the O
2 O
groups O
. O

These O
results O
indicate O
that O
defective O
recruitment O
of O
NF B
- I
kappa I
B I
may O
underlie O
Nef B
' O
s O
negative O
transcriptional O
effects O
on O
the O
HIV B
- I
1 I
and I
interleukin I
2 I
promoters I
. O

This O
high B
- I
affinity I
site I
has O
been O
conserved O
in O
the O
promoters B
of O
both O
human B
and I
mouse I
CD19 I
genes I
and O
was O
furthermore O
shown O
to O
confer O
B O
- O
cell O
specificity O
to O
a O
beta O
- O
globin O
reporter O
gene O
in O
transient O
transfection O
experiments O
. O

In O
addition O
, O
BSAP B
was O
found O
to O
be O
the O
only O
abundant O
DNA O
- O
binding O
activity O
of O
B O
- O
cell O
nuclear O
extracts O
that O
interacts O
with O
the O
CD19 B
promoter I
. O

Possible O
relationship O
between O
the O
changes O
in O
IL B
- I
1 I
and O
GR B
in O
aged O
long O
- O
distance O
runner O
and O
its O
physiological O
significance O
are O
discussed O
. O

MR B
were O
reduced O
before O
delivery O
( O
96 O
+ O
/ O
- O
27 O
receptors O
/ O
cell O
) O
, O
and O
SPD O
increased O
( O
64 O
+ O
/ O
- O
8 O
mV O
) O
, O
with O
both O
parameters O
normalizing O
after O
delivery O
( O
MR B
, O
242 O
+ O
/ O
- O
79 O
; O
SPD O
, O
14 O
. O
0 O
+ O
/ O
- O
4 O
mV O
) O
. O

MR B
were O
reduced O
before O
delivery O
( O
96 O
+ O
/ O
- O
27 O
receptors O
/ O
cell O
) O
, O
and O
SPD O
increased O
( O
64 O
+ O
/ O
- O
8 O
mV O
) O
, O
with O
both O
parameters O
normalizing O
after O
delivery O
( O
MR B
, O
242 O
+ O
/ O
- O
79 O
; O
SPD O
, O
14 O
. O
0 O
+ O
/ O
- O
4 O
mV O
) O
. O

Pulse O
exposure O
of O
HL60 O
to O
radiolabeled O
hormone O
for O
3 O
h O
followed O
by O
culture O
in O
medium O
without O
serum O
and O
calcitriol O
lead O
to O
nuclear O
retention O
of O
approximately O
1600 B
radiolabeled I
VDR I
by O
8 O
h O
and O
approximately O
1000 O
VDR B
by O
24 O
h O
. O

Enhanced O
activity O
of O
topoisomerases B
in O
nuclear O
extracts O
upon O
translocation O
of O
VDR B
might O
reflect O
interaction O
of O
both O
within O
the O
nuclear O
compartment O
, O
thus O
initiating O
DNA O
- O
unwinding O
, O
a O
prerequisite O
of O
transcription O
initiation O
. O

Enhanced O
activity O
of O
topoisomerases B
in O
nuclear O
extracts O
upon O
translocation O
of O
VDR B
might O
reflect O
interaction O
of O
both O
within O
the O
nuclear O
compartment O
, O
thus O
initiating O
DNA O
- O
unwinding O
, O
a O
prerequisite O
of O
transcription O
initiation O
. O

Regulation O
of O
replicative O
functions O
in O
the O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
genome I
is O
mediated O
through O
activation O
of O
a O
virally B
encoded I
transcription I
factor I
, O
Z B
( O
BZLF1 B
) O
. O

Regulation O
of O
replicative O
functions O
in O
the O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
genome I
is O
mediated O
through O
activation O
of O
a O
virally B
encoded I
transcription I
factor I
, O
Z B
( O
BZLF1 B
) O
. O

REV B
LTRs I
work O
efficiently O
in O
human O
lymphoid O
cells O
, O
and O
are O
viable O
alternatives O
to O
promoters B
commonly O
used O
for O
expression O
of O
cloned B
genes I
. O

Although O
okadaic O
acid O
provides O
a O
potent O
inductive O
signal O
for O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
it O
did O
not O
induce O
either O
B O
cell O
proliferation O
or O
immunoglobulin B
secretion O
. O

A O
novel B
T I
cell I
- I
specific I
negative I
regulatory I
element I
( O
NRE B
) O
composed O
of O
two O
protein O
- O
binding O
sites O
were O
mapped O
in O
the O
5 O
' O
flanking O
region O
of O
the O
IL B
- I
4 I
gene I
: O
- O
311CTCCCTTCT O
- O
303 O
( O
NRE B
- I
I I
) O
and O
- O
288CTTTTTGCTT O
- O
TGC O
- O
300 O
( O
NRE B
- I
II I
) O
. O

The O
addition O
of O
antisense O
oligonucleotides O
to O
c B
- I
fos I
significantly O
inhibited O
IL B
6 I
- O
induced O
IgM B
production O
by O
SKW O
6 O
. O
4 O
cells O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
whereas O
control O
oligonucleotides O
had O
no O
inhibitory O
effect O
. O

Rather O
, O
TNF B
and O
PMA B
can O
exert O
their O
effect O
only O
if O
cells O
are O
in O
an O
appropriate O
redox O
status O
, O
because O
prior O
modification O
toward O
reduction O
with O
BHA O
treatment O
prevents O
this O
activation O
. O

Rather O
, O
TNF B
and O
PMA B
can O
exert O
their O
effect O
only O
if O
cells O
are O
in O
an O
appropriate O
redox O
status O
, O
because O
prior O
modification O
toward O
reduction O
with O
BHA O
treatment O
prevents O
this O
activation O
. O

Analysis O
of O
the O
p50 B
and O
p65 B
subunits I
of O
the O
NF B
- I
kappa I
B I
transcription I
factor I
complex I
has O
revealed O
that O
both O
proteins O
can O
interact O
with O
related O
DNA O
sequences O
through O
either O
homo O
- O
or O
heterodimer O
formation O
. O

Using O
purified O
recombinant O
p50 B
, O
p65 B
, O
and O
c B
- I
Rel I
proteins I
, O
optimal O
DNA O
- O
binding O
motifs O
were O
selected O
from O
a O
pool O
of O
random O
oligonucleotides O
. O

Using O
purified O
recombinant O
p50 B
, O
p65 B
, O
and O
c B
- I
Rel I
proteins I
, O
optimal O
DNA O
- O
binding O
motifs O
were O
selected O
from O
a O
pool O
of O
random O
oligonucleotides O
. O

Although O
under O
standard O
culture O
conditions O
, O
bovine O
brain O
gangliosides O
( O
100 O
micrograms O
/ O
ml O
) O
suppressed O
LPS O
- O
stimulated O
TNF B
production O
5 O
- O
fold O
in O
PBMC O
and O
10 O
- O
fold O
in O
Mono O
Mac O
6 O
cells O
, O
suppression O
was O
more O
efficient O
under O
serum O
- O
free O
conditions O
. O

Taken O
together O
, O
our O
data O
demonstrate O
that O
TNF B
gene O
expression O
in O
monocytes O
induced O
by O
different O
types O
of O
stimuli O
can O
be O
blocked O
by O
gangliosides O
at O
an O
early O
step O
of O
signal O
transduction O
. O

Because O
of O
the O
efficient O
binding O
of O
TG B
by O
surrogate B
receptors I
on O
non O
- O
T O
cells O
, O
we O
assessed O
the O
ability O
of O
such O
cells O
to O
present O
TG B
to O
T O
cells O
. O

Because O
of O
the O
efficient O
binding O
of O
TG B
by O
surrogate B
receptors I
on O
non O
- O
T O
cells O
, O
we O
assessed O
the O
ability O
of O
such O
cells O
to O
present O
TG B
to O
T O
cells O
. O

Proliferation O
in O
response O
to O
TG B
was O
observed O
in O
T O
cells O
from O
only O
1 O
of O
5 O
Hashimoto O
patients O
. O

Expression O
of O
M10 B
did O
not O
affect O
induction O
of O
HIV O
transcription O
mediated O
by O
the O
kappa B
B I
regulatory I
element I
or O
Tat B
. O

Expression O
of O
M10 B
did O
not O
affect O
induction O
of O
HIV O
transcription O
mediated O
by O
the O
kappa B
B I
regulatory I
element I
or O
Tat B
. O

Two O
types O
of O
helper O
T O
cell O
( O
Th O
) O
clones O
( O
Th1 O
and O
Th2 O
) O
are O
defined O
on O
the O
basis O
of O
different O
patterns O
of O
cytokine B
( O
lymphokine B
) O
secretion O
. O

Two O
types O
of O
helper O
T O
cell O
( O
Th O
) O
clones O
( O
Th1 O
and O
Th2 O
) O
are O
defined O
on O
the O
basis O
of O
different O
patterns O
of O
cytokine B
( O
lymphokine B
) O
secretion O
. O

Yet O
phorbol O
ester O
alone O
or O
calcium O
ionophore O
alone O
produce O
several O
lymphokines B
. O

GM2 B
defines O
a O
binding B
site I
for O
protein O
( O
s O
) O
whose O
binding O
is O
inducible O
by O
PMA O
. O

Pit B
- I
1 I
is O
a O
pituitary B
- I
specific I
transcription I
factor I
that O
binds O
to O
and O
transactivates O
promoters B
of O
growth B
hormone I
and I
prolactin I
genes I
. O

We O
have O
earlier O
found O
that O
in O
Jurkat O
cells O
activation O
of O
protein B
kinase I
C I
( O
PKC B
) O
enhances O
the O
cyclic O
adenosine O
monophosphate O
( O
cAMP O
) O
accumulation O
induced O
by O
adenosine O
receptor O
stimulation O
or O
activation O
of O
Gs B
. O

We O
have O
earlier O
found O
that O
in O
Jurkat O
cells O
activation O
of O
protein B
kinase I
C I
( O
PKC B
) O
enhances O
the O
cyclic O
adenosine O
monophosphate O
( O
cAMP O
) O
accumulation O
induced O
by O
adenosine O
receptor O
stimulation O
or O
activation O
of O
Gs B
. O

CsA O
was O
found O
not O
to O
inhibit O
lck B
gene O
expression O
, O
nor O
the O
activity O
of O
the O
lck B
gene I
product O
. O

The O
IL B
- I
2 I
promoter I
contains O
binding B
sites I
for O
nuclear B
factors I
including O
NFAT B
- I
1 I
, O
Oct B
, O
NF B
- I
kappa I
B I
, O
and O
AP B
- I
1 I
, O
which O
are O
all O
potentially O
sensitive O
to O
activation O
of O
PKC B
. O

The O
IL B
- I
2 I
promoter I
contains O
binding B
sites I
for O
nuclear B
factors I
including O
NFAT B
- I
1 I
, O
Oct B
, O
NF B
- I
kappa I
B I
, O
and O
AP B
- I
1 I
, O
which O
are O
all O
potentially O
sensitive O
to O
activation O
of O
PKC B
. O

Our O
results O
indicate O
that O
the O
AP B
- I
1 I
site I
at O
- B
150 I
bp I
represents O
a O
major O
, O
if O
not O
the O
only O
, O
site O
of O
PKC B
responsiveness O
in O
the O
IL B
- I
2 I
promoter I
. O

Here O
, O
Stuart O
Schreiber O
and O
Gerald O
Crabtree O
review O
recent O
findings O
that O
indicate O
CsA O
and O
FK506 O
operate O
as O
prodrugs O
: O
they O
bind O
endogenous B
intracellular I
receptors I
, O
the O
immunophilins B
, O
and O
the O
resulting O
complex O
targets O
the O
protein B
phosphatase I
, I
calcineurin B
, O
to O
exert O
the O
immunosuppressive O
effect O
. O

Here O
, O
Stuart O
Schreiber O
and O
Gerald O
Crabtree O
review O
recent O
findings O
that O
indicate O
CsA O
and O
FK506 O
operate O
as O
prodrugs O
: O
they O
bind O
endogenous B
intracellular I
receptors I
, O
the O
immunophilins B
, O
and O
the O
resulting O
complex O
targets O
the O
protein B
phosphatase I
, I
calcineurin B
, O
to O
exert O
the O
immunosuppressive O
effect O
. O

First O
is O
an O
expansion O
phase O
prior O
to O
TCR B
rearrangement O
, O
which O
appears O
to O
be O
correlated O
with O
programming O
of O
at O
least O
some O
response O
genes O
for O
inducibility O
. O

Chloramphenicol B
acetyl I
transferase I
( O
CAT B
) O
assays O
using O
the O
HIV B
- I
1 I
( I
- I
139 I
) I
long I
terminal I
repeat I
- I
CAT I
construct I
showed O
no O
PMA O
induction O
of O
CAT B
activity O
in O
these O
subclones O
( O
unlike O
the O
parental O
line O
and O
other O
subclones O
) O
. O

Chloramphenicol B
acetyl I
transferase I
( O
CAT B
) O
assays O
using O
the O
HIV B
- I
1 I
( I
- I
139 I
) I
long I
terminal I
repeat I
- I
CAT I
construct I
showed O
no O
PMA O
induction O
of O
CAT B
activity O
in O
these O
subclones O
( O
unlike O
the O
parental O
line O
and O
other O
subclones O
) O
. O

The O
response O
to O
antigen O
proceeds O
at O
the O
T O
helper O
cell O
level O
through O
two O
independent O
forms O
of O
cellular O
collaboration O
, O
contact O
and O
lymphokine B
. O

It O
is O
evident O
that O
assembly O
of O
the O
surface B
domain I
of O
TF B
with O
VIIa B
to O
form O
the O
binary O
TF B
. I
VIIa I
complex I
induces O
a O
significant O
increase O
in O
the O
Kcat O
of O
the O
catalytic B
domain I
of O
VIIa B
for O
small O
peptidyl O
substrates O
and O
more O
profoundly O
for O
protein B
substrate I
. O

It O
is O
evident O
that O
assembly O
of O
the O
surface B
domain I
of O
TF B
with O
VIIa B
to O
form O
the O
binary O
TF B
. I
VIIa I
complex I
induces O
a O
significant O
increase O
in O
the O
Kcat O
of O
the O
catalytic B
domain I
of O
VIIa B
for O
small O
peptidyl O
substrates O
and O
more O
profoundly O
for O
protein B
substrate I
. O

It O
is O
evident O
that O
assembly O
of O
the O
surface B
domain I
of O
TF B
with O
VIIa B
to O
form O
the O
binary O
TF B
. I
VIIa I
complex I
induces O
a O
significant O
increase O
in O
the O
Kcat O
of O
the O
catalytic B
domain I
of O
VIIa B
for O
small O
peptidyl O
substrates O
and O
more O
profoundly O
for O
protein B
substrate I
. O

It O
is O
also O
evident O
that O
association O
of O
X B
with O
charged O
phospholipid O
surfaces O
enhances O
the O
proteolytic O
activation O
of O
this O
zymogen B
by O
increasing O
recognition O
and O
susceptibility O
of O
the O
sessile O
peptide O
bond O
deduced O
from O
the O
markedly O
decreased O
Km O
and O
increased O
Kcat O
. O

It O
is O
also O
evident O
that O
association O
of O
X B
with O
charged O
phospholipid O
surfaces O
enhances O
the O
proteolytic O
activation O
of O
this O
zymogen B
by O
increasing O
recognition O
and O
susceptibility O
of O
the O
sessile O
peptide O
bond O
deduced O
from O
the O
markedly O
decreased O
Km O
and O
increased O
Kcat O
. O

There O
is O
little O
information O
available O
on O
the O
response O
of O
NF B
kappa I
B I
to O
cytokines B
in O
normal O
human O
monocytes O
. O

These O
studies O
suggest O
that O
antagonism O
by O
dexamethasone O
of O
endotoxin B
- O
induced O
inflammation O
is O
a O
specific O
instance O
of O
the O
general O
biological O
principle O
that O
the O
glucocorticoid B
receptor I
is O
a O
hormone O
- O
dependent O
regulator O
of O
transcription O
. O

Biochemical O
purification O
and O
cDNA O
cloning O
has O
now O
revealed O
that O
BSAP B
belongs O
to O
the O
family O
of O
paired B
domain I
proteins I
. O

BSAP B
is O
encoded O
by O
the O
Pax B
- I
5 I
gene I
and O
has O
been O
highly O
conserved O
between O
human O
and O
mouse O
. O

Specific O
NF B
- I
kappa I
B I
subunits I
act O
in O
concert O
with O
Tat B
to O
stimulate O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
. O

We O
have O
found O
that O
the O
p49 B
( I
100 I
) I
DNA I
binding I
subunit I
, O
together O
with O
p65 B
, O
can O
act O
in O
concert O
with O
Tat B
- I
I I
to O
stimulate O
the O
expression O
of O
HIV B
- I
CAT I
plasmid I
. O

Little O
effect O
was O
observed O
with O
50 B
- I
kDa I
forms I
of O
p105 B
NF B
- I
kappa I
B I
or O
rel B
, O
in O
combination O
with O
p65 B
or O
full B
- I
length I
c I
- I
rel I
, O
which O
do O
not O
stimulate O
the O
HIV B
enhancer I
in O
these O
cells O
. O

Little O
effect O
was O
observed O
with O
50 B
- I
kDa I
forms I
of O
p105 B
NF B
- I
kappa I
B I
or O
rel B
, O
in O
combination O
with O
p65 B
or O
full B
- I
length I
c I
- I
rel I
, O
which O
do O
not O
stimulate O
the O
HIV B
enhancer I
in O
these O
cells O
. O

Little O
effect O
was O
observed O
with O
50 B
- I
kDa I
forms I
of O
p105 B
NF B
- I
kappa I
B I
or O
rel B
, O
in O
combination O
with O
p65 B
or O
full B
- I
length I
c I
- I
rel I
, O
which O
do O
not O
stimulate O
the O
HIV B
enhancer I
in O
these O
cells O
. O

Stable O
expression O
of O
HB24 B
, O
a O
diverged B
human I
homeobox I
gene I
, O
in O
T O
lymphocytes O
induces O
genes O
involved O
in O
T O
cell O
activation O
and O
growth O
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
identified O
two O
potential O
Ets B
binding I
sites I
, O
EBS1 O
and O
EBS2 B
, O
which O
are O
conserved O
in O
both O
the O
human B
and I
murine I
interleukin I
- I
2 I
enhancers I
. O

A O
Tat B
- I
responsive I
element I
is O
found O
upstream O
within O
the O
viral B
promoter I
that O
in O
glial O
- O
derived O
cell O
lines O
allows O
transactivation O
in O
the O
absence O
of O
TAR B
. O

The O
promoter O
of O
the O
major B
histocompatibility I
class I
II I
gene I
DRA B
contains O
an O
octamer B
element I
( O
ATTTGCAT O
) O
that O
is O
required O
for O
efficient O
DRA B
expression O
in O
B O
cells O
. O

The O
promoter O
of O
the O
major B
histocompatibility I
class I
II I
gene I
DRA B
contains O
an O
octamer B
element I
( O
ATTTGCAT O
) O
that O
is O
required O
for O
efficient O
DRA B
expression O
in O
B O
cells O
. O

However O
, O
the O
increase O
in O
ISGF3 B
activity O
ultimately O
correlates O
with O
the O
accumulation O
of O
ISGF3 B
gamma I
induced O
by O
IFN B
- I
alpha I
or O
IFN B
- I
gamma I
. O

It O
was O
found O
that O
lipopolysaccharide O
induced O
strongly O
both O
c B
- I
fos I
and O
c B
- I
jun I
expression O
as O
well O
as O
AP1 B
formation O
. O

In O
addition O
, O
p65 B
gave O
per O
se O
, O
with O
low O
affinity O
, O
a O
protein B
- I
DNA I
complex I
that O
migrated O
more O
slowly O
than O
native O
NF B
- I
GM2 I
complex I
. O

Furthermore O
, O
an O
antiserum O
against O
KBF1 B
( O
identical O
to O
50 B
kDa I
NF I
- I
kappa I
B I
protein I
) O
reacted O
with O
the O
p50 B
of O
NF B
- I
GM2 I
, O
indicating O
that O
the O
NF B
- I
GM2 I
polypeptide I
can O
not O
be O
immunologically O
differentiated O
from O
the O
50 B
kDa I
subunit I
of O
NF B
- I
kappa I
B I
. O

Furthermore O
, O
an O
antiserum O
against O
KBF1 B
( O
identical O
to O
50 B
kDa I
NF I
- I
kappa I
B I
protein I
) O
reacted O
with O
the O
p50 B
of O
NF B
- I
GM2 I
, O
indicating O
that O
the O
NF B
- I
GM2 I
polypeptide I
can O
not O
be O
immunologically O
differentiated O
from O
the O
50 B
kDa I
subunit I
of O
NF B
- I
kappa I
B I
. O

The O
pAT B
133 I
gene I
is O
immediately O
induced O
, O
with O
FOS B
- O
like O
kinetics O
, O
in O
human O
T O
cells O
and O
in O
fibroblasts O
. O

v B
- I
erbA I
overexpression O
is O
required O
to O
extinguish O
c B
- I
erbA I
function O
in O
erythroid O
cell O
differentiation O
and O
regulation O
of O
the O
erbA B
target I
gene I
CAII B
. O

This O
erbA B
- I
binding I
site I
confers O
thyroid O
hormone O
responsiveness O
to O
a O
heterologous B
promoter I
in O
transient O
expression O
experiments O
and O
is O
a O
target O
for O
efficient O
down O
- O
regulation O
of O
CAII B
transcription O
by O
the O
v B
- I
erbA I
oncoprotein I
. O

A O
mutant O
of O
KBF1 B
/ I
p50 I
( O
delta B
SP I
) O
, O
unable O
to O
bind O
to O
DNA O
but O
able O
to O
form O
homo O
- O
or O
heterodimers B
, O
has O
been O
constructed O
. O

One O
gene O
of O
interest O
is O
the O
glycoprotein B
IIb I
( I
GPIIb I
) I
gene I
; O
GPIIb B
, O
the O
alpha B
subunit I
of O
the O
platelet B
cytoadhesin I
GPIIb I
- I
IIIa I
, O
is O
produced O
in O
megakaryocytes O
at O
an O
early O
stage O
of O
the O
differentiation O
, O
whereas O
the O
other O
subunit O
of O
this O
complex O
, O
GPIIIa B
, O
is O
expressed O
in O
other O
cells O
. O

One O
gene O
of O
interest O
is O
the O
glycoprotein B
IIb I
( I
GPIIb I
) I
gene I
; O
GPIIb B
, O
the O
alpha B
subunit I
of O
the O
platelet B
cytoadhesin I
GPIIb I
- I
IIIa I
, O
is O
produced O
in O
megakaryocytes O
at O
an O
early O
stage O
of O
the O
differentiation O
, O
whereas O
the O
other O
subunit O
of O
this O
complex O
, O
GPIIIa B
, O
is O
expressed O
in O
other O
cells O
. O

The O
promoters B
and O
enhancers B
of O
cell O
type O
- O
specific O
genes O
are O
often O
conserved O
in O
evolution O
, O
and O
hence O
one O
might O
expect O
that O
a O
given O
enhancer B
has O
evolved O
to O
work O
best O
with O
its O
own O
promoter B
. O

The O
promoters B
and O
enhancers B
of O
cell O
type O
- O
specific O
genes O
are O
often O
conserved O
in O
evolution O
, O
and O
hence O
one O
might O
expect O
that O
a O
given O
enhancer B
has O
evolved O
to O
work O
best O
with O
its O
own O
promoter B
. O

The O
promoters B
and O
enhancers B
of O
cell O
type O
- O
specific O
genes O
are O
often O
conserved O
in O
evolution O
, O
and O
hence O
one O
might O
expect O
that O
a O
given O
enhancer B
has O
evolved O
to O
work O
best O
with O
its O
own O
promoter B
. O

The O
promoters B
and O
enhancers B
of O
cell O
type O
- O
specific O
genes O
are O
often O
conserved O
in O
evolution O
, O
and O
hence O
one O
might O
expect O
that O
a O
given O
enhancer B
has O
evolved O
to O
work O
best O
with O
its O
own O
promoter B
. O

Circadian O
rhythm O
in O
glucocorticoid B
receptor I
( O
GR B
) O
was O
studied O
in O
the O
rat O
liver O
and O
human O
peripheral O
leukocytes O
. O

The O
conversion O
of O
the O
TCEd B
to O
a O
' B
perfect I
' I
NF I
- I
kB I
binding I
site I
leads O
to O
a O
tighter O
binding O
of O
NF B
- I
kB I
to O
TCEd B
DNA I
and O
, O
as O
a O
functional O
consequence O
, O
to O
the O
activity O
of O
the O
' B
converted I
' I
TCEd I
motifs I
in O
HeLa O
cells O
. O

Prolonged O
corticosteroid O
treatment O
resulted O
in O
down O
- O
regulation O
of O
GcR B
, O
while O
the O
mean O
level O
of O
GcR B
in O
Cushing O
' O
s O
disease O
was O
normal O
. O

Prolonged O
corticosteroid O
treatment O
resulted O
in O
down O
- O
regulation O
of O
GcR B
, O
while O
the O
mean O
level O
of O
GcR B
in O
Cushing O
' O
s O
disease O
was O
normal O
. O

Furthermore O
, O
GcR B
were O
unaltered O
after O
these O
patients O
received O
ketoconazole O
, O
in O
spite O
of O
a O
marked O
reduction O
in O
morning O
plasma O
cortisol O
and O
urinary O
free O
cortisol O
. O

Previously O
, O
transcription O
of O
the O
c B
- I
fos I
gene I
has O
been O
reported O
to O
be O
transactivated O
by O
the O
viral B
transcription I
factor I
, O
Tax1 B
. O

However O
, O
combination O
of O
OKT3 B
and O
phorbol O
myristate O
acetate O
produced O
a O
concentration O
of O
binding O
sites O
similar O
to O
the O
PHA O
- O
activated O
cells O
. O

The O
receptor O
from O
OKT3 B
and O
OKT3 B
+ O
phorbol O
myristate O
acetate O
- O
activated O
lymphocytes O
exhibited O
decreased O
binding O
to O
DNA O
- O
cellulose O
compared O
to O
PHA O
- O
activated O
lymphocytes O
. O

The O
receptor O
from O
OKT3 B
and O
OKT3 B
+ O
phorbol O
myristate O
acetate O
- O
activated O
lymphocytes O
exhibited O
decreased O
binding O
to O
DNA O
- O
cellulose O
compared O
to O
PHA O
- O
activated O
lymphocytes O
. O

In O
lymphocytes O
activated O
either O
by O
PHA B
or O
OKT3 B
( O
but O
not O
in O
resting O
cells O
) O
, O
a O
50 B
- I
kDa I
species I
cross O
- O
reacting O
with O
a O
monoclonal B
antibody I
against O
the O
intestinal B
vitamin I
D I
receptor I
was O
detected O
. O

In O
lymphocytes O
activated O
either O
by O
PHA B
or O
OKT3 B
( O
but O
not O
in O
resting O
cells O
) O
, O
a O
50 B
- I
kDa I
species I
cross O
- O
reacting O
with O
a O
monoclonal B
antibody I
against O
the O
intestinal B
vitamin I
D I
receptor I
was O
detected O
. O

These O
findings O
suggest O
that O
expression O
of O
the O
1 B
, I
25 I
- I
( I
OH I
) I
2D3 I
receptor I
in O
lymphocytes O
is O
triggered O
by O
distinct O
and O
contingent O
signals O
, O
and O
that O
the O
protein O
and O
the O
mRNA B
encoding O
it O
are O
identical O
to O
the O
classical B
vitamin I
D I
receptor I
. O

A O
dimerization B
cofactor I
of O
HNF B
- I
1 I
alpha I
( O
DCoH B
) O
was O
identified O
that O
displayed O
a O
restricted O
tissue O
distribution O
and O
did O
not O
bind O
to O
DNA O
, O
but O
, O
rather O
, O
selectively O
stabilized O
HNF B
- I
1 I
alpha I
dimers I
. O

The O
expression O
of O
active O
NF B
- I
kappa I
B I
might O
therefore O
also O
be O
regulated O
by O
the O
extent O
of O
processing O
of O
p105 B
. O

Levels O
of O
RNA O
coding O
for O
the O
receptor B
were O
not O
modulated O
by O
exposure O
to O
high O
levels O
of O
ligand O
. O

Cotransfection O
studies O
with O
this O
cDNA B
indicate O
that O
it O
can O
repress O
basal B
promoter I
activity O
. O

The O
activity O
of O
dihydropyrimidine B
dehydrogenase I
( O
DPD B
) O
, O
the O
initial O
enzyme B
of O
pyrimidine O
( O
and O
FUra O
) O
catabolism O
, O
in O
peripheral O
blood O
mononuclear O
cells O
was O
measured O
in O
each O
subject O
by O
a O
specific O
radiometric O
assay O
using O
FUra O
as O
the O
substrate O
. O

The O
activity O
of O
dihydropyrimidine B
dehydrogenase I
( O
DPD B
) O
, O
the O
initial O
enzyme B
of O
pyrimidine O
( O
and O
FUra O
) O
catabolism O
, O
in O
peripheral O
blood O
mononuclear O
cells O
was O
measured O
in O
each O
subject O
by O
a O
specific O
radiometric O
assay O
using O
FUra O
as O
the O
substrate O
. O

Monitoring O
DPD B
activity O
may O
be O
important O
in O
the O
management O
of O
patients O
experiencing O
severe O
toxicity O
secondary O
to O
FUra O
chemotherapy O
. O

The O
human B
T I
cell I
- I
specific I
transcription I
factor I
TCF B
- I
1 I
alpha I
plays O
a O
key O
role O
in O
the O
tissue O
- O
specific O
activation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
C O
alpha O
enhancer O
and O
binds O
to O
pyrimidine B
- I
rich I
elements I
( O
5 O
' O
- O
PyCTTTG O
- O
3 O
' O
) O
present O
in O
a O
variety O
of O
other O
T B
cell I
- I
specific I
control I
regions I
. O

Different O
amounts O
of O
the O
various O
isoforms B
are O
present O
within O
the O
same O
B O
- O
cell O
regardless O
of O
the O
developmental O
stage O
of O
B O
- O
cell O
differentiation O
and O
at O
least O
some O
of O
the O
isoforms B
are O
conserved O
between O
mouse O
and O
humans O
. O

Different O
amounts O
of O
the O
various O
isoforms B
are O
present O
within O
the O
same O
B O
- O
cell O
regardless O
of O
the O
developmental O
stage O
of O
B O
- O
cell O
differentiation O
and O
at O
least O
some O
of O
the O
isoforms B
are O
conserved O
between O
mouse O
and O
humans O
. O

In O
cotransfection O
experiments O
we O
show O
that O
all O
the O
isoforms B
are O
able O
to O
activate O
an O
octamer B
containing O
promoter B
element I
in O
fibroblasts O
revealing O
an O
unexpected O
functional O
redundancy O
. O

In O
cotransfection O
experiments O
we O
show O
that O
all O
the O
isoforms B
are O
able O
to O
activate O
an O
octamer B
containing O
promoter B
element I
in O
fibroblasts O
revealing O
an O
unexpected O
functional O
redundancy O
. O

An O
age O
- O
related O
decrease O
in O
the O
number O
of O
GR B
was O
suggested O
between O
subjects O
younger O
than O
20 O
years O
and O
elderly O
subjects O
; O
there O
was O
no O
apparent O
seasonal O
variation O
in O
GR B
. O

An O
age O
- O
related O
decrease O
in O
the O
number O
of O
GR B
was O
suggested O
between O
subjects O
younger O
than O
20 O
years O
and O
elderly O
subjects O
; O
there O
was O
no O
apparent O
seasonal O
variation O
in O
GR B
. O

Eight O
patients O
with O
dermatomyositis O
/ O
polymyositis O
were O
examined O
to O
determine O
whether O
the O
number O
of O
GR B
in O
MNL O
could O
be O
down O
- O
regulated O
by O
their O
cognate O
ligands O
. O

Formation O
of O
the O
protein B
- I
DNA I
complex I
with O
the O
C26 B
subfragment I
was O
positively O
affected O
by O
p40tax B
. O

We O
have O
generated O
a O
monoclonal B
antibody I
, O
BZ1 B
, O
to O
BZLF1 B
which O
reacts O
in O
immunohistology O
, O
immunoblotting O
, O
and O
immunoprecipitation O
and O
which O
recognizes O
both O
the O
active B
, I
dimeric I
form I
and O
the O
inactive B
, I
monomeric I
form I
of O
the O
protein O
. O

We O
have O
generated O
a O
monoclonal B
antibody I
, O
BZ1 B
, O
to O
BZLF1 B
which O
reacts O
in O
immunohistology O
, O
immunoblotting O
, O
and O
immunoprecipitation O
and O
which O
recognizes O
both O
the O
active B
, I
dimeric I
form I
and O
the O
inactive B
, I
monomeric I
form I
of O
the O
protein O
. O

The O
hormone B
receptors I
of O
the O
primary O
tumor O
were O
known O
in O
15 O
( O
ER B
) O
and O
14 O
( O
PR B
) O
patients O
, O
respectively O
. O

The O
hormone B
receptors I
of O
the O
primary O
tumor O
were O
known O
in O
15 O
( O
ER B
) O
and O
14 O
( O
PR B
) O
patients O
, O
respectively O
. O

[ O
Regulatory O
effect O
of O
insulin B
on O
glucocorticoid B
receptor I
in O
human O
peripheral O
leukocytes O
] O

After O
3 O
h O
incubation O
the O
specific O
binding O
power O
with O
[ O
3H O
] O
Dex O
was O
decreased O
by O
23 O
. O
3 O
+ O
/ O
- O
10 O
. O
0 O
, O
32 O
. O
2 O
+ O
/ O
- O
13 O
. O
2 O
and O
54 O
. O
3 O
+ O
/ O
- O
9 O
. O
2 O
% O
( O
P O
greater O
than O
0 O
. O
05 O
, O
P O
greater O
than O
0 O
. O
05 O
and O
P O
less O
than O
0 O
. O
01 O
as O
compared O
with O
the O
control O
value O
of O
100 O
in O
the O
absence O
of O
insulin B
) O
respectively O
in O
the O
presence O
of O
20 O
mU O
/ O
L O
( O
physiological O
testing O
concentration O
) O
, O
200 O
mU O
/ O
L O
( O
physiological O
upper O
limit O
) O
and O
2 O
, O
000 O
mU O
/ O
L O
( O
pharmacological O
concentration O
) O
insulin B

Other O
cellular O
parameters O
, O
such O
as O
glycosidase O
activities O
, O
cytokine B
release O
, O
and O
filament O
expression O
, O
returned O
to O
levels O
similar O
to O
that O
observed O
in O
uninduced O
cells O
. O

Levels O
of O
c B
- I
fos I
and I
c I
- I
jun I
transcripts I
remained O
elevated O
during O
periods O
of O
PKC B
activation O
and O
also O
returned O
to O
levels O
observed O
in O
control O
cells O
by O
30 O
- O
36 O
days O
, O
when O
the O
cells O
entered O
retrodifferentiation O
. O

In O
contrast O
, O
mild O
oxidation O
with O
glucose B
oxidase I
selectively O
inhibits O
p75 B
and O
p85 B
binding O
while O
not O
blocking O
p50 B
and O
p55 B
interactions O
. O

In O
contrast O
, O
mild O
oxidation O
with O
glucose B
oxidase I
selectively O
inhibits O
p75 B
and O
p85 B
binding O
while O
not O
blocking O
p50 B
and O
p55 B
interactions O
. O

In O
contrast O
, O
mild O
oxidation O
with O
glucose B
oxidase I
selectively O
inhibits O
p75 B
and O
p85 B
binding O
while O
not O
blocking O
p50 B
and O
p55 B
interactions O
. O

In O
contrast O
, O
mild O
oxidation O
with O
glucose B
oxidase I
selectively O
inhibits O
p75 B
and O
p85 B
binding O
while O
not O
blocking O
p50 B
and O
p55 B
interactions O
. O

The O
numbers O
of O
estrogen B
receptor I
( O
ER B
) O
in O
human O
peripheral O
leucocytes O
in O
22 O
women O
with O
climacteric O
syndrome O
were O
measured O
by O
radioligand O
method O
. O

These O
studies O
have O
been O
extended O
to O
show O
that O
( O
i O
) O
a O
mutant O
EBV O
strain O
lacking O
the O
gene O
encoding O
EBNA B
2 I
fails O
to O
switch O
from O
Wp O
to O
Cp B
usage O
in O
primary O
B O
lymphocytes O
, O
although O
the O
virus O
contains O
a O
functional O
Cp B
; O
( O
ii O
) O
a O
region O
from O
- B
429 I
to I
- I
245 I
base I
pairs I
upstream O
of O
Cp B
is O
essential O
for O
Cp B
activity O
in O
B O
lymphocytes O
, O
but O
only O
in O
the O
context O
of O
upstream B
and I
downstream I
sequences I
; O
( O
iii O
) O
this O
region O
contains O
an O
EBNA B
2 I
- I
dependent I
enhancer I
; O
and O
( O
iv O
) O
DNase B
I I
protection O
employing O
nuclear O
extracts O
from O
B O
and O

These O
studies O
have O
been O
extended O
to O
show O
that O
( O
i O
) O
a O
mutant O
EBV O
strain O
lacking O
the O
gene O
encoding O
EBNA B
2 I
fails O
to O
switch O
from O
Wp O
to O
Cp B
usage O
in O
primary O
B O
lymphocytes O
, O
although O
the O
virus O
contains O
a O
functional O
Cp B
; O
( O
ii O
) O
a O
region O
from O
- B
429 I
to I
- I
245 I
base I
pairs I
upstream O
of O
Cp B
is O
essential O
for O
Cp B
activity O
in O
B O
lymphocytes O
, O
but O
only O
in O
the O
context O
of O
upstream B
and I
downstream I
sequences I
; O
( O
iii O
) O
this O
region O
contains O
an O
EBNA B
2 I
- I
dependent I
enhancer I
; O
and O
( O
iv O
) O
DNase B
I I
protection O
employing O
nuclear O
extracts O
from O
B O
and O

These O
studies O
have O
been O
extended O
to O
show O
that O
( O
i O
) O
a O
mutant O
EBV O
strain O
lacking O
the O
gene O
encoding O
EBNA B
2 I
fails O
to O
switch O
from O
Wp O
to O
Cp B
usage O
in O
primary O
B O
lymphocytes O
, O
although O
the O
virus O
contains O
a O
functional O
Cp B
; O
( O
ii O
) O
a O
region O
from O
- B
429 I
to I
- I
245 I
base I
pairs I
upstream O
of O
Cp B
is O
essential O
for O
Cp B
activity O
in O
B O
lymphocytes O
, O
but O
only O
in O
the O
context O
of O
upstream B
and I
downstream I
sequences I
; O
( O
iii O
) O
this O
region O
contains O
an O
EBNA B
2 I
- I
dependent I
enhancer I
; O
and O
( O
iv O
) O
DNase B
I I
protection O
employing O
nuclear O
extracts O
from O
B O
and O

These O
studies O
have O
been O
extended O
to O
show O
that O
( O
i O
) O
a O
mutant O
EBV O
strain O
lacking O
the O
gene O
encoding O
EBNA B
2 I
fails O
to O
switch O
from O
Wp O
to O
Cp B
usage O
in O
primary O
B O
lymphocytes O
, O
although O
the O
virus O
contains O
a O
functional O
Cp B
; O
( O
ii O
) O
a O
region O
from O
- B
429 I
to I
- I
245 I
base I
pairs I
upstream O
of O
Cp B
is O
essential O
for O
Cp B
activity O
in O
B O
lymphocytes O
, O
but O
only O
in O
the O
context O
of O
upstream B
and I
downstream I
sequences I
; O
( O
iii O
) O
this O
region O
contains O
an O
EBNA B
2 I
- I
dependent I
enhancer I
; O
and O
( O
iv O
) O
DNase B
I I
protection O
employing O
nuclear O
extracts O
from O
B O
and O

Five O
T O
- O
cell O
clones O
specific O
for O
a O
T B
- I
cell I
epitope I
located O
at O
the O
carboxyterminal B
region I
of O
HBxAg B
were O
established O
and O
found O
to O
belong O
to O
the O
CD2 O
/ O
CD4 O
- O
positive O
, O
CD8 O
- O
negative O
subtype O
. O

The O
rate O
of O
LTR B
- O
directed O
gene O
expression O
increased O
in O
response O
to O
treatment O
with O
either O
a O
phorbol O
ester O
or O
tumor B
necrosis I
factor I
alpha I
if O
either O
the O
NFAT B
- I
1 I
or O
NF B
kappa I
B I
binding I
sites I
were O
deleted O
, O
but O
failed O
to O
respond O
to O
these O
mitogenic O
stimuli O
if O
both O
sequences O
were O
absent O
. O

Activation O
of O
proenkephalin O
transcription O
by O
JunD B
is O
dependent O
upon O
a O
previously O
characterized O
cAMP B
- I
, I
phorbol I
ester I
- I
, I
and I
Ca I
( I
2 I
+ I
) I
- I
inducible I
enhancer I
, O
and O
JunD B
is O
shown O
to O
bind O
the O
enhancer B
as O
a O
homodimer B
. O

Activation O
of O
proenkephalin O
transcription O
by O
JunD B
is O
dependent O
upon O
a O
previously O
characterized O
cAMP B
- I
, I
phorbol I
ester I
- I
, I
and I
Ca I
( I
2 I
+ I
) I
- I
inducible I
enhancer I
, O
and O
JunD B
is O
shown O
to O
bind O
the O
enhancer B
as O
a O
homodimer B
. O

Activation O
of O
proenkephalin O
transcription O
by O
JunD B
is O
dependent O
upon O
a O
previously O
characterized O
cAMP B
- I
, I
phorbol I
ester I
- I
, I
and I
Ca I
( I
2 I
+ I
) I
- I
inducible I
enhancer I
, O
and O
JunD B
is O
shown O
to O
bind O
the O
enhancer B
as O
a O
homodimer B
. O

Activation O
of O
proenkephalin O
transcription O
by O
JunD B
is O
dependent O
upon O
a O
previously O
characterized O
cAMP B
- I
, I
phorbol I
ester I
- I
, I
and I
Ca I
( I
2 I
+ I
) I
- I
inducible I
enhancer I
, O
and O
JunD B
is O
shown O
to O
bind O
the O
enhancer B
as O
a O
homodimer B
. O

Plasma O
cortisol O
concentration O
and O
blood O
leukocyte O
content O
of O
glucocorticoid B
receptors I
( O
GCR B
) O
were O
assayed O
in O
20 O
patients O
with O
deficiency O
syndromes O
, O
10 O
cold O
in O
property O
( O
deficiency O
- O
cold O
) O
, O
the O
other O
10 O
hot O
in O
property O
( O
deficiency O
- O
heat O
) O
, O
and O
also O
in O
10 O
healthy O
individuals O
as O
normal O
control O
for O
the O
purpose O
of O
investigating O
the O
nature O
of O
cold O
and O
heat O
syndromes O
. O

The O
induction O
of O
AP1 B
by O
okadaic O
acid O
suggests O
that O
protein B
phosphatases I
1 I
and I
2A I
( O
PP1 B
and O
PP2A B
) O
may O
be O
involved O
in O
T O
cell O
activation O
as O
important O
negative O
regulators O
of O
the O
transcription B
factor I
AP1 B
. O

The O
induction O
of O
AP1 B
by O
okadaic O
acid O
suggests O
that O
protein B
phosphatases I
1 I
and I
2A I
( O
PP1 B
and O
PP2A B
) O
may O
be O
involved O
in O
T O
cell O
activation O
as O
important O
negative O
regulators O
of O
the O
transcription B
factor I
AP1 B
. O

The O
induction O
of O
AP1 B
by O
okadaic O
acid O
suggests O
that O
protein B
phosphatases I
1 I
and I
2A I
( O
PP1 B
and O
PP2A B
) O
may O
be O
involved O
in O
T O
cell O
activation O
as O
important O
negative O
regulators O
of O
the O
transcription B
factor I
AP1 B
. O

The O
induction O
of O
AP1 B
by O
okadaic O
acid O
suggests O
that O
protein B
phosphatases I
1 I
and I
2A I
( O
PP1 B
and O
PP2A B
) O
may O
be O
involved O
in O
T O
cell O
activation O
as O
important O
negative O
regulators O
of O
the O
transcription B
factor I
AP1 B
. O

CD3 B
- O
epsilon O
gene O
expression O
is O
confined O
to O
the O
T O
cell O
lineage O
. O

There O
is O
a O
single O
methionine B
codon I
- I
initiated I
open I
reading I
frame I
of O
1 O
, O
458 O
nt O
in O
frame O
with O
a O
homeobox B
and O
a O
CAX B
repeat I
, O
and O
the O
open B
reading I
frame I
is O
predicted O
to O
encode O
a O
protein O
of O
51 O
, O
659 O
daltons O
. O

Characterization O
of O
HB24 B
expression O
in O
lymphoid O
and O
select O
developing O
tissues O
was O
performed O
by O
in O
situ O
hybridization O
. O

Platelet B
- I
activating I
factor I
induces O
phospholipid O
turnover O
, O
calcium O
flux O
, O
arachidonic O
acid O
liberation O
, O
eicosanoid O
generation O
, O
and O
oncogene B
expression O
in O
a O
human O
B O
cell O
line O
. O

Footprinting O
analysis O
revealed O
that O
the O
identical O
sequence O
CCGAAACTGAAAAGG O
, O
designated O
E6 B
, O
was O
protected O
by O
nuclear O
extracts O
from O
B O
cells O
, O
T O
cells O
, O
or O
HeLa O
cells O
. O

The O
involvement O
of O
ion O
channels O
in O
B O
and O
T O
lymphocyte O
activation O
is O
supported O
by O
many O
reports O
of O
changes O
in O
ion O
fluxes O
and O
membrane O
potential O
after O
mitogen B
binding O
. O

From O
information O
available O
in O
the O
literature O
on O
the O
substrate O
specificity O
of O
the O
three O
enzymes B
, O
it O
is O
clear O
that O
a O
cysteine O
is O
not O
accepted O
in O
any O
of O
the O
S2 B
, I
S1 I
, I
S1 I
' I
, I
and I
S2 I
' I
subsites I
of O
cathepsin B
B I
and I
L I
, O
and O
not O
in O
the O
S1 B
and O
S1 B
' I
subsites O
of O
cathepsin B
D I
. O

From O
information O
available O
in O
the O
literature O
on O
the O
substrate O
specificity O
of O
the O
three O
enzymes B
, O
it O
is O
clear O
that O
a O
cysteine O
is O
not O
accepted O
in O
any O
of O
the O
S2 B
, I
S1 I
, I
S1 I
' I
, I
and I
S2 I
' I
subsites I
of O
cathepsin B
B I
and I
L I
, O
and O
not O
in O
the O
S1 B
and O
S1 B
' I
subsites O
of O
cathepsin B
D I
. O

Starting O
with O
a O
replication O
- O
incompetent O
molecular O
clone O
of O
human O
immunodeficiency O
virus O
type O
1 O
, O
lacking O
all O
the O
NF B
- I
kappa I
B I
and I
Sp1 I
binding I
sites I
present O
in O
the O
native B
long I
terminal I
repeat I
( O
LTR B
) O
, O
proviruses O
containing O
reconstructed B
LTRs I
with O
individual O
or O
combinations O
of O
NF B
- I
kappa I
B I
and I
Sp1 I
elements I
were O
generated O
and O
evaluated O
for O
their O
capacity O
to O
produce O
virus O
progeny O
following O
transfection O
- O
cocultivation O
. O

The O
human B
interferon I
beta I
( I
IFN I
- I
beta I
) I
regulatory I
element I
consists O
of O
multiple O
enhanson B
domains I
which O
are O
targets O
for O
transcription B
factors I
involved O
in O
inducible O
expression O
of O
the O
promoter B
. O

A O
2 O
- O
4 O
- O
fold O
increase O
in O
IFN B
- I
beta I
promoter I
transcription O
was O
observed O
in O
Sendai O
virus O
induced O
extracts O
, O
and O
deletion O
of O
PRDI B
and O
PRDII B
elements I
decreased O
this O
induced O
level O
of O
transcription O
. O

Human B
and I
mouse I
Rhom I
- I
2 I
are O
highly O
conserved O
and O
, O
like O
rhombotin B
, O
encode O
two O
tandem B
cysteine I
- I
rich I
LIM I
domains I
. O

Furthermore O
, O
while O
PMA O
activation O
was O
inhibited O
by O
the O
PKC B
inhibitor O
staurosporin O
, O
the O
TNF B
alpha I
effect O
was O
unchanged O
. O

Mutations O
at O
the O
B2 B
site O
abolish O
this O
transcriptional O
activation O
. O

The O
purified O
homodimer B
( O
two O
p50s B
) O
of O
the O
DNA B
- I
binding I
subunit I
of O
NF B
- I
kappa I
B I
binds O
the O
B2 B
site O
of O
proenkephalin O
relatively O
better O
than O
does O
the O
heterotetramer B
( O
two O
p65s B
plus O
two O
p50s B
) O
form O
of O
the O
factor O
. O

The O
purified O
homodimer B
( O
two O
p50s B
) O
of O
the O
DNA B
- I
binding I
subunit I
of O
NF B
- I
kappa I
B I
binds O
the O
B2 B
site O
of O
proenkephalin O
relatively O
better O
than O
does O
the O
heterotetramer B
( O
two O
p65s B
plus O
two O
p50s B
) O
form O
of O
the O
factor O
. O

The O
purified O
homodimer B
( O
two O
p50s B
) O
of O
the O
DNA B
- I
binding I
subunit I
of O
NF B
- I
kappa I
B I
binds O
the O
B2 B
site O
of O
proenkephalin O
relatively O
better O
than O
does O
the O
heterotetramer B
( O
two O
p65s B
plus O
two O
p50s B
) O
form O
of O
the O
factor O
. O

The O
purified O
homodimer B
( O
two O
p50s B
) O
of O
the O
DNA B
- I
binding I
subunit I
of O
NF B
- I
kappa I
B I
binds O
the O
B2 B
site O
of O
proenkephalin O
relatively O
better O
than O
does O
the O
heterotetramer B
( O
two O
p65s B
plus O
two O
p50s B
) O
form O
of O
the O
factor O
. O

The O
purified O
homodimer B
( O
two O
p50s B
) O
of O
the O
DNA B
- I
binding I
subunit I
of O
NF B
- I
kappa I
B I
binds O
the O
B2 B
site O
of O
proenkephalin O
relatively O
better O
than O
does O
the O
heterotetramer B
( O
two O
p65s B
plus O
two O
p50s B
) O
form O
of O
the O
factor O
. O

The O
purified O
homodimer B
( O
two O
p50s B
) O
of O
the O
DNA B
- I
binding I
subunit I
of O
NF B
- I
kappa I
B I
binds O
the O
B2 B
site O
of O
proenkephalin O
relatively O
better O
than O
does O
the O
heterotetramer B
( O
two O
p65s B
plus O
two O
p50s B
) O
form O
of O
the O
factor O
. O

However O
, O
as O
NF B
- I
kappa I
B I
is O
ubiquitous O
and O
the O
transcriptional O
activation O
through O
the O
B2 B
site O
is O
T O
cell O
specific O
, O
yet O
another O
T B
- I
cell I
- I
specific I
factor I
which O
synergizes O
with O
NF B
- I
kappa I
B I
should O
be O
considered O
. O

The O
fusion B
cDNA I
results O
from O
an O
interstitial O
deletion O
between O
a O
previously O
unknown B
locus I
, O
SIL B
( O
SCL B
interrupting I
locus I
) O
, O
and O
the O
5 B
' I
untranslated I
region I
of O
SCL B
. O

The O
fusion B
cDNA I
results O
from O
an O
interstitial O
deletion O
between O
a O
previously O
unknown B
locus I
, O
SIL B
( O
SCL B
interrupting I
locus I
) O
, O
and O
the O
5 B
' I
untranslated I
region I
of O
SCL B
. O

This O
was O
compared O
with O
the O
TREp B
binding O
of O
reticulocyte B
lysate I
- I
synthesized I
TRs I
. O

Incubation O
of O
each O
of O
the O
TRs B
with O
NE O
from O
COS O
- O
7 O
cells O
, O
which O
do O
not O
possess O
sufficient O
endogenous O
TRs B
to O
mediate O
T3 O
- O
responses O
, O
resulted O
in O
formation O
of O
a O
new O
, O
more O
greatly B
shifted I
complex I
. O

Incubation O
of O
each O
of O
the O
TRs B
with O
NE O
from O
COS O
- O
7 O
cells O
, O
which O
do O
not O
possess O
sufficient O
endogenous O
TRs B
to O
mediate O
T3 O
- O
responses O
, O
resulted O
in O
formation O
of O
a O
new O
, O
more O
greatly B
shifted I
complex I
. O

In O
30 O
of O
these O
cases O
ER B
enzyme O
immunoassay O
( O
ER B
- O
EIA O
) O
was O
also O
performed O
. O

In O
30 O
of O
these O
cases O
ER B
enzyme O
immunoassay O
( O
ER B
- O
EIA O
) O
was O
also O
performed O
. O

Quantitation O
of O
glucocorticoid B
receptors I
( O
GCR B
) O
and O
the O
study O
of O
their O
affinity O
for O
glucocorticosteroids O
( O
GCS O
) O
were O
made O
in O
peripheral O
blood O
lymphocytes O
of O
bronchial O
asthma O
( O
BA O
) O
patients O
in O
consideration O
of O
GCR B
treatment O
and O
serum O
levels O
of O
endogenous O
cortisol O
. O

Quantitation O
of O
glucocorticoid B
receptors I
( O
GCR B
) O
and O
the O
study O
of O
their O
affinity O
for O
glucocorticosteroids O
( O
GCS O
) O
were O
made O
in O
peripheral O
blood O
lymphocytes O
of O
bronchial O
asthma O
( O
BA O
) O
patients O
in O
consideration O
of O
GCR B
treatment O
and O
serum O
levels O
of O
endogenous O
cortisol O
. O

These O
data O
indicate O
that O
CVZ O
is O
recognizing O
two O
glucocorticoid B
binding I
sites I
on O
the O
human O
GR B
or O
a O
protein O
very O
similar O
to O
it O
. O

Retroviral O
mediated O
transfer O
and O
expression O
of O
exogenous B
genes I
in O
primary O
lymphoid O
cells O
: O
assaying O
for O
a O
viral O
transactivator B
activity O
in O
normal O
and O
malignant O
cells O
. O

ER B
content O
in O
lymphocytes O
of O
each O
sample O
was O
expressed O
by O
both O
fmol O
/ O
mg O
of O
lymphocyte B
cytosolic I
protein I
and O
fmol O
/ O
micrograms O
of O
lymphocyte B
DNA I
. O

The O
results O
showed O
that O
there O
was O
no O
significant O
difference O
between O
the O
ER B
content O
of O
lymphocytes O
from O
the O
controls O
and O
that O
from O
patients O
with O
SLE O
. O

When O
the O
human B
epsilon I
- I
or I
beta I
- I
globin I
genes I
driven O
by O
the O
dominant B
control I
region I
( O
DCR B
) O
are O
introduced O
into O
this O
system O
, O
the O
human B
epsilon I
- I
globin I
gene I
, O
in O
contrast O
to O
the O
beta B
- I
globin I
gene I
, O
is O
not O
deregulated O
by O
the O
presence O
of O
the O
DCR B
and O
is O
expressed O
strictly O
as O
an O
embryonic B
gene I
. O

When O
the O
human B
epsilon I
- I
or I
beta I
- I
globin I
genes I
driven O
by O
the O
dominant B
control I
region I
( O
DCR B
) O
are O
introduced O
into O
this O
system O
, O
the O
human B
epsilon I
- I
globin I
gene I
, O
in O
contrast O
to O
the O
beta B
- I
globin I
gene I
, O
is O
not O
deregulated O
by O
the O
presence O
of O
the O
DCR B
and O
is O
expressed O
strictly O
as O
an O
embryonic B
gene I
. O

However O
, O
one O
palindrome B
, O
either O
alone O
or O
duplicated O
, O
or O
the O
overlapping B
palindromes I
did O
not O
respond O
to O
R O
. O

The O
clinical O
implications O
of O
nuclear O
T3R B
alterations O
of O
circulating O
lymphocytes O
in O
hyperthyroidism O
, O
hypothyroidism O
and O
nonthyroidal O
diseases O
were O
investigated O
. O

These O
studies O
detected O
two O
novel B
domains I
referred O
to O
as O
L1 B
and O
L2 B
with O
a O
variety O
of O
lymphoid O
but O
not O
HeLa O
extracts O
. O

These O
studies O
detected O
two O
novel B
domains I
referred O
to O
as O
L1 B
and O
L2 B
with O
a O
variety O
of O
lymphoid O
but O
not O
HeLa O
extracts O
. O

Characterization O
of O
defensin B
resistance O
phenotypes O
associated O
with O
mutations O
in O
the O
phoP B
virulence I
regulon I
of O
Salmonella O
typhimurium O
. O

The O
defensin B
sensitivities O
of O
Salmonella O
typhimurium O
strains O
with O
mutations O
in O
the O
phoP B
/ I
phoQ I
two I
- I
component I
virulence I
regulon I
were O
tested O
by O
using O
purified B
defensins I
NP B
- I
1 I
and O
NP B
- I
2 I
. O

The O
predicted O
periplasmic B
domain I
of O
the O
PhoQ B
protein I
contained O
a O
markedly O
anionic O
domain O
that O
could O
interact O
with O
cationic B
proteins I
and O
that O
could O
be O
responsible O
for O
resistance O
to O
defensin B
. O

This O
implied O
that O
a O
pag B
( I
phoP I
- I
activated I
gene I
) I
product I
is O
responsible O
for O
defensin B
resistance O
. O

Both O
proteins O
impart O
cAMP O
- O
regulated O
transcriptional O
activity O
to O
a O
heterologous B
DNA I
- I
binding I
domain I
, O
showing O
that O
cAMP O
directly O
modulates O
the O
transcriptional O
stimulatory O
activity O
of O
CREB B
. O

Competition O
experiments O
did O
not O
reveal O
any O
high B
- I
affinity I
binding I
site I
for O
BSAP B
in O
known O
regulatory B
regions I
of O
immunoglobulin B
and I
class I
II I
major I
histocompatibility I
( I
MHC I
) I
genes I
, O
suggesting O
that O
BSAP B
is O
a O
regulator O
of O
a O
different O
set O
of O
B B
- I
lymphoid I
- I
specific I
genes I
. O

Competition O
experiments O
did O
not O
reveal O
any O
high B
- I
affinity I
binding I
site I
for O
BSAP B
in O
known O
regulatory B
regions I
of O
immunoglobulin B
and I
class I
II I
major I
histocompatibility I
( I
MHC I
) I
genes I
, O
suggesting O
that O
BSAP B
is O
a O
regulator O
of O
a O
different O
set O
of O
B B
- I
lymphoid I
- I
specific I
genes I
. O

TAR B
independent O
activation O
of O
the O
human O
immunodeficiency O
virus O
in O
phorbol O
ester O
stimulated O
T O
lymphocytes O
. O

Results O
in O
all O
cell O
lines O
indicated O
that O
mutations O
of O
the O
SP1 B
, O
TATA B
and O
the O
TAR O
loop O
and O
stem O
secondary O
structure O
resulted O
in O
marked O
decreases O
in O
gene O
expression O
while O
mutations O
of O
the O
enhancer B
motif I
or O
TAR B
primary I
sequence I
resulted O
in O
only O
slight O
decreases O
. O

Results O
in O
all O
cell O
lines O
indicated O
that O
mutations O
of O
the O
SP1 B
, O
TATA B
and O
the O
TAR O
loop O
and O
stem O
secondary O
structure O
resulted O
in O
marked O
decreases O
in O
gene O
expression O
while O
mutations O
of O
the O
enhancer B
motif I
or O
TAR B
primary I
sequence I
resulted O
in O
only O
slight O
decreases O
. O

The O
protein O
synthesis O
inhibitor O
cycloheximide O
did O
not O
block O
the O
induction O
of O
any O
of O
these O
genes O
, O
and O
in O
fact O
, O
super O
- O
induced O
the O
expression O
of O
c B
- I
jun I
and O
hck B
. O

These O
genes O
may O
then O
play O
a O
role O
in O
altering O
the O
physiologic O
status O
of O
the O
cells O
in O
response O
to O
CSF B
. O

We O
have O
purified O
a O
new O
T B
- I
cell I
- I
specific I
factor I
, O
TCF B
- I
1 I
alpha I
, O
that O
is O
implicated O
in O
the O
activation O
of O
genes O
encoding O
a O
major O
component O
of O
the O
human B
T I
- I
cell I
receptor I
( O
TCR B
) O
. O

DNA O
- O
protein O
binding O
assays O
with O
nuclear O
extracts O
from O
induced O
cells O
demonstrate O
a O
high B
molecular I
weight I
complex I
on O
the O
enhancer B
. O

Purified O
OTF1 B
from O
HeLa O
cells O
and O
OTF1 B
and O
OTF2 B
from O
B O
cells O
bound O
to O
identical O
sequences O
within O
the O
heavy B
- I
chain I
promoter I
. O

Purified O
OTF1 B
from O
HeLa O
cells O
and O
OTF1 B
and O
OTF2 B
from O
B O
cells O
bound O
to O
identical O
sequences O
within O
the O
heavy B
- I
chain I
promoter I
. O

Purified O
OTF1 B
from O
HeLa O
cells O
and O
OTF1 B
and O
OTF2 B
from O
B O
cells O
bound O
to O
identical O
sequences O
within O
the O
heavy B
- I
chain I
promoter I
. O

PMA O
enhanced O
slightly O
the O
stimulatory O
effect O
of O
PHA B
. O

Two O
distinct O
signal O
transmission O
pathways O
in O
T O
lymphocytes O
are O
inhibited O
by O
complexes O
formed O
between O
an O
immunophilin B
and O
either O
FK506 O
or O
rapamycin O
. O

In O
lymphoid O
cells O
, O
Z B
or O
R B
alone O
produced O
only O
small O
increases O
in O
EA B
- I
D I
promoter I
activity O
, O
whereas O
both O
transactivators B
together O
produced O
a O
large O
stimulatory O
effect O
. O

In O
lymphoid O
cells O
, O
Z B
or O
R B
alone O
produced O
only O
small O
increases O
in O
EA B
- I
D I
promoter I
activity O
, O
whereas O
both O
transactivators B
together O
produced O
a O
large O
stimulatory O
effect O
. O

In O
lymphoid O
cells O
, O
Z B
or O
R B
alone O
produced O
only O
small O
increases O
in O
EA B
- I
D I
promoter I
activity O
, O
whereas O
both O
transactivators B
together O
produced O
a O
large O
stimulatory O
effect O
. O

In O
this O
study O
we O
present O
evidence O
for O
reactivity O
of O
pregnancy O
lymphocytes O
, O
but O
not O
nonpregnancy O
lymphocytes O
, O
with O
the O
progesterone B
receptor I
- I
specific I
monoclonal I
antibody I
mPRI B
. O

Interaction O
of O
fibronectin B
with O
VLA B
- I
5 I
receptor I
on O
CD4 O
cells O
induces O
the O
AP B
- I
1 I
transcription I
factor I
. O

A O
somewhat O
surprising O
finding O
however O
was O
a O
very O
strong O
association O
between O
oncogene B
amplification O
and O
dense O
lymphocyte O
infiltration O
of O
the O
tumor O
( O
P O
= O
. O
05 O
) O
. O
This O
correlation O
is O
even O
stronger O
when O
only O
high O
levels O
of O
amplification O
are O
considered O
, O
either O
for O
each O
oncogene O
separately O
( O
P O
= O
. O
0048 O
) O
or O
in O
combination O
( O
P O
= O
. O
0007 O
) O
. O

Transcription B
factor I
IID I
( O
TFIID B
) O
binds O
to O
the O
TATA B
box I
promoter I
element I
and O
regulates O
the O
expression O
of O
most O
eukaryotic B
genes I
transcribed O
by O
RNA B
polymerase I
II I
. O

Complementary B
DNA I
( O
cDNA B
) O
encoding O
a O
human B
TFIID I
protein I
has O
been O
cloned O
. O

Fourth O
, O
extensive O
purification O
by O
several O
cycles O
of O
TRE B
- O
DNA O
affinity O
chromatography O
resulted O
in O
the O
32 B
, I
36 I
to I
42 I
and I
110 I
kD I
proteins I
and O
to O
less O
extent O
the O
50 B
kD I
factor I
. O

The O
cAMP B
- I
response I
element I
CRE B
, O
TGACGTCA O
, O
present O
in O
the O
21 B
base I
- I
pair I
sequence I
, O
appears O
to O
be O
essential O
for O
specific O
protein O
- O
TRE B
- O
DNA O
interactions O
because O
mutation O
of O
the O
two O
G O
' O
s O
destroys O
this O
complex O
. O

The O
cAMP B
- I
response I
element I
CRE B
, O
TGACGTCA O
, O
present O
in O
the O
21 B
base I
- I
pair I
sequence I
, O
appears O
to O
be O
essential O
for O
specific O
protein O
- O
TRE B
- O
DNA O
interactions O
because O
mutation O
of O
the O
two O
G O
' O
s O
destroys O
this O
complex O
. O

Patients O
with O
AD O
( O
n O
= O
15 O
) O
exhibited O
significantly O
more O
glucocorticoid B
receptors I
( O
GR B
) O
per O
cell O
than O
the O
control O
group O
( O
n O
= O
22 O
) O
, O
while O
the O
GR B
affinity O
did O
not O
differ O
. O

Patients O
with O
AD O
( O
n O
= O
15 O
) O
exhibited O
significantly O
more O
glucocorticoid B
receptors I
( O
GR B
) O
per O
cell O
than O
the O
control O
group O
( O
n O
= O
22 O
) O
, O
while O
the O
GR B
affinity O
did O
not O
differ O
. O

Methylprednisolone O
treatment O
resulted O
in O
a O
significant O
reduction O
of O
the O
GR B
sites O
per O
cell O
in O
the O
steroid O
- O
treated O
control O
group O
( O
n O
= O
10 O
) O
in O
contrast O
to O
the O
patients O
. O

The O
internal O
methionine O
codons O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
II I
rex I
gene I
are O
not O
required O
for O
p24rex B
production O
or O
virus O
replication O
and O
transformation O
. O

Human O
T O
- O
cell O
leukemia O
virus O
types O
I O
( O
HTLV O
- O
I O
) O
and O
II O
( O
HTLV O
- O
II O
) O
have O
two O
nonstructural B
trans I
- I
acting I
regulatory I
genes I
, O
tax B
and O
rex B
, O
located O
in O
the O
3 B
' I
region I
of O
the O
viral B
genome I
. O

Human O
T O
- O
cell O
leukemia O
virus O
types O
I O
( O
HTLV O
- O
I O
) O
and O
II O
( O
HTLV O
- O
II O
) O
have O
two O
nonstructural B
trans I
- I
acting I
regulatory I
genes I
, O
tax B
and O
rex B
, O
located O
in O
the O
3 B
' I
region I
of O
the O
viral B
genome I
. O

Rex B
acts O
posttranscriptionall O
to O
facilitate O
accumulation O
of O
full O
- O
length O
gag B
/ I
pol I
and O
singly O
spliced O
env B
mRNA I
in O
the O
cytoplasm O
of O
HTLV O
- O
infected O
cells O
. O

By O
using O
an O
infectious O
molecular O
clone O
of O
HTLV O
- O
II O
, O
we O
investigated O
the O
importance O
of O
the O
internal O
ATGs O
of O
the O
rex B
gene I
on O
Rex B
protein O
production O
and O
function O
. O

Therefore O
, O
the O
phosphorylation O
of O
Rex B
is O
required O
for O
the O
viral O
RNA O
partition O
of O
HTLV O
- O
I O
. O

Proteins O
that O
bind O
this O
octamer O
have O
been O
purified O
, O
and O
cDNAs B
encoding O
octamer B
- I
binding I
proteins I
have O
been O
cloned O
. O

Thus O
, O
EBNA B
- I
2 I
transactivation O
of O
LMP1 B
amplifies O
the O
biological O
impact O
of O
EBNA B
- I
2 I
and O
underscores O
its O
central O
role O
in O
EBV O
- O
induced O
growth O
transformation O
. O

Anti O
- O
HBx B
antibody O
titers O
as O
revealed O
by O
peptide O
ELISAs O
were O
highest O
and O
most O
frequent O
in O
patients O
with O
chronic O
hepatitis O
and O
usually O
low O
in O
acutely O
infected O
patients O
and O
asymptomatic O
carriers O
. O

The O
transcription O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
is O
under O
the O
control O
of O
cellular B
proteins I
that O
bind O
to O
the O
viral B
long I
terminal I
repeat I
( O
LTR B
) O
. O

It O
has O
previously O
been O
shown O
that O
9S B
, O
untransformed B
progestin I
, I
estrogen I
, I
androgen I
, I
and I
glucocorticoid I
receptor I
complexes I
in O
rabbit O
uterine O
and O
liver O
cytosols O
contain O
a O
59 B
- I
kDa I
protein I
[ O
Tai O
, O
P O
. O
K O
. O
, O
Maeda O
, O
Y O
. O
, O
Nakao O
, O
K O
. O
, O
Wakim O
, O
N O
. O
G O
. O
, O
Duhring O
, O
J O
. O
L O
. O
, O
& O
Faber O
, O
L O
. O
E O
. O
( O
1986 O
) O
Biochemistry O
25 O
, O
5269 O
- O
5275 O
] O
. O

Over O
a O
72 O
- O
hr O
period O
of O
activation O
, O
the O
expression O
of O
the O
50 B
- I
kDa I
NF I
- I
kappa I
B I
, O
p50 B
, O
and O
its O
precursor O
, O
p105 B
, O
was O
increased O
progressively O
. O

Over O
a O
72 O
- O
hr O
period O
of O
activation O
, O
the O
expression O
of O
the O
50 B
- I
kDa I
NF I
- I
kappa I
B I
, O
p50 B
, O
and O
its O
precursor O
, O
p105 B
, O
was O
increased O
progressively O
. O

Further O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
inhibited O
the O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
in O
Jurkat O
cells O
transiently O
transfected O
with O
a O
construct B
containing O
four O
tandem B
repeats I
of O
the O
NF B
- I
kappa I
B I
binding I
sequence I
of O
the O
immunoglobulin B
kappa I
light I
chain I
gene I
linked O
to O
the O
chloramphenicol B
acetyltransferase I
reporter I
gene I
. O

The O
MZF B
- I
1 I
binding I
sites I
are O
present O
in O
the O
promoters B
of O
several O
genes B
expressed O
during O
myeloid O
differentiation O
, O
including O
the O
CD34 B
promoter I
. O

The O
MZF B
- I
1 I
binding I
sites I
are O
present O
in O
the O
promoters B
of O
several O
genes B
expressed O
during O
myeloid O
differentiation O
, O
including O
the O
CD34 B
promoter I
. O

The O
role O
of O
BSAP B
( O
Pax B
- I
5 I
) O
in O
B O
- O
cell O
development O
. O

Analysis O
of O
the O
biochemical O
and O
cell O
biological O
properties O
of O
these O
HSFs B
reveals O
that O
HSF3 B
has O
properties O
in O
common O
with O
both O
HSF1 B
and O
HSF2 B
and O
yet O
has O
features O
which O
are O
distinct O
from O
both O
. O

Analysis O
of O
the O
biochemical O
and O
cell O
biological O
properties O
of O
these O
HSFs B
reveals O
that O
HSF3 B
has O
properties O
in O
common O
with O
both O
HSF1 B
and O
HSF2 B
and O
yet O
has O
features O
which O
are O
distinct O
from O
both O
. O

Analysis O
of O
the O
biochemical O
and O
cell O
biological O
properties O
of O
these O
HSFs B
reveals O
that O
HSF3 B
has O
properties O
in O
common O
with O
both O
HSF1 B
and O
HSF2 B
and O
yet O
has O
features O
which O
are O
distinct O
from O
both O
. O

Analysis O
of O
the O
biochemical O
and O
cell O
biological O
properties O
of O
these O
HSFs B
reveals O
that O
HSF3 B
has O
properties O
in O
common O
with O
both O
HSF1 B
and O
HSF2 B
and O
yet O
has O
features O
which O
are O
distinct O
from O
both O
. O

HSF3 B
is O
constitutively O
expressed O
in O
the O
erythroblast O
cell O
line O
HD6 O
, O
the O
lymphoblast O
cell O
line O
MSB O
, O
and O
embryo O
fibroblasts O
, O
and O
yet O
its O
DNA O
- O
binding O
activity O
is O
induced O
only O
upon O
exposure O
of O
HD6 O
cells O
to O
heat O
shock O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
regulates O
transcription O
of O
a O
number O
of O
cytokine B
genes I
, O
and O
NFAT B
DNA O
binding O
activity O
is O
stimulated O
following O
T O
cell O
activation O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
regulates O
transcription O
of O
a O
number O
of O
cytokine B
genes I
, O
and O
NFAT B
DNA O
binding O
activity O
is O
stimulated O
following O
T O
cell O
activation O
. O

Treatment O
of O
immunoprecipitated O
NFATp B
from O
untreated O
HT O
- O
2 O
cells O
with O
calcineurin B
resulted O
in O
the O
dephosphorylation O
of O
NFATp B
, O
demonstrating O
that O
NFATp B
is O
an O
in O
vitro O
substrate O
for O
calcineurin B
. O

Treatment O
of O
immunoprecipitated O
NFATp B
from O
untreated O
HT O
- O
2 O
cells O
with O
calcineurin B
resulted O
in O
the O
dephosphorylation O
of O
NFATp B
, O
demonstrating O
that O
NFATp B
is O
an O
in O
vitro O
substrate O
for O
calcineurin B
. O

Treatment O
of O
immunoprecipitated O
NFATp B
from O
untreated O
HT O
- O
2 O
cells O
with O
calcineurin B
resulted O
in O
the O
dephosphorylation O
of O
NFATp B
, O
demonstrating O
that O
NFATp B
is O
an O
in O
vitro O
substrate O
for O
calcineurin B
. O

Treatment O
of O
immunoprecipitated O
NFATp B
from O
untreated O
HT O
- O
2 O
cells O
with O
calcineurin B
resulted O
in O
the O
dephosphorylation O
of O
NFATp B
, O
demonstrating O
that O
NFATp B
is O
an O
in O
vitro O
substrate O
for O
calcineurin B
. O

Treatment O
of O
immunoprecipitated O
NFATp B
from O
untreated O
HT O
- O
2 O
cells O
with O
calcineurin B
resulted O
in O
the O
dephosphorylation O
of O
NFATp B
, O
demonstrating O
that O
NFATp B
is O
an O
in O
vitro O
substrate O
for O
calcineurin B
. O

Both O
of O
these O
events O
were O
blocked O
by O
preincubation O
of O
the O
cells O
with O
FK506 O
, O
a O
calcineurin B
inhibitor O
, O
consistent O
with O
the O
hypothesis O
that O
NFATp B
is O
a O
calcineurin B
substrate O
in O
cells O
. O

Both O
of O
these O
events O
were O
blocked O
by O
preincubation O
of O
the O
cells O
with O
FK506 O
, O
a O
calcineurin B
inhibitor O
, O
consistent O
with O
the O
hypothesis O
that O
NFATp B
is O
a O
calcineurin B
substrate O
in O
cells O
. O

Both O
of O
these O
events O
were O
blocked O
by O
preincubation O
of O
the O
cells O
with O
FK506 O
, O
a O
calcineurin B
inhibitor O
, O
consistent O
with O
the O
hypothesis O
that O
NFATp B
is O
a O
calcineurin B
substrate O
in O
cells O
. O

Activation O
and O
expression O
of O
the O
nuclear B
factors I
of O
activated O
T O
cells O
, O
NFATp B
and O
NFATc B
, O
in O
human O
natural O
killer O
cells O
: O
regulation O
upon O
CD16 B
ligand O
binding O
. O

Activation O
and O
expression O
of O
the O
nuclear B
factors I
of O
activated O
T O
cells O
, O
NFATp B
and O
NFATc B
, O
in O
human O
natural O
killer O
cells O
: O
regulation O
upon O
CD16 B
ligand O
binding O
. O

Activation O
and O
expression O
of O
the O
nuclear B
factors I
of O
activated O
T O
cells O
, O
NFATp B
and O
NFATc B
, O
in O
human O
natural O
killer O
cells O
: O
regulation O
upon O
CD16 B
ligand O
binding O
. O

The O
results O
of O
supershift O
assays O
using O
NFATp B
- I
and I
NFATc I
- I
specific I
antibodies I
indicate O
that O
NK O
cell O
activation O
early O
after O
CD16 B
ligand O
binding O
involves O
primarily O
, O
if O
not O
exclusively O
, O
NFATp B
, O
and O
Western O
blot O
analysis O
shows O
that O
this O
has O
the O
same O
electrophoretic O
mobility O
( O
approximately O
120 O
kD O
) O
as O
that O
of O
T O
lymphocytes O
. O

The O
results O
of O
supershift O
assays O
using O
NFATp B
- I
and I
NFATc I
- I
specific I
antibodies I
indicate O
that O
NK O
cell O
activation O
early O
after O
CD16 B
ligand O
binding O
involves O
primarily O
, O
if O
not O
exclusively O
, O
NFATp B
, O
and O
Western O
blot O
analysis O
shows O
that O
this O
has O
the O
same O
electrophoretic O
mobility O
( O
approximately O
120 O
kD O
) O
as O
that O
of O
T O
lymphocytes O
. O

Since O
many O
cytokines B
that O
activate O
Jak B
kinases I
also O
lead O
to O
the O
tyrosine O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Stat B
family I
of O
transcription B
factors I
, O
the O
ability O
of O
IL B
- I
2 I
to O
trigger O
Stat O
phosphorylation O
was O
examined O
. O

Exposure O
of O
activated O
human O
T O
lymphocytes O
or O
of O
a O
natural O
killer O
cell O
line O
( O
NKL O
) O
to O
IL B
- I
2 I
leads O
to O
the O
phosphorylation O
of O
Stat1 B
alpha I
, O
Stat1 O
beta O
, O
and O
Stat3 B
, O
as O
well O
as O
of O
two O
Stat B
- I
related I
proteins I
, O
p94 B
and O
p95 B
. O

Exposure O
of O
activated O
human O
T O
lymphocytes O
or O
of O
a O
natural O
killer O
cell O
line O
( O
NKL O
) O
to O
IL B
- I
2 I
leads O
to O
the O
phosphorylation O
of O
Stat1 B
alpha I
, O
Stat1 O
beta O
, O
and O
Stat3 B
, O
as O
well O
as O
of O
two O
Stat B
- I
related I
proteins I
, O
p94 B
and O
p95 B
. O

Exposure O
of O
activated O
human O
T O
lymphocytes O
or O
of O
a O
natural O
killer O
cell O
line O
( O
NKL O
) O
to O
IL B
- I
2 I
leads O
to O
the O
phosphorylation O
of O
Stat1 B
alpha I
, O
Stat1 O
beta O
, O
and O
Stat3 B
, O
as O
well O
as O
of O
two O
Stat B
- I
related I
proteins I
, O
p94 B
and O
p95 B
. O

Results O
indicated O
that O
( O
i O
) O
constitutive O
c B
- I
fos I
transcript I
levels O
are O
significantly O
higher O
in O
patients O
subsequently O
responding O
to O
IFN B
- I
alpha I
therapy O
( O
p O
< O
0 O
. O
01 O
) O
and O
positively O
correlated O
with O
the O
proportion O
of O
lymphocytes O
( O
r O
= O
0 O
. O
6895 O
, O
p O
< O
0 O
. O
01 O
) O
and O
negatively O
with O
the O
proportion O
of O
immature O
cells O
( O
r O
= O
- O
0 O
. O
568 O
, O
p O
< O
0 O
. O
01 O
) O
contained O
in O
the O
pbmc O
preparations O
tested O
, O
( O
ii O
) O
constitutive B
mRNA I
levels O
of O
the O
hybrid B
bcr I
/ I
abl I
, O
c B
- I
myc I
and O
p53 B
are O

Yet O
, O
IL B
- I
2 I
- O
driven O
proliferation O
remained O
profoundly O
inhibited O
, O
suggesting O
that O
signaling O
events O
other O
than O
Jak3 B
/ B
Stat I
activation O
had O
also O
been O
changed O
following O
SE B
stimulation O
. O

Yet O
, O
IL B
- I
2 I
- O
driven O
proliferation O
remained O
profoundly O
inhibited O
, O
suggesting O
that O
signaling O
events O
other O
than O
Jak3 B
/ B
Stat I
activation O
had O
also O
been O
changed O
following O
SE B
stimulation O
. O

Cytokine B
- O
modulating O
activity O
of O
tepoxalin O
, O
a O
new O
potential O
antirheumatic O
. O

Interestingly O
, O
microtubule B
disruption O
also O
decreased O
monocyte O
1 O
, O
25 O
( O
OH O
) O
2D3 O
synthesis O
, O
not O
by O
decreasing O
the O
Vmax O
of O
monocyte B
mitochondrial I
1 I
alpha I
- I
hydroxylase I
but O
through O
an O
increase O
in O
the O
Km O
for O
25 O
( O
OH O
) O
2D3 O
. O

Activation O
through O
the O
Ca2 O
+ O
/ O
calcineurin B
pathway O
is O
essential O
to O
the O
transcription O
of O
many O
cytokine B
genes I
. O

Coexpression O
of O
NF B
- I
kappa I
B I
/ I
Rel I
and O
Sp1 B
transcription B
factors I
in O
human O
immunodeficiency O
virus O
1 O
- O
induced O
, O
dendritic O
cell O
- O
T O
- O
cell O
syncytia O
. O

T O
cells O
lack O
active O
NF B
- I
kappa I
B I
but O
express O
Sp1 B
as O
expected O
. O

Cloning O
a O
cDNA B
from O
human O
NK O
/ O
T O
cells O
which O
codes O
for O
a O
protein O
with O
high O
proline O
content O
. O

The O
present O
study O
verified O
the O
ability O
of O
IL B
- I
2 I
to O
cause O
tyrosine O
phosphorylation O
and O
activation O
of O
JAK1 B
and O
JAK3 B
, O
but O
demonstrated O
that O
IL B
- I
2 I
stimulated O
JAK3 B
to O
a O
significantly O
larger O
extent O
than O
JAK1 B
in O
human O
T O
lymphocytes O
and O
the O
YT O
cell O
line O
. O

The O
present O
study O
verified O
the O
ability O
of O
IL B
- I
2 I
to O
cause O
tyrosine O
phosphorylation O
and O
activation O
of O
JAK1 B
and O
JAK3 B
, O
but O
demonstrated O
that O
IL B
- I
2 I
stimulated O
JAK3 B
to O
a O
significantly O
larger O
extent O
than O
JAK1 B
in O
human O
T O
lymphocytes O
and O
the O
YT O
cell O
line O
. O

The O
present O
study O
verified O
the O
ability O
of O
IL B
- I
2 I
to O
cause O
tyrosine O
phosphorylation O
and O
activation O
of O
JAK1 B
and O
JAK3 B
, O
but O
demonstrated O
that O
IL B
- I
2 I
stimulated O
JAK3 B
to O
a O
significantly O
larger O
extent O
than O
JAK1 B
in O
human O
T O
lymphocytes O
and O
the O
YT O
cell O
line O
. O

The O
present O
study O
verified O
the O
ability O
of O
IL B
- I
2 I
to O
cause O
tyrosine O
phosphorylation O
and O
activation O
of O
JAK1 B
and O
JAK3 B
, O
but O
demonstrated O
that O
IL B
- I
2 I
stimulated O
JAK3 B
to O
a O
significantly O
larger O
extent O
than O
JAK1 B
in O
human O
T O
lymphocytes O
and O
the O
YT O
cell O
line O
. O

Nonetheless O
, O
a O
membrane B
- I
proximal I
region I
of O
human O
IL B
- I
2R I
beta I
( O
Asn240 B
- I
Leu335 I
) O
was O
critical O
for O
JAK3 B
activation O
, O
and O
the O
amount O
of O
JAK3 B
present O
in O
activated O
IL B
- I
2 I
receptor I
complexes I
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B
binding O
to O
the O
receptor B
complex I
relies O
on O
both O
IL B
- I
2R I
beta I
and O
IL B
- I
2R I
gamma I
. O

Nonetheless O
, O
a O
membrane B
- I
proximal I
region I
of O
human O
IL B
- I
2R I
beta I
( O
Asn240 B
- I
Leu335 I
) O
was O
critical O
for O
JAK3 B
activation O
, O
and O
the O
amount O
of O
JAK3 B
present O
in O
activated O
IL B
- I
2 I
receptor I
complexes I
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B
binding O
to O
the O
receptor B
complex I
relies O
on O
both O
IL B
- I
2R I
beta I
and O
IL B
- I
2R I
gamma I
. O

Nonetheless O
, O
a O
membrane B
- I
proximal I
region I
of O
human O
IL B
- I
2R I
beta I
( O
Asn240 B
- I
Leu335 I
) O
was O
critical O
for O
JAK3 B
activation O
, O
and O
the O
amount O
of O
JAK3 B
present O
in O
activated O
IL B
- I
2 I
receptor I
complexes I
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B
binding O
to O
the O
receptor B
complex I
relies O
on O
both O
IL B
- I
2R I
beta I
and O
IL B
- I
2R I
gamma I
. O

In O
most O
cases O
, O
the O
transcriptional B
factor I
NF B
- I
kappa I
B I
is O
a O
heterodimer B
consisting O
of O
two O
subunits O
, O
p50 B
and O
p65 B
, O
which O
are O
encoded O
by O
two O
distinct O
genes O
of O
the O
Rel B
family I
. O

In O
most O
cases O
, O
the O
transcriptional B
factor I
NF B
- I
kappa I
B I
is O
a O
heterodimer B
consisting O
of O
two O
subunits O
, O
p50 B
and O
p65 B
, O
which O
are O
encoded O
by O
two O
distinct O
genes O
of O
the O
Rel B
family I
. O

In O
most O
cases O
, O
the O
transcriptional B
factor I
NF B
- I
kappa I
B I
is O
a O
heterodimer B
consisting O
of O
two O
subunits O
, O
p50 B
and O
p65 B
, O
which O
are O
encoded O
by O
two O
distinct O
genes O
of O
the O
Rel B
family I
. O

It O
has O
been O
suggested O
that O
the O
ubiquitin B
- B
proteasome I
system O
is O
involved O
in O
the O
process O
; O
however O
, O
the O
specific O
enzymes B
involved O
and O
the O
mechanism O
of O
limited O
proteolysis O
, O
in O
which O
half O
of O
the O
molecule O
is O
spared O
, O
have O
been O
obscure O
. O

It O
has O
been O
suggested O
that O
the O
ubiquitin B
- B
proteasome I
system O
is O
involved O
in O
the O
process O
; O
however O
, O
the O
specific O
enzymes B
involved O
and O
the O
mechanism O
of O
limited O
proteolysis O
, O
in O
which O
half O
of O
the O
molecule O
is O
spared O
, O
have O
been O
obscure O
. O

To O
identify O
osteoblast B
- I
specific I
cis I
- I
acting I
elements I
and O
trans B
- I
acting I
factors I
, O
we O
initiated O
an O
analysis O
of O
the O
promoter B
of O
a O
mouse B
osteocalcin I
gene I
, O
an O
osteoblast B
- I
specific I
gene I
. O

A O
variety O
of O
other O
cells O
, O
including O
transformed O
erythroid O
precursors O
, O
do O
not O
have O
IBR B
but O
a O
factor O
referred O
to O
as O
IBF B
( O
68 O
to O
70 O
kDa O
) O
that O
recognizes O
the O
same O
IBR B
sites O
. O

A O
variety O
of O
other O
cells O
, O
including O
transformed O
erythroid O
precursors O
, O
do O
not O
have O
IBR B
but O
a O
factor O
referred O
to O
as O
IBF B
( O
68 O
to O
70 O
kDa O
) O
that O
recognizes O
the O
same O
IBR B
sites O
. O

A O
variety O
of O
other O
cells O
, O
including O
transformed O
erythroid O
precursors O
, O
do O
not O
have O
IBR B
but O
a O
factor O
referred O
to O
as O
IBF B
( O
68 O
to O
70 O
kDa O
) O
that O
recognizes O
the O
same O
IBR B
sites O
. O

IBR B
is O
a O
503 B
- I
amino I
- I
acid I
- I
long I
acidic I
protein I
which O
is O
99 O
. O
0 O
% O
identical O
to O
the O
recently O
reported O
human B
NRF I
- I
1 I
/ I
alpha I
- I
Pal I
factor I
and O
highly O
related O
to O
the O
invertebrate O
transcription B
factors I
P3A2 B
and O
erected B
wing I
gene I
product I
( O
EWG B
) O
. O

IBR B
is O
a O
503 B
- I
amino I
- I
acid I
- I
long I
acidic I
protein I
which O
is O
99 O
. O
0 O
% O
identical O
to O
the O
recently O
reported O
human B
NRF I
- I
1 I
/ I
alpha I
- I
Pal I
factor I
and O
highly O
related O
to O
the O
invertebrate O
transcription B
factors I
P3A2 B
and O
erected B
wing I
gene I
product I
( O
EWG B
) O
. O

IBR B
is O
a O
503 B
- I
amino I
- I
acid I
- I
long I
acidic I
protein I
which O
is O
99 O
. O
0 O
% O
identical O
to O
the O
recently O
reported O
human B
NRF I
- I
1 I
/ I
alpha I
- I
Pal I
factor I
and O
highly O
related O
to O
the O
invertebrate O
transcription B
factors I
P3A2 B
and O
erected B
wing I
gene I
product I
( O
EWG B
) O
. O

We O
present O
evidence O
that O
IBR B
and O
IBF B
are O
most O
likely O
identical O
proteins O
, O
differing O
in O
their O
degree O
of O
glycosylation O
. O

We O
present O
evidence O
that O
IBR B
and O
IBF B
are O
most O
likely O
identical O
proteins O
, O
differing O
in O
their O
degree O
of O
glycosylation O
. O

Mutation O
of O
Jak3 B
in O
a O
patient O
with O
SCID O
: O
essential O
role O
of O
Jak3 B
in O
lymphoid O
development O
. O

Mutation O
of O
Jak3 B
in O
a O
patient O
with O
SCID O
: O
essential O
role O
of O
Jak3 B
in O
lymphoid O
development O
. O

The O
lack O
of O
Jak3 B
expression O
correlated O
with O
impaired O
B O
cell O
signaling O
, O
as O
demonstrated O
by O
the O
inability O
of O
IL B
- I
4 I
to O
activate O
Stat6 B
in O
the O
EBV O
- O
transformed O
cell O
line O
from O
the O
patient O
. O
These O
observations O
indicate O
that O
the O
functions O
of O
gamma B
c I
are O
dependent O
on O
Jak3 B
and O
that O
Jak3 B
is O
essential O
for O
lymphoid O
development O
and O
signaling O
. O

The O
lack O
of O
Jak3 B
expression O
correlated O
with O
impaired O
B O
cell O
signaling O
, O
as O
demonstrated O
by O
the O
inability O
of O
IL B
- I
4 I
to O
activate O
Stat6 B
in O
the O
EBV O
- O
transformed O
cell O
line O
from O
the O
patient O
. O
These O
observations O
indicate O
that O
the O
functions O
of O
gamma B
c I
are O
dependent O
on O
Jak3 B
and O
that O
Jak3 B
is O
essential O
for O
lymphoid O
development O
and O
signaling O
. O

The O
lack O
of O
Jak3 B
expression O
correlated O
with O
impaired O
B O
cell O
signaling O
, O
as O
demonstrated O
by O
the O
inability O
of O
IL B
- I
4 I
to O
activate O
Stat6 B
in O
the O
EBV O
- O
transformed O
cell O
line O
from O
the O
patient O
. O
These O
observations O
indicate O
that O
the O
functions O
of O
gamma B
c I
are O
dependent O
on O
Jak3 B
and O
that O
Jak3 B
is O
essential O
for O
lymphoid O
development O
and O
signaling O
. O

The O
lack O
of O
Jak3 B
expression O
correlated O
with O
impaired O
B O
cell O
signaling O
, O
as O
demonstrated O
by O
the O
inability O
of O
IL B
- I
4 I
to O
activate O
Stat6 B
in O
the O
EBV O
- O
transformed O
cell O
line O
from O
the O
patient O
. O
These O
observations O
indicate O
that O
the O
functions O
of O
gamma B
c I
are O
dependent O
on O
Jak3 B
and O
that O
Jak3 B
is O
essential O
for O
lymphoid O
development O
and O
signaling O
. O

The O
induction O
of O
Tax B
expression O
in O
JPX9 O
cells O
resulted O
in O
about O
a O
twofold O
increase O
in O
the O
mRNA B
expression O
levels O
compared O
with O
the O
basal O
level O
. O

The O
induction O
of O
Tax B
expression O
in O
JPX9 O
cells O
resulted O
in O
about O
a O
twofold O
increase O
in O
the O
mRNA B
expression O
levels O
compared O
with O
the O
basal O
level O
. O

These O
results O
indicated O
that O
ATL O
cells O
constitutively O
overexpress O
the O
L B
- I
selectin I
gene I
that O
can O
be O
transactivated O
by O
HTLV O
- O
1 O
Tax B
. O

There O
was O
no O
difference O
between O
the O
distribution O
of O
the O
VDR B
alleles O
in O
the O
patient O
population O
when O
compared O
with O
the O
normal O
population O
. O

The O
exon B
- I
intron I
structure I
of O
the O
5 B
' I
portion I
of O
the O
thromboxane B
receptor I
gene I
was O
determined O
initially O
by O
comparing O
the O
nucleotide B
sequence I
of O
the O
5 B
' I
flanking I
genomic I
clone I
with O
that O
of O
a O
novel B
human I
uterine I
thromboxane I
receptor I
cDNA I
that O
extended O
the O
mRNA B
141 B
bp I
further I
upstream I
than O
the O
previously B
identified I
human I
placental I
cDNA I
. O

As O
in O
HMG1B B
, O
the O
overall O
structure O
of O
the O
Sox B
- I
4 I
HMG B
box I
is O
L O
- O
shaped O
and O
is O
maintained O
by O
a O
cluster O
of O
conserved O
, O
mainly O
aromatic O
residues O
. O

This O
death O
- O
promoting O
activity O
of O
Bik B
can O
be O
suppressed O
by O
coexpression O
of O
Bcl B
- I
2 I
, O
Bcl B
- I
XL I
, O
EBV B
- I
BHRF1 I
and O
E1B B
- I
19 I
kDa I
proteins O
suggesting O
that O
Bik B
may O
be O
a O
common O
target O
for O
both O
cellular B
and I
viral I
anti I
- I
apoptotic I
proteins I
. O

This O
death O
- O
promoting O
activity O
of O
Bik B
can O
be O
suppressed O
by O
coexpression O
of O
Bcl B
- I
2 I
, O
Bcl B
- I
XL I
, O
EBV B
- I
BHRF1 I
and O
E1B B
- I
19 I
kDa I
proteins O
suggesting O
that O
Bik B
may O
be O
a O
common O
target O
for O
both O
cellular B
and I
viral I
anti I
- I
apoptotic I
proteins I
. O

Signalling O
via O
CD28 B
of O
human O
naive O
neonatal O
T O
lymphocytes O
. O

We O
have O
examined O
the O
role O
of O
CD28 B
in O
modulating O
the O
' O
naive O
' O
neonatal O
T O
cell O
response O
to O
anti B
- I
CD2 I
- O
mediated O
activation O
. O

We O
have O
analyzed O
the O
expression O
of O
TCL1 B
mRNA I
and O
protein B
in O
peripheral O
blood O
lymphocytes O
( O
PBLs O
) O
from O
four O
AT O
cases O
and O
from O
healthy O
controls O
. O

Deregulation O
of O
TCL1 B
is O
the O
first O
event O
in O
the O
initiation O
of O
malignancy O
in O
these O
types O
of O
leukemias O
and O
represents O
a O
potential O
tool O
for O
clinical O
evaluation O
. O

Since O
expression O
of O
the O
viruses O
is O
in O
large O
part O
regulated O
by O
the O
sequence B
elements I
in O
their O
long B
terminal I
repeats I
( O
LTRs B
) O
, O
this O
study O
was O
directed O
to O
an O
analysis O
of O
the O
regulatory B
elements I
in O
the O
HIV B
- I
2 I
LTR I
. O

The O
HIV B
- I
2 I
LTR I
was O
found O
to O
contain O
two O
enhancers B
. O

A O
comparison O
with O
the O
Stat B
proteins I
induced O
by O
interferon B
- I
gamma I
, O
PRL B
, O
and O
IL B
- I
6 I
in O
T47D O
mammary O
tumor O
cells O
was O
made O
. O

Activation O
of O
a O
second O
protein O
related O
to O
Stat1 B
was O
also O
observed O
. O

Granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
is O
one O
such O
cytokine B
whose O
increased O
expression O
results O
partly O
from O
increases O
in O
transcription O
. O

A O
number O
of O
the O
ETS B
family I
of O
transcription B
factors I
are O
expressed O
in O
T O
cells O
, O
including O
ETS1 B
and O
ELF1 B
. O

A O
number O
of O
the O
ETS B
family I
of O
transcription B
factors I
are O
expressed O
in O
T O
cells O
, O
including O
ETS1 B
and O
ELF1 B
. O

Other O
unidentified O
ETS B
- I
like I
factors I
present O
in O
Jurkat O
cells O
are O
also O
capable O
of O
binding O
GM5 B
. O

The O
effects O
of O
CsA O
on O
endothelial O
cells O
were O
also O
detected O
at O
the O
chromatin B
structure O
level O
, O
as O
DNasel B
hypersensitive I
sites I
within O
both O
the O
GM B
- I
CSF I
enhancer O
and O
the O
E B
- I
selectin I
promoter I
were O
suppressed O
by O
CsA O
. O

Integration O
of O
the O
signals O
generated O
by O
TCR B
and O
CD28 B
engagement O
occurs O
along O
this O
pathway O
, O
which O
then O
bifurcates O
to O
induce O
I B
kappa I
B I
phosphorylation O
and O
NF B
- I
kappa I
B I
activation O
on O
the O
one O
hand O
, O
and O
JNK B
activation O
and O
c B
- I
Jun I
phosphorylation O
on O
the O
other O
. O

Integration O
of O
the O
signals O
generated O
by O
TCR B
and O
CD28 B
engagement O
occurs O
along O
this O
pathway O
, O
which O
then O
bifurcates O
to O
induce O
I B
kappa I
B I
phosphorylation O
and O
NF B
- I
kappa I
B I
activation O
on O
the O
one O
hand O
, O
and O
JNK B
activation O
and O
c B
- I
Jun I
phosphorylation O
on O
the O
other O
. O

Integration O
of O
the O
signals O
generated O
by O
TCR B
and O
CD28 B
engagement O
occurs O
along O
this O
pathway O
, O
which O
then O
bifurcates O
to O
induce O
I B
kappa I
B I
phosphorylation O
and O
NF B
- I
kappa I
B I
activation O
on O
the O
one O
hand O
, O
and O
JNK B
activation O
and O
c B
- I
Jun I
phosphorylation O
on O
the O
other O
. O

Increased O
intracellular O
stores O
of O
latent B
NF I
- I
kappa I
B I
may O
also O
result O
in O
rapid O
inducibility O
of O
NF B
- I
kappa I
B I
- O
dependent O
cytokine B
gene O
expression O
. O

Full O
- O
length O
cDNAs B
and O
genomic B
clones I
were O
isolated O
, O
and O
the O
gene O
structure O
was O
determined O
. O
Comparison O
of O
the O
deduced O
amino O
acids O
shows O
88 O
% O
sequence O
identity O
between O
mouse B
and I
human I
BOB I
. I
1 I
/ I
OBF I
. I
1 I
. O

The O
NH2 B
- I
terminal I
126 I
amino I
acids I
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
are O
both O
essential O
and O
sufficient O
for O
interaction O
with O
the O
POU B
domains I
of O
either O
Oct1 B
or O
Oct2 B
. O

The O
NH2 B
- I
terminal I
126 I
amino I
acids I
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
are O
both O
essential O
and O
sufficient O
for O
interaction O
with O
the O
POU B
domains I
of O
either O
Oct1 B
or O
Oct2 B
. O

GP B
Ib I
alpha I
promoter I
activity O
was O
evaluated O
by O
transfection O
of O
human O
erythroleukemia O
cells O
with O
reporter O
plasmids O
coding O
for O
the O
enzyme B
, O
luciferase B
. O

GP B
Ib I
alpha I
promoter I
activity O
was O
evaluated O
by O
transfection O
of O
human O
erythroleukemia O
cells O
with O
reporter O
plasmids O
coding O
for O
the O
enzyme B
, O
luciferase B
. O

CD30 B
is O
a O
recently O
described O
member O
of O
the O
tumor B
necrosis I
factor I
/ I
nerve I
growth I
factor I
receptor I
superfamily I
. O

In O
all O
cell O
lines O
investigated O
, O
the O
NF B
- I
kappa I
B I
complexes I
induced O
following O
CD30 B
engagement O
were O
shown O
to O
contain O
p50 B
NF I
- I
kappa I
B1 I
, O
p65 B
RelA I
, O
and O
possibly O
other O
transcription B
factors I
. O

Estrogen B
and O
progesterone B
receptors I
in O
vernal O
keratoconjunctivitis O
. O

Because O
HLA B
class I
II I
molecules I
present O
antigen O
to O
T B
cell I
receptors I
( O
TCRs B
) O
, O
we O
have O
searched O
for O
a O
TCR B
gene I
associated O
with O
the O
production O
of O
anti B
- I
Ro I
( I
SSA I
) I
antibodies I
. O

This O
RFLP B
pair I
occurs O
in O
76 O
% O
of O
patients O
with O
Ro B
( I
SSA I
) I
precipitins O
, O
84 O
% O
of O
anti O
- O
Ro B
( I
SSA I
) I
- O
positive O
patients O
lacking O
La B
( I
SSB I
) I
precipitins B
, O
but O
only O
41 O
% O
of O
the O
patients O
lacking O
both O
precipitins B
( O
P O
= O
0 O
. O
0004 O
) O
. O

This O
RFLP B
pair I
occurs O
in O
76 O
% O
of O
patients O
with O
Ro B
( I
SSA I
) I
precipitins O
, O
84 O
% O
of O
anti O
- O
Ro B
( I
SSA I
) I
- O
positive O
patients O
lacking O
La B
( I
SSB I
) I
precipitins B
, O
but O
only O
41 O
% O
of O
the O
patients O
lacking O
both O
precipitins B
( O
P O
= O
0 O
. O
0004 O
) O
. O

The O
majority O
of O
patients O
who O
have O
these O
RFLPs B
and O
HLA B
class I
II I
antigens I
previously O
associated O
with O
the O
anti O
- O
Ro B
( I
SSA I
) I
response O
make O
this O
antibody O
, O
suggesting O
that O
interactions O
between O
products O
of O
these O
loci B
occur I
in O
response O
to O
Ro B
( I
SSA I
) I
. O

However O
, O
while O
IL2 B
expression O
requires O
the O
contribution O
of O
Ca O
( O
2 O
+ O
) O
- O
and O
protein B
kinase I
C I
- O
dependent O
signals O
, O
we O
report O
that O
activation O
of O
human B
IL4 I
transcription O
through O
the O
Ca O
( O
2 O
+ O
) O
- O
dependent O
pathway O
is O
diminished O
by O
protein B
kinase I
C I
stimulation O
in O
Jurkat O
T O
cells O
. O

Many O
cytokines B
activate O
signal B
transducer I
and I
activation I
of I
transcription I
( I
STAT I
) I
transcription I
factors I
, O
which O
, O
in O
turn O
, O
activate O
transcription O
of O
inflammatory O
effector O
genes O
. O

The O
present O
study O
demonstrates O
that O
triggering O
of O
complement B
receptors I
CR1 B
( O
CD35 B
) O
and O
CR3 B
( O
CD11b B
/ I
CD18 I
) O
enhances O
viral O
replication O
in O
HIV O
- O
infected O
human O
monocytic O
cells O
. O

The O
present O
study O
demonstrates O
that O
triggering O
of O
complement B
receptors I
CR1 B
( O
CD35 B
) O
and O
CR3 B
( O
CD11b B
/ I
CD18 I
) O
enhances O
viral O
replication O
in O
HIV O
- O
infected O
human O
monocytic O
cells O
. O

The O
present O
study O
demonstrates O
that O
triggering O
of O
complement B
receptors I
CR1 B
( O
CD35 B
) O
and O
CR3 B
( O
CD11b B
/ I
CD18 I
) O
enhances O
viral O
replication O
in O
HIV O
- O
infected O
human O
monocytic O
cells O
. O

In O
contrast O
, O
in O
cells O
infected O
with O
L O
. O
donovani O
, O
tyrosine O
phosphorylation O
of O
Jak1 B
, O
Jak2 B
, O
and O
Stat1 B
was O
markedly O
impaired O
. O

In O
contrast O
, O
in O
cells O
infected O
with O
L O
. O
donovani O
, O
tyrosine O
phosphorylation O
of O
Jak1 B
, O
Jak2 B
, O
and O
Stat1 B
was O
markedly O
impaired O
. O

In O
contrast O
, O
in O
cells O
infected O
with O
L O
. O
donovani O
, O
tyrosine O
phosphorylation O
of O
Jak1 B
, O
Jak2 B
, O
and O
Stat1 B
was O
markedly O
impaired O
. O

To O
understand O
the O
role O
of O
MARs B
in O
IgH B
enhancer I
regulation O
, O
we O
have O
identified O
a O
novel O
MAR B
- I
binding I
protein I
, O
MAR B
- I
BP1 I
, O
from O
soluble O
nuclear O
matrix O
preparations O
based O
on O
its O
ability O
to O
bind O
to O
the O
MARs B
associated O
with O
the O
IgH B
enhancer I
. O

To O
understand O
the O
role O
of O
MARs B
in O
IgH B
enhancer I
regulation O
, O
we O
have O
identified O
a O
novel O
MAR B
- I
binding I
protein I
, O
MAR B
- I
BP1 I
, O
from O
soluble O
nuclear O
matrix O
preparations O
based O
on O
its O
ability O
to O
bind O
to O
the O
MARs B
associated O
with O
the O
IgH B
enhancer I
. O

This O
effect O
is O
thought O
to O
be O
largely O
mediated O
through O
inactivation O
of O
the O
phosphatase O
calcineurin B
, O
which O
in O
turn O
inhibits O
translocation O
of O
an O
NFAT B
component O
to O
the O
nucleus O
. O

This O
effect O
is O
thought O
to O
be O
largely O
mediated O
through O
inactivation O
of O
the O
phosphatase O
calcineurin B
, O
which O
in O
turn O
inhibits O
translocation O
of O
an O
NFAT B
component O
to O
the O
nucleus O
. O

These O
data O
point O
to O
a O
new O
mechanism O
for O
CsA O
- O
sensitive O
regulation O
of O
NFATp B
in O
which O
dephosphorylation O
is O
critical O
for O
DNA O
binding O
. O

The O
T O
cell O
activation O
is O
initiated O
by O
interaction O
of O
specific O
Ags B
with O
TCR B
, O
followed O
by O
activation O
of O
intracellular O
biochemical O
events O
leading O
to O
activation O
of O
several O
genes O
. O

The O
T O
cell O
activation O
is O
initiated O
by O
interaction O
of O
specific O
Ags B
with O
TCR B
, O
followed O
by O
activation O
of O
intracellular O
biochemical O
events O
leading O
to O
activation O
of O
several O
genes O
. O

As O
neutralizing B
anti I
- I
IL I
- I
6 I
Abs I
effectively O
down O
- O
regulated O
the O
early O
induction O
of O
STAT B
proteins I
and O
as O
exogenously O
added O
IL B
- I
6 I
rapidly O
activated O
DNA O
binding O
similar O
to O
TCR B
- O
mediated O
bindings O
, O
it O
can O
be O
concluded O
that O
IL B
- I
6 I
is O
the O
factor O
responsible O
for O
the O
activation O
of O
STAT B
proteins I
in O
a O
primary O
T O
cell O
response O
. O

Our O
data O
suggest O
an O
involvement O
of O
BLR2 B
in O
the O
regulation O
of O
migration O
in O
activated O
lymphocytes O
and O
in O
viral O
pathogenesis O
. O

c B
- I
Myb I
protein I
was O
strongly O
evident O
in O
T O
lymphoblasts O
in O
which O
the O
enhancer B
was O
active O
and O
was O
localized O
within O
discrete O
nuclear O
structures O
. O

We O
conclude O
that O
transcription O
activation O
by O
LEF B
- I
1 I
in O
vitro O
is O
a O
chromatin B
- O
dependent O
process O
that O
requires O
a O
functional O
trans B
- I
activation I
domain I
in O
addition O
to O
the O
HMG B
domain I
. O

Immunoprecipitation O
of O
the O
gp B
160 I
- O
induced O
nuclear O
extracts O
with O
polyclonal B
antibodies I
to O
Fos B
and O
Jun B
proteins I
indicates O
that O
AP B
- I
1 I
complex I
is O
comprised O
of O
members O
of O
these O
family O
of O
proteins O
. O

